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Background: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but anticoagulation is
underused in clinical care. The risk of venous thromboembolic disease during hospitalisation can be
reduced by low-molecular-weight heparin (LMWH): warfarin is the most frequently prescribed
anticoagulant for treatment and secondary prevention of venous thromboembolism (VTE). Warfarin-related
bleeding is a major reason for hospitalisation for adverse drug effects. Warfarin is cheap but therapeutic
monitoring increases treatment costs. Novel oral anticoagulants (NOACs) have more rapid onset and offset
of action than warfarin, and more predictable dosing requirements.
Objective: To determine the best oral anticoagulant/s for prevention of stroke in AF and for primary
prevention, treatment and secondary prevention of VTE.
Design: Four systematic reviews, network meta-analyses (NMAs) and cost-effectiveness analyses (CEAs) of
randomised controlled trials.
Setting: Hospital (VTE primary prevention and acute treatment) and primary care/anticoagulation clinics
(AF and VTE secondary prevention).
Participants: Patients eligible for anticoagulation with warfarin (stroke prevention in AF, acute treatment
or secondary prevention of VTE) or LMWH (primary prevention of VTE).
Interventions: NOACs, warfarin and LMWH, together with other interventions (antiplatelet therapy,
placebo) evaluated in the evidence network.
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Main outcome measures: Efficacy Stroke, symptomatic VTE, symptomatic deep-vein thrombosis and
symptomatic pulmonary embolism. Safety Major bleeding, clinically relevant bleeding and intracranial
haemorrhage. We also considered myocardial infarction and all-cause mortality and evaluated
cost-effectiveness.
Data sources: MEDLINE and PREMEDLINE In-Process & Other Non-Indexed Citations, EMBASE and The
Cochrane Library, reference lists of published NMAs and trial registries. We searched MEDLINE and
PREMEDLINE In-Process & Other Non-Indexed Citations, EMBASE and The Cochrane Library. The stroke
prevention in AF review search was run on the 12 March 2014 and updated on 15 September 2014,
and covered the period 2010 to September 2014. The search for the three reviews in VTE was run on the
19 March 2014, updated on 15 September 2014, and covered the period 2008 to September 2014.
Review methods: Two reviewers screened search results, extracted and checked data, and assessed
risk of bias. For each outcome we conducted standard meta-analysis and NMA. We evaluated
cost-effectiveness using discrete-time Markov models.
Results: Apixaban (Eliquis®, Bristol-Myers Squibb, USA; Pfizer, USA) [5 mg bd (twice daily)] was ranked as
among the best interventions for stroke prevention in AF, and had the highest expected net benefit.
Edoxaban (Lixiana®, Daiichi Sankyo, Japan) [60 mg od (once daily)] was ranked second for major bleeding
and all-cause mortality. Neither the clinical effectiveness analysis nor the CEA provided strong evidence
that NOACs should replace postoperative LMWH in primary prevention of VTE. For acute treatment and
secondary prevention of VTE, we found little evidence that NOACs offer an efficacy advantage over
warfarin, but the risk of bleeding complications was lower for some NOACs than for warfarin. For a
willingness-to-pay threshold of > £5000, apixaban (5 mg bd) had the highest expected net benefit for
acute treatment of VTE. Aspirin or no pharmacotherapy were likely to be the most cost-effective
interventions for secondary prevention of VTE: our results suggest that it is not cost-effective to prescribe
NOACs or warfarin for this indication.
Conclusions: NOACs have advantages over warfarin in patients with AF, but we found no strong evidence
that they should replace warfarin or LMWH in primary prevention, treatment or secondary prevention
of VTE.
Limitations: These relate mainly to shortfalls in the primary data: in particular, there were no head-to-head
comparisons between different NOAC drugs.
Future work: Calculating the expected value of sample information to clarify whether or not it would be
justifiable to fund one or more head-to-head trials.
Study registration: This study is registered as PROSPERO CRD42013005324, CRD42013005331
and CRD42013005330.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
CHADS2 A clinical prediction rule for estimating the risk of stroke in patients with non-rheumatic
atrial fibrillation.
CHADS2 VASC A modified clinical prediction rule for estimating the risk of stroke in patients with
non-rheumatic atrial fibrillation.
HAS-BLED Hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile
international normalised ratio, elderly (aged > 65 years), drugs/alcohol concomitantly: this estimates risk of
major bleeding for patients on anticoagulation for atrial fibrillation.
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Plain English summary
B lood clots, which can occur in both arteries and veins, sometimes break loose and move to otherorgans where they cause serious health problems. Venous thromboembolism (VTE) includes clots in
deep veins of the legs or pelvis, and their displacement to the artery from the heart to the lungs. Atrial
fibrillation (AF) is a form of irregular heartbeat that is associated with an increased risk of stroke. The UK
NHS tries to reduce these problems in high-risk patients through anticoagulant drugs, which lower the risk
of blood clots but increase the risk of bleeding. New oral anticoagulant drugs (NOACs) offer potential
advantages compared with warfarin and low-molecular-weight heparin (LMWH), the current standard
treatments. They cost more, but this might be offset by reduced need for anticoagulation services, better
effectiveness or improved safety. We compared the clinical effectiveness and cost-effectiveness of these
treatments in people with AF, and people with, or at risk of, VTE. We searched for relevant randomised
trials, and compared all of the treatments that had been evaluated. One of the NOACs, apixaban, was
among the best treatments for stroke prevention in AF, and was the most cost-effective. We found little
evidence, in terms of clinical effectiveness or cost-effectiveness, that NOACs should replace LMWH for
prevention of VTE after hip or knee surgery. For treatment of VTE, and for preventing repeat venous
thromboembolisms, risk of complications due to bleeding was lower for some NOACs than for warfarin.
Apixaban was the most cost-effective treatment for VTE, but it is not cost-effective to prescribe NOACs or
warfarin for preventing recurrence of VTE.
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Scientific summary
Background
Warfarin is an effective oral anticoagulant for stroke prevention in atrial fibrillation (AF), but
anticoagulation is underused in clinical care. The risk of venous thromboembolic disease during
hospitalisation can be reduced by low-molecular-weight heparin (LMWH): warfarin is the most frequently
prescribed anticoagulant for treatment and secondary prevention of venous thromboembolism (VTE).
Warfarin-related bleeding is a major reason for hospitalisation for adverse drug effects. The cost of
warfarin is low, but therapeutic monitoring increases treatment costs. Novel oral anticoagulants (NOACs)
have a more rapid onset and offset of action than warfarin, and more predictable dosing requirements.
Objectives
To identify the most effective, safe and cost-effective anticoagulant for stroke prevention in AF, and for
primary prevention, treatment and secondary prevention of VTE.
Methods
We conducted four systematic reviews, with network meta-analyses (NMAs), of randomised controlled
trials addressing (1) stroke prevention in AF (for which the search was run on 12 March 2014 and updated
on 15 September 2014, and covered the period 2010 to September 2014), (2) primary prevention of VTE,
(3) acute treatment of VTE and (4) secondary prevention of VTE (for all three of which the search was run
on 19 March 2014, updated on 15 September 2014, and covered the period 2008 to September 2014).
We extracted data on clinically relevant efficacy outcomes [stroke, symptomatic VTE, symptomatic deep-vein
thrombosis (DVT) and symptomatic pulmonary embolism] and safety outcomes [major bleeding, clinically
relevant bleeding (CRB) and intracranial haemorrhage], as well as myocardial infarction (MI) and all-cause
mortality. We searched MEDLINE and PREMEDLINE In-Process & Other Non-Indexed Citations, EMBASE and
The Cochrane Library, reference lists of published NMAs and trial registries. Two reviewers screened search
results, extracted and checked data, and assessed risk of bias. For each outcome we analysed each direct
pairwise comparison and performed NMAs to compare all interventions simultaneously.
We constructed discrete-time Markov models to evaluate cost-effectiveness of the different interventions
included in the four networks. These synthesised evidence on a number of parameters (e.g. incidence of
VTE and ischaemic stroke, relative treatment efficacy, adverse events, costs) to estimate the relative
cost-effectiveness of treatment options. Model inputs were based on a variety of evidence sources,
including routine data on drug costs and observational studies of long-term costs of, and quality of life
with, AF and VTE. Model inputs on relative treatment efficacy and safety of anticoagulants were derived
from the results of the NMAs.
Results
For stroke prevention in AF, apixaban (Eliquis®, Bristol-Myers Squibb, USA; Pfizer, USA) [5 mg twice daily
(bd)] was ranked as being among the best interventions for a wide range of the outcomes evaluated, including
stroke or systemic embolism (SE), MI, major bleeding, and all-cause mortality. Edoxaban (Lixiana®, Daiichi
Sankyo, Japan) [60 mg od (once daily)] was ranked second for major bleeding and all-cause mortality. Except
for all-cause mortality, outcomes for rivaroxaban (Xarelto®, Bayer HealthCare, Germany) (20 mg od) were
ranked less highly than several other NOACs. The non-NOAC interventions {warfarin [international normalised
DOI: 10.3310/hta21090 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 9
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Sterne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xlv
ratio (INR) 2–3] and antiplatelet therapy [aspirin/clopidogrel (Plavix®, Sanofi, USA) ≥ 150 mg od]} were ranked
worst for stroke or SE, and were not among the best three interventions for any of the outcomes.
At a willingness-to-pay threshold of £20,000 per quality-adjusted life-year (QALY), all NOACs had positive
expected incremental net benefit (INB) compared with warfarin (INR 2–3), suggesting that their use in
AF may be a cost-effective use of UK NHS resources. Apixaban (5 mg bd) had the highest expected INB
(£7533), followed by rivaroxaban (20 mg od) (£6365), edoxaban (£5279) and dabigatran (Pradaxa®,
Prazaxa®, Pradax®, Boehringer Ingelheim GmbH, Germany) (£5279). Apixaban (5 mg bd) was the only
NOAC for which the 95% confidence interval around INB was positive, suggesting that it is cost-effective
compared with warfarin.
For primary prevention of VTE, we found little evidence that risk of symptomatic VTE, symptomatic DVT or
symptomatic PE were lower for NOACs than for LMWH. We also found little evidence that risk of major
bleeding or CRB is lower for NOACs than for LMWH. Warfarin was ranked with high probability as the
best intervention for major bleeding events and LMWH [postoperative (post-op), standard dose] was
ranked with high probability as best, or second-best, intervention for CRB. Neither the clinical effectiveness
analysis nor the cost-effectiveness analysis (CEA) provided strong evidence that NOACs should replace
post-op LMWH in primary prevention of VTE in patients undergoing hip or knee surgery.
For acute treatment of VTE, we found little evidence that NOACs reduced risk of symptomatic VTE,
symptomatic DVT or symptomatic PE compared with warfarin or that the risk of any of these outcomes
differed between licensed doses of NOACs. However, there was evidence that risk of major bleeding and
CRB was lower with apixaban (5 mg bd) and rivaroxaban (15 mg bd then 20 mg od) than with warfarin
(INR 2–3). There was a high probability that warfarin (INR 2–3) was ranked worst for major bleeding and
CRB. There was a high probability that apixaban 5 mg bd was ranked best for major bleeding and CRB,
and this intervention also had a high probability of being ranked best, or second best, for symptomatic
DVT, symptomatic VTE and all-cause mortality. For a willingness-to-pay threshold of > £5000, apixaban
5 mg bd was the most cost-effective alternative to warfarin.
For secondary prevention of VTE, risk of symptomatic VTE and risk of symptomatic DVT were lower for all
NOACS (at the doses included in the network) than placebo and aspirin. However, there was no clear
evidence that risk of these outcomes differed between the NOAC interventions and warfarin. Risk of major
bleeding and CRB was higher with warfarin and some NOAC interventions than placebo, but there
was evidence that risk of these outcomes is lower with apixaban (2.5 mg or 5 mg bd) and dabigatran
(150 mg bd) than warfarin. Aspirin had the highest expected net benefit for secondary prevention of VTE
at willingness-to-pay thresholds of £20,000 and £30,000 per QALY. By contrast, all NOAC interventions
had negative expected INBs at the £20,000 and £30,000 thresholds, indicating that they are not cost-
effective compared with no pharmacotherapy.
Conclusions
Novel oral anticoagulants have advantages over warfarin in patients with AF. Of the available NOACs,
apixaban 5 mg bd offers the best balance between efficacy and safety, and has the highest probability of
being most cost-effective. NOACs offer no efficacy advantage over warfarin in the acute treatment of VTE,
but have a lower rate of bleeding complications albeit at a higher cost. For a willingness-to-pay threshold
of > £5000, apixaban 5 mg bd emerges as the most cost-effective alternative to warfarin. Neither the
clinical effectiveness analysis nor the CEA provided strong evidence that NOACs should replace post-op
LMWH in primary prevention of VTE in patients who are undergoing hip or knee surgery. If secondary
prevention after 3–6 months of anticoagulation for a first episode of VTE is to be considered (this is not
currently established practice), NOACs provide no advantage over aspirin 100 mg od.
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The research needs identified by this review are for (1) calculations of the expected value of sample
information, in order to clarify whether or not it would be justifiable to fund one more trial making direct
comparisons between the most promising NOACs and NOAC doses, in situations typical of NHS clinical
practice; (2) information on long-term rates of the main efficacy and safety outcomes among patients
receiving anticoagulants for AF, for example from registries or health record data; (3) information on the
role (if any) of therapeutic monitoring to enhance the safety and efficacy of NOACs; and (4) information
on long-term adherence rates in patients receiving NOACs for AF.
Study registration
This study is registered as PROSPERO CRD42013005324, CRD42013005331 and CRD42013005330.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of health problem
Atrial fibrillation, stroke and myocardial infarction
Atrial fibrillation (AF) is the most common cardiac arrhythmia.1 The prevalence of AF roughly doubles with
each decade of age, rising to almost 9% at age 80–90 years.2 AF substantially increases (by up to five
times) the risk of thromboembolic stroke (annual incidence 114 per 100,000) because of blood pooling in
the left atrium and systemic embolisation to the brain. More than 20% of the 130,000 annual strokes in
England and Wales are attributed to AF. Approximately one-third of stroke patients die in the first 10 days,
one-third recover in 1 month and one-third have disabilities necessitating rehabilitation, making stroke the
leading cause of adult disability. Patients with thromboembolic stroke from AF have higher mortality and
morbidity and longer hospital stay than patients with other stroke subtypes. Warfarin is an effective oral
anticoagulant for the prevention of stroke in patients with AF.3 Although the incidence and mortality of
stroke continue to fall in the UK, the underutilisation of anticoagulation in patients with AF at high risk of
stroke is a major gap in clinical care.4 In patients with AF, antiplatelet and anticoagulant therapies are
generally considered from the perspective of mitigation of stroke risk. However, the presence of AF is also
associated with an approximately twofold higher risk of future acute myocardial infarction (MI),5 whose
annual incidence in England (130 and 55.9 per 100,000 for men and women, respectively)6 is higher than
that of stroke.
Venous thromboembolic disease
The annual incidence of venous thromboembolic disease from a study7 conducted in Europe is 183 per
100,000. It encompasses clot formation in deep veins of the legs or pelvis [deep-vein thrombosis (DVT);
annual incidence 124 per 100,000] and the displacement of clots to the pulmonary arteries [pulmonary
embolism (PE); annual incidence 60 per 100,000]. Important risk factors for venous thromboembolism
(VTE) include major surgery, particularly lower limb orthopaedic surgery and surgery for cancer, as well as
hospitalisation in acutely ill general medical patients (approximate incidence 15%). VTE costs the UK NHS
£640M and is responsible for approximately 30,000 deaths each year in hospitals in England. DVT is an
important cause of long-term morbidity, being a risk factor for chronic leg ulceration. PE may also lead to
long-term morbidity due to pulmonary hypertension. There is an approximately 30% risk of recurrence of
VTE within 8 years.
The risk of VTE during hospitalisation for surgical or medical treatment can be reduced by low-molecular-
weight heparin (LMWH), fondaparinux (Arixtra®, GlaxoSmithKline, London, UK) or unfractionated heparin.8
Warfarin is the most frequently prescribed anticoagulant for the initial treatment and for the long-term
secondary prevention of VTE in those who are deemed to be at high risk of recurrence.
Current usage and cost of warfarin in the NHS
A 2007 Health Technology Assessment report9 stated that approximately 950,000 people (2% of the
general practice population) in the UK are prescribed warfarin, increasing by about 10% per year.
Warfarin-related bleeding is one of the top five reasons for hospitalisation for adverse drug effects in
England10 because of the narrow therapeutic index and numerous drug/dietary interactions. Although the
approximate acquisition cost of warfarin is only £10 per patient per year, the requirement for therapeutic
monitoring to ensure optimal efficacy and to reduce the risk of bleeding, through hospital-, primary
care- or pharmacist-based anticoagulation clinics, or by home monitoring with anticoagulant clinic support,
increases the cost of warfarin treatment. The estimated annual cost of managing patients on warfarin in
the NHS in England and Wales is approximately £90M.11 A 2006 National Institute for Health and Care
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Excellence (NICE) report11 estimated that 46% of patients who should be on warfarin are not receiving it,
and that many receiving anticoagulation are not in the optimal therapeutic range, perhaps because of
concern about the risk and inconvenience of warfarin treatment.
Description of interventions under assessment: new oral
anticoagulants
The class of novel oral anticoagulants (NOACs) [or non-vitamin K antagonist (VKA)], sometimes called
direct-acting oral anticoagulants, includes dabigatran (Pradaxa®, Prazaxa®, Pradax®, Boehringer Ingelheim GmbH,
Germany) (a direct inhibitor of clotting factor II) and rivaroxaban (Xarelto®, Bayer HealthCare, Germany), apixaban
(Eliquis®, Bristol-Myers Squibb, USA; Pfizer, USA), edoxaban (Lixiana®, Daiichi Sankyo, Japan), otamixaban (Sanofi,
Paris, France) and betrixaban (Portola Pharmaceuticals, San Francisco, CA, USA) (which are factor X inhibitors).
These agents have a more rapid onset and offset of action than warfarin, and are considered to have more
predictable dosing requirements than warfarin, possibly reducing the need for therapeutic drug monitoring,
increasing convenience and reducing overall cost.12 However, the safety and efficacy of at least one of the
NOACs (dabigatran) may vary according to achieved plasma concentration, which may differ between individuals
receiving the same dose,13 suggesting a potential benefit from therapeutic drug monitoring. If this proved to be
the case, the corollary would be an increase in the overall cost of treatment.
These drugs have been evaluated in clinical trials as an alternative to warfarin for the prevention of stroke in
patients with AF (in whom warfarin is given lifelong); as an alternative to LMWH for prevention of VTE in
high-risk patients who are undergoing major orthopaedic surgery, as well as those hospitalised with acute
medical conditions (in whom LMWH is given to cover the high-risk period); as an alternative to a period of
LMWH and then warfarin for acute treatment of a first VTE (usually for 6 months); and for secondary
prevention after a first episode of VTE, for which there is currently no widely used treatment.
The estimated annual acquisition cost per patient of new anticoagulants is substantially higher than that of
warfarin and will remain so until patent expiry (e.g. 2020 for rivaroxaban). However, the higher acquisition
cost could be offset by the reduced need for therapeutic monitoring through anticoagulation services,
by increased effectiveness, or by improved safety. Potential limitations of NOACs include class- and
drug-specific cautions/contraindications, potential for subtherapeutic dosing, reduced adherence owing to
lack of regular monitoring, and absence of, or limited experience with, antidotes, as well as the added
cost of maintaining stocks of numerous different anticoagulants and the potential for prescribing errors as
a result of unfamiliarity.
Rationale for undertaking this evidence review
Limitations of the previous evidence base (and shortfalls in previous attempts at evidence synthesis)
make rational selection from the now wide range of available oral anticoagulants difficult for NHS
commissioners, doctors and patients. Much of the existing NICE guidance in this area is limited to
technology appraisals of the individual agents.
Clinical trials in this area have the following limitations:
l Few, if any, trials have made direct comparisons of NOAC drugs with one another. This limitation can
be addressed through the use of network meta-analysis (NMA) to estimate the comparative efficacy
and safety of agents that have been tested against a common comparator, for example warfarin.
l Different rates of subtherapeutic anticoagulation with warfarin within trials (as measured by the time
spent in the therapeutic range) may have artificially inflated the apparent efficacy of newer agents.
This limitation can be addressed to some extent by investigating the relation of average time in
therapeutic range (TTR) with efficacy, within the NMA framework.
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Prior synthesis research in this area has the following limitations:
l Some meta-analyses preceded recently published, potentially influential trials.
l Failure to fully incorporate evidence on the adverse effects of oral anticoagulants by including data
from all trials, regardless of indication, to maximise power and provide the most robust evidence on the
balance between benefit and harm.
l The lack of cost-effective analyses (CEAs) relevant to England and Wales.
Thus, there is a need for an up-to-date comprehensive evidence synthesis of all competing treatments to
inform the rational choice of a minimum set of oral anticoagulants needed by NHS hospitals for the main
therapeutic indications to avoid unnecessary overstocking and to reduce the risk of prescription error due
to unfamiliarity.
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Chapter 2 Research questions
Aim
We set out to determine what is/are the best oral anticoagulant(s) for prevention of stroke in AF, and for
primary prevention, treatment and secondary prevention of venous thromboembolic disease.
Objectives of evidence review
Our specific objectives were to:
l identify the most effective, safe and cost-effective anticoagulant for stroke prevention in AF, and
consider whether or not the evidence is consistent across important patient subgroups (e.g. presence of
comorbidities, age)
l identify the most effective, safe and cost-effective oral anticoagulant for primary prevention, treatment
and secondary prevention of venous thromboembolic disease, and consider whether or not the
evidence is consistent for both prevention and treatment, and across important patient subgroups
(e.g. patients undergoing cancer surgery or hip and knee replacement and hospital admission for acute
medical illness)
l identify optimal anticoagulation strategies for use by Trust Drugs and Therapeutics Committees, based
on the best drug(s) for each of the main therapeutic indications
l estimate the value of conducting further research on the cost-effectiveness of these drugs, for example
by conducting a head-to-head trial of two or more new anticoagulants.
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Chapter 3 Review methods (1): assessment of
clinical effectiveness and safety
Introduction
We conducted four systematic reviews, with NMAs, of randomised controlled trials (RCTs) addressing
questions relevant to the study objectives.
Effectiveness and safety of oral anticoagulants for:
1. prevention of stroke in non-valvular AF
2. primary prevention of venous thromboembolic disease
3. acute treatment of venous thromboembolic disease
4. secondary prevention of venous thromboembolic disease.
We undertook these reviews in accordance with the Centre for Reviews and Dissemination (CRD)
guidelines for undertaking systematic reviews14 and the Cochrane Handbook for Systematic Reviews of
Interventions15 (as updated online during 2011: see www.cochrane-handbook.org). We prospectively
registered the reviews in the PROSPERO (international prospective register of systematic reviews) database
(www.crd.york.ac.uk/prospero), with registration numbers CRD42013005324, CRD42013005331 and
CRD42013005330.
Eligibility criteria
Study designs
In all reviews we included Phase II or Phase III RCTs using either a superiority or a non-inferiority design.
Participants
In all reviews we included adults (≥ 18 years) who were eligible for oral anticoagulation or (antithrombotic)
treatment. Trials in participants who were eligible for only parenteral (injected) anticoagulation were
excluded. Unless otherwise specified, anticoagulation services may have been delivered in hospital-,
primary care- and pharmacy-based clinics or through home monitoring and telephone support. The review
was not limited to NHS anticoagulation services.
Specific criteria for inclusion in the four reviews were as follows.
1. Stroke prevention in AF Adults with non-valvular AF.
2. Primary prevention of VTE Adults admitted to hospital who were considered to be at high risk
of VTE, including those with a medical condition (e.g. cancer, major trauma, stroke) or undergoing a
surgical procedure (e.g. total knee or hip arthroplasty, hip fracture surgery) that carries a high risk
of VTE.
3. Acute treatment of VTE Adults who have received a new or recurrent objectively confirmed diagnosis
of acute symptomatic VTE.
4. Secondary prevention of VTE Adults who have completed a minimum of 3 months of anticoagulant
treatment for objectively confirmed first VTE without recurrence (secondary prevention).
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Interventions and comparators
Five NOACs were the focus of all reviews: dabigatran, apixaban, edoxaban, betrixaban, rivaroxaban.
NOACs not considered were eribaxaban (the current stage of development was unclear), ximelagatran
(withdrawn because of liver toxicity), darexaban (YM150) and AZD0837 (both discontinued), LY517717
and letaxaban (TAK442) (no available information on any further clinical development for both); and
otamixaban (parenteral administration).
As the reviews were conducted to inform NMAs, we determined the comparator interventions to ensure
that they would provide information on the relative effectiveness of the interventions of interest. We
constructed preliminary networks of available treatment comparisons from trials included in previously
published NMAs (irrespective of the outcome data available from them). Comparators were chosen based
on the possibility of informing indirect evidence on the relative effectiveness of oral anticoagulants, and on
the ‘distance’ of these comparators from our interventions of interest in the network, which relates to the
likely increase in precision in the estimates of relative effectiveness of the oral anticoagulants.
Specific comparators in the four reviews were as follows:
1. Stroke prevention in AF Therapeutic doses of warfarin or other VKA [with optimal international
normalised ratio (INR) range 2–4]; aspirin; clopidogrel (Plavix®, Sanofi, USA).
2. Primary prevention of VTE Standard dose LMWH; therapeutic doses of warfarin or other VKA
(with optimal INR range 2–4); placebo.
3. Acute treatment of VTE Therapeutic doses of warfarin or other VKA (with optimal INR range 2–4).
4. Secondary prevention of VTE Therapeutic doses of warfarin or other VKA (with optimal INR range 2–4);
placebo; no treatment.
Studies evaluating fixed-dose administration of warfarin were excluded. Studies evaluating warfarin with
suboptimal target INR compared with UK guidelines were excluded from the main analyses but combined
with studies evaluating warfarin with standard target INR in sensitivity analyses. Unfractionated heparin and
fondaparinux were excluded from the primary prevention of VTE review, as they would be distant from the
NOACs in the network and hence contribute very little information. Non-standard doses of LMWH that were
excluded from this review included enoxaparin (Lovenox®, Clexane®, Sanofi-Aventis, France) at 20 mg twice
daily (bd), ardeparin (Normiflo, Wyeth-Ayerst, USA) at 25 anti-Xa units/kg bd or 35 anti-Xa units/kg bd and
nadroparin (Fraxiparine®, Sanofi-Synthelabo, France) 3800 IU anti-Xa once daily (od).
Outcomes of interest
Prevention of stroke in atrial fibrillation
We sought data on the following outcomes:
l stroke or systemic embolism (SE)*
l all stroke
l ischaemic stroke (major ischaemic stroke or minor ischaemic stroke)*
l fatal stroke
l non-fatal stroke
l haemorrhagic stroke (major haemorrhagic stroke or minor haemorrhagic stroke)
l any bleeding
l minor bleeding
l major bleeding*
l clinically relevant non-major (CRNM) bleeding
l clinically relevant bleeding (CRB)* (defined as CRNM bleeding or major bleeding)
l intracranial bleeding*
l extracranial major bleeding
REVIEW METHODS (1): ASSESSMENT OF CLINICAL EFFECTIVENESS AND SAFETY
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l extracranial minor bleeding
l fatal bleeding
l bleeding from surgical site
l thrombocytopenia
l MI*
l transient ischaemic attack (TIA)
l arterial event
l quality-of-life outcomes
l hospital admission
l death (cardiovascular)
l all-cause mortality.*
The outcomes addressed in NMAs are marked with an asterisk in the list above. These were chosen based
on three considerations: (1) their clinical importance; (2) the consistency of reporting across studies
included in the network; and (3) the number of data that were available for inclusion in NMAs.
Venous thromboembolism
For all VTE reviews we sought data on the following outcomes.
Efficacy
l Symptomatic VTE.*
l Non-symptomatic VTE.
l Major VTE (defined as symptomatic or asymptomatic proximal DVT, non-fatal PE and VTE-related
death).
l Fatal VTE.
l Symptomatic DVT.*
l Non-symptomatic DVT.
l Distal DVT.
l Symptomatic distal DVT.
l Proximal DVT.
l Symptomatic proximal DVT.
l PE.
l Symptomatic PE.*
l Non-symptomatic PE.
l Fatal PE.
l Non-fatal PE.
l Symptomatic non-fatal PE.
Safety
l Any bleeding.
l Minor bleeding.
l Major bleeding.*
l CRNM bleeding.
l CRB* (defined as CRNM bleeding or major bleeding).
l Intracranial bleeding.
l Extracranial major bleeding.
l Extracranial minor bleeding.
l Fatal bleeding.
l Bleeding from surgical site.
l Thrombocytopenia.
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Other
l MI.*
l TIA.
l Arterial event.
l Quality-of-life outcomes.
l Hospital admission.
l Cardiovascular mortality.
l All-cause mortality.*
The outcomes addressed in NMAs are marked with an asterisk in the list above. These were chosen based
on three considerations: (1) their clinical importance; (2) the consistency of reporting across studies
included in the network; and (3) the number of data that were available for inclusion in NMAs.
Identification of evidence
Search strategy
Scoping searches that were conducted during protocol development identified some previously published
NMAs of oral anticoagulants. We rescreened the studies included in these NMAs against our eligibility
criteria, and developed searches to identify any additional studies published beyond the search dates of the
most recent NMAs in each population.8,16–18
We used two separate search strategies, one for the review of stroke prevention in AF (for which the search was
run on 12 March 2014 and updated on 15 September 2014, and covered the period 2010 to September 2014)
and one for the three reviews in VTE (for all three of which the search was run on 19 March 2014, updated on
15 September 2014, and covered the period 2008 to September 2014). In each search strategy we combined
terms for either AF or VTE with terms for the interventions and comparators of interest and added a filter to
focus the search on RCTs. We searched MEDLINE and PREMEDLINE In-Process & Other Non-Indexed Citations,
EMBASE and The Cochrane Library. The stroke prevention in AF review search was run on the 12 March 2014
and updated on 15 September 2014, and covered the period 2010 to September 2014. The search for the three
reviews in VTE was run on the 19 March 2014, updated on the 15 September 2014 and covered the period
2008 to September 2014. We applied no restrictions on language. The principal search strategy is included in
Appendix 1. We removed duplicate records, identified by title, authors, journal citation and date published.
We sought information on studies in progress, unpublished research or research reported in the grey
literature from www.clinicaltrials.gov (to September 2012). We screened reference lists of retrieved studies
and relevant review articles. We also searched the NHS Economic Evaluation Database (NHS EED) and NICE
Technology Appraisals.
Assessing relevance and inclusion
Two reviewers independently screened the results of the searches by title and abstract. We resolved
disagreements through consensus or referral to a third reviewer where necessary. We obtained full texts
of all potentially relevant reports and two reviewers assessed these independently against the eligibility
criteria, with disagreements resolved by a third reviewer. We collated multiple reports of the same study
and mapped them to unique studies.
Data extraction
We developed data extraction forms and piloted them on a small selection of studies. Data were extracted
from the trial reports by one reviewer and checked by a second. Disagreements were resolved through
consensus or by referral to a third reviewer where necessary. We extracted data on the following: study
REVIEW METHODS (1): ASSESSMENT OF CLINICAL EFFECTIVENESS AND SAFETY
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details (identifier, study design, location, year, length of follow-up, industry sponsorship); participant details
(number of participants, age, gender); intervention details (drug name, dose, timing); comparator details;
details relevant to risk-of-bias assessment (including adherence to and withdrawal from randomised allocation);
and effect modifiers. Multiple reports from a study informed a single data extraction form. We extracted and
managed data using Microsoft Access® 2013 software (Microsoft Corporation, Redmond, WA, USA).
We extracted dichotomous data based on the full randomised samples, as number of events in
intervention and control groups and numbers of participants, and we sought details of follow-up time
(e.g. participant-years in each treatment group). We also extracted estimates of hazard ratios (HRs) and
their confidence intervals (CIs) when available.
Assessment of risk of bias in included trials
We assessed studies using the Cochrane Risk of Bias Tool.19 This assigns a judgement of high, low or unclear
risk of bias for each of the following domains: selection bias (randomisation sequence and allocation
concealment), performance bias (blinding of participants and carers), detection bias (blinding of outcome
assessment), attrition bias (due to dropouts and exclusions), and reporting bias (selective outcome reporting).
Assessments were carried out by one reviewer and checked by a second. We resolved disagreements
through consensus or by referral to a third reviewer where necessary.
Selection of data for analysis
Choice of interventions
To perform NMAs we had to allocate each intervention group in each trial to a category, with each
intervention category forming a ‘node’ in the network. We kept different doses or frequencies of
administration (i.e. od or bd) of oral anticoagulants in separate nodes. We assigned different VKAs to one
node (named ‘Warfarin’), but separated intended INR range 2–3 from intended INR range 3–4 and from
other ranges. For LMWH interventions in the review of primary prevention of VTE, we separated
preoperative (pre-op) LMWH from postoperative (post-op) LMWH. The intervention categories (or network
nodes) are labelled throughout the report using drug, frequency and dose, or INR range, as appropriate.
Choice of time points
When outcome data were presented for multiple time points, we took the longest period of follow-up,
except for bleeding events in the review of primary prevention of VTE, which we assessed at the end of
the treatment period.
Choice of outcomes
When outcome data were not presented directly, we computed or substituted them, using data for other
outcomes, making assumptions that we considered to be reasonable. When we could not extract data for
the outcome ‘stroke or SE’ in the review of stroke prevention in AF, we used ‘all stroke’. When CRB was
not reported but both major bleeding and CRNM bleeding events were, we used the total number of
events across these two categories. If symptomatic PE was not reported in any of the three VTE reviews,
we used symptomatic non-fatal PE if available, or the sum of fatal PE and non-fatal PE. Additionally, in the
review of primary prevention of VTE, when symptomatic VTE was not reported, we added across
symptomatic DVT and symptomatic PE, if available.
Quantitative synthesis (including network meta-analysis)
For each analysed outcome in each review (see Choice of outcomes), we undertook both standard
meta-analyses of ‘direct evidence’ (evidence based on head-to-head comparisons between interventions
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made within studies) and a NMA. Results of the individual studies are available in forest plots, arranged
within each possible pairwise analysis. The comparisons displayed in the forest plots were computed from the
raw data reported in the studies, and we calculated effect estimates using standard frequentist techniques.
Network meta-analysis is a method of synthesising information from a collection of studies by combining
evidence from all intervention comparisons that have been made among the studies. The results it
produces for each pairwise comparison combine all of the ‘direct evidence’ (evidence based on
head-to-head comparisons between interventions made within individual studies) with all of the ‘indirect
evidence’ (comparisons between interventions inferred from the network via common comparator
interventions).20,21 For example, indirect evidence comparing the effect of interventions A and B can be
inferred from the direct evidence provided by a trial comparing A with C and a trial comparing B with C.
NMA thus enables estimation of relative intervention effect estimates for every pair of interventions,
regardless of whether or not they have been compared directly in a RCT. It also enables the ranking of
treatments according to the probability that each is the best, or worst, for a given outcome.
We plotted the networks to illustrate the data structure for each review and outcome. In these plots,
the size of the node for each intervention is proportional to the number of patients randomised to that
intervention. When direct evidence comparing two interventions was available, these two interventions are
connected by an edge (line) thats thickness is proportional to the number of patients who contributed to
the comparison. The intervention labels are formatted as follows:
l Licensed doses of NOACs are written in bold typeface; these are interventions of primary interest.
l Interventions that were excluded from the primary analysis labels are presented in square brackets.
Such exclusions are because (1) they were not considered to be of interest to inform health decisions in
the UK (e.g. warfarin interventions using subtherapeutic INR ranges); or (2) the total number of events
was zero, so they are uninformative; or (3) they do not connect with the other trials in the network.
l Excluded interventions that were included in sensitivity analyses are marked with an asterisk.
We had planned to take a random-effects approach to the meta-analyses, assuming a common
heterogeneity variance across all comparisons.20 In most networks there was insufficient replication of
intervention comparisons to allow estimation of the heterogeneity variance. All of our analyses are
therefore based on fixed-effects models.
The primary NMAs treat the data as binomial, modelling the number of events out of the total number of
participants using a logistic model. When there were no events in either arm of a trial, it was omitted from
the analysis. When there were events in at least one arm of a trial, but no events in at least one other arm,
we added 0.5 events to all intervention arms in the trial. In supplementary analyses for some outcomes we
modelled HRs rather than odds ratios (ORs). For this we used a complementary log–log link to account for
differential follow-up times (thereby assuming a constant hazard of the outcome over time), modelled
possibly repeated events as rate data or included HRs extracted directly from trial reports. Some of these
analyses were used in the economic models (see Chapter 4).
All meta-analyses were performed within a Bayesian framework, using freely available WinBUGS software
version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK) and code.22 We assessed convergence of the
Markov chains using the potential scale reduction factor, as well as visual examination of history and
autocorrelation plots for each estimated parameter. We assessed goodness of fit by calculating the
posterior mean residual deviance. This is defined as the difference between the deviance for the fitted
model and the saturated model, whereby the deviance measures the fit of the model using the likelihood
function. Comparisons of models were made using the deviance information criterion (DIC), which is equal
to the sum of the posterior mean of the residual deviance and the effective number of parameters.23 The
DIC penalises the posterior mean residual deviance (a measure of model fit) by the effective number of
parameters in the model (as measure of complexity) and can therefore be viewed as a trade-off between
the fit and complexity of the model.
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Investigation of heterogeneity
We had planned to use subgroup and meta-regression24 analyses to examine the extent to which
patient- and study-level characteristics explain between-study heterogeneity. We prespecified the
important characteristics to be age, gender, ethnicity/race, body mass index (BMI) or weight, renal status or
creatinine clearance, blood pressure, diabetes mellitus, hypertension, previous thrombotic event, liver
disease, chronic heart failure, cancer, pregnancy, intervention dose, average TTR in the warfarin group,
and summary assessment of risk of bias for each outcome. Additional factors for AF trials were CHADS2,
CHADS2 VASC, HAS-BLED, history of previous stroke or TIA and previous MI. Additional factors for primary
prevention of VTE were general surgery compared with orthopaedic surgery, elective emergency surgery
compared with non-elective emergency surgery, and medical trials compared with surgical trials. An
additional factor for acute treatment or secondary prevention of VTE was the nature of the index event
(whether PE or DVT). When available, inferences about subgroup effects would be based on within-trial
subgroup analyses (e.g. comparing relative intervention effects in older and younger participants).
Investigation of between-study variation using these characteristics could not be studied in most cases
because of the lack of multiple trials of the same pairwise comparison, although we conducted some
sensitivity analyses for the review of stroke prevention in patients with AF. Specifically, we performed
several meta-regressions using the average TTR in the warfarin group as a covariate.
Investigation of inconsistency
The validity of a NMA depends on the assumption that there is no effect modification of the pairwise
intervention effects or, that the prevalence of effect modifiers is similar in the different studies. This key
assumption has been referred to variously as exchangeability,22 transitivity,25 similarity26 and consistency.27,28
For a clinical and epidemiological judgement of the plausibility of this assumption we examined whether or
not the trials were similar in ways that might modify treatment effect, based on the prespecified list of
potential effect modifiers (see Investigation of heterogeneity).
‘Evidence inconsistency’ can be considered an additional layer of heterogeneity that occurs in networks of
evidence when there is a discrepancy between the direct and indirect estimates of relative intervention
effects. Therefore, inconsistency is a property of ‘closed loops’ of evidence, in which both direct and
indirect evidence are available for each comparison. We visually inspected the network diagrams to identify
potential for inconsistency (closed loops), and used model fit and selection statistics to informally assess
whether or not it was evident. Where there was potential for inconsistency, we compared the residual
deviance from the consistency model (providing NMA evidence) with the residual deviance from an
‘inconsistency model’, without consistency constraints (in which only direct evidence is analysed for each
comparison). When both direct and indirect evidence were available, and the direct evidence had a
standard error that differed (beyond the second decimal place) from the NMA estimate, we used results
from these two analyses to back-compute the indirect estimates, on the basis that the NMA estimates
(from the consistency model) would be equivalent to a weighted average of the direct estimate (from the
inconsistency model) and the indirect estimate. In the results tables we present all three of these estimates.
The extent of the disagreement between the direct and indirect estimates can be used as a local measure
of inconsistency for that comparison. Note that for the vast majority of comparisons there was either only
direct evidence or only indirect evidence, so that the NMA estimates correspond to one of these.
DOI: 10.3310/hta21090 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 9
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Sterne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
13

Chapter 4 Review methods (2): cost-effectiveness
analysis
Introduction
This chapter describes the structure of the decision analysis models that we developed to assess the
cost-effectiveness of NOACs in the primary prevention, treatment and secondary prevention of venous
thromboembolic disease, and for prevention of ischaemic stroke in AF. We also provide a brief overview of
previous cost-effectiveness models that we identified and used to inform the development of our models.
Our models synthesise evidence on a number of parameters [e.g. incidence of VTE or ischaemic
stroke, relative treatment efficacy, adverse events (AEs), costs, etc.] in order to estimate the relative
cost-effectiveness of treatment options. The ‘model inputs’ are based on a variety of evidence sources.
These include routine data on drug costs and observational studies of the long-term costs and quality
of life (i.e. utilities) in AF and VTE. Many of these model inputs are shared between the AF and VTE
cost-effectiveness models, and we summarise them in this chapter. However, other model inputs (e.g. on
relative treatment efficacy and safety of anticoagulants) are derived from the results of meta-analyses of
RCTs that are identified in our systematic review. We summarise these efficacy and safety model inputs in
Chapters 6 and 11, which present the results of the cost-effectiveness models for AF and VTE, respectively.
The VTE secondary prevention, acute treatment and primary prevention models were constructed in
Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA) and the AF model was constructed in
R version 3.02 (The R Foundation for Statistical Computing, Vienna, Austria).29 All (network) meta-analyses
were conducted in WinBUGS.30
Decision questions
The questions we addressed were:
1. What is the most cost-effective first-line anticoagulant in the prevention of ischaemic stroke for patients
with AF?
2. What is the most cost-effective first-line strategy for the secondary prevention of VTE after an initial PE
or DVT?
3. What is the most cost-effective first-line anticoagulant for the acute treatment of symptomatic VTE?
4. What is the most cost-effective first-line anticoagulant for primary prevention of VTE following two
types of elective surgery [a, total hip replacement (THR) or b, total knee replacement (TKR)]?
In each case, we evaluated cost-effectiveness from a NHS perspective. We modelled costs and outcomes
over the expected lifetime of patients. In the next section, we give a brief overview of previous cost-
effectiveness models addressing these decision questions. We then describe the patients, interventions,
outcomes, model structure and shared model inputs for each of the four decision questions.
Previous economic models
We performed an informal search of the literature, including NICE technology appraisals, for previous
model-based CEAs addressing one of the four decision questions. Our literature search was not intended
to be exhaustive, but we aimed to identify a representative sample of existing modelling methods and
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structures to inform our models. We developed the structure of our models from a critical appraisal of
these previous models together with discussions with clinical experts and patient group representatives on
the project team.
For prevention of ischaemic stroke in AF, we identified 18 previous models, summarised in Table 1 and
discussed in detail in Appendix 6. A recently published systematic review49 identified 30 models on
prevention of stroke in AF; however, the main model structures identified in that review were covered by
the 12 studies we found. For the prevention and treatment of VTE, we identified 16 previous models, two
acute treatment models (Table 2) and 14 primary prevention models post orthopaedic surgery (Table 3).
Atrial fibrillation: patients and interventions
Atrial fibrillation: patient population
We considered patients with non-valvular AF who were eligible for anticoagulation. We made no
distinction between paroxysmal, persistent and permanent AF. The RCTs identified in the systematic review
did not distinguish between AF type, but patients with paroxysmal AF are less likely to be included in RCTs
than those with other AF types; therefore, our results are most applicable to patients with persistent and
permanent AF. We consider a cohort of patients receiving first-line anticoagulation at the age of 70 years,
based on the mean age observed in the RCTs identified in the systematic review [mean age 70 years,
standard deviation (SD) 8 years], and consider costs and benefits over a lifetime. We assume a 60 : 40 split
in favour of males, similar to that observed in the RCTs.
Atrial fibrillation: interventions
The first-line treatments for AF included in the CEA, alongside their standard or licensed doses, are listed in
Table 4. We consider only licensed treatments and doses in our analysis. Although a few small RCTs have
compared betrixaban with warfarin in AF, there was not enough evidence to include it in the economic
model. Standard care for patients with AF, before the introduction of NOACs, was warfarin.68
Treatment switching may occur as a result of treatment failure, indicated by ischaemic stroke or serious AEs,
such as intracranial haemorrhage (ICH). For patients on warfarin first-line treatment, the only second-line
intervention available was assumed to be no treatment. For patients on a NOAC first-line treatment,
second-line treatment may be either warfarin or no treatment. No treatment is the only third-line treatment.
These rules are illustrated in Figure 1, where the events that may lead to treatment switching are indicated.
Venous thromboembolism: patients and interventions
Venous thromboembolism: patient populations
For primary prevention, we estimated cost-effectiveness in two distinct subpopulations: patients
undergoing elective THR or TKR. We considered including other populations (e.g. patients who were
hospitalised for medical treatment) but there was not enough evidence identified in the literature review to
inform a model.
After a confirmed VTE event, patients receive acute treatment. The population of patients in the acute
treatment model includes those for whom a non-fatal symptomatic VTE event (DVT or PE) followed a THR
or TKR, as well as patients with a symptomatic VTE from other causes. Patients who completed at least
3 months of anticoagulant treatment for symptomatic VTE without recurrence are included in the
secondary prevention model.
We assumed an average age of subjects entering the primary prevention model of 68.7 years (SD 11.4 years)
and the split between males and females of 40 : 60, based on estimates from the National Joint Registry.69
The assumed age is in line with the median of the mean age of patients enrolled in the primary prevention
REVIEW METHODS (2): COST-EFFECTIVENESS ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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RCTs (median 64.6 years). The starting age in the acute and secondary prevention populations was 57.35 years,
the median (across RCTs) of the mean age of patients enrolled in the acute treatment and secondary prevention
RCTs. We assumed that the index VTE event on entry to the acute treatment and secondary prevention models
was split between DVT and based on the proportion of non-fatal PE and DVT in the acute treatment population.
Venous thromboembolism: interventions
For each indication we compared first-line treatments for which we have sufficient evidence to
estimate model parameters. There are seven comparators evaluated in the secondary prevention model
(Table 5), four in the acute treatment model (Table 6) and four in each of the two primary prevention
subpopulations (Table 7). Before the introduction of NOACs, standard practice70 for primary prevention
was LMWH, and for acute treatment was LMWH and warfarin for at least 5 days, then continue with
warfarin only. In secondary prevention, NICE guidance71 recommends that clinicians, after discussion with
patients, consider extending warfarin therapy beyond 3 months if the risk of VTE recurrence is high and
there is no additional risk of major bleeding. However, NICE also acknowledged the need for further
research to establish the cost-effectiveness of long-term anticoagulation after unprovoked VTE. In clinical
practice, patients may be offered long-term anticoagulation after a second VTE event. Owing to this
uncertainty about best practice, we compared all anticoagulants to a ‘no pharmacotherapy’ secondary
TABLE 4 First-line anticoagulants and dose compared in the CEA
Intervention Dose/target INR Time on treatment
Apixaban 2.5 mg bd (elderly) Lifetime
5mg bd
Dabigatran 110 mg bd (elderly)
150 mg bd
Rivaroxaban 20mg od
Warfarin INR 2–3
Source: British National Formulary67 or trial based.
NOAC
treatment
Warfarin
treatment
Warfarin
treatment
No
treatment
No
treatment
Ischaemic stroke, SE, TIA,
major bleed, MI
(if dabigatran)
ICH 
ICH, major bleed
ICH, major bleed
First line
Second line
Third line
FIGURE 1 Treatment strategies and switching/discontinuation rules. The events that may lead to treatment
switching are indicated next to the arrows between treatments.
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prevention strategy in the base-case model. In a sensitivity analysis, we assumed that patients in this
reference group would receive warfarin after a second VTE event. We assumed that all treatment will be
stopped for subjects who have an ICH and that no other treatment switching occurs. This assumption
differs from the AF population for whom treatment can be stopped or switched for other reasons
(see Atrial fibrillation: interventions, above).
TABLE 6 Acute treatment comparators
Intervention Dose Time on treatment
Apixaban 10 mg bd for 7 days then 5 mg bd 6 months
Dabigatran 150 mg bd
Rivaroxaban 15 mg bd for 21 days then 20mg od
Warfarin INR range 2–3 plus LMWHa for initial 5 days
a LMWHs [enoxaparin 1 mg/kg bd, enoxaparin 1.5 mg/kg od and tinzaparin (Innohep®, LEO Pharmaceutical Products,
Germany) 175 IU/kg].
Source: British National Formulary.67
TABLE 5 Secondary prevention comparators
Intervention Dose/target INR Time on treatment
Apixaban 2.5 mg bd Lifetime
5 mg bd Lifetime
Aspirin 75 mg od Lifetime
Dabigatran 150 mg bd Lifetime
Rivaroxaban 20 mg od Lifetime
Warfarin INR 2–3 Lifetime
No long-term pharmacotherapy – –
Source: British National Formulary.67
TABLE 7 Total hip replacement and TKR primary prevention comparators
Intervention Dose
Time on treatment
THR TKR
Apixaban 2.5 mg bd 28–35 days 10–14 days
Dabigatran 220mg od
LMWH a
Rivaroxaban 10mg od
a LMWHs [enoxaparin 40 mg od, enoxaparin 30 mg bd, enoxaparin 20 mg bd, ardeparin 25 anti-Xa units/kg bd, ardeparin
35 anti-Xa units/kg bd, ardeparin 50 anti-Xa units/kg bd, nadroparin 3800IU anti-Xa od, certoparin (Mono-Embolex®,
Novartis, Switzerland) 3000 IU od, dalteparin 2.5 mg od, dalteparin 5000 IU od].
Source: British National Formulary.67
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Outcomes of atrial fibrillation and venous thromboembolism models
We present results on total costs and quality-adjusted life-years (QALYs), both discounted at 3.5%.
We present a probabilistic analysis, for which model parameters are given probability distributions to
reflect uncertainty in their values.72 We summarised the results with the expected costs, expected QALYs
and expected net monetary benefit (NMB) for a range of willingness to pay per additional QALY gained
(where expected values are an average over the joint distribution of the model parameters). NICE has a
stated willingness-to-pay threshold of £20,000–30,000 per QALY.73
Uncertainty in the model input parameters is captured using simulation [Monte Carlo simulation for
parameters with assumed distributions, and Markov chain Monte Carlo (MCMC) simulation for parameters
estimated from the NMA]. We represent decision uncertainty using the cost-effectiveness plane,
cost-effectiveness acceptability curves (CEACs), and cost-effectiveness acceptability frontiers (CEAFs).
The cost-effectiveness plane plots incremental effects (QALYs) against incremental costs for each
simulation sample. The CEAC plots the proportion of the simulation samples where each strategy had the
highest net benefit (i.e. was most cost-effective) against willingness-to-pay-per-QALY threshold. These
proportions are estimates of the probability that the treatment is the most cost-effective. If this probability
is close to one for a particular treatment, this suggests very little uncertainty as to the most cost-effective
treatment, whereas if it is low the choice of most cost-effective treatment is uncertain. This allows
decision-makers to identify interventions that are unlikely to be cost-effective at any plausible threshold
and to judge how sensitive treatment choice is to the amount that the NHS is willing to pay for a QALY.
The CEAC is not robust when there is a treatment with a high degree of uncertainty in net benefit, giving
high probabilities of being both most cost-effective and least cost-effective. For this reason the CEAF has
been proposed.74 This plots, for each willingness-to-pay threshold, the probability of being most cost-
effective only for the treatment with the highest expected net benefit at that willingness-to-pay threshold.
We use value of information (VOI) methods to explore how sensitive the optimal treatment is to
uncertainty in the model inputs, and guide research recommendations. We estimate the expected value of
perfect information (EVPI) and the expected value of partial perfect information (EVPPI). EVPI and EVPPI
measure the expected improvement to our decision-making (in monetary units) if we were to eliminate
uncertainty in all (EVPI) or some (EVPPI) of the model input parameters. We present EVPI per person per
year and also per population over 10 years discounted at 3.5%, for given annual incidence for each of our
populations. EVPPI for subsets of parameters are computed using the Sheffield Accelerated Value of
Information (SAVI) version 2.0.9 (University of Sheffield, Sheffield, UK) web application.75,76 This method
gives only approximate results, which can be interpreted as indicative of the relative sensitivity of the
decision to different groups of parameters.
Atrial fibrillation model structure
The discrete-time Markov multistate model structure (Figure 2) used a cycle length of 3 months, as in other
recent models.33,40,42 We ran the model for a cohort starting at age 70 years and used a lifetime time
horizon with a cut-off at 100 years, thus giving 120 cycles. Patients were initially assigned to first-line
treatment, which may be warfarin or a NOAC. There is a probability of switching to another therapy or
discontinuing treatment entirely (see Figure 1).
Each of the treatment strategies has the same model structure but with different costs, utilities and event
probabilities. From any state, a patient can have a clinically relevant (extracranial) bleed, an ICH, an
ischaemic stroke, a MI, a TIA, a SE, can discontinue or switch treatment because of these events or die.
These events are similar to those used in earlier models.34,42 The primary difference is that we do not
distinguish between minor and major ischaemic stroke, as there was limited evidence from the RCTs to
estimate the relative rates of these events. We also do not include non-clinically relevant minor bleed events,
as it is assumed that they will not have a significant impact on costs, quality of life or future risks. As in most
previous models, memory states are used to record a history of the most important previous events.
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The model assumes that SE and TIA have only short-term effects on future risks, costs and utilities, whereas
ischaemic stroke, ICH, other CRB and MI have long-term consequences that must be modelled. Up to four
major events are therefore recorded and assumed to affect future risks, costs and utilities. For example,
patients with MI + ICH will have different risks, costs and utilities to patients with MI or ICH alone. Unlike
the Wisloff 2013 model,41 our model does not distinguish between bleed locations, such as gastrointestinal
and other types of bleed. Based on advice from clinical project team members, we assumed that the
greatest impact on risks, costs and effects is captured by the broad definition of ‘clinically relevant bleeds’,
as reported in the RCTs. In total, our model has 17 states, including a well state (‘AF Well’) and death.
At any cycle, patients can switch treatments to second-line or no treatment. All adverse health events
increase the probability of treatment switching. An ICH is assumed to always lead to treatment switching.
Patients are assumed to always switch treatment from dabigatran to warfarin if they experience a MI as a
result of recent findings suggesting a link between dabigatran and MI risk.77 Whether or not patients
switch treatment after an ischaemic stroke depends on whether it was due to treatment failure or
non-compliance. We assume it is due to treatment failure but that only a proportion of patients will
switch treatment following an ischaemic stroke.
In the Markov model, future state transitions depend only on the current state in which the patient is
(and not past history). We assume homogeneous transition probabilities that do not change with time.
However, the age of the cohort will increase with each cycle and mortality risk increases accordingly, based
on general population life tables. There is no available evidence to suggest treatment effects change with
age or that they depend on event history. The model therefore makes the assumption that treatment
effects are independent of age and event history.
Venous thromboembolism model structures: overview
There were three model structures for the primary prevention, acute treatment and secondary prevention
decision problems. The structure of the primary prevention model was identical in the two subpopulations
(THR and TKR); however, the parameter values differ. Decision trees were used to model the initial costs and
outcomes of primary prevention and acute treatment, where anticoagulation is used over short periods of
time, and a Markov model evaluated secondary prevention, where anticoagulation may be prescribed over
prolonged periods. The models are linked because most patients who have acute treatment for VTE will be
considered for extended secondary prevention of recurrence and it is possible that a patient receiving
anticoagulation for primary prevention will have a VTE requiring acute treatment and eventually secondary
prevention (Figure 3). Therefore, we modelled the decision problems sequentially. We first estimated the
most cost-effective method of secondary prevention. We then estimated the most cost-effective method of
acute treatment, assuming that all patients who subsequently require secondary prevention are managed
using the most cost-effective method from the secondary prevention model. Finally, we estimated the most
cost-effective method of primary prevention, with the therapy used for acute treatment and secondary
prevention determined based on the results of the first two models. For this reason, we begin our detailed
discussion of the three models with the secondary prevention model.
Venous thromboembolism model structure: secondary prevention
A Markov model with half-cycle correction78 was used to evaluate the cost-effectiveness of prophylaxis in
patients who have experienced a previous non-fatal VTE event (Figure 4). The model has a cycle length of
1 year and includes eight health states (Table 8). Subjects enter the model in post PE or post DVT. Subjects
in the ‘post DVT’ (or ‘post PE’) state can have an additional non-fatal DVT (or PE) event with a transient
utility decrement and cost, but remain in the same health state. Subjects in the ‘post DVT’ state who
experience a non-fatal PE and subjects in ‘post PE’ who experience a non-fatal DVT transition to
‘post PE DVT’. Subjects in the ‘post DVT’ and ‘post PE DVT’ states can develop post-thrombotic syndrome
(PTS) and transition to either ‘mild/moderate PTS’ or ‘severe PTS’. Subjects who have had a PE may
experience chronic thromboembolic pulmonary hypertension (CTPH). Subjects can transition to CTPH from
‘post PE’ and ‘post PE DVT’.
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VTE with acute
treatment
Secondary
prevention
TKR primary
prevention
THR primary
prevention
Patients
other than
TKR and THR
No VTE
FIGURE 3 Population pathway. THR primary prevention, TKR primary prevention, VTE with acute treatment and
secondary prevention.
Post DVT Post PE
Post PE DVT
CTPHPTS mild/moderatePTS severe
Post ICH
Death
FIGURE 4 Venous thromboembolism secondary prevention Markov model. Nodes represent the health states;
lines between nodes represent possible transitions; all health states can transition to death. ICH, other clinically
relevant bleeds, DVT and PE are acute events, which may lead to a change in chronic health state (e.g. post ICH).
TABLE 8 Health states in the secondary prevention model
Health state Description
Post DVT Experienced at least one DVT event and no PE events
Post PE Experienced at least one PE event and no DVT events
Post PE DVT Experienced at least one DVT event and at least one PE event
PTS mild/moderate Mild/moderate PTS after one or more DVT events
PTS severe Severe PTS after one or more DVT events
CTPH CTPH after PE event
Post ICH Post ICH
Death Dead (any cause)
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All subjects who are receiving treatment can transition to the ICH health state. After entering this state,
we assumed that anticoagulation therapy will be stopped and subjects will remain there until death, as this
is considered to be the state with the lowest quality of life.
Venous thromboembolism model structure: acute treatment
The acute treatment of symptomatic VTE was modelled using a decision tree covering the first 6 months of
therapy, in line with current guidelines for the duration of acute treatment (Figure 5). There is a probability
that patients will experience recurrent symptomatic VTE during the acute treatment period and, regardless
of VTE recurrence, all patients are at risk of other CRB or ICH. Longer-term costs and outcomes following
acute treatment were estimated using the secondary prevention Markov model for patients who are alive
at the end of acute treatment.
No AE
No AE
Other CRB
Other CRB
ICH
ICH
Dead
Post DVTRecurrent
symptomatic
VTE
Post PE
Death
Treated symptomatic DVT
Treated symptomatic PE
Dead
No AE
Other CRB
ICH
Dead
No AE
Other CRB
ICH
Dead
FIGURE 5 Venous thromboembolism acute treatment decision tree. At the end of each branch in the decision tree,
patients progress to the secondary prevention model. ICH branches enter in ‘post ICH’ state; treated symptomatic
DVT (with bleed or no AE) will enter the post DVT state; treated symptomatic PE (with bleed or no AE) will enter
the post PE state; recurrent symptomatic VTE post DVT will enter the post DVT or post DVT PE state, depending on
the previous event; and recurrent symptomatic VTE post PE will enter the post PE or post DVT PE state, depending
on the previous event.
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Venous thromboembolism model structure: primary prevention
The primary prevention model consists of a decision tree covering the first 180 days of prophylactic
anticoagulation (Figure 6). After this initial period, the long-term cost and outcomes of patients who do
not have a symptomatic VTE are tracked using a two-state Markov model (Figure 7). This Markov model
has two health states: no VTE/asymptomatic VTE and dead. The Markov model has a lifetime time horizon
and yearly cycles. The longer-term costs and outcomes of patients who have a symptomatic VTE are
tracked in the acute treatment model (see Figure 5) and the secondary prevention model (see Figure 4).
Patients enter the primary prevention model after having elective surgery (TKR or THR). They then
experience either a symptomatic VTE event or no VTE/asymptomatic VTE. Patients who experience a
symptomatic event have a fatal PE, non-fatal PE or DVT, and are treated. Regardless of VTE incidence, all
patients are at risk of another CRB during the initial 90-day period of anticoagulation. Because treatment
duration is short for primary prevention, the risk of ICH is very low. and there is no evidence of a relative
effect of NOACs compared with LMWH in this patient population. Therefore, we have not incorporated
ICH in the primary prevention model.
No AE
Other CRB
Death
No AE
Other CRB
Death
No AE
Asymptomatic/no VTE
Symptomatic VTE
Symptomatic PE
Symptomatic DVT
Fatal DVT
Other CRB
Death
FIGURE 6 Primary prevention decision tree. At the end of the decision tree, subjects will have experienced a
symptomatic VTE or not; if they have then they will enter the acute treatment model. Those who did not
experience a symptomatic VTE will enter the two-stage Markov model.
No VTE/
asymptomatic VTE
Dead
FIGURE 7 Primary prevention Markov model.
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Inputs partially shared between atrial fibrillation and venous
thromboembolism models
Cost of pharmacotherapy
Average drug costs were based on the British National Formulary (BNF) March 2015 update,67 using the
most economical pack size (Tables 9–11). Edoxaban does not currently have a list price in the UK. For the
base case we assume that the 6-monthly cost is equivalent to dabigatran. We tested this assumption in
a sensitivity analysis. As all of the NOACs are taken orally, it was assumed that there are no administration
or monitoring costs, following the costing report in AF of Ali et al.79 Average drug and monitoring cost of
warfarin comes from a costing report by NICE68 and is cited in the study by Kansal et al.42 The cost of
LMWH was an average over all of the LMWHs included in the meta-analyses and listed in the BNF.
The unit costs of drugs are assumed to be fixed and known, so that point estimates – rather than
distributions – are entered into the models. However, the administration and monitoring cost of warfarin is
uncertain, and in the absence of other information we assumed a uniform distribution ranging from 50%
to 150% of the estimated cost from the NICE costing report.68 We performed a sensitivity analysis for the
assumed cost of warfarin monitoring.
TABLE 9 Drug dose, duration and costs for the AF and VTE secondary prevention interventions
Intervention
Dose per
day (mg)
mg per
tablet
No. in
pack
Cost (£)
per pack
Cost (£)
per day
Administration
cost (£)
Cost (£) per
3-month
cycle AF
model
Cost (£) per
annual cycle
VTE secondary
prevention
model
Apixaban 10 5 56 61.50 2.20 0.00 200.42 802.25
5 2.5 60 65.90 2.20 0.00 200.44 802.33
Dabigatran 300 150 60 65.90 2.20 0.00 200.44 802.33
220 110 60 65.90 2.20 0.00 200.44 NA
Rivaroxaban 20 20 100 210.00 2.10 0.00 191.63 767.03
Warfarin a105.1368 420.52a
NA, not applicable.
a We inflated to 2013–14 values using the Office for National Statistics (ONS) Consumer Price Inflation Index for Medical
Services (DKC3)80 and placed a uniform distribution ∼(52.57, 157.70) and (210.26, 630.79) (on the cost per 3-month
and yearly cycles, respectively.
TABLE 10 Drug dose, duration and costs for VTE acute treatment interventions
Intervention
Dose per
day (mg)
mg per
tablet
No. in
pack
Cost (£)
per pack Time (days)
Cost (£) per
treatment
Warfarin 182.5 210.26a
Dabigatran 300 150 60 65.90 182.5 400.89
Edoxaban 60 – – – – 400.89b
Rivaroxaban 30 15 14 29.40 21 427.35
20 20 100 210 161.5
Apixaban 10 5 56 61.50 182.5 400.85
a Total cost of warfarin includes 5 days of LMWH at £9.38 per day.
b The 6-monthly cost of edoxaban is assumed to be equal to that of dabigatran.
REVIEW METHODS (2): COST-EFFECTIVENESS ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
Cost of acute venous thromboembolism, atrial fibrillation and
anticoagulant-related events
All costs of acute and chronic care were inflated to 2013–14 values using the Office for National Statistics
(ONS) Consumer Price Inflation Index for Medical Services (DKC3).80 Acute management costs for SE, MI, TIA,
DVT, PE and CRB come from the 2012–13 NHS reference costs.81 The reference costs for MI account for only
direct hospitalisation; we assumed that total costs would be double this amount to account for follow-up
costs.82 The cost of a sudden fatal PE is assumed to be zero and the patients who have a non-fatal PE are
assumed to accrue the full cost of a PE. Acute management costs for ischaemic stroke and ICH come from a
study of patients with AF on a UK stroke registry.83 Normal distributions are assumed for the mean acute
costs, with SDs defined by the standard errors of the source data (Table 12).
Cost of chronic care for venous thromboembolism, atrial fibrillation and
anticoagulant-related events
Long-term management costs of stroke (ischaemic stroke or ICH) also come from the UK stroke registry83
(Table 13). This registry83 stratified the severity of ischaemic strokes by disability (non-disabling, moderately
disabling, totally disabling) and we averaged their annual costs and SDs, weighted by the number of
events. As in the study by Kansal et al.,42 we assumed the same cost for ICH as for ischaemic stroke.
Normal distributions are assumed, with SDs defined by the standard errors of the source data.
TABLE 11 Drug dose per day for VTE primary prevention comparators
Intervention
Dose per
day (mg) mg per tablet No. in pack Cost (£) per pack Cost (£) per day
Apixaban (2.5 mg bd) 5 2.5 60 65.90 2.20
Dabigatran (220 mg od) 220 110 60 65.90 2.20
Rivaroxaban (10 mg od) 10 10 100 210.00 2.10
LMWH (post-op, standard dose) – – – – 4.17a
a Average daily cost of enoxaparin 20 mg bd, enoxaparin 40 mg od, dalteparin 5000 IU, fondaparinux 2.5 mg od.
TABLE 12 Acute event costs and their distributions
Event Mean event cost (£) Distribution(mean, standard error) Source
Ischaemic stroke 11,626 (SD = 16,868) Normal(11,626, 1325) aIschaemic stroke, all strokes83
ICH 11,453 (SD = 13,815) Normal(11,453, 3350) ICH or haemorrhagic stroke, all
haemorrhagic strokes83
SE (non-fatal) 2373 Uniform(1186.5, 3559.5) NHS reference costs81
TIA 1064 Uniform(532, 1596) NHS reference costs81
PEb 1596 Normal(1596, 159.6)c NHS reference costs81
DVTd 712 Normal(712, 71.2)c NHS reference costs81
CRBe 1751.50 Uniform(875.75, 2627.25) NHS reference costs81
MI 4830 Uniform(2415.24, 7245.72) Acute MI, NHS reference costs for
hospitalisation,81 doubled to include
follow-up costs
HRG, Healthcare Resource Group.
a We inflated to 2013–14 values using the ONS Consumer Price Inflation index for medical services (DKC3).80
b Weighted average of HRG codes DZ09D, DZ09E, DZ09F, DZ09G, DZ09H.
c We assumed a standard error of 10% of the mean event cost.
d Weighted average of HRG codes YQ51A, YQ51B, YQ51C, YQ51D, YQ51E.
e Average of gastrointestinal and non-gastrointestinal bleed.
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For states with a history of multiple events, we assumed that the additional post-event management costs
were the maximum of the management costs for the constituent events. We divided sampled costs by four
to obtain 3-monthly cycle costs.
Costs for mild to moderate and severe PTS have previously been estimated in a NICE technology appraisal,84
which looked at the clinical effectiveness and cost-effectiveness of dabigatran for the prevention of VTE
after a TKR or TKR in adults. This study84 converted and inflated costs from a US economic burden study85 of
long-term complications of primary prevention of DVT after a THR. This study84 estimated the cost of mild to
moderate PTS to be £541 for the first year and £220 for subsequent years, and severe PTS to be £2461 for
the first year and £602 for subsequent years. Inflating to 2013–14 values resulted in a cost of £689 for the
first year and £280 for subsequent years for mild/moderate PTS, and £3136 for the first year and £767
for subsequent years of severe PTS. NICE guidance for the management of VTE71 estimated a 4-weekly cost
of CTPH to be £2173, equivalent to an annual cost of £33,028 in 2013–14 prices.
Utilities
The AF and VTE models used utility weights combined with survival to estimate QALYs. Utility weights are
anchored at 1 (best health) and 0 (as bad as death), such that a year spent in an intermediate health state
with a utility weight of 0.5 would be considered equivalent to 6 months in the best health state with a
utility value of 1. The models have a number of acute health events that affect patients for a short period,
followed by a partial or full recovery and a number of chronic health states from which patients do not
recover. Several of these health events and health states are shared between the AF and VTE models.
Utilities were identified from a previous NICE technology appraisal submission on rivaroxaban33 and from a
rapid literature review to identify quality-of-life studies in VTE. The rivaroxaban technology appraisal
submission33 conducted a systematic literature search for evidence on EQ-5D (European Quality of Life-5
Dimensions) utility index in health states related to AF. For VTE events (DVT and PE), Locadia et al.86 estimated
health utilities, using time trade-off methods, from a cohort of 53 patients who had experienced a VTE event.
Utilities of venous thromboembolism, atrial fibrillation and
anticoagulant-related acute health events
The acute health event disutilities for AF for other CRB, SE and TIA are reported in Table 14. The remaining
acute health event disutilities for AF (acute ICH and acute MI; see Table 14) are obtained by subtracting
‘Stable AF’ from the utility of the event. For example, the disutility for MI would be 0.683 – 0.779 = –0.096.
These disutilities are capped above at 0. Further acute event utility values extracted from the literature for
VTE primary prevention, acute treatment and secondary prevention models are reported in Table 15. When
uncertainty estimates were reported, we assumed that mean utilities would be normally distributed, as
indicated by the central limit theorem. When uncertainty estimates and sample sizes were not available
(acute ischaemic stroke, TIA, SE), we assumed mean utilities to follow a uniform distribution ranging from
50% to 150% of the reported mean. The duration of the decrements for DVT and PE was assumed to be
TABLE 13 Annual post-ischaemic stroke and post-ICH management costsa
Event Mean cost (£) Distribution Source
Non-disabling 2135 (SD = 3676, n = 66) Luengo et al.83
Moderately disabling 4165 (SD = 7668, n = 58)
Totally disabling 6324 (SD = 14,898, n= 6324)
All (ischaemic stroke and ICH) 3613 (SD = 4235, n = 136) Normal (3613, 363) Weighted average of the
mean and SD, inflated to
2013–14 prices
a These are divided by four to obtain 3-monthly cycle costs.
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TABLE 14 Utilities
Health state Utility score Distributiona Source
Reference group health state
Stable AF quality of life
(for AF model)
0.779 (SD = 0.253,
n = 3045, standard
error = 0.0045)
Normal(0.779, 0.0045) Berg 201087
No VTE quality of life
(for VTE model)
0.96 (SD = 0.046) Beta(16.52, 0.69) Locadia 200486
Acute health eventsb
TIA and SE disutility –0.131 Uniform(–0.197, –0.066) Robinson 200188
Acute ischaemic stroke
disutility
–0.59 Uniform(–0.885, –0.295) Robinson 200188
DVT (first and subsequent) 0.84 (SD= 0.087) Beta(14.17, 2.70) Locadia 200486
PE (first and subsequent) 0.63 (SD= 0.128) Beta(8.40, 4.93) Locadia 200486
Acute ICH disutility Median 0.60
(95% CI 0.02 to 1.00)
(n= 60)
Normal(0.60, 0.064) – AF well Lenert 199789
Other CRB disutility –0.03 (standard
error = 0.001531)
Normal(–0.03, 0.001531) Robinson 200188
Acute MI disutility 0.683 (SD = 0.233,
n = 222, standard
error = 0.0156)
Normal(0.683, 0.0156) – AF well cLacey 200390
Chronic health states
Post ischaemic stroke quality
of life
0.69 (SD = 0.18, n= 77,
standard error = 0.0205)
Normal(0.69, 0.0205) dHaacke 200691
Mild/moderate PTS –0.02e Beta(97.98, 4801.02) Lenert 199789
Severe PTS –0.07e Beta(92.93, 1234.64) Lenert 199789
CTPH 0.57 (SD 0.31) Beta(1.20, 0.94) Meads 200893
Post ICH quality of life 0.74 (SD = 0.39, n= 5,
standard error = 0.1744)
Beta(3.941, 1.385) fHaacke 200691
Post MI quality of life 0.718 (SD = 0.243,
n = 222, standard
error = 0.0163)
Normal(0.718, 0.0163) cLacey 200390
a Capped above at 1 for quality of life and 0 for disutility.
b Disutilities assumed to last for 3 months.
c Table 3, year mean EQ-5D score utility decrement.
d Table 2 in source article, weighted average EQ-5D score for ischaemic stroke
e Utility decrement with an assumed standard error of 10% of the mean.
f Table 3 in source article, EQ-5D for haemorrhagic stroke.
TABLE 15 Transient event utility values for primary prevention, acute treatment and secondary prevention models
Transient event Utility/decrement Duration of decrement Source
DVT (first and subsequent) 0.84 (0.64 to 0.98) 6 months Locadia 200486
PE (first and subsequent) 0.63 (0.36 to 0.86) 6 months Locadia 200486
ICH 0.60 (0.02 to > 0.99) 3 months Lenert 199789
Other clinically relevant bleed 0.03 (standard error
0.001531)a
Absolute decrement Robinson 200188
a Decrement.
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6 months71 and 3 months for ICH, before moving to the post-ICH health state.51 Duration of decrements
was generally not reported for the AF disutilities, so they were assumed to last one cycle.
In both the AF and VTE model, to account for quality of life decreasing with age, all utility decrements
were multiplied by the ratio of the utility for a given age range relative to a reference age (65–75 years),
based on general population utilities estimated in Kind et al.92 (Table 16). Utilities were also adjusted by
gender in this way for the VTE models, whereas for the AF models all utilities were weighted averages
across gender.
Utilities of venous thromboembolism, atrial fibrillation and
anticoagulant-related chronic health states
In the AF model, for which patients can have more than one chronic health condition, utilities for chronic
health states are assumed to be multiplicative. For example, the utility of a patient who has experienced
both an ischaemic stroke and a MI will be the product of the two utility scores (see Table 14):
0.690 × 0.718 = 0.495.
Utilities are multiplied by 0.25 to get a QALY for 3-month cycle.
For the VTE-related chronic health states, we used estimates from the study by Lenert and Soetikno,89 who
elicited preferences in 30 volunteers and 30 medicine physicians with mild/moderate PTS and severe PTS,
and the study of Meads et al.,93 who used the Cambridge Pulmonary Hypertension Outcome Review utility
index94 to estimate a utility value for CTPH from 308 patients (see Table 14). Further chronic VTE-related
chronic health-state utilities extracted from the literature are reported in Table 17.
TABLE 16 General population utility values (mean and SD) by age and gendera
Age (years)
Male Female
SourceMean (SD) Alpha, beta Mean (SD) Alpha, beta
< 25 0.94 (0.12) 0.94 (0.12) Kind 199992
25–34 0.93 (0.16) 0.93 (0.15)
35–44 0.91 (0.17) 656.7, 65.0 0.91 (0.15) 1006.6, 99.5
45–54 0.84 (0.27) 341.4, 65.0 0.85 (0.23) 544.1, 96.0
55–64 0.78 (0.28) 330.4, 93.2 0.81 (0.26) 526.6, 123.5
65–74 0.78 (0.28) 388.5, 109.6 0.78 (0.25) 551.7, 155.6
≥ 75 0.75 (0.28) 191.2, 63.7 0.71 (0.27) 406.4, 166.0
a Assumed beta distribution parameters; alpha and beta are given by age and gender.
TABLE 17 Health-state utility values for primary prevention, acute treatment and secondary prevention models
Health state Utility/decrement Source
Reference – no VTE 0.96 (0.82 to 1.00) Locadia 200486
Mild/moderate PTS 0.02 (SD 0.04)a Lenert 199789
Severe PTS 0.07 (SD 0.07)a Lenert 199789
CTPH 0.57 (SD 0.31) Meads 200893
Post ICH 0.74 (standard error 0.1744) Haacke 200691
Death 0.00 (0 to 0) Definition
a Decrement.
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Summary
This chapter summarises the decision problems addressed by the cost-effectiveness models; the structure,
perspective, and target population of the models; and the interventions and outcomes represented by the
models. We developed the structure of the model based on existing cost-effectiveness models that were
identified in the literature, and the structure evolved based on feedback from clinical experts in order to
reflect current disease knowledge and clinical practice. We used decision trees to reflect the short-term
nature of the VTE primary prevention and acute treatment decision problems, and Markov models to
address the AF-related ischaemic stroke and VTE secondary prevention decision problems for which longer
periods of prophylaxis are required.
This chapter also summarises the cost and utility model inputs shared by the AF and VTE models.
Model inputs on the relative treatment efficacy and safety of anticoagulants were derived from the results
of meta-analyses of RCTs identified in our systematic review. We summarise these efficacy and safety
model inputs in Chapters 6 and 11, which also present the results of the cost-effectiveness models for
AF and VTE.
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Chapter 5 Clinical results (1): stroke prevention in
atrial fibrillation
Included studies
A total of 1852 unique records were identified from various data sources for the review of stroke
prevention in AF (Figure 8).
Twenty-three completed eligible RCTs were identified for inclusion in the review, with a total of
41 associated references for these trials.95–135 No ongoing trials were identified. A summary of the
characteristics of the 23 trials is presented in Table 18. Twenty of the trials were multicentre;
Records identified through
database searching
(n = 3332)
Papers identified from 
previous NMAs
(n = 44)
Records after duplicates removed
(n = 1852)
Records screened
(n = 1852)
Records excluded
(n = 1651)
Full-text articles assessed
for eligibility
(n = 201)
Included studies
(n = 23; 41 references)
Id
en
ti
fi
ca
ti
o
n
Sc
re
en
in
g
El
ig
ib
ili
ty
In
cl
u
d
ed
Full-text articles
excluded 
(n = 84)
• Not a RCT, n = 50
• Unsuitable population,
   n = 4
• Not a comparison of
   interest, n = 25
• No relevant outcomes,
   n = 3
• Subgroup analysis not
   of interest, n = 2
• Full-text articles
   assessed as eligible
   but not used in data
   extraction, n = 76
FIGURE 8 The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart for review
of stroke prevention in AF.
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two trials were each conducted in two centres; and one trial was conducted in one centre. The majority
of the multicentre trials were conducted across several countries in North and South America, Europe,
Asia, Russia and Israel, Australia and South Africa. The two-centre trials were conducted in one country:
one in China and the other in Denmark. The single-centre trial was conducted in Denmark. Sixteen of
the trials were Phase III studies and seven were Phase II studies. The number of patients randomised
across the 23 trials ranged from 75 to 21,105, with a total of 94,656 patients, of whom 97% (91,333)
were from the Phase III studies. Thirteen studies: six Phase III and seven Phase II studies examined a
NOAC. Four studies examined edoxaban, three each examined apixaban and dabigatran, two examined
rivaroxaban and one examined betrixaban.
Eligibility criteria for patient participation were similar across studies: all patients having non-valvular AF,
whether new or existing, and including paroxysmal, persistent or permanent types. Diagnosis of AF was
predominantly by electrocardiography. In a few cases, Holter recording, pacemaker or other intracardiac
recording was used. The mean age of included patients was reported in only 61% of the studies and this
ranged from 63.3 to 81.5 years. The percentage of male patients was reported in 78% of the studies, and
this varied significantly across the studies, ranging from 44.9% to 82.9%. Mean BMI was not often reported
and ranged from 24.4 to 30.5 kg/m2. Percentage of patients with previous stroke, hypertension and chronic
heart failure varied significantly across the studies, ranging from 5% to 63.8%, from 38% to 93.7%, and
from 0% to 100%, respectively. Bleeding risk among patients was assessed predominantly with the CHADS2
scoring system.
Warfarin was examined in all but two of the 23 of the included studies, against a NOAC in 12 studies,
and against aspirin in nine studies. Standard intensity warfarin (INR 2–3) was examined by all of the
studies, although in a few studies the warfarin arm was a mixture of low intensity (INR < 2) and
standard intensity, in unknown proportions. Across all of the studies, mean TTR for warfarin ranged
from 45.1% to 83% of the treatment duration. One study98 compared both low intensity warfarin
(INR < 2) and standard intensity (INR 2.5–3.5) dicoumarol with aspirin, but the mean TTR was not
reported for the standard intensity dicoumarol arm. The doses of NOACs we examined were edoxaban
30 mg, 45 mg, and 60 mg od and 30 mg and 60 mg bd; apixaban 2.5 mg and 5 mg bd; dabigatran
50 mg, 110 mg, 150 mg and 300 mg bd; rivaroxaban 15 mg and 20 mg od; and betrixaban 40 mg,
60 mg and 80 mg od. Examined aspirin dosages ranged from 75 mg to 325 mg od.
Treatment duration in the edoxaban and dabigatran studies was predominantly 3 months, although one
study reported mean treatment durations of 24 months and another reported a median treatment duration
of 29.8 months. Mean treatment duration for apixaban studies ranged from 13.1 to 21.6 months and
one study reported 3 months’ treatment duration. The two studies on rivaroxaban reported 30 months’
treatment duration and a mean treatment duration of 19.4 months, respectively. Mean treatment duration
4.9 months was reported in the betrixaban study. Treatment duration was similar for each comparator in
almost all the NOAC studies. Reported efficacy and safety outcome types were similar across studies and
these were reported at the end of the treatment periods. All 23 studies reported data on stroke, 15 studies
reported data on MI, 18 studies reported data on major bleeding, 12 studies reported data on CRB, and
18 studies reported data on all-cause mortality. Fifteen of the 23 studies, including all the NOAC studies,
were sponsored by pharmaceutical companies. Six studies were funded by grants from medical research
bodies although two of these grants contained contributions from a pharmaceutical company. Sponsor detail
was not reported in two studies. In most of the pharmaceutical company sponsored studies, the sponsor(s)
had influence on the study design, data management and analysis.
Time in therapeutic range for warfarin interventions
Table 19 shows the comparator interventions, target INR and (where reported) mean TTR for the
22 studies that included a warfarin intervention arm. Sixteen (73%) of these studies reported mean TTR,
which varied substantially (from 45.1% to 83%) between studies.
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TABLE 19 Mean TTR for warfarin in stroke prevention in AF
Study
Interventions that were compared
with warfarin Warfarin INR
Mean TTR
(INR), %
ACTIVE W100 Antiplatelet (clopidogrel
75 mg+ (aspirin 75–100mg) od
2–3 (some patients may
have received other VKAs)
63.8
AFASAK95 Aspirin 75 mg od
Placebo od
2–3 73
AFASAK II97 Aspirin 300 mg od 2–3 73
AF-ASA-VKA-CHINA135 Aspirin 100 mg od 1.6–2.5 NR
AF-DABIG-VKA-JAPAN110 Dabigatran 110 mg, 150 mg bd 2–3 (≥ 1.6 to ≤ 2.6 in
≥ 70 years)
NR
AF-EDOX-VKA-ASIA115 Edoxaban 30mg, 60 mg od 2–3 45.1
AF-EDOX-VKA-JAPAN118 Edoxaban 30mg, 45 mg, 60 mg od 2–3 (1.6–2.6 in ≥ 70 years) 83 (≥ 70) 73
(< 70 years)
AF-EDOX-VKA-MULTI108 Edoxaban 30mg, 60 mg od, 30 mg,
60 mg bd
2–3 49.7
AF-VKA-ASA-CHINA122 Aspirin 200 mg od 2.1–2.5 NR
ARISTOTLE107,114,119,124–127,130,132–134 Apixaban 5mg bd 2–3 62.2
ARISTOTLE-J113 Apixaban 2.5 mg, 5 mg bd 2–3 (2–2.6 in ≥ 70 years) 60
BAFTA103 Aspirin 75 mg od 2–3 67
Chinese ATAFS99 Aspirin 150–160mg od 2–3 (1.6–2.5 in > 75 years) NR
ENGAGE AF-TIMI 48111,131 Edoxaban 30mg, 60 mg od 2–3 64.9
EXPLORE-Xa128 Betrixaban 40mg, 60 mg, 80 mg od 2–3 63.4
J-ROCKET AF120 Rivaroxaban 15mg od 2–3 (1.6–2.6 in ≥ 70 years) 65
PATAF98 Aspirin 150 mg od 2.5–3.5 (some patients
received other coumarins –
phenprocoumon or
acenocoumarol)
NR
PETRO102 Dabigatran 50mg, 50 mg + (aspirin
81 mg), 50 mg + (aspirin 325mg),
150mg, 150 mg + (aspirin 81 mg),
150mg + (aspirin 325 mg), 300 mg,
300mg + (aspirin 81 mg),
300mg + (aspirin 325 mg) bd
2–3 57.2
RE-LY104,109 Dabigatran 110 mg, 150 mg bd 2–3 64
ROCKET AF106,112,123,129 Rivaroxaban 20mg od 2–3 55
SPAF II96 Aspirin 325 mg (in < 75 years),
325mg (in > 75 years) od
2–4.5 in < 75 years
2–4.5 in > 75 years
NR
WASPO101 Aspirin 300 mg od 2–3 69.2
NR, not reported.
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Risk of bias in included studies
Detailed risk-of-bias assessments for each included study for each domain of the Cochrane assessment tool
are provided in Table 20. The assessments ranged from low to high risk of bias, but it was difficult to judge
some studies as a result of inaccessibility of study protocols. For most of the outcomes assessed in the
studies, all randomised patients were either accounted for in the analysis, or in some cases a small number
of patients were unaccounted for with reasons judged likely to be unrelated to the outcome. The majority
of the studies were judged to be at low risk of bias for allocation concealment and incomplete outcome
data. The majority of the studies were judged to be at a low or unclear risk of bias for sequence generation.
Randomisation sequence across the low-risk studies was predominantly computerised. Most studies were
also judged to be of low risk of bias for blinding of outcome assessment, with three studies judged to be
at high risk of bias in this domain. Fourteen studies were judged to be at high risk of bias for blinding of
participants and personnel, mainly because they were open label. Where studies were blinded for different
dose groups of a novel anticoagulant, but not in the comparison of these to warfarin, we assigned a high
risk of bias because the principal contribution of the study to our analyses would be the comparison of
warfarin with the licensed dose of the anticoagulant. Risk-of-bias judgements for studies contributing to
analyses of each outcome are presented graphically in the sections that follow.
Results on clinical effectiveness and safety
The 27 different interventions considered in the 23 trials are listed in Tables 21–23, which show the
number of patients analysed and the number of outcome events for each outcome reported in each trial.
We performed NMAs for seven outcomes: stroke or SE, ischaemic stroke, MI, major bleeding, CRB,
intracranial bleeding and all-cause mortality. Arms that were considered not to provide any evidence of
interest to inform health decisions in the UK were excluded from the analyses. Specifically, we excluded
the warfarin arm with INR range 1.6–2 from the AF-VKA-ASA-CHINA trial,122 the warfarin arm with INR
range of < 2 from PATAF,98 the placebo arm from AFASAK,95 and the two warfarin arms with a fixed daily
dose from AFASAK II.97
We defined two independent nodes for warfarin interventions, labelled as ‘warfarin (INR 2–3)’ and
‘warfarin (INR 3–4)’, respectively. The first of these formed the reference treatment across all networks in the
AF review. We included in ‘warfarin (INR 2–3)’ the trials with a therapeutic INR range of 2–3 (e.g. ACTIVE W,100
AFASAK95), as well as some interventions with an INR range of 2.5–3.5 (AF-EDOX-VKA-ASIA115 and PATAF98)
or 2.0–4.5 (SPAF II96). In some trials the INR range for some of patients in the warfarin arm was subtherapeutic
(< 2.0), so that the total INR range was 1.6–3.0. These interventions were excluded from the main analysis,
but merged with the INR 2–3 node in a sensitivity analysis. As a consequence, there were three two-arm
trials (J-ROCKET AF,120 Chinese ATAFS99 and AF-ASA-VKA-CHINA135) that were included only in sensitivity
analyses.
We also defined two independent nodes for antiplatelet interventions (‘aspirin’ or ‘aspirin plus
clopidogrel’), using the cut-off point of 150 mg, with the understanding that daily doses above that were
appropriate for stroke prevention in AF, whereas lower doses were appropriate for secondary prevention
of cardiovascular events. The dose range considered in the AVERROES trial105,116,117,121 (81–324 mg od) was
much wider than in any other trial, and we included this intervention in the lower-dose node (< 150 mg
od) because some patients from that study had received a low daily dose. As a sensitivity analysis, we
excluded the AVERROES trial105,116,117,121 from the network. Finally, our main analysis used a binomial
model, assuming equal follow-up times across arms within trials and ignoring some variations in how
results were reported. We undertook a separate analysis for all outcomes taking into account the
differences in duration of follow-up within and between trials, and the differences in the definition of
event used across trials (e.g. total number of events vs. first events only).
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Results are presented as follows for each of the six outcomes. First, we provide network plots to illustrate
the comparisons of interventions made in the different trials. Second, we illustrate the risk-of-bias
assessments specific to the outcome for each trial included in the network. Third, we present results tables
for each intervention compared with the reference treatment (warfarin with a target INR range of 2–3).
Fourth, we present results tables for pairwise comparisons among licensed doses of the NOACs. For both
sets of results tables, posterior median ORs and 95% credible intervals from Bayesian fixed-effects analyses
are shown, although we refer to the latter as CIs for convenience. In these tables we present results
separately for any available direct evidence, for any indirect comparisons that can be made (excluding the
direct evidence) and for the NMA (which combines the direct and the indirect evidence). Comparisons
TABLE 21 List of distinct interventions examined by
included randomised trials in stroke prevention in AF
No. Intervention
1 Warfarin (INR 2–3)
2 Warfarin (INR 1.6–3)
3 Warfarin (INR 3–4 od)
4 Antiplatelet (< 150mg od)
5 Antiplatelet (≥ 150mg od)
6 Dabigatran (50 mg bd) + aspirin (81 mg bd)
7 Dabigatran (50 mg bd) + aspirin (325 mg bd)
8 Dabigatran (150mg bd) + aspirin (81 mg bd)
9 Dabigatran (150mg bd) + aspirin (325 mg bd)
10 Dabigatran (300mg bd) + aspirin (81 mg bd)
11 Dabigatran (300mg bd) + aspirin (325 mg bd)
12 Apixaban (2.5 mg bd)
13 Apixaban (5 mg bd)
14 Dabigatran (50 mg bd)
15 Dabigatran (110mg bd)
16 Dabigatran (150mg bd)
17 Dabigatran (300mg bd)
18 Betrixaban (40 mg od)
19 Betrixaban (60 mg od)
20 Betrixaban (80 mg od)
21 Edoxaban (30 mg od)
22 Edoxaban (45 mg od)
23 Edoxaban (60 mg od)
24 Edoxaban (30 mg bd)
25 Edoxaban (60 mg bd)
26 Rivaroxaban (15 mg od)
27 Rivaroxaban (20 mg od)
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from the NMA with a ratio between interval limits of > 9 were considered ‘imprecisely estimated’ and are
presented at the bottom of each table (note that calculation of indirect evidence was not undertaken for
imprecisely estimated comparisons). A summary of results across outcomes is provided at the end, in the
form of a ‘rankogram’, which illustrates the probability that each treatment is best, second best, and so
on, for each outcome. Last, forest plots of all contributing data, with ORs calculated using standard
frequentist methods, are included in Appendix 2.
Stroke or systemic embolism
Sixteen studies reported the number of stroke or SE events, and the other seven trials reported the
number of stroke events, so that the resulting network was based on data from all 23 trials, comparing
a total of 26 interventions (Figure 9). There were 3217 stroke or SE events. Twenty studies were included
in the main analysis, with the remaining three included only in sensitivity analyses. The thicker lines joining
interventions, which mainly correspond with comparisons between licensed doses of NOACs and warfarin
(INR 2–3) represent the larger (mainly Phase III) trials. Similarly, the larger green circles represent the
interventions to which the largest number of patients were randomised. Importantly, there were no
direct comparisons between different NOACs, although there were numerous comparisons between
different doses of the same NOAC in mainly Phase II trials, and some such comparisons in larger trials.
Therefore, comparisons between the effects of different NOACs need to be inferred from the network
(indirect evidence).
Table 24 shows risk-of-bias judgements for studies reporting stroke or SE. The studies were at mixed risks
of bias: there were concerns about lack of blinding of participants for most trials, and about lack of
allocation concealment and blinding of outcome assessment in some.
Table 25, which shows comparisons of licensed doses with warfarin (INR 2–3), suggests that both
low- and high-dose antiplatelet drugs increase the risk of stroke or SE compared with warfarin (INR 2–3).
Among NOACs, there was some evidence that apixaban [5 mg bd (bd)], dabigatran (150 mg bd),
edoxaban (60 mg od) and rivaroxaban (20 mg od) reduce the risk of stroke or SE compared with warfarin
(INR 2–3). Most other comparisons were imprecisely estimated. Comparisons among licensed doses of
1. Warfarin (INR 2–3)
3. Warfarin (INR 3–4)
4. Antiplatelet (< 150 mg od)
5. Antiplatelet (> 150 mg od)
6. Dabigatran (50 mg bd) + aspirin (81 mg bd)
7. Dabigatran (50 mg bd) + aspirin (325 mg bd)
8. Dabigatran (150 mg bd) + aspirin (81 mg bd)
9. Dabigatran (150 mg bd) + aspirin (325 mg bd)
11. Dabigatran (300 mg bd) + aspirin (325 mg bd)
14. Dabigatran (50 mg bd)15. Dabigatran (110 mg bd)
17. Dabigatran (300 mg bd) 12. Apixaban (2.5 mg bd)
13. Apixaban (5 mg bd)16. Dabigatran (150 mg bd)
18. Betrixaban (40 mg od)
19. Betrixaban (60 mg od)
21. Edoxaban (30 mg od)
22. Edoxaban (45 mg od)
24. Edoxaban (30 mg bd)
25. Edoxaban (60 mg bd)
[26. Rivaroxaban (15 mg od)]a
20. Betrixaban (80 mg od)
23. Edoxaban (60 mg od)
27. Rivaroxaban (20 mg od)
10. Dabigatran (300 mg bd) + aspirin (81 mg bd)
[2. Warfarin (INR 1.6–3)]a
FIGURE 9 Network plot for stroke or SE (stroke prevention in AF). a, Excluded interventions that were included in
sensitivity analyses.
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NOACs were almost all based on indirect evidence (Table 26). Among the comparisons that were not
classified as imprecisely estimated, there was some evidence that edoxaban (60 mg od) and rivaroxaban
(20 mg od) increase the risk of stroke or SE compared with dabigatran (150 mg bd).
Results from a supplementary analysis taking into account the differences in duration of follow-up within
and between trials, and the differences in the definition of event used across trials (e.g. total number of
events vs. first events only), are presented in Tables 27 and 28. They are very similar to those for ORs.
As a post hoc sensitivity analysis, we fitted a fixed-effects meta-regression model using the mean TTR for
warfarin patients (see Table 19) as a covariate and the mean log-odds ratio (log-OR) from each pairwise
comparison (with warfarin as the reference category) as the response variable. There was little evidence
of effect modification due to mean TTR (estimated coefficient 0.0021 with 95% CI −0.07 to 0.08 per
1% increase). The model fit indices were very similar with and without the covariate.
TABLE 24 Included trials and risk-of-bias assessment for stroke or SE (stroke prevention in AF)
Study Interventions compared SG AC BPP BOA IOD SR
ACTIVE W98 1, 4 + + – + + ?
AFASAK95 1, 4 + + – ? + ?
AFASAK II97 1, 5 + ? – + + ?
AF-ASA-VKA-CHINA135 2, 4 ? – – – + ?
AF-DABIG-VKA-JAPAN110 2, 15, 16 ? ? ? ? ? ?
AF-EDOX-VKA-ASIA115 1, 21, 23 + + – + + +
AF-EDOX-VKA-JAPAN118 2, 21, 22, 23 + ? – ? + +
AF-EDOX-VKA-MULTI108 1, 21, 23, 24, 25 + + – ? + +
AF-VKA-ASA-CHINA122 1, 5 + ? ? ? ? ?
ARISTOTLE107,114,119,124–127,130,132–134 1, 13 + ? + + + +
ARISTOTLE-J113 1, 12, 13 ? ? – + + +
AVERROES103,114,115,119 4, 13 + + + + + +
BAFTA103 1, 4 + + – + + +
Chinese ATAFS99 2, 5 ? ? ? ? + ?
ENGAGE AF-TIMI 48111,131 1, 21, 23 + + + + + +
EXPLORE-Xa126 1, 18, 19, 20 ? ? – + + +
J-ROCKET AF120 2, 26 + + + ? + +
PATAF98 1, 5 + + ? + ? +
PETRO102 1, 6, 7, 8, 9 10, 11, 14,
16, 17
? ? – ? + +
RE-LY104,109 1, 15, 16 + + – + + +
ROCKET AF106,112,123,129 1, 27 + + + ? + +
SPAF II96 1, 5 + ? – + + ?
WASPO101 1, 5 + + – – + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
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TABLE 25 Results for stroke or SE (stroke prevention in AF): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Antiplatelet (< 150mg od) 1.99 (1.28 to 3.15) 1.80 (1.22 to 2.65) 1.88 (1.40 to 2.51)
Antiplatelet (≥ 150mg od) 1.61 (1.25 to 2.07) – 1.61 (1.25 to 2.07)
Apixaban (5 mg bd) 0.79 (0.66 to 0.94) – 0.79 (0.66 to 0.94)
Dabigatran (110mg bd) 0.90 (0.74 to 1.10) – 0.90 (0.74 to 1.10)
Dabigatran (150mg bd) 0.65 (0.52 to 0.81) – 0.65 (0.52 to 0.81)
Edoxaban (30 mg od) 1.13 (0.97 to 1.32) – 1.13 (0.97 to 1.32)
Edoxaban (60 mg od) 0.86 (0.74 to 1.01) – 0.86 (0.74 to 1.01)
Rivaroxaban (20 mg od) 0.88 (0.74 to 1.03) – 0.88 (0.74 to 1.03)
Imprecisely estimated comparisons
Warfarin (INR 3–4) – 0.58 (0.17 to 1.62) 0.58 (0.17 to 1.62)
Dabigatran (50 mg bd) + aspirin (81 mg bd) 11.4 (0.63 to 402) – 11.4 (0.63 to 402)
Dabigatran (50 mg bd) + aspirin (325mg bd) 1.62 (0 to 94.3) – 1.62 (0 to 94.3)
Dabigatran (150mg bd) + aspirin (81 mg bd) 1.23 (0 to 75.3) – 1.23 (0 to 75.3)
Dabigatran (150mg bd) + aspirin (325mg bd) 1.35 (0 to 81.1) – 1.35 (0 to 81.1)
Dabigatran (300mg bd) + aspirin (81 mg bd) 1.32 (0 to 77.1) – 1.32 (0 to 77.1)
Dabigatran (300mg bd) + aspirin (325mg bd) 1.50 (0 to 89.1) – 1.50 (0 to 89.1)
Apixaban (2.5 mg bd) 0.11 (0 to 1.69) – 0.11 (0 to 1.69)
Dabigatran (50 mg bd) 3.90 (0.21 to 137) – 3.90 (0.21 to 137)
Dabigatran (300mg bd) 0.42 (0 to 24) – 0.42 (0 to 24)
Betrixaban (40 mg od) 1.01 (0 to 977) – 1.01 (0 to 977)
Betrixaban (60 mg od) 5.14 (0.17 to 3780) – 5.14 (0.17 to 3780)
Betrixaban (80 mg od) 5.18 (0.17 to 3920) – 5.18 (0.17 to 3920)
Edoxaban (45 mg od) 3.36 (0.18 to 121) – 3.36 (0.18 to 121)
Edoxaban (30 mg bd) 1.39 (0.27 to 5.61) – 1.39 (0.27 to 5.61)
Edoxaban (60 mg bd) 1.19 (0.15 to 5.56) – 1.19 (0.15 to 5.56)
TABLE 26 Results for stroke or SE (stroke prevention in AF): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) – 0.82 (0.62 to 1.08) 0.82 (0.62 to 1.08)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) – 1.09 (0.87 to 1.39) 1.09 (0.87 to 1.39)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) – 1.11 (0.87 to 1.41) 1.11 (0.87 to 1.41)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) – 1.33 (1.02 to 1.75) 1.33 (1.02 to 1.75)
Rivaroxaban (20mg od) vs. dabigatran (150mg bd) – 1.35 (1.03 to 1.78) 1.35 (1.03 to 1.78)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) – 1.01 (0.80 to 1.27) 1.01 (0.80 to 1.27)
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TABLE 26 Results for stroke or SE (stroke prevention in AF): NOACs (licensed doses only) (continued )
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 7.01 (0.50 to 3450) – 7.01 (0.47 to 3450)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd) – 5.77 (0.38 to 2850) 5.77 (0.38 to 2850)
Betrixaban (40 mg od) vs. apixaban (2.5 mg bd) – 12.1 (0.01 to 70300) 12.1 (0.01 to 70300)
Edoxaban (60 mg od) vs. apixaban (2.5 mg bd) – 7.67 (0.51 to 3730) 7.67 (0.51 to 3730)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) – 7.78 (0.52 to 3820) 7.78 (0.52 to 3820)
Betrixaban (40 mg od) vs. apixaban (5 mg bd) – 1.28 (0 to 1210) 1.28 (0 to 1210)
Betrixaban (40 mg od) vs. dabigatran (150mg bd) – 1.56 (0 to 1490) 1.56 (0 to 1490)
Edoxaban (60 mg od) vs. betrixaban (40mg od) – 0.85 (0 to 566) 0.85 (0 to 566)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od) – 0.86 (0 to 575) 0.86 (0 to 575)
TABLE 27 Results for stroke or SE (stroke prevention in AF): comparisons with warfarin (INR 2–3) – sensitivity
analysis using HRs instead of ORs
Comparisons with warfarin (INR 2–3) HR (95% CI)
Warfarin (INR 3–4) 0.58 (0.18 to 1.58)
Antiplatelet (< 150mg od) 1.82 (1.39 to 2.41)
Antiplatelet (≥ 150mg od) 1.58 (1.23 to 2.02)
Apixaban (5 mg bd) 0.79 (0.67 to 0.94)
Dabigatran (110 mg bd) 0.91 (0.75 to 1.11)
Dabigatran (150 mg bd) 0.66 (0.53 to 0.82)
Edoxaban (30 mg od) 1.13 (0.98 to 1.31)
Edoxaban (60 mg od) 0.87 (0.74 to 1.01)
Rivaroxaban (20 mg od) 0.88 (0.75 to 1.03)
Imprecisely estimated comparisons
Dabigatran (50 mg bd) + aspirin (81 mg bd) 11.0 (0.66 to 366)
Dabigatran (50 mg bd) + aspirin (325mg bd) 1.73 (0 to 94.9)
Dabigatran (150 mg bd) + aspirin (81 mg bd) 1.33 (0 to 63.4)
Dabigatran (150 mg bd) + aspirin (325 mg bd) 1.41 (0 to 72.6)
Dabigatran (300 mg bd) + aspirin (81 mg bd) 1.33 (0 to 75.9)
Dabigatran (300 mg bd) + aspirin (325 mg bd) 1.48 (0 to 86.3)
Apixaban (2.5 mg bd) 0.11 (0 to 1.66)
Dabigatran (50 mg bd) 3.96 (0.18 to 121)
Dabigatran (300 mg bd) 0.44 (0 to 23.9)
Betrixaban (40 mg od) 0.82 (0 to 313)
Betrixaban (60 mg od) 4.98 (0.17 to 1420)
Betrixaban (80 mg od) 4.87 (0.16 to 1340)
Edoxaban (45 mg od) 3.54 (0.19 to 159)
Edoxaban (30 mg bd) 1.40 (0.28 to 5.57)
Edoxaban (60 mg bd) 1.20 (0.15 to 5.39)
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Ischaemic stroke
Fourteen studies reported on 2228 ischaemic stroke events, leading to a connected network comparing a
total of 15 interventions (Figure 10). Twelve studies were included in the main analysis, with the remaining
two included only in sensitivity analyses. The studies were at mixed risks of bias (Table 29). There were
concerns about lack of blinding of participants for most trials, and about lack of allocation concealment
and blinding of outcome assessment in one trial (AF-ASA-VKA-CHINA,135 only included in sensitivity
analyses due to implementation of warfarin within non-standard INR range).
TABLE 28 Results for stroke or SE (stroke prevention in AF): NOACs (licensed doses only): sensitivity analysis using
HRs instead of ORs
Licensed NOACs only HR (95% CI)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) 0.83 (0.63 to 1.10)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) 1.10 (0.87 to 1.38)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) 1.11 (0.88 to 1.40)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) 1.32 (1.01 to 1.73)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) 1.34 (1.02 to 1.76)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) 1.01 (0.81 to 1.27)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 7.39 (0.48 to 1990)
Dabigatran (150mg bd) vs. apixaban (2.5 mg bd) 6.16 (0.38 to 1650)
Betrixaban (40 mg od) vs. apixaban (2.5 mg bd) 10.1 (0 to 22900)
Edoxaban (60 mg od) vs. apixaban (2.5 mg bd) 8.11 (0.51 to 2190)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) 8.29 (0.53 to 2230)
Betrixaban (40 mg od) vs. apixaban (5 mg bd) 1.05 (0 to 401)
Betrixaban (40 mg od) vs. dabigatran (150mg bd) 1.26 (0 to 466)
Edoxaban (60 mg od) vs. betrixaban (40mg od) 1.05 (0 to 2320)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od) 1.07 (0 to 2270)
1. Warfarin (INR 2–3)
[2. Warfarin (INR 1.6–3)]a
4. Antiplatelet (< 150 mg od)
5. Antiplatelet (> 150 mg od)
12. Apixaban (2.5 mg bd)
13. Apixaban (5 mg bd)
15. Dabigatran (110 mg bd)
16. Dabigatran (150 mg bd)18. Betrixaban (40 mg od)
19. Betrixaban (60 mg od)
20. Betrixaban (80 mg od)
21. Edoxaban (30 mg od)
23. Edoxaban (60 mg od)
[26. Rivaroxaban (15 mg od)]a
27. Rivaroxaban (20 mg od)
FIGURE 10 Network plot for ischaemic stroke (stroke prevention in AF). a, Excluded interventions that were
included in sensitivity analyses.
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Table 30, which shows comparisons of all interventions with warfarin (INR 2–3), suggests that both
low- and high-dose antiplatelets increase the risk of ischaemic stroke compared with warfarin (INR 2–3).
Among NOACs, there was some evidence that dabigatran (150 mg bd) reduces the risk of ischaemic stroke
compared with warfarin, whereas edoxaban (30 mg od) increases that risk. There was little evidence that
the risk of ischaemic stroke differed between licensed doses of NOACs (Table 31).
In a sensitivity analysis to take into account the differences in duration of follow-up, NMA results were as
presented in Tables 32 and 33, and show very similar results.
TABLE 29 Included trials and risk-of-bias assessment for ischaemic stroke (stroke prevention in AF)
Study Interventions compared SG AC BPP BOA IOD SR
ACTIVE W98 1, 4 + + – + + ?
AFASAK II97 1, 5 + ? – + + ?
AF-ASA-VKA-CHINA135 2, 4 ? – – – + ?
AF-VKA-ASA-CHINA122 1, 5 + ? ? ? ? ?
ARISTOTLE107,114,119,124–127,130,132–134 1, 13 + ? + + + +
ARISTOTLE-J113 1, 12, 13 ? ? – + + +
AVERROES103,114,115,119 4, 13 + + + + + +
ENGAGE AF-TIMI 48111,131 1, 21, 23 + + + + + +
EXPLORE-Xa126 1, 18, 19, 20 ? ? – + + +
J-ROCKET AF120 2, 26 + + + ? + +
PATAF98 1, 5 + + ? + ? +
RE-LY104,109 1, 15, 16 + + – + + +
ROCKET AF106,112,123,129 1, 27 + + + ? + +
SPAF II96 1, 5 + ? – + + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 30 Results for ischaemic stroke (stroke prevention in AF): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Antiplatelet (< 150mg od) – 2.52 (1.62 to 3.99) 2.52 (1.62 to 3.99)
Antiplatelet (≥ 150mg od) 2.00 (1.51 to 2.67) – 2.00 (1.51 to 2.67)
Apixaban (5 mg bd) 0.92 (0.74 to 1.14) – 0.92 (0.74 to 1.14)
Dabigatran (110 mg bd) 1.14 (0.90 to 1.44) – 1.14 (0.90 to 1.44)
Dabigatran (150 mg bd) 0.76 (0.58 to 0.98) – 0.76 (0.58 to 0.98)
Edoxaban (30 mg od) 1.44 (1.21 to 1.71) – 1.44 (1.21 to 1.71)
Edoxaban (60 mg od) 1.01 (0.84 to 1.21) – 1.01 (0.84 to 1.21)
Rivaroxaban (20 mg od) 0.93 (0.74 to 1.16) – 0.93 (0.74 to 1.16)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) 0.26 (0 to 5.89) – 0.26 (0 to 5.89)
Betrixaban (40 mg od) 1.05 (0 to 751) – 1.05 (0 to 751)
Betrixaban (60 mg od) 5.41 (0.18 to 3290) – 5.41 (0.18 to 3290)
Betrixaban (80 mg od) 5.43 (0.17 to 3230) – 5.43 (0.17 to 3230)
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TABLE 31 Results for ischaemic stroke (stroke prevention in AF): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) – 0.83 (0.59 to 1.16) 0.83 (0.59 to 1.16)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) – 1.10 (0.83 to 1.46) 1.10 (0.83 to 1.46)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) – 1.01 (0.74 to 1.38) 1.01 (0.74 to 1.38)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) – 1.33 (0.97 to 1.83) 1.33 (0.97 to 1.83)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) – 1.22 (0.87 to 1.73) 1.22 (0.87 to 1.73)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) – 0.92 (0.69 to 1.23) 0.92 (0.69 to 1.23)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 3.47 (0.16 to 1730) – 3.47 (0.16 to 1730)
Dabigatran (150mg bd) vs. apixaban (2.5 mg bd) – 2.88 (0.13 to 1430) 2.88 (0.13 to 1430)
Betrixaban (40 mg od) vs. apixaban (2.5 mg bd) – 5.02 (0 to 25,800) 5.02 (0 to 25,800)
Edoxaban (60 mg od) vs. apixaban (2.5 mg bd) – 3.82 (0.17 to 1920) 3.82 (0.17 to 1920)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) – 3.52 (0.16 to 1740) 3.52 (0.16 to 1740)
Betrixaban (40 mg od) vs. apixaban (5 mg bd) – 1.15 (0 to 847) 1.15 (0 to 847)
Betrixaban (40 mg od) vs. dabigatran (150mg bd) – 1.39 (0 to 1010) 1.39 (0 to 1010)
Edoxaban (60 mg od) vs. betrixaban (40mg od) – 0.96 (0 to 633) 0.96 (0 to 633)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od) – 0.88 (0 to 578) 0.88 (0 to 578)
TABLE 32 Results for ischaemic stroke (stroke prevention in AF): comparisons with warfarin (INR 2–3) – sensitivity
analysis using HRs instead of ORs
Comparisons with warfarin (INR 2–3) HR (95% CI)
Antiplatelet (< 150mg od) 2.46 (1.59 to 3.92)
Antiplatelet (≥ 150mg od) 1.94 (1.47 to 2.59)
Apixaban (5 mg bd) 0.92 (0.75 to 1.15)
Dabigatran (110mg bd) 1.12 (0.89 to 1.42)
Dabigatran (150mg bd) 0.76 (0.59 to 0.99)
Edoxaban (30 mg od) 1.43 (1.22 to 1.69)
Edoxaban (60 mg od) 1.01 (0.84 to 1.20)
Rivaroxaban (20 mg od) 0.92 (0.74 to 1.15)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) 0.26 (0 to 5.77)
Betrixaban (40 mg od) 0.90 (0 to 233)
Betrixaban (60 mg od) 4.72 (0.18 to 787)
Betrixaban (80 mg od) 4.67 (0.18 to 838)
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Myocardial infarction
A total of 15 studies reported 1334 MI events, leading to a network of 16 interventions (Figure 11).
Thirteen studies were included in the main analysis, with the other two included only in sensitivity analyses.
The studies were at mixed risks of bias (Table 34). There were concerns about lack of blinding of participants
for most trials, and about lack of allocation concealment and blinding of outcome assessment in some.
TABLE 33 Results for ischaemic stroke (stroke prevention in AF): NOACs (licensed doses only) – sensitivity analysis
using HRs instead of ORs
Licensed NOACs only HR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) 0.83 (0.59 to 1.15)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) 1.09 (0.83 to 1.44)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) 1.00 (0.73 to 1.35)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) 1.32 (0.96 to 1.80)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) 1.21 (0.86 to 1.70)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) 0.92 (0.69 to 1.22)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 3.54 (0.16 to 1750)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd) 2.90 (0.13 to 1480)
Betrixaban (40 mg od) vs. apixaban (2.5 mg bd) 4.05 (0 to 9940)
Edoxaban (60 mg od) vs. apixaban (2.5 mg bd) 3.81 (0.18 to 1960)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) 3.50 (0.16 to 1780)
Betrixaban (40 mg od) vs. apixaban (5 mg bd) 0.96 (0 to 241)
Betrixaban (40 mg od) vs. dabigatran (150mg bd) 1.18 (0 to 307)
Edoxaban (60 mg od) vs. betrixaban (40mg od) 1.11 (0 to 723)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od) 1.03 (0 to 660)
1. Warfarin (INR 2–3)
[2. Warfarin (INR 1.6–3)]a
4. Antiplatelet (< 150 mg od)
5. Antiplatelet (> 150 mg od)
[12. Apixaban (2.5 mg bd)]
13. Apixaban (5 mg bd)
15. Dabigatran (110 mg bd)
16. Dabigatran (150 mg bd)
[18. Betrixaban (40 mg od)][19. Betrixaban (60 mg od)]
[20. Betrixaban (80 mg od)]
21. Edoxaban (30 mg od)
23. Edoxaban (60 mg od)
24. Edoxaban (30 mg bd)
25. Edoxaban (60 mg bd)
[26. Rivaroxaban (15 mg od)]a
27. Rivaroxaban (20 mg od)
FIGURE 11 Network plot for MI (stroke prevention in AF). a, Excluded interventions that were included in
sensitivity analyses.
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Table 35 shows weak evidence that dabigatran (110 mg bd), dabigatran (150 mg bd) and edoxaban
(30 mg od) increase the risk of MI compared with warfarin (INR 2–3), and weak evidence that rivaroxaban
(20 mg od) decreases risk of MI compared with warfarin (INR 2–3). None of the interventions was superior
or inferior to warfarin (INR 2–3). The pairwise comparisons of licensed NOACs, presented in Table 36,
show weak evidence that dabigatran (150 mg bd) increases the risk of MI compared with apixaban
(5 mg bd), and evidence that rivaroxaban (20 mg od) reduces the risk of MI compared with dabigatran
(150 mg bd). Results were similar in a sensitivity analysis, taking into account the differences in duration
of follow-up within and between trials, and the differences in the definition of event used across trials
(e.g. total number of events vs. first events only) (Tables 37 and 38).
TABLE 34 Included trials and risk-of-bias assessment for MI (stroke prevention in AF)
Study Interventions compared SG AC BPP BOA IOD SR
ACTIVE W98 1, 4 + + – + + ?
AFASAK II97 1, 5 + ? – + + ?
AF-ASA-VKA-CHINA135 2, 4 ? – – – + ?
AF-EDOX-VKA-MULTI108 1, 21, 23, 24, 25 + + – ? + +
ARISTOTLE107,114,119,124–127,130,132–134 1, 13 + ? + + + +
ARISTOTLE-J113 1, 12, 13 ? ? – + + +
AVERROES103,114,115,119 4, 13 + + + + + +
BAFTA103 1, 4 + + – + + +
ENGAGE AF-TIMI 48111,131 1, 21, 23 + + + + + +
EXPLORE-Xa126 1, 18, 19, 20 ? ? – + + +
J-ROCKET AF120 2, 26 + + + ? + +
PATAF98 1, 5 + + ? + ? +
RE-LY104,109 1, 15, 16 + + – + + +
ROCKET AF106,112,123,129 1, 27 + + + ? + +
SPAF II96 1, 5 + ? – – + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 35 Results for MI (stroke prevention in AF): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Antiplatelet (< 150mg od) 1.00 (0.47 to 2.10) 1.02 (0.55 to 1.87) 1.01 (0.64 to 1.61)
Antiplatelet (≥ 150mg od) 1.38 (0.94 to 2.03) – 1.38 (0.94 to 2.03)
Apixaban (5 mg bd) 0.87 (0.66 to 1.15) – 0.87 (0.66 to 1.15)
Dabigatran (110mg bd) 1.32 (0.97 to 1.79) – 1.32 (0.97 to 1.79)
Dabigatran (150mg bd) 1.29 (0.96 to 1.75) – 1.29 (0.96 to 1.75)
Edoxaban (30 mg od) 1.22 (0.97 to 1.53) – 1.22 (0.97 to 1.53)
Edoxaban (60 mg od) 0.96 (0.75 to 1.22) – 0.96 (0.75 to 1.22)
Rivaroxaban (20 mg od) 0.80 (0.61 to 1.04) – 0.80 (0.61 to 1.04)
Imprecisely estimated comparisons
Edoxaban (30 mg bd) 0.71 (0.06 to 3.97) – 0.71 (0.06 to 3.97)
Edoxaban (60 mg bd) 0.19 (0 to 2.60) – 0.19 (0 to 2.60)
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TABLE 36 Results for MI (stroke prevention in AF): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) – 1.48 (0.98 to 2.22) 1.48 (0.98 to 2.22)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) – 1.10 (0.76 to 1.58) 1.10 (0.76 to 1.58)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) – 0.92 (0.63 to 1.34) 0.92 (0.63 to 1.34)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) – 0.74 (0.50 to 1.09) 0.74 (0.50 to 1.09)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) – 0.62 (0.41 to 0.93) 0.62 (0.41 to 0.93)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) – 0.84 (0.59 to 1.20) 0.84 (0.59 to 1.20)
TABLE 37 Results for MI (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity analysis using
HRs instead of ORs
Comparisons with warfarin (INR 2–3) HR (95% CI)
Antiplatelet (< 150mg od) 1.01 (0.64 to 1.61)
Antiplatelet (≥ 150mg od) 1.36 (0.93 to 2.01)
Apixaban (5 mg bd) 0.88 (0.67 to 1.16)
Dabigatran (110 mg bd) 1.31 (0.96 to 1.77)
Dabigatran (150 mg bd) 1.30 (0.96 to 1.77)
Edoxaban (30 mg od) 1.22 (0.97 to 1.52)
Edoxaban (60 mg od) 0.96 (0.76 to 1.22)
Rivaroxaban (20 mg od) 0.80 (0.62 to 1.04)
Imprecisely estimated comparisons
Edoxaban (30 mg bd) 0.97 (0.09 to 5.40)
Edoxaban (60 mg bd) 0.13 (0 to 1.81)
TABLE 38 Results for MI (stroke prevention in AF): NOACs (licensed doses only): sensitivity analysis using HRs
instead of ORs
Licensed NOACs only HR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) 1.48 (0.98 to 2.23)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) 1.09 (0.76 to 1.57)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) 0.91 (0.62 to 1.33)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) 0.74 (0.49 to 1.08)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) 0.62 (0.41 to 0.92)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) 0.84 (0.59 to 1.19)
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Major bleeding
Eighteen studies reported 4314 major bleeding events, leading to a network of 24 interventions
(Figure 12). Seventeen studies were included in the main analysis, with the remaining study included only
in sensitivity analyses. These studies were at mixed risks of bias (Table 39). There were concerns about lack
of blinding of participants for most trials, and about lack of allocation concealment and blinding of
outcome assessment in some.
1. Warfarin (INR 2–3)
[2. Warfarin (INR 1.6–3)]a
4. Antiplatelet (< 150 mg od)
5. Antiplatelet (> 150 mg od)
6. Dabigatran (50 mg bd) + aspirin (81 mg bd)
7. Dabigatran (50 mg bd) + aspirin (325 mg bd)
8. Dabigatran (150 mg bd) + aspirin (81 mg bd)
9. Dabigatran (150 mg bd) + aspirin (325 mg bd)
10. Dabigatran (300 mg bd) + aspirin (81 mg bd)
11. Dabigatran (300 mg bd) + aspirin (325 mg bd)
12. Apixaban (2.5 mg bd)
13. Apixaban (5 mg bd)
14. Dabigatran (50 mg bd)15. Dabigatran (110 mg bd)
16. Dabigatran (150 mg bd)
17. Dabigatran (300 mg bd)
18. Betrixaban (40 mg od)
19. Betrixaban (60 mg od)
20. Betrixaban (80 mg od)
21. Edoxaban (30 mg od)
22. Edoxaban (45 mg od)
23. Edoxaban (60 mg od)
24. Edoxaban (30 mg bd)
25. Edoxaban (60 mg bd)
27. Rivaroxaban (20 mg od)
FIGURE 12 Network plot for major bleeding (stroke prevention in AF). a, Excluded interventions that were
included in sensitivity analyses.
TABLE 39 Included trials and risk-of-bias assessment for major bleeding (stroke prevention in AF)
Study Interventions compared SC AC BPP BOA IOD SR
ACTIVE W98 1, 4 + + – + + ?
AFASAK II97 1, 5 + ? – + + ?
AF-ASA-VKA-CHINA135 2, 4 ? – – – + ?
AF-DABIG-VKA-JAPAN110 2, 15, 16 ? ? ? ? ? ?
AF-EDOX-VKA-ASIA115 1, 21, 23 + + – + + +
AF-EDOX-VKA-JAPAN118 2, 21, 22, 23 + ? – ? + +
AF-EDOX-VKA-MULTI108 1, 21, 23, 24, 25 + + – + + +
AF-VKA-ASA-CHINA122 1, 5 + ? – ? ? ?
ARISTOTLE107,114,119,124–127,130,132–134 1, 13 + ? + + ? +
ARISTOTLE-J113 1, 12, 13 ? ? – + + +
AVERROES103,114,115,119 4, 13 + + + + + +
BAFTA103 1, 4 + + – + + +
ENGAGE AF-TIMI 48111,131 1, 21, 23 + + + + + +
EXPLORE-Xa126 1, 18, 19, 20 ? ? – + + +
PETRO102 1, 6, 7, 8, 9, 10, 11, 14, 16, 17 ? ? – + + +
RE-LY104,109 1, 15, 16 + + – + + +
ROCKET AF106,112,123,129 1, 27 + + + ? + +
WASPO101 1, 5 + + – – + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
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There was weak evidence that antiplatelet therapy (< 150 mg od) reduced major bleeding compared with
warfarin (INR 2–3). There was evidence that apixaban (5 mg bd), dabigatran (110 mg bd), edoxaban
(30 mg od) and edoxaban (60 mg od) reduced major bleeding risk compared with warfarin (INR 2–3)
(Table 40). Comparisons among licensed doses of NOACs, presented in Table 41, suggest that dabigatran
(150 mg bd) increases risk of major bleeding compared with apixaban (5 mg bd), whereas rivaroxaban
(20 mg od) increases risk of major bleeding compared with apixaban (5 mg bd) and edoxaban (60 mg od).
In a sensitivity analysis to take into account the differences in duration of follow-up, NMA results were as
presented in Tables 42 and 43, and show very similar results. Another sensitivity analysis involved fitting a
fixed-effects meta-regression model using the mean TTR for warfarin patients (see Table 19) as a covariate
and the mean log-OR from each pairwise comparison (with warfarin as the reference category) as the
response variable. We found no evidence of an effect modification according to mean TTR (estimated
coefficient 0.04 with 95% CI −0.03 to 0.12 per 1% increase). The model fit indices yielded almost
identical values for the models with and without the covariate.
TABLE 40 Results for major bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Antiplatelet (< 150mg od) 1.00 (0.56 to 1.77) 0.63 (0.40 to 0.98) 0.75 (0.52 to 1.06)
Antiplatelet (≥ 150mg od) 1.07 (0.82 to 1.42) – 1.07 (0.82 to 1.42)
Apixaban (5 mg bd) 0.71 (0.61 to 0.81) – 0.71 (0.61 to 0.81)
Dabigatran (110 mg bd) 0.80 (0.69 to 0.93) – 0.80 (0.69 to 0.93)
Dabigatran (150 mg bd) 0.94 (0.81 to 1.08) – 0.94 (0.81 to 1.08)
Edoxaban (30 mg od) 0.46 (0.40 to 0.54) – 0.46 (0.40 to 0.54)
Edoxaban (60 mg od) 0.78 (0.69 to 0.90) – 0.78 (0.69 to 0.90)
Rivaroxaban (20 mg od) 1.03 (0.89 to 1.18) – 1.03 (0.89 to 1.18)
Imprecisely estimated comparisons
Dabigatran (50 mg bd) + aspirin (81 mg bd) 2.54 (0 to 146) – 2.54 (0 to 146)
Dabigatran (50 mg bd) + aspirin (325mg bd) 1.99 (0 to 112) – 1.99 (0 to 112)
Dabigatran (150 mg bd) + aspirin (81 mg bd) 1.52 (0 to 82.0) – 1.52 (0 to 82.0)
Dabigatran (150 mg bd) + aspirin (325 mg bd) 1.63 (0 to 90.4) – 1.63 (0 to 90.4)
Dabigatran (300 mg bd) + aspirin (81 mg bd) 8.38 (0.45 to 266) – 8.38 (0.45 to 266)
Dabigatran (300 mg bd) + aspirin (325 mg bd) 27.6 (3.05 to 749) – 27.6 (3.05 to 749)
Apixaban (2.5 mg bd) 0.24 (0 to 5.48) – 0.24 (0 to 5.48)
Dabigatran (50 mg bd) 0.89 (0 to 52.4) – 0.89 (0 to 52.4)
Dabigatran (300 mg bd) 0.50 (0 to 28.6) – 0.50 (0 to 28.6)
Betrixaban (40 mg od) 0.04 (0 to 0.58) – 0.04 (0 to 0.58)
Betrixaban (60 mg od) 0.04 (0 to 0.59) – 0.04 (0 to 0.59)
Betrixaban (80 mg od) 0.60 (0.13 to 2.40) – 0.60 (0.13 to 2.40)
Edoxaban (45 mg od) 1.45 (0.27 to 8.29) – 1.45 (0.27 to 8.29)
Edoxaban (30 mg bd) 3.68 (0.94 to 16.9) – 3.68 (0.94 to 16.9)
Edoxaban (60 mg bd) 6.01 (1.64 to 27.0) – 6.01 (1.64 to 27.0)
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TABLE 41 Results for major bleeding (stroke prevention in AF): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) – 1.33 (1.09 to 1.62) 1.33 (1.09 to 1.62)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) – 1.11 (0.92 to 1.35) 1.11 (0.92 to 1.35)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) – 1.45 (1.19 to 1.78) 1.45 (1.19 to 1.78)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) – 0.84 (0.69 to 1.02) 0.84 (0.69 to 1.02)
Rivaroxaban (20mg od) vs. dabigatran (150mg bd) – 1.10 (0.90 to 1.34) 1.10 (0.90 to 1.34)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) – 1.31 (1.07 to 1.59) 1.31 (1.07 to 1.59)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 2.93 (0.13 to 1320) – 2.93 (0.13 to 1320)
Dabigatran (150mg bd) vs. apixaban (2.5 mg bd) – 3.88 (0.17 to 1740) 3.88 (0.17 to 1740)
Betrixaban (40 mg od) vs. apixaban (2.5 mg bd) – 0.17 (0 to 124) 0.17 (0 to 124)
Edoxaban (60 mg od) vs. apixaban (2.5 mg bd) – 3.25 (0.14 to 1460) 3.25 (0.14 to 1460)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) – 4.27 (0.19 to 1910) 4.27 (0.19 to 1910)
Betrixaban (40 mg od) vs. apixaban (5 mg bd) – 0.06 (0 to 0.84) 0.06 (0 to 0.84)
Betrixaban (40 mg od) vs. dabigatran (150mg bd) – 0.04 (0 to 0.63) 0.04 (0 to 0.63)
Edoxaban (60 mg od) vs. betrixaban (40mg od) – 18.7 (1.34 to 9160) 18.7 (1.34 to 9160)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od) – 24.5 (1.76 to 12,000) 24.5 (1.76 to 12,000)
TABLE 42 Results for major bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity
analysis using HRs instead of ORs
Comparisons with warfarin (INR 2–3) HR (95% CI)
Antiplatelet (< 150mg od) 0.76 (0.53 to 1.08)
Antiplatelet (≥ 150mg od) 1.07 (0.82 to 1.41)
Apixaban (5 mg bd) 0.72 (0.62 to 0.82)
Dabigatran (110mg bd) 0.81 (0.70 to 0.93)
Dabigatran (150mg bd) 0.94 (0.82 to 1.07)
Edoxaban (30 mg od) 0.47 (0.41 to 0.55)
Edoxaban (60 mg od) 0.79 (0.70 to 0.90)
Rivaroxaban (20 mg od) 1.02 (0.89 to 1.18)
Imprecisely estimated comparisons
Dabigatran (50 mg bd) + aspirin (81 mg bd) 2.58 (0 to 151)
Dabigatran (50 mg bd) + aspirin (325mg bd) 2.07 (0 to 114)
Dabigatran (150mg bd) + aspirin (81 mg bd) 1.51 (0 to 78.3)
Dabigatran (150mg bd) + aspirin (325mg bd) 1.62 (0 to 94.8)
Dabigatran (300mg bd) + aspirin (81 mg bd) 8.36 (0.50 to 281)
Dabigatran (300mg bd) + aspirin (325mg bd) 26.3 (3.08 to 697)
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Clinically relevant bleeding
Twelve studies reported 9556 CRB events, leading to a network of 23 interventions (Figure 13). Eleven
studies were included in the main analysis, with the remaining study included only in sensitivity analyses.
These studies were at mixed risks of bias (Table 44), the concerns being due to lack of blinding of
participants for most trials.
TABLE 42 Results for major bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity
analysis using HRs instead of ORs (continued )
Comparisons with warfarin (INR 2–3) HR (95% CI)
Apixaban (2.5 mg bd) 0.25 (0 to 5.49)
Dabigatran (50 mg bd) 0.93 (0 to 53.2)
Dabigatran (300 mg bd) 0.52 (0 to 29.7)
Betrixaban (40 mg od) 0.05 (0 to 0.55)
Betrixaban (60 mg od) 0.04 (0 to 0.60)
Betrixaban (80 mg od) 0.60 (0.13 to 2.38)
Edoxaban (45 mg od) 1.49 (0.28 to 8.31)
Edoxaban (30 mg bd) 3.64 (0.95 to 17.1)
Edoxaban (60 mg bd) 6.00 (1.66 to 27.5)
TABLE 43 Results for major bleeding (stroke prevention in AF): NOACs (licensed doses only) – sensitivity analysis
using HRs instead of ORs
Licensed NOACs only HR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) 1.31 (1.08 to 1.59)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) 1.10 (0.91 to 1.33)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) 1.43 (1.17 to 1.75)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) 0.84 (0.70 to 1.02)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) 1.09 (0.90 to 1.33)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) 1.30 (1.07 to 1.57)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 2.89 (0.13 to 519)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd) 3.80 (0.17 to 683)
Betrixaban (40 mg od) vs. apixaban (2.5 mg bd) 0.18 (0 to 61.9)
Edoxaban (60 mg od) vs. apixaban (2.5 mg bd) 3.19 (0.14 to 579)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) 4.13 (0.19 to 751)
Betrixaban (40 mg od) vs. apixaban (5 mg bd) 0.06 (0 to 0.77)
Betrixaban (40 mg od) vs. dabigatran (150mg bd) 0.05 (0 to 0.58)
Edoxaban (60 mg od) vs. betrixaban (40mg od) 17.1 (1.44 to 2160)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od) 22.1 (1.89 to 2770)
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Results presented in Table 45 suggest that antiplatelet therapy (< 150 mg od) reduces CRB compared
with warfarin (INR 2–3). Note that the licensed dose for of antiplatelet therapy for AF is ≥ 150 mg od: no
studies provided data for that dose for CRB. Among NOACs, there was evidence that apixaban (5 mg bd),
edoxaban (30 mg od) and edoxaban (60 mg od) reduce CRB compared with warfarin (INR 2–3). However,
edoxaban (30 mg bd) and edoxaban (60 mg bd) increased CRB compared with warfarin (INR 2–3). Among
licensed NOACs (Table 46), there was evidence that edoxaban (60 mg od) and rivaroxaban (20 mg od)
increase CRB compared with apixaban (5 mg bd) and that rivaroxaban (20 mg od) increased CRB
compared with edoxaban (60 mg od).
Supplementary NMAs of HRs rather than ORs show very similar results (Tables 47 and 48).
1. Warfarin (INR 2–3)
[2. Warfarin (INR 1.6–3)]a
4. Antiplatelet (< 150 mg od)
6. Dabigatran (50 mg bd) + aspirin (81 mg bd)
7. Dabigatran (50 mg bd) + aspirin (325 mg bd)
8. Dabigatran (150 mg bd) + aspirin (81 mg bd)
9. Dabigatran (150 mg bd) + aspirin (325 mg bd)
10. Dabigatran (300 mg bd) + aspirin (81 mg bd)
11. Dabigatran (300 mg bd) + aspirin (325 mg bd)
12. Apixaban (2.5 mg bd)
13. Apixaban (5 mg bd)
14. Dabigatran (50 mg bd)
15. Dabigatran (110 mg bd)16. Dabigatran (150 mg bd)
17. Dabigatran (300 mg bd)
18. Betrixaban (40 mg od)
19. Betrixaban (60 mg od)
20. Betrixaban (80 mg od)
21. Edoxaban (30 mg od)
22. Edoxaban (45 mg od)
23. Edoxaban (60 mg od)
24. Edoxaban (30 mg bd)
25. Edoxaban (60 mg bd)
[26. Rivaroxaban (15 mg od)]a
27. Rivaroxaban (20 mg od)
FIGURE 13 Network plot for CRB (stroke prevention in AF). a, Excluded interventions that were included in
sensitivity analyses.
TABLE 44 Included trials and risk-of-bias assessment for CRB (stroke prevention in AF)
Study Interventions compared SG AC BPP BOA IOD SR
AF-DABIG-VKA-JAPAN110 2, 15, 16 ? ? ? ? ? ?
AF-EDOX-VKA-ASIA115 1, 21, 23 + + – + + +
AF-EDOX-VKA-JAPAN118 2, 21, 22, 23 + ? – ? + +
AF-EDOX-VKA-MULTI108 1, 21, 23, 24, 25 + + – + + +
ARISTOTLE107,114,119,124–127,130,132–134 1, 13 + ? + + ? +
ARISTOTLE-J113 1, 12, 13 ? ? – + + +
AVERROES103,114,115,119 4, 13 + + + + + +
ENGAGE AF-TIMI 48111,131 1, 21, 23 + + + + + +
EXPLORE-Xa126 1, 18, 19, 20 ? ? – + + +
J-ROCKET AF120 2, 26 + + + ? + +
PETRO102 1, 6, 7, 8, 9, 10, 11, 14, 16, 17 ? ? – + + +
ROCKET AF106,112,123,129 1, 27 + + + ? + +
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
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TABLE 45 Results for CRB (stroke prevention in AF): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Antiplatelet (< 150mg od) – 0.59 (0.45 to 0.77) 0.59 (0.45 to 0.77)
Apixaban (5 mg bd) 0.67 (0.60 to 0.75) – 0.67 (0.60 to 0.75)
Edoxaban (30 mg od) 0.59 (0.54 to 0.64) – 0.59 (0.54 to 0.64)
Edoxaban (45 mg od) 1.09 (0.37 to 3.04) – 1.09 (0.37 to 3.04)
Edoxaban (60 mg od) 0.84 (0.77 to 0.90) – 0.84 (0.77 to 0.90)
Edoxaban (30 mg bd) 1.97 (1.04 to 3.67) – 1.97 (1.04 to 3.67)
Edoxaban (60 mg bd) 2.76 (1.46 to 5.17) – 2.76 (1.46 to 5.17)
Rivaroxaban (20 mg od) 1.03 (0.95 to 1.11) – 1.03 (0.95 to 1.11)
Imprecisely estimated comparisons
Dabigatran (50 mg bd) + aspirin (81 mg bd) 0.91 (0.07 to 5.87) – 0.91 (0.07 to 5.87)
Dabigatran (50 mg bd) + aspirin (325mg bd) 0.70 (0.06 to 4.50) – 0.70 (0.06 to 4.50)
Dabigatran (150 mg bd) + aspirin (81 mg bd) 0.99 (0.15 to 4.99) – 0.99 (0.15 to 4.99)
Dabigatran (150 mg bd) + aspirin (325 mg bd) 1.08 (0.17 to 5.58) – 1.08 (0.17 to 5.58)
Dabigatran (300 mg bd) + aspirin (81 mg bd) 2.76 (0.71 to 11.7) – 2.76 (0.71 to 11.7)
Dabigatran (300 mg bd) + aspirin (325 mg bd) 3.98 (1.10 to 16.3) – 3.98 (1.10 to 16.3)
Apixaban (2.5 mg bd) 0.25 (0.01 to 1.88) – 0.25 (0.01 to 1.88)
Dabigatran (50 mg bd) 0.06 (0 to 0.91) – 0.06 (0 to 0.91)
Dabigatran (110 mg bd) 0.67 (0.06 to 5.47) – 0.67 (0.06 to 5.47)
Dabigatran (150 mg bd) 1.56 (0.50 to 5.74) – 1.56 (0.50 to 5.74)
Dabigatran (300 mg bd) 0.96 (0.27 to 3.78) – 0.96 (0.27 to 3.78)
Betrixaban (40 mg od) 0.10 (0 to 0.67) – 0.10 (0 to 0.67)
Betrixaban (60 mg od) 0.69 (0.19 to 2.27) – 0.69 (0.19 to 2.27)
Betrixaban (80 mg od) 0.69 (0.19 to 2.22) – 0.69 (0.19 to 2.22)
TABLE 46 Results for CRB (stroke prevention in AF): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) – 1.24 (1.09 to 1.42) 1.24 (1.09 to 1.42)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) – 1.53 (1.33 to 1.75) 1.53 (1.33 to 1.75)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) – 1.23 (1.10 to 1.37) 1.23 (1.10 to 1.37)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 2.69 (0.35 to 79.9) – 2.69 (0.35 to 79.9)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd) – 6.59 (0.60 to 220) 6.59 (0.60 to 220)
Betrixaban (40 mg od) vs. apixaban (2.5 mg bd) – 0.39 (0.01 to 18.7) 0.39 (0.01 to 18.7)
Edoxaban (60 mg od) vs. apixaban (2.5 mg bd) – 3.35 (0.44 to 99.4) 3.35 (0.44 to 99.4)
continued
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TABLE 47 Results for CRB (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity analysis using
HRs instead of ORs
Comparisons with warfarin (INR 2–3) HR (95% CI)
Antiplatelet (< 150mg od) 0.59 (0.46 to 0.76)
Apixaban (5 mg bd) 0.67 (0.60 to 0.75)
Edoxaban (30 mg od) 0.59 (0.55 to 0.64)
Edoxaban (45 mg od) 1.09 (0.37 to 3.01)
Edoxaban (60 mg od) 0.83 (0.77 to 0.90)
Edoxaban (30 mg bd) 1.98 (1.05 to 3.71)
Edoxaban (60 mg bd) 2.78 (1.46 to 5.20)
Rivaroxaban (20 mg od) 1.03 (0.95 to 1.11)
Imprecisely estimated comparisons
Dabigatran (50 mg bd) + aspirin (81 mg bd) 0.93 (0.07 to 5.79)
Dabigatran (50 mg bd) + aspirin (325mg bd) 0.72 (0.06 to 4.54)
Dabigatran (150mg bd) + aspirin (81 mg bd) 1.01 (0.15 to 4.99)
Dabigatran (150mg bd) + aspirin (325mg bd) 1.10 (0.17 to 5.53)
Dabigatran (300mg bd) + aspirin (81 mg bd) 2.84 (0.72 to 11.4)
Dabigatran (300mg bd) + aspirin (325mg bd) 4.06 (1.10 to 16.1)
Apixaban (2.5 mg bd) 0.25 (0.01 to 1.87)
Dabigatran (50 mg bd) 0.06 (0 to 0.89)
Dabigatran (110mg bd) 0.68 (0.06 to 5.65)
Dabigatran (150mg bd) 1.60 (0.51 to 5.72)
Dabigatran (300mg bd) 0.99 (0.28 to 3.71)
Betrixaban (40 mg od) 0.10 (0 to 0.66)
Betrixaban (60 mg od) 0.69 (0.19 to 2.26)
Betrixaban (80 mg od) 0.69 (0.19 to 2.30)
TABLE 46 Results for CRB (stroke prevention in AF): NOACs (licensed doses only) (continued )
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) – 4.12 (0.54 to 123) 4.12 (0.54 to 123)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) – 2.32 (0.74 to 8.63) 2.32 (0.74 to 8.63)
Betrixaban (40 mg od) vs. apixaban (5 mg bd) – 0.15 (0 to 1.00) 0.15 (0 to 1.00)
Betrixaban (40 mg od) vs. dabigatran (150mg bd) – 0.06 (0 to 0.60) 0.06 (0 to 0.60)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) – 0.54 (0.14 to 1.68) 0.54 (0.14 to 1.68)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) – 0.66 (0.18 to 2.07) 0.66 (0.18 to 2.07)
Edoxaban (60 mg od) vs. betrixaban (40mg od) – 8.50 (1.25 to 251) 8.50 (1.25 to 251)
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Intracranial bleeding
Eight studies reported a total of 757 intracranial bleeds, leading to a network of 10 interventions
(Figure 14). Seven trials were included in the primary analysis, with the remaining study included only in
sensitivity analyses. These studies were at mixed risks of bias (Table 49), the concerns being due to lack of
blinding of participants and, in one study, lack of blinding of outcome assessment.
There was strong evidence that apixaban (5 mg bd), dabigatran (110 mg bd), dabigatran (150 mg bd),
edoxaban (30 mg od), edoxaban (60 mg od) and rivaroxaban (20 mg od) reduced risk of intracranial
bleeding compared with warfarin (INR 2–3) (Table 50). For each of these NOAC doses except rivaroxaban
TABLE 48 Results for CRB (stroke prevention in AF): NOACs (licensed doses only): sensitivity analysis using HRs
instead of ORs
Licensed NOACs only HR (95% CI)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) 1.24 (1.09 to 1.42)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) 1.53 (1.33 to 1.74)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) 1.23 (1.10 to 1.37)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 2.67 (0.36 to 81.0)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd) 6.69 (0.61 to 235)
Betrixaban (40 mg od) vs. apixaban (2.5 mg bd) 0.39 (0.01 to 19.0)
Edoxaban (60 mg od) vs. apixaban (2.5 mg bd) 3.32 (0.44 to 100)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) 4.08 (0.55 to 124)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) 2.38 (0.75 to 8.56)
Betrixaban (40 mg od) vs. apixaban (5 mg bd) 0.15 (0.01 to 0.99)
Betrixaban (40 mg od) vs. dabigatran (150mg bd) 0.06 (0 to 0.58)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) 0.52 (0.15 to 1.64)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) 0.64 (0.18 to 2.03)
Edoxaban (60 mg od) vs. betrixaban (40mg od) 8.45 (1.25 to 247)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od) 10.4 (1.55 to 305)
1. Warfarin (INR 2–3)
[2. Warfarin (INR 1.6–3)]a
4. Antiplatelet (< 150 mg od)
5. Antiplatelet (> 150 mg od)
13. Apixaban (5 mg bd)
15. Dabigatran (110 mg bd)16. Dabigatran (150 mg bd)
21. Edoxaban (30 mg od)
23. Edoxaban (60 mg od)
[26. Rivaroxaban (15 mg od)]a
27. Rivaroxaban (20 mg od)
FIGURE 14 Network plot for intracranial bleeding (stroke prevention in AF). a, Excluded interventions that were
included in sensitivity analyses.
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(20 mg od), the estimated reduction in risk was > 50%. There was weak evidence that risk of intracranial
bleeding was increased for rivaroxaban (20 mg od) compared with apixaban (5 mg bd), dabigatran
(150 mg bd) and edoxaban (60 mg od) (Table 51). Analysing HRs rather than ORs led to similar results
(Tables 52 and 53).
TABLE 49 Included trials and risk-of-bias assessment for intracranial bleeding (stroke prevention in AF)
Study Interventions compared SG AC BPP BOA IOD SR
AFASAK II97 1, 5 + ? – + + ?
ARISTOTLE107,114,119,124–127,130,132–134 1, 13 + ? + + ? +
AVERROES103,114,115,119 4, 13 + + + + + +
ENGAGE AF-TIMI 48111,131 1, 21, 23 + + + + + +
RE-LY104,109 1, 15, 16 + + – + + +
J-ROCKET AF120 2, 26 + + + ? + +
ROCKET AF106,112,123,129 1, 27 + + + ? + +
SPAF II96 1, 5 + ? – – + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 50 Results for intracranial bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Antiplatelet (< 150mg od) – 0.50 (0.21 to 1.23) 0.50 (0.21 to 1.23)
Antiplatelet (≥ 150mg od) 0.39 (0.13 to 0.98) – 0.39 (0.13 to 0.98)
Apixaban (5 mg bd) 0.42 (0.30 to 0.58) – 0.42 (0.30 to 0.58)
Dabigatran (110mg bd) 0.31 (0.19 to 0.47) – 0.31 (0.19 to 0.47)
Dabigatran (150mg bd) 0.40 (0.27 to 0.59) – 0.40 (0.27 to 0.59)
Edoxaban (30 mg od) 0.31 (0.21 to 0.43) – 0.31 (0.21 to 0.43)
Edoxaban (60 mg od) 0.46 (0.33 to 0.62) – 0.46 (0.33 to 0.62)
Rivaroxaban (20 mg od) 0.65 (0.46 to 0.91) – 0.65 (0.46 to 0.91)
TABLE 51 Results for intracranial bleeding (stroke prevention in AF): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) – 0.96 (0.58 to 1.60) 0.96 (0.58 to 1.60)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) – 1.09 (0.69 to 1.70) 1.09 (0.69 to 1.70)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) – 1.55 (0.97 to 2.49) 1.55 (0.97 to 2.49)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) – 1.13 (0.69 to 1.87) 1.13 (0.69 to 1.87)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) – 1.61 (0.96 to 2.72) 1.61 (0.96 to 2.72)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) – 1.43 (0.90 to 2.26) 1.43 (0.90 to 2.26)
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All-cause mortality
Eighteen studies reported 6479 all-cause mortality events, leading to a network of fifteen interventions
(Figure 15). Fifteen studies were included in the primary analysis, with the remaining three studies included
in sensitivity analyses. These studies were at mixed risks of bias (Table 54). There were concerns about lack
of blinding of participants for most trials, and about lack of allocation concealment and blinding of
outcome assessment in some studies.
Table 55 suggests that all NOAC doses with comparisons that were not imprecisely estimated [apixaban
(5 mg bd), dabigatran (110 mg bd), dabigatran (150 mg bd), edoxaban (30 mg od), edoxaban (60 mg od)
TABLE 52 Results for intracranial bleeding (stroke prevention in AF): comparisons with warfarin (INR 2–3) –
sensitivity analysis using HRs instead of ORs
Comparisons with warfarin (INR 2–3) HR (95% CI)
Antiplatelet (< 150mg od) 0.50 (0.21 to 1.20)
Antiplatelet (≥ 150mg od) 0.39 (0.14 to 0.97)
Apixaban (5 mg bd) 0.42 (0.30 to 0.58)
Dabigatran (110 mg bd) 0.31 (0.19 to 0.46)
Dabigatran (150 mg bd) 0.41 (0.27 to 0.59)
Edoxaban (30 mg od) 0.31 (0.21 to 0.43)
Edoxaban (60 mg od) 0.46 (0.34 to 0.62)
Rivaroxaban (20 mg od) 0.66 (0.47 to 0.91)
TABLE 53 Results for intracranial bleeding (stroke prevention in AF): NOACs (licensed doses only) – sensitivity
analysis using HRs instead of ORs
Licensed NOACs only HR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) 0.97 (0.57 to 1.58)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) 1.09 (0.70 to 1.71)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) 1.55 (0.97 to 2.48)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) 1.13 (0.70 to 1.87)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) 1.62 (0.96 to 2.74)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) 1.43 (0.91 to 2.25)
1. Warfarin (INR 2–3)
[2. Warfarin (INR 1.6–3)a
3. Warfarin (INR 3–4)
4. Antiplatelet (< 150 mg od)
5. Antiplatelet (> 150 mg od)
[12. Apixaban (2.5 mg bd)]
13. Apixaban (5 mg bd)
15. Dabigatran (110 mg bd)
16. Dabigatran (150 mg bd)
18. Betrixaban (40 mg od)
19. Betrixaban (60 mg od)
20. Betrixaban (80 mg od)
21. Edoxaban (30 mg od)
23. Edoxaban (60 mg od)
[26. Rivaroxaban (15 mg od)]a
27. Rivaroxaban (20 mg od)
FIGURE 15 Network plot for all-cause mortality (stroke prevention in AF). a, Excluded interventions that were
included in sensitivity analyses.
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TABLE 54 Included trials and risk-of-bias assessment for all-cause mortality (stroke prevention in AF)
Study Interventions compared SG AC BPP BOA IOD SR
ACTIVE W98 1, 4 + + – + + ?
AFASAK95 1, 4 + + – ? + ?
AFASAK II97 1, 5 + ? – + + ?
AF-ASA-VKA-CHINA135 2, 4 ? – – – + ?
AF-VKA-ASA-CHINA122 1, 5 + ? – ? ? ?
ARISTOTLE107,114,119,124–127,130,132–134 1, 13 + ? + + + +
ARISTOTLE-J113 1, 12, 13 ? ? – + + +
AVERROES103,114,115,119 4, 13 + + + + + +
BAFTA103 1, 4 + + – + + +
Chinese ATAFS99 2, 5 ? ? ? ? + ?
ENGAGE AF-TIMI 48111,131 1, 21, 23 + + + + + +
EXPLORE-Xa126 1, 18, 19, 20 ? ? – + + +
J-ROCKET AF120 2, 26 + + + ? + +
PATAF98 1, 5 + + ? + ? +
RE-LY104,109 1, 15, 16 + + – + + +
ROCKET AF106,112,123,129 1, 27 + + + + + +
SPAF II96 1, 5 + ? – – + ?
WASPO101 1, 5 + + – – + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 55 Results for all-cause mortality (stroke prevention in AF): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Antiplatelet (< 150mg od) 1.02 (0.75 to 1.38) 1.13 (0.87 to 1.47) 1.08 (0.88 to 1.33)
Antiplatelet (≥ 150mg od) 1.04 (0.87 to 1.25) – 1.04 (0.87 to 1.25)
Apixaban (5 mg bd) 0.88 (0.79 to 0.98) – 0.88 (0.79 to 0.98)
Dabigatran (110mg bd) 0.91 (0.80 to 1.04) – 0.91 (0.80 to 1.04)
Dabigatran (150mg bd) 0.88 (0.77 to 1.01) – 0.88 (0.77 to 1.01)
Edoxaban (30 mg od) 0.86 (0.78 to 0.96) – 0.86 (0.78 to 0.96)
Edoxaban (60 mg od) 0.91 (0.82 to 1.01) – 0.91 (0.82 to 1.01)
Rivaroxaban (20 mg od) 0.83 (0.69 to 1.00) – 0.83 (0.69 to 1.00)
Imprecisely estimated comparisons
Warfarin (INR 3–4) – 0.24 (0.05 to 0.81) 0.24 (0.05 to 0.81)
Betrixaban (40 mg od) 0.99 (0.06 to 15.5) – 0.99 (0.06 to 15.5)
Betrixaban (60 mg od) 0.19 (0 to 5.70) – 0.19 (0 to 5.70)
Betrixaban (80 mg od) 0.19 (0 to 5.88) – 0.19 (0 to 5.88)
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and rivaroxaban (20 mg od)] were associated with a reduced risk of all-cause mortality compared with
warfarin (INR 2–3). There was little evidence that the risk of all-cause mortality differed between licensed
doses of NOACs (Table 56). Analysing HRs rather than ORs produced similar results (Tables 57 and 58).
Summary of results and ranking of interventions
Results from NMAs suggest that a number of the licensed doses of NOACs reduce the risk of the
outcomes stroke or SE, major bleeding, CRB, intracranial bleeding and all-cause mortality compared with
the reference treatment, warfarin (INR 2–3). There was evidence that edoxaban increased CRB compared
TABLE 56 Results for all-cause mortality (stroke prevention in AF): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) – 1.00 (0.84 to 1.19) 1.00 (0.84 to 1.19)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) – 1.03 (0.89 to 1.20) 1.03 (0.89 to 1.20)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) – 0.94 (0.76 to 1.17) 0.94 (0.76 to 1.17)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) – 1.03 (0.87 to 1.22) 1.03 (0.87 to 1.22)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) – 0.94 (0.74 to 1.18) 0.94 (0.74 to 1.18)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) – 0.91 (0.73 to 1.13) 0.91 (0.73 to 1.13)
Imprecisely estimated comparisons
Betrixaban (40 mg od) vs. apixaban (5 mg bd) – 1.13 (0.07 to 17.7) 1.13 (0.07 to 17.7)
Betrixaban (40 mg od) vs. dabigatran (150mg bd) – 1.12 (0.07 to 17.6) 1.12 (0.07 to 17.6)
Edoxaban (60 mg od) vs. betrixaban (40mg od) – 0.92 (0.06 to 14.1) 0.92 (0.06 to 14.1)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od) – 0.83 (0.05 to 13.0) 0.83 (0.05 to 13.0)
TABLE 57 Results for all-cause mortality (stroke prevention in AF): comparisons with warfarin (INR 2–3): sensitivity
analysis using HRs instead of ORs
Comparisons with warfarin (INR 2–3) HR (95% CI)
Antiplatelet (< 150mg od) 1.07 (0.88 to 1.30)
Antiplatelet (≥ 150mg od) 1.04 (0.87 to 1.24)
Apixaban (5 mg bd) 0.89 (0.80 to 0.99)
Dabigatran (110 mg bd) 0.91 (0.80 to 1.04)
Dabigatran (150 mg bd) 0.89 (0.78 to 1.01)
Edoxaban (30 mg od) 0.88 (0.80 to 0.97)
Edoxaban (60 mg od) 0.92 (0.83 to 1.02)
Rivaroxaban (20 mg od) 0.83 (0.69 to 1.00)
Imprecisely estimated comparisons
Warfarin (INR 3–4) 0.24 (0.05 to 0.81)
Betrixaban (40 mg od) 1.01 (0.06 to 15.7)
Betrixaban (60 mg od) a
Betrixaban (80 mg od) a
a Not enough information to compute this pairwise comparison.
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with warfarin (INR 2–3). Risk of MI appeared higher for some NOACs than for warfarin (INR 2–3).
Comparisons for some licensed NOAC doses, such as apixaban (2.5 mg bd) and betrixaban (40 mg od),
could not be estimated precisely.
Several studies conducted in Asian countries considered a lower INR range for warfarin interventions in
elderly patients. We excluded these from the main analysis but included them (merged with the reference
treatment, warfarin INR 2–3) as a second sensitivity analysis for each outcome. This allowed us to
incorporate a non-licensed dose of rivaroxaban (15 mg od) that was included in the J-ROCKET AF
trial,106,112,123,129 showing a reduced risk of stroke compared with warfarin (INR 1.6–3), with a median
OR of 0.49 (95% CI 0.24 to 0.99). Apart from this, results (available on request) showed the same trends
as described above.
The dose range for the antiplatelet arm in the AVERROES trial105,116,117,121 was unusually wide (81–324 mg
od). Because some of the patients had received a dose that was below standard, it was decided to merge
it with the antiplatelets (< 150 mg od) node for the primary analysis. In a further sensitivity analysis for
each outcome, this trial105,116,117,121 was excluded. Again, the results (available from the authors) were not
substantially different from those presented above. With regard to model appraisal, we did not identify any
instance of lack of convergence among the Markov chains, poor model fit or inconsistency. Few of the
comparisons were replicated across studies; when there were multiple estimates we did not find evidence
of statistical heterogeneity.
Rankograms plotting the probability that each of the licensed interventions for AF is ranked best, second
best, and so on, for preventing each outcome, are displayed in Figure 16. The non-NOAC interventions
(warfarin, INR 2–3) and antiplatelet therapy (aspirin/clopidogrel, ≥ 150 mg od) were ranked worst for
stroke or SE and ischaemic stroke and were not among the best three interventions for any of the
outcomes. Warfarin (INR 2–3) was also ranked as the worst intervention to reduce the risk of intracranial
bleeding. Among the licensed NOACs, apixaban (5 mg bd) was ranked as among the best interventions for
major bleeding, intracranial bleeding, all-cause mortality, stroke or SE, ischaemic stroke and MI. Edoxaban
(60 mg od) was ranked second for major bleeding and all-cause mortality. Except for all-cause mortality
and MI, outcomes for rivaroxaban (20 mg od) were ranked less highly than those for apixaban (5 mg bd),
dabigatran (150 mg bd) and edoxaban (60 mg od).
TABLE 58 Results for all-cause mortality (stroke prevention in AF): NOACs (licensed doses only): sensitivity analysis
using HRs instead of ORs
Licensed NOACs only HR (95% CI)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) 1.00 (0.85 to 1.18)
Edoxaban (60 mg od) vs. apixaban (5 mg bd) 1.03 (0.90 to 1.20)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) 0.94 (0.76 to 1.15)
Edoxaban (60 mg od) vs. dabigatran (150mg bd) 1.03 (0.88 to 1.22)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) 0.93 (0.75 to 1.17)
Rivaroxaban (20 mg od) vs. edoxaban (60mg od) 0.90 (0.73 to 1.11)
Imprecisely estimated comparisons
Betrixaban (40 mg od) vs. apixaban (5 mg bd) 1.13 (0.07 to 17.6)
Betrixaban (40 mg od) vs. dabigatran (150mg bd) 1.14 (0.07 to 17.6)
Edoxaban (60 mg od) vs. betrixaban (40mg od) 0.91 (0.06 to 14.7)
Rivaroxaban (20 mg od) vs. betrixaban (40 mg od) 0.82 (0.05 to 13.2)
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FIGURE 16 Rankogram for licensed interventions examined in stroke prevention in AF. IC, intracranial. (continued )
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Chapter 6 Cost-effectiveness results (1) stroke
prevention in atrial fibrillation
Introduction
In this chapter we present the results of the CEA for first-line treatments for patients with AF. The decision
question, population, interventions, outcomes, model structure, cost and utility inputs have been previously
described in Chapter 4. In this chapter we begin by describing clinical effectiveness inputs to the model,
including relative treatment effects based on the evidence identified in the systematic review (see Chapter 5),
other state-transition probabilities based on evidence from longitudinal studies, transition probabilities on
the reference treatment (warfarin) on which relative effects are applied, mortality, and treatment switching
parameters. We then present the results from our cost-effectiveness model, together with sensitivity analyses
to key assumptions made. Results are presented from Bayesian analyses with 95% credible intervals,
although we refer to these as confidence intervals for convenience.
Model inputs
Relative treatment efficacy
The NMA results presented in Chapter 5 consider each outcome separately and independently. However,
for our economic model we need to consider the different outcomes jointly. We use a competing risks
NMA model to jointly estimate the log-HRs for the different possible events needed in the economic
model. The analysis uses data from the RCTs identified in our systematic review; however, results were
reported in three different ways in the RCTs: number of first events, number of patients experiencing at
least one event, and total number of events. The analysis needs to account for the way the results are
reported. For example, if a patient’s first event was CRB, they cannot also have ischaemic stroke as their
first event. Joint estimation leads to correlated estimates that need to be reflected in the economic model.
In Appendix 7 we provide details on the competing risks NMA, and HRs relative to warfarin (INR 2–3)
are given in Table 59. Note that it was possible to include studies with zero events in this analysis. Lower
doses for apixaban and dabigatran are included, as they were evaluated in a sensitivity analysis. MI and
all-cause mortality are common to both the NMA of Chapter 5 and the competing risks analysis, and their
estimated HRs are similar. The competing risks model is restricted to ischaemic stroke and excludes both
haemorrhagic stroke and SE, and so it is not precisely comparable to the stroke outcome of Chapter 5.
Patients may discontinue NOACs and warfarin, and so we also need estimates of the relative efficacy of
warfarin compared with no treatment. Warfarin has been the established standard of care for patients with
AF for at least 20 years and we therefore relied on previous meta-analyses to estimate the relative effect of
warfarin compared with no treatment. We chose the meta-analysis by Hart et al.,136 as it is the most recent
and comprehensive. Hart et al.136 identified six studies137–142 comparing warfarin to either ‘control’ or placebo,
from which we extracted evidence on stroke, bleeds, ICH, death, SE and TIA, summarised in Table 60. The
Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) study139 used patients on no treatment but
with the option of aspirin as the control; this study was omitted in a sensitivity analysis. The INR ranges
for warfarin were frequently outside the 2–3 range chosen for our NMA. Under clinical advice, we did not
exclude on the basis of INR range; however, we note that the results from the only study with INR 2–3
[the Canadian Atrial Fibrillation Anticoagulation (CAFA) study140] were in line with the results from the other
studies, providing support for the inclusion of all six studies. For each outcome, we separately conducted a
random-effects meta-analysis using a Poisson likelihood, as described in Appendix 7, but without accounting
for competing risks as a result of insufficient detail available from the trials. Random-effects models were
used, as we expected some heterogeneity because of differences in INR range; however, on the basis of the
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Deviance Information Criteria23 there was not any evidence in favour of or against a fixed-effects model, and
results were similar. We excluded studies with no events in any arm and added a continuity correction of 0.5
to arms with zero events if other arms in the trial had an event. The results of this analysis are presented in
Table 60. Owing to insufficient evidence for ICH, we assumed the treatment effect was the same as that for
bleeds, as these are clinically similar AEs. However, the estimated HRs for NOACs presented in Table 59 do
not support this assumption of similarity. We therefore conducted a sensitivity analysis that sets the HR of ‘no
treatment’ against warfarin for ICH to 1.
Effect of past health events and states on future event rates
The primary source of evidence for the effect of prior events on stroke, SE, TIA and bleed risk is a study
in 182,678 Swedish patients by Friberg et al.143 Reported HRs (Table 61) are for male patients aged
< 65 years. We make the assumption that these HRs can be generalised to a population of 70-year-olds
with 60 : 40 split of males–females.
We also estimated the effect of previous events on mortality. Andersen and Olsen144 provided estimates
of the HRs for the effect of prior stroke or MI in patients with AF. These are reproduced in Table 62,
and normal distributions representing uncertainty in the estimated log-HRs are summarised in Table 63.
No evidence was available for the effect of prior bleeds or ICH on mortality. We made the assumption that
bleeds and ICH would have the same effect as stroke on future risk of death. We conducted a sensitivity
analysis in which we assumed bleeds and ICH to have no effect on future risk of death. The effects of prior
events on future risks are assumed to be multiplicative, so a history of both stroke and MI will give a HR
for mortality of 1/0.758 × 1/0.972 = 1.03 × 1.32 = 1.36.
TABLE 62 Reported HRs for effect of no previous events on mortality in patients with AF (Andersen and Olsen144)
Event history Effect on mortality (HR with 95% CI)
No MI 0.972 (0.687 to 1.378)
No stroke 0.758 (0.565 to 1.017)
TABLE 61 Hazard ratios of effect of history of previous events on future events (Friberg et al.143)
Risk factor
Future ischaemic
stroke (95% CI) Future TIA/SE (95% CI)
Future intracranial
bleeding (ICH)
(95% CI)
Future bleed
(95% CI)
Ischaemic stroke 4.00 (3.78 to 4.22) 3.61 (3.44 to 3.78) 1.64 (1.39 to 1.94) 1.39 (1.27 to 1.52)
ICH 1.78 (1.56 to 2.03) 1.82 (1.62 to 2.04) 10.2 (8.59 to 12.2) 2.95 (2.57 to 3.39)
Any significant bleeding
(major bleed)
1.32 (1.21 to 1.44) 1.36 (1.26 to 1.46) 3.54 (3.02 to 4.17) 3.32 (3.06 to 3.60)
MI 1.24 (1.17 to 1.33) 1.29 (1.22 to 1.36) 0.94 (0.78 to 1.12) 1.24 (1.15 to 1.35)
TABLE 63 Estimated log-HR (standard error) for the effect of previous events on future events
Risk factor Future ischaemic stroke Future TIA/SE Future ICH Future bleed Future death
Stroke 1.39 (0.03) 1.28 (0.02) 0.49 (0.09) 0.33 (0.05) 0.28 (0.15)
ICH 0.58 (0.07) 0.60 (0.06) 2.32 (0.09) 1.08 (0.07) 0.28 (0.15)
Bleed 0.28 (0.04) 0.31 (0.04) 1.26 (0.08) 1.20 (0.04) 0.28 (0.15)
MI 0.22 (0.03) 0.25 (0.03) –0.06 (0.09) 0.22 (0.04) 0.03 (0.18)
Normal distributions are used to reflect uncertainty in the estimated log-HRs.
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We reflect uncertainty in the mean estimates by assuming normal distributions for the logs of these HRs
(see Table 63).
Transition probabilities with usual care (warfarin)
We estimated transition probabilities for the usual care (first-line warfarin) treatment strategy using the
trials identified in our systematic review that included a warfarin arm. The model includes the following
correlated outcomes: (1) ischaemic stroke; (2) ICH; (3) other clinically relevant bleed; (4) TIA; (5) SE; (6) MI;
and (7) death.
Previous economic models have used evidence from single trials, such as RE-LY104,109 in Kansal et al.,42 to
estimate the risk of events with warfarin treatment. However, this disregards the evidence available from
other published trials. QRISK2145 provides long-term information on MI in patients with AF. However, this
estimates only a joint risk of stroke and MI, rather than for each event individually. Another possible source
of evidence for the rate of MI in AF is Soliman et al.,5 but this provides a HR for MI only in AF relative to
the non-AF population, which is not what is needed for our model. Therefore, we used evidence from the
warfarin arms in the trials that were identified in our systematic review because it is based on patients with
AF, has similar demographics to our target population and represented the risk for patients specifically on
warfarin treatment.
We estimated the hazard of events on warfarin, taking into account the competing risks nature of the
outcomes and the format in which results are reported, in the same way as we did for the relative effects
(see Appendix 7). Details of the model are given in Appendix 8 and estimated hazards are shown in
Table 64.
Mortality
The risk of death in a 70-year-old AF population on warfarin with a 60 : 40 male–female split is obtained
from the usual care hazard described above. This is adjusted for each age group aged > 70 years using
the 2011–13 life tables for England and Wales,146 which provide the probability that an individual from the
general population and at a specific age will die within 1 year. The hazard of death (λ) in each age group
is: λ = –log(1 – (0.6 × PDmale + 0.4 × PDfemale)), where PDmale and PDfemale are the annual probability of death
for males and females, respectively. We use the ratio of this hazard for each age group to the hazard for
70-year-olds to adjust the usual care (warfarin) hazard of death for each age group in the model.
Treatment switching probabilities
Post-event treatment switching rules and probabilities were based on clinical opinion. Clinicians advised
‘definite’ switching in the event of ICH for all treatments and also in the event of MI for dabigatran; a
‘chance’ of switching in the case of CRB and ischaemic stroke; and a ‘slight chance’ of switching following
TABLE 64 Mean and 95% CI for hazard of events, estimated from warfarin arms of RCTs identified in our
systematic review
Event Mean hazard (95% CI)
MI 0.0079 (0.0064 to 0.01)
Ischaemic stroke 0.012 (0.01 to 0.013)
Death (all causes) 0.038 (0.028 to 0.052)
TIA 0.025 (0.006 to 0.089)
CRB 0.066 (0.031 to 0.13)
SE 0.017 (0.0059 to 0.041)
ICH 0.0094 (0.0057 to 0.017)
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SE or TIA, due to concern about treatment failure. We assume a probability of switching of 0.3 for ‘chance’
and 0.1 for ‘slight chance’, but reflect our high degree of uncertainty in these switching probabilities with beta
distributions, summarised in Table 65. We subject these assumed switching probabilities to sensitivity analysis.
Sensitivity analyses
We explored the robustness of our results to various assumptions through sensitivity analyses.
Warfarin monitoring costs In this sensitivity analysis, we assumed that there is no drug or monitoring cost
associated with warfarin. This explores whether or not warfarin is cost-effective, even in the absence of
monitoring costs. We also considered running sensitivity analyses to fixed warfarin monitoring costs at £70.75
and £106.13 per 3-month cycle (mean and upper limit of assumed distribution for warfarin monitoring costs).
Note, however, it is worth doing these sensitivity analyses only if warfarin is found to be cost-effective with no
monitoring costs (otherwise it clearly will not be cost-effective for positive monitoring costs).
Mortality risk following bleeds/ICH In this sensitivity analysis we assumed that there is no effect of previous
bleeds and ICH on future risk of death. This was motivated by the lack of evidence on this effect and the
assumption of the base case that the effect of previous bleeds and ICH on mortality risk was the same as
that of stroke.
Probabilities of treatment switching We ran three sensitivity analyses to the assumptions around treatment
switching: in the first, we assumed that no patients switch treatment following ischaemic stroke, bleed,
SE or TIA; in the second, we assumed that all patients switch after a ischaemic stroke or bleed, but none
switches after a SE or TIA; and, in the third, we assumed that all patients switch treatments following
these four events. In all sensitivity analyses, it is assumed that all patients discontinue treatment following
an ICH, and patients on dabigatran switch to warfarin following a MI, as in the base case.
Excluding ‘no treatment control’ study from meta-analysis of warfarin vs. placebo trials The meta-analysis
estimating the effect of warfarin compared with ‘no treatment’ included five studies comparing warfarin
with placebo and one study, BAATAF,139 comparing warfarin with ‘control’. This control arm consisted of
patients on no treatment who had the option of starting aspirin. When the BAATAF study139 is removed
from the meta-analysis comparing warfarin with no treatment (Table 66), the effect of no treatment,
compared with warfarin, on bleeds and deaths is decreased, although the uncertainty is greatly increased.
This sensitivity analysis uses a meta-analysis that excludes the BAATAF study.139
Sensitivity to initial age of cohort We ran two sensitivity analyses to the initial age of the cohort, ages 60
and 80 years, respectively, rather than 70 years in the base case. These ages are roughly one SD from the
mean age of patients included in the trials.
TABLE 65 Treatment switching rules and assumed probabilities
Event leading
to switching
Probability of switching,
mean (95% CI)
Distribution for
probability of switching Rule for switching
ICH 1.00 – Always switch to no treatment
MI 1.00 – If on dabigatran, switch to
warfarin; no switching otherwise
CRB 0.30 (0.00 to 1.00) Beta(0.3,0.7) Switch to next line treatment
Ischaemic stroke 0.30 (0.00 to 1.00) Beta(0.3,0.7) Switch to next line treatment
TIA 0.10 (0.00 to 1.00) Beta(0.1,0.9) Switch to next line treatment
SE 0.10 (0.00 to 1.00) Beta(0.1,0.9) Switch to next line treatment
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Apixaban 2.5 mg bd and dabigatran 110 mg bd This sensitivity analysis uses different doses (apixaban
2.5 mg bd and dabigatran 110 mg bd) than those used in the base-case analysis (5 mg and 150 mg,
respectively). This is motivated by the licensing of these drugs by the European Medicines Agency, which
specifies that the lower dose should be prescribed for older patients (> 75 years).
No difference in hazard of ICH between ‘no treatment’ and warfarin As our meta-analysis comparing
warfarin and ‘no treatment’ had insufficient evidence to estimate the HR for ICH, we assumed it to be the
same as for bleeds. In this sensitivity analysis we assumed that the hazard of ICH is the same in warfarin
patients and ‘no treatment’ patients.
Results of the cost-effectiveness model: atrial fibrillation
Results of base-case analyses
We ran 10,000 iterations of our model for 120 cycles (each iteration representing a simulation from the
joint distribution of our model parameters). We estimated expected total costs and QALYs for each
first-line anticoagulation strategy (Table 67). Expected incremental costs and QALYs for each first-line
strategy compared with warfarin (INR 2–3) are also given.
Dabigatran (150 mg bd) has the lowest expected total cost (£23,064), followed by apixaban (5 mg bd),
edoxaban (60 mg od), warfarin (INR 2–3) and rivaroxaban (20 mg od) which has the highest expected total
cost (£24,841). Expected costs are similar across all treatments, and there is a high degree of uncertainty
around the costs for all treatments.
Apixaban (5 mg bd) has the highest expected QALYs (5.49), followed by rivaroxaban (20 mg od) (5.45),
dabigatran (150 mg bd) and edoxaban (60 mg od) (both with 5.41), and warfarin (INR 2–3) (5.16).
The NOACs have similar expected QALYs, all of which are higher than for warfarin (INR 2–3). There is
a high degree of uncertainty around the QALY estimates.
At a willingness-to-pay threshold of £20,000 per QALY, all NOACs have positive expected incremental net
benefit (INB) compared with warfarin (INR 2–3), suggesting that they may be a cost-effective use of NHS
resources. Apixaban (5 mg bd) has the highest expected INB (£7533), followed by dabigatran (150 mg bd;
£6365), rivaroxaban (20 mg od; £5279) and edoxaban (60 mg od; £5212). Apixaban (5 mg bd) is the only
NOAC for which the 95% CI around INB is positive, suggesting that apixaban is cost-effective compared
with warfarin. These conclusions also hold at the higher threshold of £30,000.
TABLE 66 Hazard ratio from meta-analysis of no treatment/placebo vs. warfarin, including and excluding
BAATAF study139
Event
Mean HR
Including BAATAF139 (SD) Excluding BAATAF139 (SD)
Strokes 0.359 (0.213) 0.391 (0.246)
Bleeds 2.3 (3.53) 3.23 (18.9)
Deaths 0.849 (3) 1.37 (13.6)
TIA 4.86 (369) 4.86 (369)
SE 3.18 (63) 3.18 (63)
ICH NA NA
NA, not available.
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The key drivers of the results are the lower rates of MI, ICH and other CRB for apixaban (see Table 59),
as found in the NMA of Chapter 5. The high cost and disutility of ICH has a great influence on total costs,
total QALYs and net benefits. Apixaban also has a low rate of TIA, but the uncertainty surrounding the
other treatment effects, and the minimal impact of this event, means that it is not a driving factor in the
results. Dabigatran also has a low rate of ICH but the higher rate of MI offsets this benefit.
The uncertainty in the estimated total costs and QALYs is illustrated in the cost-effectiveness plane
(Figure 17). The CEAC (Figure 18) plots the probability of each intervention having the highest net benefit
against a willingness to pay per QALY. It indicates that apixaban (5 mg bd) has the highest probability of
being the most cost-effective first-line therapy for AF – close to 60% in the £20,000–30,000 range of
willingness-to-pay thresholds generally considered by NICE. Dabigatran (150 mg bd) has the highest
probability of being cost-effective if the willingness-to-pay threshold is very low, as a result of having the
lowest expected total costs. Warfarin (INR 2–3) and edoxaban (60 mg od) are unlikely to be cost-effective.
These results are further highlighted by the CEAF (Figure 19), which plots the probability of having the
highest net benefit against a willingness to pay per QALY for the intervention with the highest expected
net benefit. Apixaban (5 mg bd) has the highest expected net benefit at a wide range of willingness-to-pay
thresholds. Apixaban (5 mg bd) is likely to be the most cost-effective first-line therapy for AF, under the
assumptions of our model.
The per-person EVPI (Figure 20) estimated was £608 at a willingness-to-pay of £20,000 and £938 at £30,000.
Assuming an incidence of 1%,147 and that there are 500,000 70-year-olds in England and Wales,148 there are
5000 new cases of AF every year. Extrapolating the EVPI over 10 years for 5000 patients, and discounting at
3.5%, gives a population EVPI of approximately £26M at a willingness to pay of £20,000, and £40M at
£30,000. This suggests that there may be value in conducting further research to inform this decision.
Expected value of partial perfect information (Figure 21) was estimated for various groups of parameters
using the SAVI tool.76 Note that this is an approximation only, with large standard errors. We therefore
interpret the results cautiously but as indicative of the relative impact of the different groups of parameters
on decision uncertainty. The optimal decision is most sensitive to the HRs for the NOACs, suggesting that
a head-to-head trial may be of value. The decision is also sensitive to costs, the effect of past events on
future HRs and probabilities of treatment switching. The decision is less sensitive to utilities and event rates
on the reference treatment (warfarin). The estimated EVPPI for a trial comparing apixaban and dabigatran
(the two NOACs with highest probability of being most cost-effective at willingness to pay per QALY of
£20,000), with a warfarin control arm, indicated that such a trial could potentially be of value, particularly
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FIGURE 17 Incremental cost-effectiveness plane, warfarin (INR 2–3) is reference. See Chapter 4 (Outcomes of atrial
fibrillation and venous thromboembolism models) for further details.
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FIGURE 20 Per-person EVPI over range of willingness-to-pay thresholds.
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if it were designed to inform baseline event rates on warfarin, costs and switching probabilities. However,
a study powered to measure all of these outcomes with sufficient precision would require a very large
sample size, which may be prohibitively expensive.
Expected (mean) values are reported with 95% CIs. Incremental values are relative to warfarin (INR 2–3). INB
is the difference in QALYs and costs for willingness-to-pay thresholds of £20,000 and £30,000 per QALY.
Results of sensitivity analyses
We used 1000 simulations of the model for each sensitivity analysis. To explore whether or not results
were sensitive to the assumed costs of warfarin, we began with the extreme case in which there is no
administration or monitoring costs for warfarin. We found that this had little effect on the conclusion that
apixaban 5 mg bd is the most cost-effective strategy (Figure 22). Clearly, if warfarin is not cost-effective
with zero monitoring costs then it will not be cost-effective with monitoring costs greater than this.
We therefore omit the sensitivity analyses with higher monitoring costs. Similarly, the assumption that
ICH and other CRBs have no effect on future mortality risk did not alter the conclusion that apixaban
5 mg bd is most likely to be cost-effective (Figure 23).
Different treatment switching strategies were also explored. If patients switch to no treatment only when
they experience an ICH or a MI (if on dabigatran), the results are similar to our primary analysis (Figure 24).
If all patients switch treatments after ischaemic stroke, bleed, SE and TIA, in addition to the switching
after ICH and MI (for dabigatran) then patients spend only a short time on a NOAC before switching to
warfarin. In this scenario, it is perhaps unsurprising that warfarin is the most cost-effective strategy
(Figure 25). We also considered a switching strategy by which all patients switch after an ischaemic stroke
or clinically relevant bleed, and none switches after a TIA or SE, and found that the results are similar to
our primary analysis (Figure 26). Excluding the BAATAF study139 has no effect on the conclusion that
apixaban 5 mg bd is likely to be the most cost-effective treatment (Figure 27).
Event costs
Post-event state costs
Post-event state utilities
All utilities
Switching probabilities
Effect on future HR
Baseline log-hazard
All NOAC HRs
Warfarin vs. no treatment HR
Baseline log-hazard and NOAC HR
Apixaban vs. dabigatran log-HR
A vs. D log-HR and baseline
A vs. D log-HR, baseline, switching, event costs/utilities
All costs
Event utilities
0.0 0.2 0.4 0.6 0.8 1.0
Proportion total EVPI
FIGURE 21 Expected value of partial perfect information for subsets of parameters. SAVI-estimated EVPPI scaled by
EVPPI of all parameters as estimated by SAVI. 95% intervals are ± 1.96 × standard error and are truncated above at
1 and below at 0. ‘A vs. D’ is apixaban vs. dabigatran vs. warfarin trial.
COST-EFFECTIVENESS RESULTS (1) STROKE PREVENTION IN ATRIAL FIBRILLATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94
Different initial ages for the cohort were also explored. Apixaban 5 mg bd is the strategy that is most likely
to be cost-effective, assuming an initial cohort age of 60 years (Figure 28) or 80 years (Figure 29). Lower
doses of apixaban (2.5 mg bd) and dabigatran (110 mg bd) are recommended for elderly patients, and
were compared in a sensitivity analysis (Figure 30). The uncertainty is much greater in this comparison, but
apixaban (2.5 mg bd) is most likely to be the most cost-effective first-line therapy for the prevention of
stroke in AF. Results were robust to assuming that the hazard of ICH is the same for no treatment as for
warfarin (Figure 31).
Summary of cost-effectiveness findings
We found that although there was a high degree of uncertainty in the inputs to our model, apixaban
(5 mg bd) was identified with the highest probability of being the most cost-effective first-line treatment
over a range of willingness-to-pay-per-QALY thresholds. The driver of this result is the generally lower rates
of MI, ICH and other CRB on apixaban (5 mg bd) than the other NOACs.
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FIGURE 23 Cost-effectiveness acceptability curves for sensitivity analysis assuming no effect of bleed or ICH on
mortality risk. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 22 Cost-effectiveness acceptability curves for sensitivity analysis assuming that the cost of warfarin
treatment is zero. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 25 Cost-effectiveness acceptability curves for sensitivity analysis assuming that all patients switch treatment
following stroke, bleed, SE or TIA. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism
models) for further details.
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FIGURE 26 Cost-effectiveness acceptability curves for sensitivity analysis assuming that all patients switch treatment
following stroke or bleed, and none switches following SE or TIA. See Chapter 4 (Outcomes of atrial fibrillation and
venous thromboembolism models) for further details.
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FIGURE 24 Cost-effectiveness acceptability curves for sensitivity analysis assuming that no patients switch
treatment following stroke, bleed, SE or TIA. See Chapter 4 (Outcomes of atrial fibrillation and venous
thromboembolism models) for further details.
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FIGURE 28 Cost-effectiveness acceptability curves for sensitivity analysis assuming that the cohort starts at age
60 years, rather than 70 years. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)
for further details.
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FIGURE 27 Cost-effectiveness acceptability curves for sensitivity analysis excluding the BAATAF study139 from
meta-analysis of the treatment effect of warfarin compared with no treatment. See Chapter 4 (Outcomes of atrial
fibrillation and venous thromboembolism models) for further details.
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FIGURE 29 Cost-effectiveness acceptability curves for sensitivity analysis assuming that the cohort starts at age
80 years, rather than 70 years. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)
for further details.
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Our model makes several assumptions (summarised in Table 68). However, the conclusion was robust to a wide
range of sensitivity analyses. The only sensitivity analysis found to affect the conclusion was the assumption
about treatment switching strategy; if treatment switching is assumed to always occur after stroke, bleed, SE or
TIA then warfarin was identified as most cost-effective treatment. However, our clinical advice was that this
extreme switching strategy was not considered realistic in practice. We have taken the costs of warfarin from
the NICE costing report68 but there is uncertainty in this estimate, which is difficult to quantify. We therefore
conducted an extreme case scenario analysis in which we assumed zero cost for warfarin treatment and
monitoring. Apixaban 5mg bd was still the most cost-effective treatment under this assumption. Apixaban
and dabigatran may be given in lower doses to the elderly. We assumed that all patients would receive the
higher dose, and remain on it, even as they age. However, results were robust to a sensitivity analysis assuming
only the lower doses of apixaban (2.5 mg bd) and dabigatran (110mg bd) were administered.
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FIGURE 30 Cost-effectiveness acceptability curves for sensitivity analysis comparing lower doses of apixaban and
dabigatran, as would be administered in older patients with AF. See Chapter 4 (Outcomes of atrial fibrillation and
venous thromboembolism models) for further details.
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FIGURE 31 Cost-effectiveness acceptability curves for sensitivity analysis assuming that the hazard of ICH is the
same on warfarin and no treatment.
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We were unable to include betrixaban due to lack of evidence, and are therefore unable to draw any
conclusions about the relative cost-effectiveness of betrixaban or other unlicensed treatments. We have
assumed that age determines mortality rate, but that other event rates and relative treatment effects do
not depend on age. We have not distinguished between minor and major stroke in our model. Some
previous models have done so34,37,149 but we found that there was insufficient evidence to be able to
estimate rates differently. We have assumed that SE is a transient event with no long-term consequences.
Although there can be long-term consequences, such as limb loss, these are very rare, and we would not
expect inclusion of these to affect the results.
One notable limitation of our model is that we have not distinguished between different types of AF.
There is emerging evidence that there may be a ‘dose–response’ relationship in stroke risk with increasing
‘persistence’ of AF,150 although others have suggested that risk of stroke is as high in paroxysmal patients
with AF as with persistent or permanent AF.151 The RCTs included in our review are likely to have recruited
mostly persistent or permanent patients with AF, and so our conclusions may not extend to patients with
paroxysmal AF.
There have been few CEAs of NOACs for the prevention of stroke in AF in the UK population. Kansal et al.42
found dabigatran to be cost-effective compared with warfarin and aspirin in the UK setting, as in our model.
However, they did not include any other NOACs. The Bayer submission to NICE on rivaroxaban33 found it be
cost-effective compared with warfarin. This submission also found rivaroxaban and dabigatran to have
equivalent effects but dabigatran to have higher costs, thus concluding that rivaroxaban is the most
cost-effective. Their CEACs compared only rivaroxaban with warfarin but found close to a 60% probability
TABLE 68 Main assumptions in the AF model
1. Does not include minor non-clinically relevant bleeds as transient events
2. No distinction between severity of ischaemic strokes
SE assumed to be a transient event without long-term consequences
3. Dose of apixaban and dabigatran given does not reduce as patients age
4. Bleeds and ICH (and with it, haemorrhagic stroke) have same effect on future risk of death as stroke
5. Patients on dabigatran who experience a MI will always switch to warfarin
6. Patients switch to no treatment after ICH/haemorrhagic stroke
7. Patients may switch (with an assumed probability) from NOAC to warfarin or warfarin to no treatment after
ischaemic stroke, bleed, SE or TIA
8. Patients may (with an assumed probability) discontinue warfarin treatment or switch from a NOAC to warfarin,
even if they do not experience an event (due to lack of compliance)
9. Warfarin arms from the RCTs identified in our systematic review are representative of the AF population in
England and Wales
10. Events rate and relative treatment effects are assumed not to vary with age
11. Relative mortality rate in patients with AF relative to the general population does not vary with age
12. Warfarin treatment costs over 3 months are taken from the NICE costing report. Uncertainty in this is represented
using a uniform distribution from 50% to 150% of the NICE costing report estimate
14. Assumes no monitoring or administration costs for NOACs
15. Assumes post-ICH management costs to be similar to post-ischaemic stroke management costs
16. Combined management costs for post-multiple event states (e.g. MI+ stroke) to be the maximum of management
costs for constituent events
17. Assumed quality of life for patients with a history of multiple events to be multiplicative combination of quality of life
for constituent events
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that rivaroxaban was cost-effective in the £20,000–30,000 threshold range, similar to our probability that
a NOAC (apixaban) was most cost-effective. The Harrington et al.38 model in the US setting compared
apixaban (5 mg bd), dabigatran (110 mg bd), rivaroxaban (20 mg od), and warfarin, and found that
apixaban had the highest expected QALYs, followed by dabigatran, rivaroxaban and warfarin. Our model
also found apixaban to have the highest expected QALYs and that dabigatran and rivaroxaban would have
higher expected QALYs than warfarin, although the high degree of uncertainty in our results renders them
compatible with the order found by Harrington et al.38 Harrington et al.38 also found apixaban and
dabigatran to be cost-effective compared with warfarin, and other US studies found apixaban,36
rivaroxaban37 and dabigatran34 to be cost-effective compared with warfarin. Although costs in the USA are
not strictly comparable with those in the UK setting, our results are in line with these earlier findings.
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Chapter 7 Clinical results (2): primary prevention
of venous thromboembolism
Included studies
A total of 2727 unique records were identified from various data sources for the three VTE reviews
(Figure 32).
Forty-three completed eligible RCTs were identified for inclusion in the review of primary prevention of VTE,
with a total of 46 associated references.152–197 One further trial198 contained insufficient detail to include in
the quantitative synthesis. Three additional ongoing trials199–201 were also identified; two trials199,200 in knee
surgery patient population and one trial201 in medical patient population. A summary of the characteristics of
the completed trials included in the analyses is presented in Table 69. There were 18 trials in hip surgery
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FIGURE 32 The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart for
reviews of primary prevention, acute treatment and secondary prevention of VTE.
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patient population (with 20 associated references153–155,158–160,164–166,174,176,177,179,181,183,186,189,192–194), 17 trials in
knee surgery patient population (with 18 associated references152,156,157,161–163,167–169,171–173,175,178,180,182,187,196),
seven trials in medical patient population (with seven associated references170,184,185,188,190,191,197) and one trial
(with one associated reference195) involving both hip and knee surgery patients. Thirty-nine of the trials were
multicentre and four were single-centre trials. Most of the multicentre trials were conducted across several
countries mainly in North and South America, Europe, Asia, Russia and Israel, Australia and South Africa.
Three of the single-centre studies were conducted in Japan, Brazil and China, and one study did not report
the country where it was conducted. Thirty-one of the trials were Phase III studies and 12 were Phase II
studies. The number of patients randomised ranged from 67 to 5407 patients across the 18 trials on
hip surgery; 160 to 3195 patients across the 17 trials on knee surgery (one trial was below-knee
fracture patient population); 125 to 8823 patients across the seven trials on medical cases; 1973 patients
in the trial involving both hip and knee surgery patients; and 67 to 8323 patients across the whole trials,
with a total of 77,563 patients of whom 88.9% (68,953 patients) were from Phase III studies. Thirty-one
studies (19 Phase III and 12 Phase II) examined a NOAC. Overall, 11 studies examined rivaroxaban, seven
studies examined dabigatran, six studies each examined apixaban and edoxaban, and one study examined
betrixaban. Apart from two studies without sponsor information, all studies on NOACs were sponsored by
one or more pharmaceutical companies. The role of sponsor was not declared in some of the studies,
but, where the sponsor role was declared, the sponsor was commonly involved in the study design, data
management and analysis.
Eligibility criteria for patient participation were similar across surgical studies of the same type, with all
patients in hip surgery studies having elective unilateral hip arthroplasty, and all patients in knee surgery
studies having elective unilateral knee arthroplasty. Patients in medical studies were selected based on
specific clinical conditions, either having a metastatic cancer or one or more acute medical conditions,
so the criteria varied slightly across the medical studies. The minimum age for inclusion in a majority
of the studies was 18 years, the mean age across studies (where reported) ranged from 41 years
to 76 years. The percentage of male patients, reported in 88% of the studies, ranged from 13.1% to
62.7%. Mean BMI and mean weight ranged from 23 to 32.4 kg/m2 and from 52.3 to 90.9 kg,
respectively, across studies, when reported. Proportions of comorbidities were poorly reported
across studies. When reported, the proportion of patients with a previous thromboembolic event,
chronic heart failure and cancer ranged from 0.1% to 10.2%, 0.6% to 34.8% (higher of the range
from medical patient population studies), and 6% to 100% (100% in cancer patient studies),
respectively.
Of the 31 studies that examined NOACs, a NOAC was compared with a LMWH in 27 studies, with
placebo in three studies, and with both a LMWH and warfarin in one study. Fourteen of the 31 studies
were on hip surgery patients, 12 on knee surgery patients, one on below knee fracture patients, one on
both hip and knee surgery patients, and three on medical patients. The doses of NOACs examined were
apixaban 5 mg, 10 mg and 20 mg od, and 2.5 mg, 5 mg and 10 mg bd; edoxaban 5 mg, 15 mg, 30 mg,
60 mg and 90 mg od; rivaroxaban 5 mg, 10 mg, 20 mg, 30 mg and 40 mg od, and 2.5 mg, 5 mg,
10 mg, 20 mg and 30 mg bd; betrixaban 15 mg and 40 mg bd; and dabigatran 110 mg, 150 mg,
220 mg and 300 mg od, and 50 mg, 150 mg and 225 mg bd. Among the studies that did not examine
a NOAC, six studies each compared LMWH with warfarin, and with placebo. Standard intensity warfarin
(INR 2–3) was examined in all studies involving a warfarin arm, although in one study the lower end of
the INR range was 1.8. None of these studies that examined warfarin reported mean TTR. LMWHs
varied in type and dose across studies. Start of treatment with LMWH varied across surgical patient
studies with pre-op treatment start in 11 studies in hip surgery, four studies in knee surgery, and one
study involving both hip and knee surgery patients, and post-op treatment start in eight studies in hip
surgery and 11 studies in knee surgery. In one (hip surgery) study, pre- and post-op LMWH treatment
start were compared.
Treatment duration varied greatly across hip surgery, knee surgery and medical patient studies, from 4 to
130 days. There is less variation in treatment duration within the knee and hip surgery studies, with
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treatment duration ranging from 10 to 14 days in most of the knee surgery studies, and from 5 to
14 days and 28 to 35 days in most of the hip surgery studies. Treatment duration was the same for the
interventions compared with studies, except in three studies where the LMWH comparator was given for a
shorter duration than the NOAC (rivaroxaban in two studies and apixaban in one study). However, time to
outcome assessment was the same in all studies including those with different treatment durations for the
interventions compared.
Reported efficacy and safety outcome types were similar across studies irrespective of the patient group,
and were reported at the end of the treatment periods. Two rivaroxaban studies reported only efficacy
outcomes: in both cases few outcomes were reported. One study reported only safety outcomes. Overall,
29 studies reported data on symptomatic VTE; 25 on symptomatic DVT, 35 on symptomatic PE, nine on
MI, 39 on major bleeding, 27 on CRB, and 28 on all-cause mortality. Diagnosis of VTE was predominantly
by compression ultrasonography or venography for DVT, and by spiral computerised tomography scan or
ventilation/perfusion lung scan for PE.
Time in therapeutic range for warfarin interventions
Seven studies of primary prevention of VTE included a warfarin intervention arm, but none of these
reported mean TTR.
Risk of bias in included studies
Detailed risk-of-bias assessments for each included study for each domain of the Cochrane assessment tool
are provided in Table 70. Overall, the studies were judged to be at low risk of bias. Assessment of a few
studies was based on abstract information only, in which case risk of bias for most domains was judged to
be unclear. The majority of the studies were judged to be at low risk of bias for blinding of outcome
assessment and incomplete outcome data. The risk of bias in these two domains differed slightly in a few
studies because of differences in blinding of outcome assessment and the number of patients included in
analysis according to outcome type, mainly whether an outcome is for efficacy or for safety. Most studies
were judged to be at low risk of bias for selective outcome reporting. Among those not judged to be at
low risk, the main reason for the judgement was either unavailability of the study protocol or insufficient
information to enable a judgement of low risk. Randomisation sequence generation and allocation
concealment were predominantly by computer generation and central allocation, respectively. In some
studies, randomisation was used a standard permuted block and some of the studies were stratified
according to study centre. A few studies,153,154,156,168,174,193,194 predominantly of open-label design, were
judged to be at high risk of bias for blinding of participants. The risk-of-bias judgements for studies
contributing to analyses of each outcome are presented graphically in the sections that follow.
Results of clinical effectiveness and safety
Three trials (TOPIC-1,197 TOPIC-2197 and ARDEPARIN ARTHROPLASTY STUDY196) were not included in any of
the networks. They used non-standard variants of heparin that could not be assumed to be comparable
with standard heparin, so these studies do not contribute information on the comparisons of interest.
The 38 trials included in these analyses implemented a total of 35 interventions, listed in Table 71. The
interventions labelled as ‘standard dose’ for LMWH included tinzaparin (0.45 ml od), enoxaparin (40 mg od
or 30 mg bd) and dalteparin (5000 IU). The ‘warfarin variable’ node included interventions in which a
subtherapeutic INR range had been considered for some patients, and for that reason this node was
included only in sensitivity analyses in which it was merged with the warfarin (INR 2–3 node). Tables 72
and 73 show the numbers of events for each outcome reported in each trial. We performed NMAs for
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TABLE 71 List of distinct interventions examined by included randomised trials of primary prevention of VTE
1 LMWH Post-op (standard dose)
2 Pre-op (standard dose)
3 Standard dose
4 Noxaparin 20 mg bd
5 (100 IU od)
6 (ardeparin 3800 IU anti-Xa od
7 Warfarin (INR 2–3)
8 Variable
9 Placebo
10 Apixaban 2.5 mg bd
11 5mg od
12 5mg bd
13 10mg od
14 10mg bd
15 20mg od
16 Betrixaban 15mg bd
17 40mg bd
18 Dabigatran 110 mg od
19 150mg od
20 220mg od
21 Edoxaban 5mg od
22 15mg od
23 30mg od
24 60mg od
25 90mg od
26 Rivaroxaban 2.5 mg bd
27 5mg od
28 5mg bd
29 10mg od
30 10mg bd
31 20mg od
32 30mg od
33 20mg bd
34 40mg od
35 30mg bd
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seven outcomes: symptomatic VTE, symptomatic DVT, symptomatic PE, MI, major bleeding, CRB and
all-cause mortality. For the first three outcomes, hip surgery, knee surgery and non-surgical patients were
analysed separately, whereas for each of the four remaining outcomes all patients were combined in a
single network.
Results are presented as follows for each of the seven outcomes. First, we provide network plots to
illustrate the comparisons of interventions made in the different trials. Second, we illustrate the
risk-of-bias assessments that were specific to the outcome for each trial included in the network. Third,
we present results tables for each intervention compared with the reference treatment (standard dose of
LMWH administered before surgery for hip surgery patients, after surgery for knee surgery patients, or
at start of treatment for other patients). Fourth, we present results tables for pairwise comparisons
among licensed doses of the NOACs. For both sets of results tables, posterior median ORs and 95%
credible intervals from Bayesian fixed-effects analyses are shown, although we refer to the latter as CIs
for convenience. In these tables we present results separately for any available direct evidence, for any
indirect comparisons that can be made (excluding the direct evidence) and for the NMA (which
combines the direct and the indirect evidence). Comparisons from the NMA with a ratio between
interval limits exceeding nine were considered ‘imprecisely estimated’ and are presented at the bottom
of each table (note that calculation of indirect evidence was not undertaken for imprecisely estimated
comparisons). A summary of results across outcomes is provided at the end in the form of a
‘rankogram’, which illustrates the probability that each treatment is best, second best, and so on, for
each outcome. Last, forest plots of all contributing data, with ORs calculated using standard frequentist
methods, are included in Appendix 3.
Symptomatic venous thromboembolism
Of 28 studies that contributed data to analyses of symptomatic VTE, 11 reported direct data on
symptomatic VTE events (see Table 72). Table 74 shows risk-of-bias judgements for these studies.
They were generally judged to be at low risk of bias, although with some concerns about allocation
concealment and blinding of participants and personnel.
Nine studies of hip surgery patients reported 231 symptomatic VTE events, leading to a network of
13 interventions (Figure 33). This network was disconnected so that two interventions could not be
included in the analysis. Most comparisons were imprecisely estimated, but there was evidence
that risk of symptomatic VTE is lower with rivaroxaban (10 mg od) than LMWH (pre-op, standard dose)
but higher with LMWH (post-op, standard dose) and warfarin (INR 2–3) than LMWH (pre-op,
standard dose) (Table 75). Indirect evidence about warfarin (INR 2–3) versus LMWH (pre-op, standard
dose) pointed in the opposite direction to the direct evidence, but was extremely imprecisely
estimated.
Comparisons between licensed doses of NOACs were imprecisely estimated (Table 76). In addition, there
was some heterogeneity in the direction of effects among studies of dabigatran (150 mg od) compared
with post-op LMWH (standard dose) and of dabigatran (220 mg od) compared with post-op LMWH
(standard dose) (see Appendix 3).
Ten trials including knee surgery patients reported 186 symptomatic VTE events, leading to a network
of 21 interventions (Figure 34). There was little evidence that risk of symptomatic VTE differed between
apixaban (2.5 mg bd), dabigatran (220 mg od) or rivaroxaban (10 mg od) compared with LMWH
(post-op, standard dose) (Table 77). Comparisons between licensed doses of NOACs were imprecisely
estimated (Table 78).
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TABLE 74 Included trials and risk-of-bias assessment for symptomatic VTE (primary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
ADOPT188 3, 10 + + + + + +
ADVANCE-1171 1, 10 ? ? + + + +
ADVANCE-3176 2, 10 + + + + + +
APROPOS162 1, 7, 10, 11, 12, 13, 14,
15
+ ? ? + + +
EXPERT168 1, 16, 17 + ? – + ? +
MAGELLAN184,191 3, 29 + + + + + +
ODiXa-KNEE157 1, 26, 28, 30, 33, 35 + + + + ? +
ODiXa-OD.HIP158 2, 27, 29, 31, 32, 34 ? ? + + ? ?
PROTECHT170 6, 9 + + + + + +
RECORD 1165 2, 29 + + ? + + +
RECORD 2166 2, 29 + + ? + ? +
RECORD 3163 2, 29 ? + ? + ? +
RECORD 4173 1, 29 + + ? + + +
RE-MOBILISE167 1, 19, 20 + + + + + +
RE-MODEL161 2, 19, 20 + + ? + + +
RE-NOVATE160 2, 19, 20 + + + + ? +
RE-NOVATE II183,189 2, 20 + + + + + +
VTE-APIX-PLACEBO-USACAN190 9, 11, 13, 15 + + + + + +
VTE-DABIG-PLAC-JAPAN175 9, 18, 19, 20 + ? ? + + +
VTE-LMWH-PLAC-JAPAN186 1, 4, 9 ? ? ? + + ?
VTE-VKA-LMWH-CANADA152 1, 7 + ? + + + ?
VTE-VKA-LMWH-US-2154 1, 7 ? ? – ? + ?
VTE-VKA-LMWH-US-3153 1, 2, 7 + ? + + + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
1. LMWH post-op (standard dose)
2. LMWH pre-op (standard dose)
[4. LMWH (enoxaparin 20 mg bd)]
7. Warfarin (INR 2–3)
[9. Placebo]
10. Apixaban (2.5 mg bd)
19. Dabigatran (150 mg od)20. Dabigatran (220 mg od)
27. Rivaroxaban (5 mg od)
29. Rivaroxaban (10 mg od)
31. Rivaroxaban (20 mg od)
32. Rivaroxaban (30 mg od)
34. Rivaroxaban (40 mg od)
FIGURE 33 Network plot for symptomatic VTE in hip surgery patients (primary prevention of VTE).
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TABLE 75 Results for symptomatic VTE in hip surgery patients (primary prevention of VTE): comparisons with LMWH
Comparisons with LMWH
(pre-op, standard dose)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
LMWH post-op (standard dose) 2.16 (0.73 to 7.03) 6.49 (0.50 to 83.8) 2.59 (1.03 to 8.36)
Warfarin (INR 2–3) 3.33 (1.21 to 10.4) 0.29 (0 to 19.5) 2.87 (1.14 to 9.25)
Dabigatran (150 mg od) 1.46 (0.57 to 3.75) – 1.46 (0.57 to 3.75)
Dabigatran (220 mg od) 1.20 (0.51 to 2.86) – 1.20 (0.51 to 2.86)
Rivaroxaban (10 mg od) 0.33 (0.16 to 0.64) – 0.33 (0.16 to 0.64)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) 0.38 (0.10 to 1.16) – 0.38 (0.10 to 1.16)
Rivaroxaban (5 mg od) 0.22 (0 to 4.76) – 0.22 (0 to 4.76)
Rivaroxaban (20 mg od) 0.19 (0 to 4.01) – 0.19 (0 to 4.01)
Rivaroxaban (30 mg od) 0.19 (0 to 4.19) – 0.19 (0 to 4.19)
Rivaroxaban (40 mg od) 0.21 (0 to 4.62) – 0.21 (0 to 4.62)
TABLE 76 Results for symptomatic VTE in hip surgery patients (primary prevention of VTE): NOACs
(licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Rivaroxaban (10 mg od) vs. dabigatran (220mg od) – 0.28 (0.09 to 0.81) 0.28 (0.09 to 0.81)
Imprecisely estimated comparisons
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd) – 3.21 (0.77 to 15.5) 3.21 (0.77 to 15.5)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd) – 0.89 (0.23 to 3.90) 0.89 (0.23 to 3.90)
1. LMWH post-op (standard dose)
2. LMWH pre-op (standard dose)
7. Warfarin (INR 2–3)
9. Placebo
10. Apixaban (2.5 mg bd)
11. Apixaban (5 mg od)
12. Apixaban (5 mg bd)
13. Apixaban (10 mg od)
14. Apixaban (10 mg bd)
15. Apixaban (20 mg od)
16. Betrixaban (15 mg bd)17. Betrixaban (40 mg bd)
18. Dabigatran (110 mg od)
19. Dabigatran (150 mg od)
20. Dabigatran (220 mg od)
26. Rivaroxaban (2.5 mg bd)
28. Rivaroxaban (5 mg bd)
29. Rivaroxaban (10 mg od)
30. Rivaroxaban (10 mg bd)
33. Rivaroxaban (20 mg bd)
35. Rivaroxaban (30 mg bd)
FIGURE 34 Network plot for symptomatic VTE in knee surgery patients (primary prevention of VTE).
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Four trials in non-surgical patients reported 45 symptomatic VTE events, leading to a network of eight
interventions (Figure 35). Because the network was disconnected we excluded two Phase II trials
(PROTECHT170 and VTE-APIX-PLACEBO-USACAN190) so that analyses were of the connected network.
This enabled us to compare two licensed doses of NOACs. There was weak evidence that risk of
symptomatic VTE is lower with apixaban (2.5 mg bd) than LMWH (standard dose) (Table 79), and
also when compared with rivaroxaban (10 mg od) (Table 80), although these comparisons were
imprecisely estimated.
TABLE 77 Results for symptomatic VTE in knee surgery patients (primary prevention of VTE): comparisons with LMWH
Comparisons with LMWH
(post-op, standard dose) Direct evidence
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
LMWH pre-op (standard dose) – 1.96 (0.91 to 4.27) 1.96 (0.91 to 4.27)
Apixaban (2.5 mg bd) 1.24 (0.64 to 2.43) – 1.24 (0.64 to 2.43)
Dabigatran (150mg od) 0.82 (0.40 to 1.67) – 0.82 (0.40 to 1.67)
Dabigatran (220mg od) 0.92 (0.45 to 1.86) – 0.92 (0.45 to 1.86)
Rivaroxaban (10 mg od) 0.80 (0.43 to 1.46) – 0.80 (0.43 to 1.46)
Imprecisely estimated comparisons
Warfarin (INR 2–3) 0.25 (0.01 to 2.34) – 0.25 (0.01 to 2.34)
Placebo – 1.14 (0.12 to 8.36) 1.14 (0.12 to 8.36)
Apixaban (5 mg od) 0.12 (0 to 1.84) – 0.12 (0 to 1.84)
Apixaban (5 mg bd) 0.11 (0 to 1.66) – 0.11 (0 to 1.66)
Apixaban (10 mg od) 1.11 (0.17 to 5.41) – 1.11 (0.17 to 5.41)
Apixaban (10 mg bd) 0.57 (0.05 to 3.43) – 0.57 (0.05 to 3.43)
Apixaban (20 mg od) 0.57 (0.04 to 3.45) – 0.57 (0.04 to 3.45)
Betrixaban (15 mg bd) 1.34 (0.10 to 44.6) – 1.34 (0.10 to 44.6)
Betrixaban (40 mg bd) 0.59 (0.01 to 22.8) – 0.59 (0.01 to 22.8)
Dabigatran (110mg od) – 0.43 (0.01 to 4.41) 0.43 (0.01 to 4.41)
Rivaroxaban (2.5 mg bd) 0.59 (0.04 to 5.21) – 0.59 (0.04 to 5.21)
Rivaroxaban (5 mg bd) 1.24 (0.17 to 9.07) – 1.24 (0.17 to 9.07)
Rivaroxaban (10 mg bd) 0.12 (0 to 2.36) – 0.12 (0 to 2.36)
Rivaroxaban (20 mg bd) 0.66 (0.05 to 5.93) – 0.66 (0.05 to 5.93)
Rivaroxaban (30 mg bd) 0.12 (0 to 2.3) – 0.12 (0 to 2.33)
TABLE 78 Results for symptomatic VTE in knee surgery patients (primary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (220mg od) vs. apixaban (2.5 mg bd) – 0.74 (0.28 to 1.95) 0.74 (0.28 to 1.95)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd) – 0.64 (0.26 to 1.56) 0.64 (0.26 to 1.56)
Rivaroxaban (10 mg od) vs. dabigatran (220mg od) – 0.87 (0.37 to 2.01) 0.87 (0.37 to 2.01)
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Symptomatic deep-vein thrombosis
Twenty studies contributed data to analyses of symptomatic DVT. Table 81 shows risk-of-bias judgements
for these studies. Most were judged to be at low risk of bias, although with a few concerns about blinding
of participants and personnel.
Eight studies of hip surgery patients provided data on 157 symptomatic DVT events, leading to a network
of nine interventions (Figure 36). Because the resulting network was disconnected, we excluded several
interventions from the analysis. All comparisons were imprecisely estimated (Tables 82 and 83), but there
was evidence that risk of symptomatic DVT is higher for that LMWH (post-op, standard dose) and warfarin
(INR 2–3) than LMWH (pre-op, standard dose).
Nine studies of knee surgery patients reported 81 symptomatic DVT events, leading to a network of
24 interventions (Figure 37). All comparisons were imprecisely estimated (Tables 84 and 85). Indirect
evidence about warfarin (INR 2–3) compared with LMWH (pre-op, standard dose) pointed in the opposite
direction to the direct evidence, but was very imprecisely estimated.
Three studies of medical patients provided data on 65 symptomatic DVT events, leading to a network
of five interventions. Because the resulting network was disconnected (Figure 38), we excluded the
PROTECHT trial,170 which allowed us to make an indirect comparison between two licensed NOAC doses.
All comparisons were imprecisely estimated, although there was evidence that risk of symptomatic DVT is
lower for apixaban (2.5 mg bd) than LMWH (standard dose) (Table 86). The comparison between apixaban
(2.5 mg bd) and rivaroxaban (10 mg od) was imprecisely estimated (Table 87).
TABLE 80 Results for symptomatic VTE in medical patients (primary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd) – 3.09 (1.13 to 8.87) 3.09 (1.13 to 8.87)
TABLE 79 Results for symptomatic VTE in medical patients (primary prevention of VTE): comparisons with LMWH
Comparisons with LMWH
(standard dose)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (2.5 mg bd) 0.50 (0.24 to 0.97) – 0.50 (0.24 to 0.97)
Rivaroxaban (10 mg od) 1.53 (0.73 to 3.28) – 1.53 (0.73 to 3.28)
3. LMWH (standard dose)
[6. LMWH (nadroparin 3800 IU
      anti-Xa od)]
[9. Placebo]
10. Apixaban (2.5 mg bd)
[11. Apixaban (5 mg od)]
[13. Apixaban (10 mg od)]
[15. Apixaban (20 mg od)]
29. Rivaroxaban (10 mg od)
FIGURE 35 Network plot for symptomatic VTE in medical patients (primary prevention of VTE).
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1. LMWH post-op (standard dose)
2. LMWH pre-op (standard dose)
[4. LMWH (enoxaparin 20 mg bd)]
7. Warfarin (INR 2 – 3)
[9. Placebo]10. Apixaban (2.5 mg bd)
19. Dabigatran (150 mg od)
20. Dabigatran (220 mg od)
[23. Edoxaban (30 mg od)]
FIGURE 36 Network plot for symptomatic DVT in hip surgery patients (primary prevention of VTE).
TABLE 81 Included trials and risk-of-bias assessment for symptomatic DVT (primary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
ADOPT188 3, 10 + + + + + +
ADVANCE-1171 1, 10 ? ? + + + +
ADVANCE-3176 2, 10 + + + + + +
APROPOS162 1, 7, 10, 11, 12, 13, 14, 15 + ? ? + + +
EXPERT168 1, 16, 17 + ? – + ? +
MAGELLAN184,191 3, 29 + + + + + +
ODiXa-KNEE157 1, 26, 28, 30, 33, 35 + + + + ? +
PROTECHT170 6, 9 + + + + + +
RECORD 4173 1, 29 + + ? + + +
RE-MOBILISE167 1, 19, 20 + + + + + +
RE-MODEL161 2, 19, 20 + + ? + + +
RE-NOVATE160 2, 19, 20 + + + + ? +
RE-NOVATE II183,189 2, 20 + + + + + +
STARS J-1172,180 9, 21, 22, 23, 24 + ? ? + + +
STARS J-4181,193 4, 23 ? ? – + ? +
STARS J-V179 4, 23 ? ? ? ? ? +
VTE-DABIG-PLAC-JAPAN175 9, 18, 19, 20 + ? ? + + +
VTE-LMWH-PLAC-JAPAN186 1, 4, 9 ? ? ? + + ?
VTE-VKA-LMWH-US-2154 1, 7 ? ? – ? + ?
VTE-VKA-LMWH-US-3153 1, 2, 7 + ? + + + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
CLINICAL RESULTS (2): PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM
NIHR Journals Library www.journalslibrary.nihr.ac.uk
152
Symptomatic pulmonary embolism
Thirty studies contributed data to analyses of symptomatic PE: few reported directly on symptomatic PE
events (see Table 72) so we inferred these by summing symptomatic non-fatal and fatal PE events if that
information was available. Most studies were judged to be at low risk of bias (Table 88), although there
were some concerns about sequence generation, lack of allocation concealment, blinding of participants
and personnel, and incomplete outcome data.
TABLE 82 Results for symptomatic DVT in hip surgery patients (primary prevention of VTE): comparisons with LMWH
Comparisons with LMWH
(pre-op, standard dose)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
LMWH post-op (standard dose) 2.14 (0.72 to 7.34) 4.95 (0.57 to 42.8) 2.58 (1.03 to 7.94)
Warfarin (INR 2–3) 3.31 (1.21 to 10.8) 0.84 (0.05 to 13.1) 2.74 (1.10 to 8.39)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) 0.15 (0.01 to 1.09) – 0.15 (0.01 to 1.09)
Dabigatran (150 mg od) 2.90 (0.93 to 10.5) – 2.90 (0.93 to 10.5)
Dabigatran (220 mg od) 1.19 (0.37 to 4.05) – 1.19 (0.37 to 4.05)
TABLE 83 Results for symptomatic DVT in hip surgery patients (primary prevention of VTE): NOACs
(licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd) – 8.37 (0.79 to 286) 8.37 (0.79 to 286)
1. LMWH post-op (standard dose)
2. LMWH pre-op (standard dose)
9. Placebo
10. Apixaban (2.5 mg bd)
11. Apixaban (5 mg od)
12. Apixaban (5 mg bd)
13. Apixaban (10 mg od)
14. Apixaban (10 mg bd)
15. Apixaban (20 mg od)
16. Betrixaban (15 mg bd)
17. Betrixaban (40 mg bd)
18. Dabigatran (110 mg od)
19. Dabigatran (150 mg od)
20. Dabigatran (220 mg od)
21. Edoxaban (5 mg od)
22. Edoxaban (15 mg od)
23. Edoxaban (30 mg od)
24. Edoxaban (60 mg od)
26. Rivaroxaban (2.5 mg bd)
28. Rivaroxaban (5 mg bd)
29. Rivaroxaban (10 mg od)
30. Rivaroxaban (10 mg bd)
33. Rivaroxaban (20 mg bd)
35. Rivaroxaban (30 mg bd)
FIGURE 37 Network plot for symptomatic DVT in knee surgery patients (primary prevention of VTE).
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TABLE 84 Results for symptomatic DVT in knee surgery patients (primary prevention of VTE): comparisons with LMWH
Comparisons with LMWH
(post-op, standard dose)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150mg od) 1.58 (0.64 to 4.31) – 1.58 (0.64 to 4.31)
Dabigatran (220mg od) 1.21 (0.46 to 3.43) – 1.21 (0.46 to 3.43)
Rivaroxaban (10 mg od) 0.58 (0.19 to 1.59) – 0.58 (0.19 to 1.59)
Imprecisely estimated comparisons
LMWH pre-op (standard dose) – 6.06 (1.38 to 31.0) 6.06 (1.38 to 31.0)
Placebo – 1.82 (0.18 to 15.1) 1.82 (0.18 to 15.1)
Apixaban (2.5 mg bd) 0.50 (0.14 to 1.55) – 0.50 (0.14 to 1.55)
Apixaban (5 mg od) 0.15 (0 to 2.64) – 0.15 (0 to 2.64)
Apixaban (5 mg bd) 0.13 (0 to 2.48) – 0.13 (0 to 2.48)
Apixaban (10 mg od) 1.32 (0.18 to 8.59) – 1.32 (0.18 to 8.59)
Apixaban (10 mg bd) 0.13 (0 to 2.37) – 0.13 (0 to 2.37)
Apixaban (20 mg od) 0.13 (0 to 2.37) – 0.13 (0 to 2.37)
Betrixaban (15 mg bd) 0.57 (0.04 to 8.47) – 0.57 (0.04 to 8.47)
Betrixaban (40 mg bd) 0.12 (0 to 3.43) – 0.12 (0 to 3.43)
Dabigatran (110mg od) – 0.69 (0.02 to 8.04) 0.69 (0.02 to 8.04)
Edoxaban (5 mg od) 9.54 (0.15 to 3760) – 9.54 (0.15 to 3760)
Edoxaban (15 mg od) 1.60 (0 to 894) – 1.60 (0 to 894)
Edoxaban (30 mg od) 1.72 (0 to 978) – 1.72 (0 to 978)
Edoxaban (60 mg od) 1.69 (0 to 1010) – 1.69 (0 to 1010)
Rivaroxaban (2.5 mg bd) 0.60 (0.04 to 5.56) – 0.60 (0.04 to 5.56)
Rivaroxaban (5 mg bd) 0.12 (0 to 2.52) – 0.12 (0 to 2.52)
Rivaroxaban (10 mg bd) 0.12 (0 to 2.36) – 0.12 (0 to 2.36)
Rivaroxaban (20 mg bd) 0.66 (0.05 to 5.99) – 0.66 (0.05 to 5.99)
Rivaroxaban (30 mg bd) 0.12 (0 to 2.41) – 0.12 (0 to 2.41)
TABLE 85 Results for symptomatic DVT in knee surgery patients (primary prevention of VTE): NOACs
(licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Dabigatran (220mg od) vs. apixaban (2.5 mg bd) – 2.43 (0.54 to 12.6) 2.43 (0.54 to 12.6)
Edoxaban (30 mg od) vs. apixaban (2.5 mg bd) – 3.47 (0 to 2150) 3.47 (0 to 2150)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd) – 1.16 (0.24 to 5.84) 1.16 (0.24 to 5.84)
Edoxaban (30 mg od) vs. dabigatran (220mg od) – 1.41 (0 to 779) 1.41 (0 to 779)
Rivaroxaban (10 mg od) vs. dabigatran (220mg od) – 0.47 (0.11 to 1.97) 0.47 (0.11 to 1.97)
Rivaroxaban (10 mg od) vs. edoxaban (30mg od) – 0.33 (0 to 295) 0.33 (0 to 295)
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3. LMWH (standard dose)
[6. LMWH (nadroparin 3800 IU
     anti-Xa od)]
(9. Placebo)10. Apixaban (2.5 mg bd)
29. Rivaroxaban (10 mg od)
FIGURE 38 Network plot for symptomatic DVT in medical patients (primary prevention of VTE).
TABLE 86 Results for symptomatic DVT in medical patients (primary prevention of VTE): comparisons with LMWH
Comparisons with LMWH (standard dose)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (2.5 mg bd) 0.30 (0.10 to 0.78) – 0.30 (0.10 to 0.78)
Rivaroxaban (10 mg od) 0.89 (0.41 to 1.89) – 0.89 (0.41 to 1.89)
TABLE 87 Results for symptomatic DVT in medical patients (primary prevention of VTE): NOACs (licensed
doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd) – 3.01 (0.87 to 11.6) 3.01 (0.87 to 11.6)
TABLE 88 Included trials and risk-of-bias assessment for symptomatic PE (primary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
ADOPT188 3, 10 + + + + + +
ADVANCE-1171 1, 10 ? ? + + + +
ADVANCE-2178 2, 10 + + + + ? +
ADVANCE-3176 2, 10 + + + + + +
APROPOS162 1, 7, 10, 11, 12, 13, 14, 15 + ? ? + + +
EXPERT168 1, 16, 17 + ? – + ? +
MAGELLAN184,191 3, 29 + + + + + +
ODiXa-HIP2159 2, 26, 28, 30, 33, 35 ? ? + + ? +
ODiXa-KNEE157 1, 26, 28, 30, 33, 35 + + + + ? +
ODiXa-OD.HIP158 2, 27, 29, 31, 32, 34 ? ? + + ? ?
PROTECHT170 6, 9 + + + + + +
continued
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Thirteen studies in hip surgery patients provided data on 58 symptomatic PE events, leading to a network
of 19 interventions (Figure 39). However, most interventions were either disconnected from the network or
considered only in trials in which there were no events in any arm, so that only five interventions were
included in the analysis. All comparisons were imprecisely estimated (Tables 89 and 90).
Fourteen studies in knee surgery patients reported 74 symptomatic PE events, leading to a network of
26 interventions (Figure 40). We excluded three trials with zero events in each arm, hence some
interventions were not part of the analysis. All comparisons were imprecisely estimated (Table 91) but
there was some evidence that risk of symptomatic PE is lower with dabigatran (150 mg od) and higher
with apixaban (2.5 mg bd) than LMWH (post-op, standard dose). Among licensed doses of NOACs the risk
of symptomatic PE may be lower for rivaroxaban (10 mg od) than apixaban (2.5 mg bd) (Table 92).
Three studies in medical patients reported 45 symptomatic PE events. Because the resulting network was
disconnected (Figure 41), we excluded the PROTECHT trial.170 This led to a connected network that enabled an
indirect comparison among two licensed NOACs. All comparisons were imprecisely estimated (Tables 93 and 94).
Myocardial infarction
Nine studies provided data on 63 MI events, leading to a network of 11 interventions (Figure 42). The
included studies were mainly judged to be at low risk of bias (Table 95), although there were some
concerns about blinding of participants and personnel.
TABLE 88 Included trials and risk-of-bias assessment for symptomatic PE (primary prevention of VTE) (continued )
Study Interventions compared SG AC BPP BOA IOD SR
RECORD 1165 2, 29 + + ? + + +
RECORD 2166 2, 29 + + ? + ? +
RECORD 3163 2, 29 ? + ? + ? +
RECORD 4173 1, 29 + + ? + + +
RE-MOBILISE167 1, 19, 20 + + + + + +
RE-MODEL161 2, 19, 20 + + ? + + +
RE-NOVATE160 2, 19, 20 + + + + ? +
RE-NOVATE II183,189 2, 20 + + + + + +
STARS E-3182 1, 23 ? + ? ? ? ?
STARS J-1172,180 9, 21, 22, 23, 24 + ? ? + + +
STARS J-4181,193 4, 23 ? ? – + ? +
STARS J-V179 4, 23 ? ? ? ? ? +
VTE-DABIG-PLAC-JAPAN175 9, 18, 19, 20 + ? ? + + +
VTE-LMWH-PLAC-JAPAN186 1, 4, 9 ? ? ? + + ?
VTE-RIVAROX-LMWH-BRAZIL162 2, 29 ? ? + ? + ?
VTE-VKA-LMWH-CANADA152 1, 7 + ? + + + ?
VTE-VKA-LMWH-US-2154 1, 7 ? ? – ? + ?
VTE-VKA-LMWH-US-3153 1, 2, 7 + ? + + + ?
VTE-VKA-LMWH-US-4154 1, 7 ? + – + + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
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All comparisons were imprecisely estimated (Tables 96 and 97), although there was some evidence that
rivaroxaban (10 mg od) may reduce the risk of MI compared with LMWH (post-op, standard dose).
Major bleeding
Thirty-four studies reported 706 major bleeding events, leading to a network of 32 interventions (Figure 43).
The studies were mainly judged to be at low risk of bias (Table 98), although there were some concerns
about sequence generation and blinding of participants and personnel.
[1. LMWH post-op (standard dose)]
2. LMWH pre-op (standard dose)
[4. LMWH (enoxaparin 20 mg bd)]
[7. Warfarin (INR 2–3)]
[9. Placebo]
10. Apixaban (2.5 mg bd)
19. Dabigatran (150 mg od)
20. Dabigatran (220 mg od)
[9. Edoxaban (30 mg od)]
[26. Rivaroxaban (2.5 mg bd)][27. Rivaroxaban (5 mg od)]
[28. Rivaroxaban (5 mg bd)]
29. Rivaroxaban (10 mg od)
[30. Rivaroxaban (10 mg bd)]
[31. Rivaroxaban (20 mg od)]
[32. Rivaroxaban (30 mg od)]
[33. Rivaroxaban (20 mg bd)]
[34. Rivaroxaban (40 mg od)]
35. Rivaroxaban (30 mg bd)
FIGURE 39 Network plot for symptomatic PE in hip surgery patients (primary prevention of VTE).
TABLE 89 Results for symptomatic PE in hip surgery patients (primary prevention of VTE): comparisons with LMWH
Comparisons with LMWH
(pre-op, standard dose)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) 0.57 (0.11 to 2.40) – 0.57 (0.11 to 2.40)
Dabigatran (150 mg od) 0.20 (0.01 to 1.56) – 0.20 (0.01 to 1.56)
Dabigatran (220 mg od) 1.22 (0.35 to 4.31) – 1.22 (0.35 to 4.31)
Rivaroxaban (10 mg od) 0.82 (0.22 to 2.84) – 0.82 (0.22 to 2.84)
TABLE 90 Results for symptomatic PE in hip surgery patients (primary prevention of VTE): NOACs
(licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd) – 2.16 (0.32 to 16.7) 2.16 (0.32 to 16.7)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd) – 1.46 (0.21 to 11.1) 1.46 (0.21 to 11.1)
Rivaroxaban (10 mg od) vs. dabigatran (220mg od) – 0.67 (0.11 to 3.95) 0.67 (0.11 to 3.95)
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1. LMWH post-op (standard dose)
2. LMWH pre-op (standard dose)
[4. LMWH (enoxaparin 20 mg bd)]
7. Warfarin (INR 2 – 3)
[9. Placebo]
10. Apixaban (2.5 mg bd)
11. Apixaban (5 mg od)
12. Apixaban (5 mg bd)
13. Apixaban (10 mg od)
14. Apixaban (10 mg bd)
15. Apixaban (20 mg od)
16. Betrixaban (15 mg bd)
17. Betrixaban (40 mg bd)
[18. Dabigatran (110 mg od)]
19. Dabigatran (150 mg od)
20. Dabigatran (220 mg od)
[21. Edoxaban (5 mg od)]
[22. Edoxaban (15 mg od)]
[23. Edoxaban (30 mg od)]
[24. Edoxaban (60 mg od)]
26. Rivaroxaban (2.5 mg bd)
28. Rivaroxaban (5 mg bd)
29. Rivaroxaban (10 mg od)
30. Rivaroxaban (10 mg bd)
33. Rivaroxaban (20 mg bd)
35. Rivaroxaban (30 mg bd)
FIGURE 40 Network plot for symptomatic PE in knee surgery patients (primary prevention of VTEs).
TABLE 91 Results for symptomatic PE in knee surgery patients (primary prevention of VTE): comparisons
with LMWH
Comparisons with LMWH
(post-op, standard dose)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (2.5 mg bd) 2.14 (1.00 to 4.94) – 2.14 (1.00 to 4.94)
Dabigatran (220mg od) 1.05 (0.39 to 2.85) – 1.05 (0.39 to 2.85)
Imprecisely estimated comparisons
LMWH pre-op (standard dose) – 0.90 (0.23 to 3.39) 0.90 (0.23 to 3.39)
Warfarin (INR 2–3) 3.44 (0.58 to 44.0) – 3.44 (0.58 to 44.0)
Apixaban (5 mg od) 0.31 (0 to 5.87) – 0.31 (0 to 5.87)
Apixaban (5 mg bd) 0.28 (0 to 5.31) – 0.28 (0 to 5.31)
Apixaban (10 mg od) 0.29 (0 to 5.32) – 0.29 (0 to 5.32)
Apixaban (10 mg bd) 1.43 (0.10 to 11.6) – 1.43 (0.10 to 11.6)
Apixaban (20 mg od) 1.42 (0.11 to 11.8) – 1.42 (0.11 to 11.8)
Betrixaban (15 mg bd) 2.99 (0.10 to 1930) – 2.99 (0.10 to 1930)
Betrixaban (40 mg bd) 3.23 (0.11 to 2070) – 3.23 (0.11 to 2070)
Dabigatran (150mg od) 0.19 (0.02 to 0.80) – 0.19 (0.02 to 0.80)
Rivaroxaban (2.5 mg bd) 1.03 (0 to 759) – 1.03 (0 to 759)
Rivaroxaban (5 mg bd) 11.0 (0.61 to 6860) – 11.0 (0.61 to 6860)
Rivaroxaban (10 mg od) 0.41 (0.12 to 1.17) – 0.41 (0.12 to 1.17)
Rivaroxaban (10 mg bd) 1.08 (0 to 769) – 1.08 (0 to 769)
Rivaroxaban (20 mg bd) 1.13 (0 to 887) – 1.13 (0 to 887)
Rivaroxaban (30 mg bd) 1.10 (0 to 781) – 1.10 (0 to 781)
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There was little evidence that risk of major bleeding differs between pre-op and post-op LMWH (standard
dose). There was evidence that risk of major bleeding is lower with warfarin (INR 2–3) and higher with
rivaroxaban (10 mg od) than LMWH (post-op, standard dose) (Table 99). We observed statistical
inconsistency between the direct and indirect estimates comparing dabigatran (220 mg od) with post-op
LMWH (standard dose). The direct evidence indicated a reduction in bleeding with dabigatran and the
indirect evidence indicated an increase. The estimated OR from the NMA was 1.20 (95% CI 0.75 to 1.92).
All three of these results had CIs compatible with increases and decreases in risk. There was evidence that
risk of major bleeding is higher with rivaroxaban (10 mg od) than with LMWH (post-op, standard dose)
and than apixaban (2.5 mg bd) and dabigatran (220 mg od) (Table 100).
TABLE 92 Results for symptomatic PE in knee surgery patients (primary prevention of VTE): NOACs
(licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd) – 0.49 (0.14 to 1.66) 0.49 (0.14 to 1.66)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd) – 0.19 (0.05 to 0.67) 0.19 (0.05 to 0.67)
Rivaroxaban (10 mg od) vs. dabigatran (220mg od) – 0.39 (0.09 to 1.58) 0.39 (0.09 to 1.58)
3. LMWH (standard dose)
[6. LMWH (nadroparin 3800 IU
     anti-Xa od)]
[9. Placebo]10. Apixaban (2.5 mg bd)
29. Rivaroxaban (10 mg od)
FIGURE 41 Network plot for symptomatic PE in medical patients (primary prevention of VTE).
TABLE 93 Results for symptomatic PE in medical patients (primary prevention of VTE): comparisons with LMWH
Comparisons with LMWH
(post-op, standard dose)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (2.5 mg bd) 0.88 (0.30 to 2.48) – 0.88 (0.30 to 2.48)
Rivaroxaban (10 mg od) 0.73 (0.31 to 1.64) – 0.73 (0.31 to 1.64)
TABLE 94 Results for symptomatic PE in medical patients (primary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd) – 0.83 (0.22 to 3.18) 0.83 (0.22 to 3.18)
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1. LMWH post-op (standard dose)
2. LMWH pre-op (standard dose)
(8. Warfarin variable)a
10. Apixaban (2.5 mg bd)
11. Apixaban (5 mg od)
12. Apixaban (5 mg bd)13. Apixaban (10 mg od)
14. Apixaban (10 mg bd)
15. Apixaban (20 mg od)
20. Dabigatran (220 mg od)
29. Rivaroxaban (10 mg od)
FIGURE 42 Network plot for MI (primary prevention of VTE). a, Excluded interventions that were included in
sensitivity analyses.
TABLE 95 Included trials and risk-of-bias assessment for MI (primary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
ADVANCE-1171 1, 10 ? ? + + + +
ADVANCE-2178 2, 10 + + + + + +
ADVANCE-3176 2, 10 + + + + ? +
APROPOS162 1, 7, 10, 11, 12, 13, 14, 15 + ? ? + + +
RECORD 1165 2, 29 + + ? + + +
RECORD 2166 2, 29 + + ? + + +
RECORD 3163 2, 29 ? + ? + + +
RECORD 4173 1, 29 + + ? + + +
RE-NOVATE II183,189 2, 20 + + + ? + +
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 96 Results for MI (primary prevention of VTE): comparisons with LMWH
Comparisons with LMWH
(post-op, standard dose) Direct evidence
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
LMWH pre-op (standard dose) – 0.37 (0.09 to 1.25) 0.37 (0.09 to 1.25)
Apixaban (2.5 mg bd) 0.65 (0.18 to 2.11) – 0.65 (0.18 to 2.11)
Apixaban (5 mg od) 0.75 (0.05 to 6.23) – 0.75 (0.05 to 6.23)
Apixaban (5 mg bd) 0.14 (0 to 2.63) – 0.14 (0 to 2.63)
Apixaban (10 mg od) 0.14 (0 to 2.61) – 0.14 (0 to 2.61)
Apixaban (10 mg bd) 0.14 (0 to 2.64) – 0.14 (0 to 2.64)
Apixaban (20 mg od) 0.14 (0 to 2.69) – 0.14 (0 to 2.69)
Dabigatran (220mg od) 0.37 (0.01 to 17.5) – 0.37 (0.01 to 17.5)
Rivaroxaban (10 mg od) 0.27 (0.07 to 0.88) – 0.27 (0.07 to 0.88)
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TABLE 97 Results for MI (primary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd) – 0.57 (0.01 to 26.4) 0.57 (0.01 to 26.4)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd) – 0.42 (0.12 to 1.44) 0.42 (0.12 to 1.44)
Rivaroxaban (10 mg od) vs. dabigatran (220mg od) – 0.74 (0.02 to 31.0) 0.74 (0.02 to 31.0)
1. LMWH post-op (standard dose)
2. LMWH pre-op (standard dose)
3. LMWH (standard dose)
4. LMWH (enoxaparin 20 mg bd)
6. LMWH (nadroparin 3800 IU anti-Xa od)
7. Warfarin (INR 2–3)
(8. Warfarin variable)a
9. Placebo
10. Apixaban (2.5 mg bd)
11. Apixaban (5 mg od)
12. Apixaban (5 mg bd)
13. Apixaban (10 mg od)
14. Apixaban (10 mg bd)
15. Apixaban (20 mg od)
16. Betrixaban (15 mg bd)
17. Betrixaban (40 mg bd)
18. Dabigatran (110 mg od)
19. Dabigatran (150 mg od)
20. Dabigatran (220 mg od)
21. Edoxaban (5 mg od)
22. Edoxaban (15 mg od)
23. Edoxaban (30 mg od)
24. Edoxaban (60 mg od)
25. Edoxaban (90 mg od)
26. Rivaroxaban (2.5 mg bd)
27. Rivaroxaban (5 mg od)
28. Rivaroxaban (5 mg bd)
29. Rivaroxaban (10 mg od)
30. Rivaroxaban (10 mg bd)
31. Rivaroxaban (20 mg od)
32. Rivaroxaban (30 mg od)
33. Rivaroxaban (20 mg bd)
34. Rivaroxaban (40 mg od)
35. Rivaroxaban (30 mg bd)
FIGURE 43 Network plot for major bleeding (primary prevention of VTE). a, Excluded interventions that were
included in sensitivity analyses.
TABLE 98 Included trials and risk-of-bias assessment for major bleeding (primary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
ADOPT188 3, 10 + + + + + +
ADVANCE-1171 1, 10 ? ? + + + +
ADVANCE-2178 2, 10 + + + + + +
ADVANCE-3176 2, 10 + + + + ? +
APROPOS162 1, 7, 10, 11, 12, 13, 14, 15 + ? ? + + +
EXPERT168 1, 16, 17 + ? – + + +
LIFENOX185 3, 9 + ? + + + +
MAGELLAN184,191 3, 29 + + + + + +
ODiXa-HIP2159 2, 26, 28, 30, 33, 35 ? ? + + + +
ODiXa-KNEE157 1, 26, 28, 30, 33, 35 + + + + + +
ODiXa-OD.HIP158 2, 27, 29, 31, 32, 34 ? ? + + + ?
PROTECHT170 6, 9 + + + + + +
RECORD 1165 2, 29 + + ? + + +
continued
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TABLE 98 Included trials and risk-of-bias assessment for major bleeding (primary prevention of VTE) (continued )
Study Interventions compared SG AC BPP BOA IOD SR
RECORD 2166 2, 29 + + ? + + +
RECORD 3163 2, 29 ? + ? + + +
RECORD 4173 1, 29 + + ? + + +
RE-MOBILISE167 1, 19, 20 + + + + + +
RE-MODEL161 2, 19, 20 + + ? ? + +
RE-NOVATE160 2, 19, 20 + + + + + +
RE-NOVATE II183,189 2, 20 + + + ? + +
STARS E-3182 4, 23 ? + ? ? ? ?
STARS J-1172,180 9, 21, 22, 23, 24 + ? ? + + +
STARS J-4181,193 4, 23 ? ? – + + +
STARS J-V179 4, 23 ? ? ? ? + +
VTE-APIX-PLACEBO-USACAN190 9, 11, 13, 15 + + + + + +
VTE-DABIG-PLAC-JAPAN175 9, 18, 19, 20 + ? ? ? + +
VTE-EDOX-LMWH-MULTI177 1, 22, 23, 24, 25 + + + + + +
VTE-LMWH-PLAC-CAN169 2, 9 + ? ? ? + ?
VTE-LMWH-PLAC-JAPAN186 1, 4, 9 ? ? ? + + ?
VTE-VKA-LMWH-CANADA152 1, 7 + ? + + + ?
VTE-VKA-LMWH-US153 2, 7 ? ? – + + ?
VTE-VKA-LMWH-US-2154 1, 7 ? ? – ? + ?
VTE-VKA-LMWH-US-3153 1, 2, 7 + ? + + + ?
VTE-VKA-LMWH-US-4154 1, 7 ? + – + + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 99 Results for major bleeding (primary prevention of VTE): comparisons with LMWH
Comparisons with LMWH
(post-op, standard dose)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
LMWH pre-op (standard dose) 1.32 (0.85 to 2.06) 0.90 (0.58 to 1.40) 1.09 (0.79 to 1.49)
Warfarin (INR 2–3) 0.59 (0.39 to 0.88) 0.47 (0.18 to 1.23) 0.57 (0.39 to 0.82)
Placebo 0.68 (0.31 to 1.50) 1.75 (0.36 to 8.54) 0.82 (0.41 to 1.64)
Apixaban (2.5 mg bd) 0.93 (0.55 to 1.58) 1.02 (0.57 to 1.82) 0.97 (0.65 to 1.45)
Dabigatran (150mg od) 0.39 (0.13 to 1.16) 1.00 (0.53 to 1.89) 0.79 (0.465 to 1.35)
Dabigatran (220mg od) 0.39 (0.13 to 1.17) 1.55 (0.92 to 2.60) 1.20 (0.755 to 1.92)
Rivaroxaban (10 mg od) 2.86 (1.67 to 4.88) 1.41 (0.61 to 3.26) 2.33 (1.515 to 3.68)
Imprecisely estimated comparisons
LMWH (enoxaparin 20 mg bd) – 2.98 (0.18 to 93.9) 2.98 (0.185 to 93.9)
LMWH (nadroparin 3800 IU anti-Xa od) – 9.42 (0.61 to 4420) 9.42 (0.615 to 4420)
Apixaban (5 mg od) 3.53 (0.75 to 23.1) – 3.53 (0.755 to 23.1)
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Clinically relevant bleeding
Twenty-five studies reported 1973 CRB events, leading to a network of 29 interventions (Figure 44). The
studies were mostly judged to be at low risk of bias (Table 101), although there were some concerns
about lack of blinding of participants and personnel.
TABLE 99 Results for major bleeding (primary prevention of VTE): comparisons with LMWH (continued )
Comparisons with LMWH
(post-op, standard dose)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (5 mg bd) 4.66 (0.93 to 31.3) – 4.66 (0.935 to 31.3)
Apixaban (10 mg od) 1.25 (0.14 to 10.0) – 1.25 (0.14 to 10.0)
Apixaban (10 mg bd) 4.65 (0.95 to 30.9) – 4.65 (0.95 to 30.9)
Apixaban (20 mg od) 5.94 (1.49 to 37.4) – 5.94 (1.49 to 37.4)
Betrixaban (15 mg bd) 0.09 (0 to 2.90) – 0.09 (0 to 2.90)
Betrixaban (40 mg bd) 0.10 (0 to 3.02) – 0.10 (0 to 3.02)
Dabigatran (110 mg od) – 0.63 (0.05 to 3.72) 0.63 (0.05 to 3.72)
Edoxaban (5 mg od) – 0.85 (0 to 51.4) 0.85 (0 to 51.4)
Edoxaban (15 mg od) – 2.03 (0.16 to 55.4) 2.03 (0.165 to 55.4)
Edoxaban (30 mg od) – 2.24 (0.17 to 61.1) 2.24 (0.17 to 61.1)
Edoxaban (60 mg od) – 3.32 (0.36 to 87.5) 3.32 (0.36 to 87.5)
Edoxaban (90 mg od) – 4.80 (0.42 to 135) 4.80 (0.42 to 135)
Rivaroxaban (2.5 mg bd) – 0.56 (0.09 to 2.78) 0.56 (0.09 to 2.78)
Rivaroxaban (5 mg od) – 2.90 (0.52 to 14.2) 2.90 (0.52 to 14.2)
Rivaroxaban (5 mg bd) 0.79 (0.16 to 3.53) – 0.79 (0.16 to 3.53)
Rivaroxaban (10 mg bd) 1.31 (0.36 to 5.32) – 1.31 (0.36 to 5.32)
Rivaroxaban (20 mg od) – 5.77 (1.53 to 24.4) 5.77 (1.53 to 24.4)
Rivaroxaban (30 mg od) – 6.69 (1.87 to 27.7) 6.69 (1.87 to 27.7)
Rivaroxaban (20 mg bd) 2.41 (0.77 to 9.05) – 2.41 (0.77 to 9.05)
Rivaroxaban (40 mg od) – 6.98 (1.92 to 28.6) 6.98 (1.92 to 28.6)
Rivaroxaban (30 mg bd) 4.46 (1.43 to 16.9) – 4.46 (1.43 to 16.9)
TABLE 100 Results for major bleeding (primary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (220 mg od) vs. apixaban (2.5 mg bd) – 1.23 (0.72 to 2.12) 1.23 (0.72 to 2.12)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd) – 2.40 (1.37 to 4.29) 2.40 (1.37 to 4.29)
Rivaroxaban (10 mg od) vs. dabigatran (220mg od) – 1.95 (1.06 to 3.61) 1.95 (1.06 to 3.61)
Imprecisely estimated comparisons
Edoxaban (30 mg od) vs. apixaban (2.5 mg bd) – 2.31 (0.16 to 64.3) 2.31 (0.16 to 64.3)
Edoxaban (30 mg od) vs. dabigatran (220mg od) – 1.87 (0.13 to 52.5) 1.87 (0.13 to 52.5)
Rivaroxaban (10 mg od) vs. edoxaban (30mg od) – 1.04 (0.04 to 14.5) 1.04 (0.04 to 14.5)
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1. LMWH post-op (standard dose)
2. LMWH pre-op (standard dose)
3. LMWH (standard dose)
4. LMWH (enoxaparin 20 mg bd)
9. Placebo
10. Apixaban (2.5 mg bd)
11. Apixaban (5 mg od)
13. Apixaban (10 mg od)
15. Apixaban (20 mg od)
16. Betrixaban (15 mg bd)
17. Betrixaban (40 mg bd)
18. Dabigatran (110 mg od)
19. Dabigatran (150 mg od)
20. Dabigatran (220 mg od)
21. Edoxaban (5 mg od)22. Edoxaban (15 mg od)
23. Edoxaban (30 mg od)
24. Edoxaban (60 mg od)
25. Edoxaban (90 mg od)
26. Rivaroxaban (2.5 mg bd)
27. Rivaroxaban (5 mg od)
28. Rivaroxaban (5 mg bd)
29. Rivaroxaban (10 mg od)
30. Rivaroxaban (10 mg bd)
31. Rivaroxaban (20 mg od)
32. Rivaroxaban (30 mg od)
33. Rivaroxaban (20 mg bd)
34. Rivaroxaban (40 mg od)
35. Rivaroxaban (30 mg bd)
FIGURE 44 Network plot for CRB (primary prevention of VTE).
TABLE 101 Included trials and risk-of-bias assessment for CRB (primary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
ADOPT188 3, 10 + + + + + +
ADVANCE-1171 1, 10 ? ? + + + +
ADVANCE-2178 2, 10 + + + + + +
ADVANCE-3176 2, 10 + + + + + +
EXPERT168 1, 16, 17 + ? – + + +
LIFENOX185 3, 9 + ? + + + +
MAGELLAN184,191 3, 29 + + + + + +
ODiXa-HIP2159 2, 26, 28, 30, 33, 35 ? ? + + + +
ODiXa-KNEE157 1, 26, 28, 30, 33, 35 + + + + + +
ODiXa-OD.HIP158 2, 27, 29, 31, 32, 34 ? ? + + + ?
RECORD 1165 2, 29 + + ? + + +
RECORD 2166 2, 29 + + ? + + +
RECORD 3163 2, 29 ? + ? + + +
RECORD 4173 1, 29 + + ? + + +
RE-MODEL161 2, 19, 20 + + ? ? + +
RE-NOVATE160 2, 19, 20 + + + + + +
RE-NOVATE II183,189 2, 20 + + + ? + +
STARS E-3182 4, 23 ? + ? ? ? ?
STARS J-1172,180 9, 21, 22, 23, 24 + ? ? + + +
STARS J-2174 4, 22, 23 ? ? – + + +
STARS J-4181,193 4, 23 ? ? – + + +
STARS J-V179 4, 23 ? ? ? ? ? +
VTE-APIX-PLACEBO-USACAN190 9, 11, 13, 15 + + + + + +
VTE-DABIG-PLAC-JAPAN175 9, 18, 19, 20 + ? ? ? + +
VTE-EDOX-LMWH-MULTI177 1, 22, 23, 24, 25 + + + + + +
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
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There was evidence that risk of CRB is higher for pre-op LMWH (standard dose) than post-op LMWH
(standard dose), and higher for dabigatran (150 mg or 220 mg od) and rivaroxaban (10 mg od) than
LMWH (post-op, standard dose) (Table 102). We observed statistical inconsistency between direct and
indirect estimates comparing rivaroxaban with post-op LMWH (standard dose). In particular, the direct
evidence for rivaroxaban (5 mg bd) indicated a reduction in bleeding with rivaroxaban, whereas the
indirect evidence indicated an increase. The combined estimate for this comparison from the NMA
suggested a small increase with OR 1.53 (95% CI 0.54 to 4.47); all three of these results had CIs
compatible with increases and decreases in risk. There was evidence that risk of CRB is higher for
dabigatran (220 mg od) and rivaroxaban (10 mg od) than apixaban (2.5 mg bd) (Table 103).
TABLE 102 Results for CRB (primary prevention of VTE): comparisons with LMWH
Comparisons with LMWH
(post-op, standard dose)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
LMWH pre-op (standard dose) – 1.30 (1.03 to 1.62) 1.30 (1.03 to 1.62)
Placebo 0.71 (0.45 to 1.12) – 0.71 (0.45 to 1.12)
Apixaban (2.5 mg bd) 0.97 (0.76 to 1.24) 1.16 (0.74 to 1.82) 1.06 (0.86 to 1.30)
Dabigatran (150 mg od) – 1.53 (1.09 to 2.15) 1.53 (1.09 to 2.15)
Dabigatran (220 mg od) – 1.55 (1.12 to 2.15) 1.55 (1.12 to 2.15)
Rivaroxaban (10 mg od) 1.85 (1.52 to 2.26) 1.30 (0.91 to 1.85) 1.85 (1.52 to 2.26)
Rivaroxaban (5 mg bd) 0.56 (0.11 to 2.54) 5.94 (1.76 to 20.0) 2.45 (0.97 to 6.73)
Rivaroxaban (10 mg bd) 0.55 (0.11 to 2.49) 3.55 (0.85 to 14.9) 1.53 (0.54 to 4.47)
Rivaroxaban (20 mg od) 1.93 (0.68 to 5.07) – 1.93 (0.68 to 5.07)
Rivaroxaban (30 mg od) 2.81 (1.13 to 6.88) – 2.81 (1.13 to 6.88)
Rivaroxaban (20 mg bd) 1.84 (0.57 to 6.44) 10.5 (2.47 to 44.4) 3.73 (1.57 to 9.98)
Rivaroxaban (40 mg od) 3.26 (1.34 to 7.89) – 3.26 (1.34 to 7.89)
Rivaroxaban (30 mg bd) 3.53 (1.25 to 11.1) 32.5 (4.47 to 236) 5.94 (2.39 to 16.4)
Imprecisely estimated comparisons
LMWH (enoxaparin 20 mg bd) – 1.25 (0.35 to 4.95) 1.25 (0.35 to 4.95)
Apixaban (5 mg od) – 0.64 (0.02 to 32.0) 0.64 (0.02 to 32.0)
Apixaban (10 mg od) – 0.71 (0.02 to 36.0) 0.71 (0.02 to 36.0)
Apixaban (20 mg od) – 3.78 (0.41 to 150) 3.78 (0.41 to 150)
Betrixaban (15 mg bd) 0.03 (0 to 0.54) – 0.03 (0 to 0.54)
Betrixaban (40 mg bd) 0.33 (0.05 to 1.88) – 0.33 (0.05 to 1.88)
Dabigatran (110 mg od) – 0.25 (0.01 to 1.63) 0.25 (0.01 to 1.63)
Edoxaban (5 mg od) 0.54 (0.06 to 3.04) – 0.54 (0.06 to 3.04)
Edoxaban (15 mg od) 1.40 (0.43 to 5.03) – 1.40 (0.43 to 5.03)
Edoxaban (30 mg od) 1.42 (0.44 to 5.17) – 1.42 (0.44 to 5.17)
Edoxaban (60 mg od) 1.77 (0.56 to 6.33) – 1.77 (0.56 to 6.33)
Edoxaban (90 mg od) 2.13 (0.49 to 9.24) – 2.13 (0.49 to 9.24)
Rivaroxaban (2.5 mg bd) 1.01 (0.31 to 3.18) – 1.01 (0.31 to 3.18)
Rivaroxaban (5 mg od) 1.46 (0.43 to 4.16) – 1.46 (0.43 to 4.16)
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All-cause mortality
Twenty-four studies reported 1161 all-cause mortality events, leading to a network of 29 interventions
(Figure 45). The studies were mostly judged to be at low risk of bias (Table 104), with some concerns
about lack of blinding of participants and personnel.
Rates of all-cause mortality were substantially higher in studies of patients with cancer than in studies
of surgical patients (see Table 73). There was little evidence that risk of all-cause mortality differed for
any intervention compared with LMWH (post-op, standard dose) (Table 105). We observed statistical
inconsistency between the direct and indirect estimates comparing apixaban (2.5 mg bd) with post-op
LMWH (standard dose). The direct evidence indicated a reduction in bleeding with apixaban and the
indirect evidence showed an increase. The combined estimate from the NMA suggested a small increase
with OR 1.57 (95% CI 0.6 to 4.37). Comparisons between licensed doses of NOACs were imprecisely
estimated (Table 106).
Summary of results and ranking of interventions
Despite the substantial number of patients randomised to trials of primary prevention of VTE, low numbers
of clinically relevant outcome events meant that most comparisons were imprecisely estimated. Conclusions
can mainly be drawn from analyses of symptomatic VTE, major bleeding and CRB. There was evidence that
TABLE 103 Results for CRB (primary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (220mg od) vs. apixaban (2.5 mg bd) – 1.47 (1.09 to 1.98) 1.47 (1.09 to 1.98)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd) – 1.75 (1.40 to 2.20) 1.75 (1.40 to 2.20)
Rivaroxaban (10 mg od) vs. dabigatran (220mg od) – 1.19 (0.88 to 1.63) 1.19 (0.88 to 1.63)
Imprecisely estimated comparisons
Edoxaban (30 mg od) vs. apixaban (2.5 mg bd) – 1.34 (0.41 to 5.00) 1.34 (0.41 to 5.00)
Edoxaban (30 mg od) vs. dabigatran (220mg od) – 0.92 (0.27 to 3.44) 0.92 (0.27 to 3.44)
Rivaroxaban (10 mg od) vs. edoxaban (30mg od) – 1.30 (0.35 to 4.32) 1.30 (0.35 to 4.32)
1. LMWH post-op (standard dose)
2. LMWH pre-op (standard dose)
3. LMWH (standard dose)
[4. LMWH (enoxaparin 20 mg bd)]
6. LMWH (nadroparin 3800 IU anti-Xa od)
7. Warfarin (INR 2–3)
(8. Warfarin variable)a
9. Placebo
10. Apixaban (2.5 mg bd)
11. Apixaban (5 mg od)
12. Apixaban (5 mg bd)
13. Apixaban (10 mg od)
14. Apixaban (10 mg bd)
15. Apixaban (20 mg od)
[18. Dabigatran (110 mg od)]
19. Dabigatran (150 mg od)20. Dabigatran (220 mg od)
22. Edoxaban (15 mg od)
23. Edoxaban (30 mg od)
24. Edoxaban (60 mg od)
25. Edoxaban (90 mg od)
26. Rivaroxaban (2.5 mg bd)
27. Rivaroxaban (5 mg od)
28. Rivaroxaban (5 mg bd)
29. Rivaroxaban (10 mg od)
[30. Rivaroxaban (10 mg bd)]
[31. Rivaroxaban (20 mg od)]
[32. Rivaroxaban (30 mg od)]
[33. Rivaroxaban (20 mg bd)]
[34. Rivaroxaban (40 mg od)]
[35. Rivaroxaban (30 mg bd)]
FIGURE 45 Network plot for all-cause mortality (primary prevention of VTE). a, Excluded interventions that were
included in sensitivity analyses.
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TABLE 104 Included trials and risk-of-bias assessment for all-cause mortality (primary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
ADVANCE-1171 1, 10 ? ? + + + +
ADVANCE-2178 2, 10 + + + + + +
ADVANCE-3176 2, 10 + + + + ? +
APROPOS162 1, 7, 10, 11, 12, 13, 14, 15 + ? ? + + +
LIFENOX185 3, 9 + ? + + + +
MAGELLAN184,191 3, 29 + + + + + +
ODiXa-KNEE157 1, 26, 28, 30, 33, 35 + + + + + +
ODiXa-OD.HIP158 2, 27, 29, 31, 32, 34 ? ? + + + ?
PROTECHT170 6, 9 + + + + + +
RECORD 1165 2, 29 + + ? + + +
RECORD 2166 2, 29 + + ? + + +
RECORD 3163 2, 29 ? + ? + + +
RECORD 4173 1, 29 + + ? + + +
RE-MOBILISE167 1, 19, 20 + + + + + +
RE-MODEL161 2, 19, 20 + + ? ? + +
RE-NOVATE II183,189 2, 20 + + + ? + +
STARS J-4181,193 4, 23 ? ? – + + +
VTE-DABIG-PLAC-JAPAN175 9, 18, 19, 20 + ? ? ? + +
VTE-EDOX-LMWH-MULTI177 1, 22, 23, 24, 25 + + + + + +
VTE-LMWH-PLAC-CAN169 2, 9 + ? ? ? + ?
VTE-VKA-LMWH-CANADA152 1, 7 + ? + + + ?
VTE-VKA-LMWH-US-2154 1, 7 ? ? – ? + ?
VTE-VKA-LMWH-US-3153 1, 2, 7 + ? + + + ?
VTE-VKA-LMWH-US-4154 1, 7 ? + – + + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 105 Results for all-cause mortality (primary prevention of VTE): comparisons with LMWH
Comparisons
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
LMWH pre-op (standard dose) 2.00 (0.30 to 13.47) 1.79 (0.86 to 3.74) 1.82 (0.93 to 3.62)
LMWH (nadroparin 3800 IU anti-Xa od) – 1.06 (0.57 to 2.05) 1.06 (0.57 to 2.05)
Warfarin (INR 2–3) 1.44 (0.69 to 3.06) – 1.44 (0.69 to 3.06)
Placebo 1.03 (0.88 to 1.20) – 1.03 (0.88 to 1.20)
Apixaban (2.5 mg bd) 0.66 (0.18 to 2.29) 6.29 (1.25 to 31.5) 1.57 (0.6 to 4.37)
Rivaroxaban (10 mg od) 1.06 (0.85 to 1.33) 0.80 (0.35 to 1.83) 1.04 (0.83 to 1.29)
continued
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risk of symptomatic VTE is lower with rivaroxaban (10 mg od) than LMWH (pre-op, standard dose) in hip
surgery patients, but that risk of major bleeding and CRB is higher with rivaroxaban (10 mg od) than LMWH
(post-op, standard dose).
We conducted sensitivity analyses merging warfarin interventions with variable INR range with those with
INR range 2–3. Results, which are available from the authors up request, were similar to those presented
above. With regard to model appraisal, we did not identify any instance of lack of convergence among the
Markov chains or poor model fit. There were some instances of inconsistency between direct and indirect
estimates of the same effect, although in most instances these results were accompanied by wide CIs. Few
of the comparisons were replicated across studies; when there were multiple estimates we did not find
evidence of statistical heterogeneity.
Because of the substantial imprecision in comparisons of efficacy outcomes, we present only one
rankogram containing the bleeding and death outcomes for which all patients were jointly analysed
(Figure 46). Warfarin was ranked with high probability as the best intervention for major bleeding events,
and LMWH (post-op, standard dose) was ranked with high probability as best, or second-best, intervention
for CRB. Rivaroxaban (10 mg od) was ranked among the worst interventions for bleeding outcomes.
TABLE 106 Results for all-cause mortality (primary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Rivaroxaban (10 mg od) vs. apixaban (2.5 mg bd) – 0.66 (0.23 to 1.76) 0.66 (0.23 to 1.76)
Imprecisely estimated comparisons
Dabigatran (220mg od) vs. apixaban (2.5 mg bd) – 0.66 (0.10 to 3.85) 0.66 (0.10 to 3.85)
Edoxaban (30 mg od) vs. apixaban (2.5 mg bd) – 8.79 (0.44 to 3220) 8.79 (0.44 to 3220)
Edoxaban (30 mg od) vs. dabigatran (220mg od) – 13.8 (0.53 to 5360) 13.8 (0.53 to 5360)
Rivaroxaban (10 mg od) vs. dabigatran (220mg od) – 0.99 (0.21 to 4.95) 0.99 (0.21 to 4.95)
Rivaroxaban (10 mg od) vs. edoxaban (30mg od) – 0.08 (0 to 1.22) 0.08 (0 to 1.22)
TABLE 105 Results for all-cause mortality (primary prevention of VTE): comparisons with LMWH (continued )
Comparisons
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (5 mg od) 0.41 (0 to 9.80) – 0.41 (0 to 9.80)
Apixaban (5 mg bd) 0.37 (0 to 9.27) – 0.37 (0 to 9.27)
Apixaban (10 mg od) 0.38 (0 to 9.42) – 0.38 (0 to 9.42)
Apixaban (10 mg bd) 0.36 (0 to 8.91) – 0.36 (0 to 8.91)
Apixaban (20 mg od) 0.36 (0 to 8.71) – 0.36 (0 to 8.71)
Dabigatran (150mg od) 1.49 (0.31 to 7.13) – 1.49 (0.31 to 7.13)
Dabigatran (220mg od) 1.04 (0.21 to 4.86) – 1.04 (0.21 to 4.86)
Edoxaban (15 mg od) 4.37 (0.15 to 1610) – 4.37 (0.15 to 1610)
Edoxaban (30 mg od) 13.6 (0.87 to 4510) – 13.6 (0.87 to 4510)
Edoxaban (60 mg od) 0.88 (0 to 421) – 0.88 (0 to 421)
Edoxaban (90 mg od) 0.93 (0 to 423) – 0.93 (0 to 423)
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FIGURE 46 Rankogram for licensed interventions examined in primary prevention of VTE.
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Chapter 8 Clinical results (3): acute treatment of
venous thromboembolism
Included studies
Nine completed RCTs with 10 references202–211 were identified for inclusion in the review of acute
treatment of VTE (see Figure 32), as well as one ongoing trial.212 A summary of the characteristics
of the nine included studies202–211 is presented in Table 107. All studies were multicentre and many
were conducted across countries in North and South America, Europe, Asia, Australia, New Zealand,
South Africa, Russia and Israel. Six were Phase III205–211 studies and three were Phase II202–204 studies.
The number of patients randomised ranged from 520 to 8292, with a total of 28,803 patients across
the nine studies. The Phase III studies examined edoxaban, apixaban, dabigatran and rivaroxaban, and
these studies randomised 27,127 patients (94% of the total). The Phase II studies,202–204 which examined
apixaban and rivaroxaban, contributed 1676 patients (6%).
Eligibility criteria were similar across studies: all patients had acute symptomatic and objectively confirmed
DVT and/or PE. The mean ages of included patients were similar, ranging from 54.7 to 59.1 years.
The percentage of males across studies ranged from 51% to 62%. Mean BMI was reported by
four studies,202,203,205,211 ranged from 27 to 28.9 kg/m2, and was comparable between study arms.
Five studies203,204,209–211 reported percentages of cancer cases, which were comparable between study
arms and ranged from 2% to 12%.
All of the studies compared a NOAC with standard intensity warfarin (INR 2–3): mean TTR ranged
from 50.3% to 62.7%. Of the studies that examined rivaroxaban, two Phase III studies administered
15 mg bd and two Phase II studies examined six dosing strategies. Two studies examined apixaban:
one Phase III study administered 5 mg bd and one Phase II study compared this with two alternative
dosing strategies. Two Phase III studies examined dabigatran 150 mg bd; and one Phase III study
examined edoxaban 60 mg od.
Treatment duration ranged from 12 to 48 weeks in the rivaroxaban studies, from 12 to 24 weeks in the
apixaban studies, from 12 to 48 weeks in the edoxaban study and was 24 weeks in the dabigatran
studies. Reported efficacy and safety outcome types were similar across studies and reported at the end
of the treatment periods. All nine studies202–211 reported symptomatic DVT, symptomatic PE and major
bleeding. Eight studies reported all-cause mortality and CRB, seven reported symptomatic VTE and five
reported MI. Each of the studies was sponsored by one or more pharmaceutical companies. In almost
all studies the sponsor(s) was responsible for the study design and data collection, and in some cases
data analysis.
Time in therapeutic range for warfarin interventions
Table 108 shows the comparator interventions, target INR and (where reported) mean TTR for the nine
studies202–211 that included a warfarin intervention arm. Eight202,204–211 (89%) of these studies reported mean
TTR, which varied between 56.9% and 63.5%.
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Risk of bias in included studies
Table 109 shows the detailed risk-of-bias assessments for each included study for each domain. Generally,
the studies were judged to be at low risk of bias. The randomisation sequence was predominantly computer
generated. The studies were judged to be at low risk of bias for sequence generation, blinding of outcome
assessment and selective reporting, although one study did not explain how randomisation was performed,
stating only that a veiled randomisation process was carried out. In all studies, concealed allocation to
intervention arms was achieved through central allocation, either an interactive voice or a web-based system.
Five studies were of open-label design and, as such, were judged to be of high risk of bias for blinding of
participants and personnel. Completeness of the data analysed depended – in a few studies – on whether
the outcome was for efficacy or safety. For the majority of outcomes all patients were accounted for in the
analysis or, in some situations, a small number of patients were not included in the analysis but reasons
were provided and judged to be similar across intervention arms and unlikely to be related to the outcome.
These studies were therefore judged to be at low risk of bias as a result of incomplete outcome data.
In one study the reasons for not including some patients in the efficacy analyses were judged to be similar
across study arms but were judged to be potentially related to the outcome, and the study was therefore
considered at high risk of bias for the domain. Outcomes were reported as stated in the protocols in all
studies, which were therefore judged to be at low risk of bias because of selective reporting. Risk-of-bias
judgements for studies contributing to analyses of each outcome are presented graphically in the sections
that follow.
Results of clinical effectiveness and safety
The nine trials of acute treatment for VTE examined 13 distinct interventions (Table 110). Tables 111 and
112 show the number of outcome events for each outcome as reported in each trial. We performed NMAs
for seven outcomes: symptomatic DVT, symptomatic PE, symptomatic VTE, MI, major bleeding, CRB and
all-cause mortality.
Results are presented as follows for each of the seven outcomes. First, we provide network plots to
illustrate the comparisons of interventions made in the different trials. Second, we illustrate the risk-of-bias
assessments specific to the outcome for each trial included in the network. Third, we present results tables
TABLE 108 Mean TTR for warfarin in acute treatment of VTE
Study
Interventions that were compared
with warfarin
Warfarin
INR
Mean time (%) in
therapeutic range (INR)
AMPLIFY210 Apixaban 5mg bd 2–3 61
BOTTICELLI DVT204 Apixaban 5mg, 10 mg, 20 mg bd 2–3 57
EINSTEIN DVT206 Rivaroxaban 15mg bd (then 20mg od) 2–3 57.7
EINSTEIN DVT dose-ranging
study203
Rivaroxaban 20mg, 30 mg, 40 mg od 2–3 NR
EINSTEIN PE207 Rivaroxaban 15mg bd (then 20mg od) 2–3 62.7
HOKUSAI-VTE208,209 Edoxaban 60mg od 2–3 63.5
ODiXa-DVT202 Rivaroxaban 10mg, 20 mg, 30 mg bd, 40 mg od 2–3 60
RE-COVER205 Dabigatran 150 mg bd 2–3 59.9
RE-COVER II211 Dabigatran 150 mg bd 2–3 56.9
NR, not reported.
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for each intervention compared with the reference treatment (warfarin with a target INR range of 2–3).
Fourth, we present results tables for pairwise comparisons among licensed doses of the NOACs. For both
sets of results tables, posterior median ORs and 95% credible intervals from Bayesian fixed-effects analyses
are shown, although we refer to the latter as CIs for convenience. In these tables we present results
separately for any available direct evidence, for any indirect comparisons that can be made (excluding the
direct evidence) and for the NMA (which combines the direct and the indirect evidence). Comparisons
from the NMA with a ratio between interval limits exceeding nine were considered ‘imprecisely estimated’
and are presented at the bottom of each table (note that calculation of indirect evidence was not
undertaken for imprecisely estimated comparisons). A summary of results across outcomes is provided at
the end in the form of a ‘rankogram’, which illustrates the probability that each treatment is best, second
best, and so on, for each outcome. Last, forest plots of all contributing data, with ORs calculated using
standard frequentist methods, are included in Appendix 4.
Symptomatic venous thromboembolism
Eight studies reported 728 symptomatic VTE events, leading to a network of 11 interventions (Figure 47).
Table 113 shows risk-of-bias judgements for these studies. They were mostly judged to be at low risk of
bias, although there were some concerns about lack of blinding of participants and personnel. There was
little evidence that risk of symptomatic VTE differed for any of the NOAC interventions compared with
warfarin (INR 2–3) (Table 114). Neither was there evidence that risk of symptomatic VTE differed between
licensed doses of NOACs (Table 115).
Symptomatic deep-vein thrombosis
Nine studies reported 351 symptomatic DVT events, leading to a network of 13 interventions (Figure 48).
The studies were mostly judged to be at low risk of bias (Table 116), with some concerns about lack of
blinding of participants and personnel. There was little evidence that risk of symptomatic DVT differed for
any of the NOAC interventions compared with warfarin (INR 2–3) (Table 117). Neither was there evidence
that risk of symptomatic VTE differed between licensed doses of NOACs (Table 118).
TABLE 110 List of distinct interventions examined by
included randomised trials in acute treatment of VTE
1. Warfarin (INR 2–3)
2. Apixaban (5 mg bd)
3. Apixaban (10mg bd)
4. Apixaban (20mg od)
5. Dabigatran (150mg bd)
6. Edoxaban [60 or 30 (17.6%) mg od]a
7. Rivaroxaban (10 mg bd)
8. Rivaroxaban (20 mg od)
9. Rivaroxaban (15 mg bd then 20mg od)
10. Rivaroxaban (30 mg od)
11. Rivaroxaban (20 mg bd)
12. Rivaroxaban (40 mg od)
13. Rivaroxaban (30 mg bd)
a The planned edoxaban dose in the HOKUSAI-VTE
study208,209 was 60 mg od, but 17.6% of the patients in
that intervention arm received a lower dose of 30 mg od).
This intervention is denoted ‘Edoxaban [60 or 30 (17.6%)
mg od]’.
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1. Warfarin (INR 2–3)
2. Apixaban (5 mg bd)
5. Dabigatran (150 mg bd)
6. Edoxaban [60 or 30 (17.6%)
    mg od]
7. Rivaroxaban (10 mg bd)
8. Rivaroxaban (20 mg od)9. Rivaroxaban (15 mg bd
    then 20 mg od)
10. Rivaroxaban (30 mg od)
11. Rivaroxaban (20 mg bd)
12. Rivaroxaban (40 mg od)
13. Rivaroxaban (30 mg bd)
FIGURE 47 Network plot for symptomatic VTE (acute treatment of VTE).
TABLE 113 Included trials and risk-of-bias assessment for symptomatic VTE (acute treatment of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
AMPLIFY210 1, 2 + + + + ? +
EINSTEIN DVT206 1, 9 + + − + + +
EINSTEIN DVT dose-ranging study203 1, 8, 10, 12 + + − + − +
EINSTEIN PE207 1, 9 + + − + + +
HOKUSAI-VTE208,209 1, 2 + + + + + +
ODiXa-DVT202 1, 7, 11, 12, 13 + + ? + + +
RE-COVER205 1, 5 + + + + + +
RE-COVER II211 1, 5 + + + + + +
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 114 Results for symptomatic VTE (acute treatment of VTE): comparisons with warfarin (INR 2–3)
Comparisons
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
With warfarin (INR 2–3)
Apixaban (5 mg bd) 0.83 (0.58 to 1.18) – 0.83 (0.58 to 1.18)
Dabigatran (150mg bd) 1.09 (0.75 to 1.58) – 1.09 (0.75 to 1.58)
Edoxaban [60 or 30 (17.6%) mg od] 0.89 (0.70 to 1.13) – 0.89 (0.70 to 1.13)
Rivaroxaban (15 mg bd then 20mg od) 0.90 (0.67 to 1.20) – 0.90 (0.67 to 1.20)
Imprecisely estimated comparisons
Rivaroxaban (10 mg bd) 0.77 (0.09 to 4.53) – 0.77 (0.09 to 4.53)
Rivaroxaban (20 mg od) 0.44 (0.09 to 1.76) – 0.44 (0.09 to 1.76)
Rivaroxaban (30 mg od) 0.63 (0.15 to 2.29) – 0.63 (0.15 to 2.29)
Rivaroxaban (20 mg bd) 0.81 (0.09 to 4.81) – 0.81 (0.09 to 4.81)
Rivaroxaban (40 mg od) 0.52 (0.15 to 1.65) – 0.52 (0.15 to 1.65)
Rivaroxaban (30 mg bd) 0.73 (0.09 to 4.42) – 0.73 (0.09 to 4.42)
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TABLE 115 Results for symptomatic VTE (acute treatment of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) – 1.31 (0.79 to 2.19) 1.31 (0.79 to 2.19)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban
(5 mg bd)
– 1.06 (0.70 to 1.63) 1.06 (0.70 to 1.63)
Rivaroxaban (15 mg bd then 20mg od) vs. apixaban
(5 mg bd)
– 1.08 (0.68 to 1.71) 1.08 (0.68 to 1.71)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran
(150mg bd)
– 0.81 (0.52 to 1.27) 0.81 (0.52 to 1.27)
Rivaroxaban (15 mg bd then 20mg od) vs. dabigatran
(150mg bd)
– 0.82 (0.51 to 1.33) 0.82 (0.51 to 1.33)
Rivaroxaban (15 mg bd then 20mg od) vs. edoxaban
[60 or 30 (17.6%) mg od]
– 1.01 (0.69 to 1.48) 1.01 (0.69 to 1.48)
1. Warfarin (INR 2–3)
2. Apixaban (5 mg bd)
3. Apixaban (10 mg bd)
4. Apixaban (20 mg od)
5. Dabigatran (150 mg bd)
6. Edoxaban [60 or 30 (17.6%) mg od]
7. Rivaroxaban (10 mg bd)8. Rivaroxaban (20 mg od)
9. Rivaroxaban (15 mg bd
    then 20 mg od)
10. Rivaroxaban (30 mg od)
11. Rivaroxaban (20 mg bd)
12. Rivaroxaban (40 mg od)
13. Rivaroxaban (30 mg bd)
FIGURE 48 Network plot for symptomatic DVT (acute treatment of VTE).
TABLE 116 Included trials and risk-of-bias assessment for symptomatic DVT (acute treatment of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
AMPLIFY210 1, 2 + + + + + +
BOTTICELLI DVT204 1, 2, 3, 4 ? + – + + +
EINSTEIN DVT206 1, 9 + + – + + +
EINSTEIN DVT dose-ranging study203 1, 8, 10, 12 + + – + – +
EINSTEIN PE207 1, 9 + + – + + +
HOKUSAI-VTE206,207 1, 2 + + + + + +
ODiXa-DVT202 1, 7, 11, 12, 13 + + ? + + +
RE-COVER205 1, 5 + + + + + +
RE-COVER II211 1, 5 + + + + + +
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
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Symptomatic pulmonary embolism
One study reported direct data on symptomatic PE events (see Table 111), whereas for the remaining
eight studies, we derived symptomatic PE events by adding fatal PE and symptomatic non-fatal PE events,
leading to a total of 300 symptomatic PE events across the network, which is displayed in Figure 49.
The studies were mostly judged to be at low risk of bias (Table 119), with some concerns about lack of
TABLE 117 Results for symptomatic DVT (acute treatment of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (5 mg bd) 0.66 (0.38 to 1.11) – 0.66 (0.38 to 1.11)
Dabigatran (150mg bd) 1.18 (0.75 to 1.86) – 1.18 (0.75 to 1.86)
Edoxaban [60 or 30 (17.6%) mg od] 0.91 (0.63 to 1.30) – 0.91 (0.63 to 1.30)
Rivaroxaban (15 mg bd then 20mg od) 0.70 (0.44 to 1.10) – 0.70 (0.44 to 1.10)
Imprecisely estimated comparisons
Apixaban (10 mg bd) 1.27 (0.29 to 5.11) – 1.27 (0.29 to 5.11)
Apixaban (20 mg od) 0.25 (0.01 to 1.87) – 0.25 (0.01 to 1.87)
Rivaroxaban (10 mg bd) 0.56 (0.02 to 7.51) – 0.56 (0.02 to 7.51)
Rivaroxaban (20 mg od) 0.28 (0.03 to 1.33) – 0.28 (0.03 to 1.33)
Rivaroxaban (30 mg od) 0.12 (0 to 0.86) – 0.12 (0 to 0.86)
Rivaroxaban (20 mg bd) 0.59 (0.02 to 8.08) – 0.59 (0.02 to 8.08)
Rivaroxaban (40 mg od) 0.21 (0.03 to 0.94) – 0.21 (0.03 to 0.94)
Rivaroxaban (30 mg bd) 0.53 (0.02 to 7.27) – 0.53 (0.02 to 7.27)
TABLE 118 Results for symptomatic DVT (acute treatment of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) – 1.80 (0.90 to 3.64) 1.80 (0.90 to 3.64)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban
(5 mg bd)
– 1.38 (0.73 to 2.65) 1.38 (0.73 to 2.65)
Rivaroxaban (15 mg bd then 20mg od) vs. apixaban
(5 mg bd)
– 1.07 (0.53 to 2.18) 1.07 (0.53 to 2.18)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran
(150mg bd)
– 0.77 (0.43 to 1.38) 0.77 (0.43 to 1.38)
Rivaroxaban (15 mg bd then 20mg od) vs.
dabigatran (150 mg bd)
– 0.60 (0.31 to 1.13) 0.60 (0.31 to 1.13)
Rivaroxaban (15 mg bd then 20mg od) vs.
edoxaban [60 or 30 (17.6%) mg od]
– 0.77 (0.43 to 1.39) 0.77 (0.43 to 1.39)
Imprecisely estimated comparisons
Apixaban (10 mg bd) vs. apixaban (5 mg bd) 1.94 (0.44 to 7.95) – 1.94 (0.44 to 7.95)
Dabigatran (150mg bd) vs. apixaban (10mg bd) – 0.93 (0.21 to 4.36) 0.93 (0.21 to 4.36)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban
(10mg bd)
– 0.71 (0.17 to 3.27) 0.71 (0.17 to 3.27)
Rivaroxaban (15 mg bd then 20mg od) vs. apixaban
(10mg bd)
– 0.55 (0.13 to 2.60) 0.55 (0.13 to 2.60)
CLINICAL RESULTS (3): ACUTE TREATMENT OF VENOUS THROMBOEMBOLISM
NIHR Journals Library www.journalslibrary.nihr.ac.uk
184
blinding of participants and personnel. There was little evidence that risk of symptomatic PE differed for
any of the NOAC interventions compared with warfarin (INR 2–3) (Table 120). Neither was there evidence
that risk of symptomatic PE differed between licensed doses of NOACs (Table 121).
Myocardial infarction
Five studies reported 57 MI events, leading to a network of five interventions (Figure 50). These studies
were judged to be at low risk of bias (Table 122). All comparisons were imprecisely estimated (Tables 123
and 124).
Major bleeding
The nine trials200–209 reported 228 major bleeding events, leading to a network of 13 interventions (Figure 51).
These studies200–209 were judged to be at low risk of bias (Table 125). There was strong evidence that
apixaban (5 mg bd) and rivaroxaban (15 mg bd then 20 mg od) reduce risk of major bleeding compared
with warfarin (INR 2–3) (Table 126). There was evidence that risk of major bleeding was higher for
edoxaban [60 or 30 (17.6%) mg od] and dabigatran (150 mg bd) than apixaban (5 mg bd) (Table 127).
1. Warfarin (INR 2–3)
2. Apixaban (5 mg bd)
3. Apixaban (10 mg bd)
4. Apixaban (20 mg od)
5. Dabigatran (150 mg bd)
6. Edoxaban [60 or 30 (17.6%) mg od]
7. Rivaroxaban (10 mg bd)8. Rivaroxaban (20 mg od)
9. Rivaroxaban (15 mg bd
    then 20 mg od)
10. Rivaroxaban (30 mg od)
11. Rivaroxaban (20 mg bd)
12. Rivaroxaban (40 mg od)
13. Rivaroxaban (30 mg bd)
FIGURE 49 Network plot for symptomatic PE (acute treatment of VTE).
TABLE 119 Included trials and risk-of-bias assessment for symptomatic PE (acute treatment of VTE)
Study
Interventions
compared SG AC BPP BOA IOD SR
AMPLIFY210 1, 2 + + + + ? +
BOTTICELLI DVT204 1, 2, 3, 4 ? + – + + +
EINSTEIN DVT206 1, 9 + + – + + +
EINSTEIN DVT dose-ranging study203 1, 8, 10, 12 + + – + – +
EINSTEIN PE207 1, 9 + + – + + +
HOKUSAI-VTE206,207 1, 2 + + + + + +
ODiXa-DVT202 1, 7, 11, 12, 13 + + ? + + +
RE-COVER205 1, 5 + + + + + +
RE-COVER II211 1, 5 + + + + + +
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
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TABLE 120 Results for symptomatic PE (acute treatment of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (5 mg bd) 1.09 (0.64 to 1.87) – 1.09 (0.64 to 1.87)
Dabigatran (150mg bd) 1.00 (0.53 to 1.89) – 1.00 (0.53 to 1.89)
Edoxaban [60 or 30 (17.6%) mg od] 0.85 (0.59 to 1.23) – 0.85 (0.59 to 1.23)
Rivaroxaban (15 mg bd then 20mg od) 1.18 (0.77 to 1.83) – 1.18 (0.77 to 1.83)
Imprecisely estimated comparisons
Apixaban (10 mg bd) 0.28 (0 to 6.40) – 0.28 (0 to 6.40)
Apixaban (20 mg od) 0.29 (0 to 6.53) – 0.29 (0 to 6.53)
Rivaroxaban (10 mg bd) 0.73 (0.02 to 11.6) – 0.73 (0.02 to 11.6)
Rivaroxaban (20 mg od) 1.10 (0.07 to 14.9) – 1.10 (0.07 to 14.9)
Rivaroxaban (30 mg od) 1.12 (0.07 to 15.6) – 1.12 (0.07 to 15.6)
Rivaroxaban (20 mg bd) 0.78 (0.02 to 12.2) – 0.78 (0.02 to 12.2)
Rivaroxaban (40 mg od) 0.49 (0.04 to 4.19) – 0.49 (0.04 to 4.19)
Rivaroxaban (30 mg bd) 0.69 (0.02 to 11.3) – 0.69 (0.02 to 11.3)
TABLE 121 Results for symptomatic PE (acute treatment of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) – 0.92 (0.40 to 2.09) 0.92 (0.40 to 2.09)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban
(5 mg bd)
– 0.78 (0.41 to 1.49) 0.78 (0.41 to 1.49)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran
(150mg bd)
– 0.85 (0.41 to 1.77) 0.85 (0.41 to 1.77)
Rivaroxaban (15 mg bd then 20mg od) vs. apixaban
(5 mg bd)
– 1.09 (0.54 to 2.16) 1.09 (0.54 to 2.16)
Rivaroxaban (15 mg bd then 20mg od) vs.
dabigatran (150 mg bd)
– 1.18 (0.55 to 2.54) 1.18 (0.55 to 2.54)
Rivaroxaban (15 mg bd then 20mg od) vs.
edoxaban [60 or 30 (17.6%) mg od]
– 1.39 (0.79 to 2.46) 1.39 (0.79 to 2.46)
Imprecisely estimated comparisons
Apixaban (10 mg bd) vs. apixaban (5 mg bd) 0.25 (0 to 5.86) – 0.25 (0 to 5.86)
Dabigatran (150mg bd) vs. apixaban (10mg bd) – 3.66 (0.15 to 1860) 3.66 (0.15 to 1860)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban
(10mg bd)
– 3.10 (0.13 to 1530) 3.10 (0.13 to 1530)
Rivaroxaban (15 mg bd then 20mg od) vs. apixaban
(10mg bd)
– 4.32 (0.18 to 2160) 4.32 (0.18 to 2160)
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Clinically relevant bleeding
Eight studies201–209 reported 2365 CRB events, leading to a network of 10 interventions (Figure 52).
These studies were mostly judged to be at low risk of bias (Table 128), with some concerns about
lack of blinding of participants and personnel. There was evidence that apixaban (5 mg bd),
dabigatran (150 mg bd) and edoxaban [60 or 30 (17.6%) mg od] reduce risk of CRB compared
with warfarin (INR 2–3) (Table 129). There was some evidence that rivaroxaban (15 mg bd then 20 mg
od) reduces risk of CRB compared with warfarin (INR 2–3). There was evidence that risk of CRB is
higher with dabigatran (150 mg bd), edoxaban [60 or 30 (17.6%) mg od] and rivaroxaban (15 mg bd
then 20 mg od) than apixaban (5 mg bd) (Table 130). There was evidence that risk of CRB is higher with
edoxaban [60 or 30 (17.6%) mg od] and rivaroxaban (15 mg bd then 20 mg od) than dabigatran
(150 mg bd).
1. Warfarin (INR 2–3)
2. Apixaban (5 mg bd)
5. Dabigatran (150 mg bd)
6. Edoxaban [60 or 30 (17.6%)
    mg od]
9. Rivaroxaban (15 mg bd
    then 20 mg od)
FIGURE 50 Network plot for MI (acute treatment of VTE).
TABLE 122 Included trials and risk-of-bias assessment for MI (acute treatment of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
AMPLIFY210 1, 2 + + + + ? +
EINSTEIN DVT206 1, 9 + + – + + +
HOKUSAI-VTE206,207 1, 2 + + + + + +
RE-COVER205 1, 5 + + + + + +
RE-COVER II211 1, 5 + + + + + +
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 123 Results for MI (acute treatment of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Edoxaban [60 or 30 (17.6%) mg od] 1.56 (0.78 to 3.24) – 1.56 (0.78 to 3.24)
Imprecisely estimated comparisons
Apixaban (5 mg bd) 2.18 (0.40 to 17.9) – 2.18 (0.40 to 17.9)
Dabigatran (150 mg bd) 2.11 (0.64 to 8.12) – 2.11 (0.64 to 8.12)
Rivaroxaban (15 mg bd then 20mg od) 6.81 (0.90 to 219) – 6.81 (0.90 to 219)
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TABLE 124 Results for MI (acute treatment of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Dabigatran (150mg bd) vs. apixaban (5 mg bd) – 0.96 (0.09 to 8.47) 0.96 (0.09 to 8.47)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban
(5 mg bd)
– 0.71 (0.08 to 4.49) 0.71 (0.08 to 4.49)
Rivaroxaban (15 mg bd then 20mg od) vs. apixaban
(5 mg bd)
– 3.17 (0.17 to 145) 3.17 (0.17 to 145)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran
(150mg bd)
– 0.74 (0.16 to 3.03) 0.74 (0.16 to 3.03)
Rivaroxaban (15 mg bd then 20mg od) vs.
dabigatran (150 mg bd)
– 3.27 (0.29 to 124) 3.27 (0.29 to 124)
Rivaroxaban (15 mg bd then 20mg od) vs.
edoxaban [60 or 30 (17.6%) mg od]
– 4.44 (0.50 to 143) 4.44 (0.50 to 143)
1. Warfarin (INR 2–3)
2. Apixaban (5 mg bd)
3. Apixaban (10 mg bd)
4. Apixaban (20 mg od)
5. Dabigatran (150 mg bd)
6. Edoxaban [60 or 30 (17.6%) mg od]
7. Rivaroxaban (10 mg bd)8. Rivaroxaban (20 mg od)
9. Rivaroxaban (15 mg bd
    then 20 mg od)
10. Rivaroxaban (30 mg od)
11. Rivaroxaban (20 mg bd)
12. Rivaroxaban (40 mg od)
13. Rivaroxaban (30 mg bd)
FIGURE 51 Network plot for major bleeding (acute treatment of VTE).
TABLE 125 Included trials and risk-of-bias assessment for major bleeding (acute treatment of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
AMPLIFY210 1, 2 + + + + ? +
BOTTICELLI DVT204 1, 2, 3, 4 ? + – + + +
EINSTEIN DVT206 1, 9 + + – + + +
EINSTEIN DVT dose-ranging study203 1, 8, 10, 12 + + – + + +
EINSTEIN PE207 1, 9 + + – + + +
HOKUSAI-VTE206,207 1, 2 + + + + + +
ODiXa-DVT202 1, 7, 11, 12, 13 + + ? + + +
RE-COVER205 1, 5 + + + + + +
RE-COVER II211 1, 5 + + + + + +
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
CLINICAL RESULTS (3): ACUTE TREATMENT OF VENOUS THROMBOEMBOLISM
NIHR Journals Library www.journalslibrary.nihr.ac.uk
188
TABLE 126 Results for major bleeding (acute treatment of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (5 mg bd) 0.33 (0.18 to 0.56) – 0.33 (0.18 to 0.56)
Dabigatran (150 mg bd) 0.76 (0.48 to 1.18) – 0.76 (0.48 to 1.18)
Edoxaban [60 or 30 (17.6%) mg od] 0.85 (0.59 to 1.22) – 0.85 (0.59 to 1.22)
Rivaroxaban (15 mg bd then 20mg od) 0.55 (0.37 to 0.80) – 0.55 (0.37 to 0.80)
Imprecisely estimated comparisons
Apixaban (10 mg bd) 0.18 (0 to 3.84) – 0.18 (0 to 3.84)
Apixaban (20 mg od) 1.79 (0.23 to 15.8) – 1.79 (0.23 to 15.8)
Rivaroxaban (10 mg bd) 1.86 (0.23 to 16) – 1.86 (0.23 to 16)
Rivaroxaban (20 mg od) 0.97 (0.07 to 9.40) – 0.97 (0.07 to 9.40)
Rivaroxaban (30 mg od) 1.81 (0.24 to 14.8) – 1.81 (0.24 to 14.8)
Rivaroxaban (20 mg bd) 1.90 (0.24 to 15.4) – 1.90 (0.24 to 15.4)
Rivaroxaban (40 mg od) 1.03 (0.18 to 6.02) – 1.03 (0.18 to 6.02)
Rivaroxaban (30 mg bd) 3.58 (0.65 to 26.6) – 3.58 (0.65 to 26.6)
TABLE 127 Results for major bleeding (acute treatment of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Rivaroxaban (15 mg bd then 20mg od) vs. apixaban
(5 mg bd)
– 1.68 (0.85 to 3.40) 1.68 (0.85 to 3.40)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban
(5 mg bd)
– 2.60 (1.35 to 5.21) 2.60 (1.35 to 5.21)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran
(150mg bd)
– 1.12 (0.63 to 1.98) 1.12 (0.63 to 1.98)
Rivaroxaban (15 mg bd then 20mg od) vs.
dabigatran (150 mg bd)
– 0.72 (0.40 to 1.30) 0.72 (0.40 to 1.30)
Rivaroxaban (15 mg bd then 20mg od) vs.
edoxaban [60 or 30 (17.6%) mg od]
– 0.64 (0.38 to 1.10) 0.64 (0.38 to 1.10)
Imprecisely estimated comparisons
Apixaban (10 mg bd) vs. apixaban (5 mg bd) 0.54 (0 to 12.1) – 0.54 (0 to 12.1)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) – 2.32 (1.15 to 4.86) 2.32 (1.15 to 4.86)
Dabigatran (150 mg bd) vs. apixaban (10mg bd) – 4.31 (0.19 to 2090) 4.31 (0.19 to 2090)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban
(10mg bd)
– 4.84 (0.22 to 2300) 4.84 (0.22 to 2300)
Rivaroxaban (15 mg bd then 20mg od) vs. apixaban
(10mg bd)
– 3.12 (0.14 to 1470) 3.12 (0.14 to 1470)
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TABLE 128 Included trials and risk-of-bias assessment for CRB (acute treatment of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
AMPLIFY210 1, 2 + + + + ? +
BOTTICELLI DVT204 1, 2, 3, 4 ? + – + + +
EINSTEIN DVT206 1, 9 + + – + + +
EINSTEIN DVT dose-ranging study203 1, 8, 10, 12 + + – + + +
EINSTEIN PE207 1, 9 + + – + + +
HOKUSAI-VTE206,207 1, 2 + + + + + +
RE-COVER205 1, 5 + + + + + +
RE-COVER II211 1, 5 + + + + + +
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
1. Warfarin (INR 2–3)
2. Apixaban (5 mg bd)
3. Apixaban (10 mg bd)
4. Apixaban (20 mg od)
5. Dabigatran (150 mg bd)
6. Edoxaban [60 or 30 (17.6%) mg od]
8. Rivaroxaban (20 mg od)
9. Rivaroxaban (15 mg bd
    then 20 mg od)
10. Rivaroxaban (30 mg od)
12. Rivaroxaban (40 mg od)
FIGURE 52 Network plot for CRB (acute treatment of VTE).
TABLE 129 Results for CRB (acute treatment of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (5 mg bd) 0.44 (0.35 to 0.55) – 0.44 (0.35 to 0.55)
Apixaban (10 mg bd) 0.36 (0.12 to 0.87) – 0.36 (0.12 to 0.87)
Apixaban (20 mg od) 0.76 (0.34 to 1.61) – 0.76 (0.34 to 1.61)
Dabigatran (150mg bd) 0.61 (0.49 to 0.76) – 0.61 (0.49 to 0.76)
Edoxaban [60 or 30 (17.6%) mg od] 0.81 (0.70 to 0.94) – 0.81 (0.70 to 0.94)
Rivaroxaban (15 mg bd then 20mg od) 0.93 (0.80 to 1.08) – 0.93 (0.80 to 1.08)
Rivaroxaban (20 mg od) 0.54 (0.20 to 1.39) – 0.54 (0.20 to 1.39)
Rivaroxaban (30 mg od) 0.56 (0.21 to 1.43) – 0.56 (0.21 to 1.43)
Imprecisely estimated comparisons
Rivaroxaban (40 mg od) 0.17 (0.04 to 0.58) – 0.17 (0.04 to 0.58)
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All-cause mortality
Eight studies201–209 reported 662 all-cause mortality events, leading to a network of 10 interventions
(Figure 53). These studies201–209 were mostly judged to be at low risk of bias (Table 131), with some concerns
about lack of blinding of participants and personnel. There was little evidence that risk of all-cause mortality
differed for any of the NOAC interventions compared with warfarin (INR 2–3) (Table 132). Neither was there
evidence that risk of all-cause mortality differed between licensed doses of NOACs (Table 133).
TABLE 130 Results for CRB (acute treatment of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (10 mg bd) vs. apixaban (5 mg bd) 0.81 (0.28 to 2.00) – 0.81 (0.28 to 2.00)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) – 1.39 (1.02 to 1.90) 1.39 (1.02 to 1.90)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban
(5 mg bd)
– 1.84 (1.41 to 2.40) 1.84 (1.41 to 2.40)
Rivaroxaban (15 mg bd then 20mg od) vs. apixaban
(5 mg bd)
– 2.12 (1.63 to 2.76) 2.12 (1.63 to 2.76)
Dabigatran (150 mg bd) vs. apixaban (10mg bd) – 1.72 (0.68 to 5.02) 1.72 (0.68 to 5.02)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban
(10mg bd)
– 2.27 (0.91 to 6.56) 2.27 (0.91 to 6.56)
Rivaroxaban (15 mg bd then 20mg od) vs. apixaban
(10mg bd)
– 2.62 (1.05 to 7.55) 2.62 (1.05 to 7.55)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran
(150mg bd)
– 1.32 (1.01 to 1.73) 1.32 (1.01 to 1.73)
Rivaroxaban (15 mg bd then 20mg od) vs.
dabigatran (150 mg bd)
– 1.52 (1.17 to 1.99) 1.52 (1.17 to 1.99)
Rivaroxaban (15 mg bd then 20mg od) vs.
edoxaban [60 or 30 (17.6%) mg od]
– 1.15 (0.93 to 1.42) 1.15 (0.93 to 1.42)
1. Warfarin (INR 2–3)
2. Apixaban (5 mg bd)
3. Apixaban (10 mg bd)
4. Apixaban (20 mg od)
5. Dabigatran (150 mg bd)
6. Edoxaban [60 or 30 (17.6%) mg od]
8. Rivaroxaban (20 mg od)
9. Rivaroxaban (15 mg bd
    then 20 mg od)
10. Rivaroxaban (30 mg od)
12. Rivaroxaban (40 mg od)
FIGURE 53 Network plot for all-cause mortality (acute treatment of VTE).
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TABLE 131 Included trials and risk-of-bias assessment for all-cause mortality (acute treatment of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
AMPLIFY210 1, 2 + + + + ? +
BOTTICELLI DVT204 1, 2, 3, 4 ? + – + + +
EINSTEIN DVT206 1, 9 + + – + + +
EINSTEIN DVT dose-ranging study203 1, 8, 10, 12 + + – + + +
EINSTEIN PE207 1, 9 + + – + + +
HOKUSAI-VTE206,207 1, 2 + + + + + +
RE-COVER205 1, 5 + + + + + +
RE-COVER II211 1, 5 + + + + + +
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 132 Results for all-cause mortality (acute treatment of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (5 mg bd) 0.85 (0.57 to 1.27) – 0.85 (0.57 to 1.27)
Dabigatran (150mg bd) 1.00 (0.66 to 1.52) – 1.00 (0.66 to 1.52)
Edoxaban [60 or 30 (17.6%) mg od] 1.05 (0.82 to 1.35) – 1.05 (0.82 to 1.35)
Rivaroxaban (15 mg bd then 20mg od) 0.96 (0.73 to 1.29) – 0.96 (0.73 to 1.29)
Imprecisely estimated comparisons
Apixaban (10 mg bd) 0.58 (0.05 to 3.74) – 0.58 (0.05 to 3.74)
Apixaban (20 mg od) 0.61 (0.05 to 3.87) – 0.61 (0.05 to 3.87)
Rivaroxaban (20 mg od) 0.80 (0.18 to 3.16) – 0.80 (0.18 to 3.16)
Rivaroxaban (30 mg od) 1.73 (0.55 to 5.88) – 1.73 (0.55 to 5.88)
Rivaroxaban (40 mg od) 0.35 (0.04 to 1.82) – 0.35 (0.04 to 1.82)
TABLE 133 Results for all-cause mortality (acute treatment of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) – 1.18 (0.66 to 2.12) 1.18 (0.66 to 2.12)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban
(5 mg bd)
– 1.24 (0.77 to 1.99) 1.24 (0.77 to 1.99)
Rivaroxaban (15 mg bd then 20mg od) vs. apixaban
(5 mg bd)
– 1.14 (0.70 to 1.87) 1.14 (0.70 to 1.87)
Edoxaban [60 or 30 (17.6%) mg od] vs. dabigatran
(150mg bd)
– 1.05 (0.65 to 1.70) 1.05 (0.65 to 1.70)
Rivaroxaban (15 mg bd then 20mg od) vs.
dabigatran (150 mg bd)
– 0.97 (0.58 to 1.59) 0.97 (0.58 to 1.59)
Rivaroxaban (15 mg bd then 20mg od) vs.
edoxaban [60 or 30 (17.6%) mg od]
– 0.92 (0.63 to 1.34) 0.92 (0.63 to 1.34)
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Summary of results and ranking of interventions
There was little evidence that risk of symptomatic VTE, symptomatic DVT or symptomatic PE differed for
any of the NOAC interventions compared with warfarin (INR 2–3). Neither was there evidence that risk of
these outcomes differed between licensed doses of NOACs. However, there was evidence of substantial
reductions in risk of both major bleeding and CRB for apixaban (5 mg bd) compared with warfarin
(INR 2–3). There was also evidence that other NOACs reduced bleeding compared with warfarin (INR 2–3).
In comparisons between licensed doses of NOACs, there was evidence that apixaban (5 mg bd) reduced
major bleeding risk compared with some other NOACs. With regard to model appraisal, we did not
identify any instance of lack of convergence among the Markov chains, poor model fit or inconsistency.
Figure 54 presents the rankogram for all licensed interventions and all seven outcomes examined in this
review. There was a high probability that warfarin (INR 2–3) is ranked worst for major bleeding and CRB.
There was a high probability that apixaban 5 mg bd is ranked best for major bleeding and CRB, and
this intervention also had a high probability of being ranked best or second best for symptomatic DVT,
symptomatic VTE and all-cause mortality.
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FIGURE 54 Rankogram for licensed interventions examined in acute treatment of VTE. CR, clinically relevant. (continued)
TABLE 133 Results for all-cause mortality (acute treatment of VTE): NOACs (licensed doses only) (continued )
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (10 mg bd) vs. apixaban (5 mg bd) 0.68 (0.05 to 4.47) – 0.68 (0.05 to 4.47)
Dabigatran (150 mg bd) vs. apixaban (10mg bd) – 1.73 (0.25 to 22.6) 1.73 (0.25 to 22.6)
Edoxaban [60 or 30 (17.6%) mg od] vs. apixaban
(10mg bd)
– 1.82 (0.27 to 23.2) 1.82 (0.27 to 23.2)
Rivaroxaban (15 mg bd then 20mg od) vs. apixaban
(10mg bd)
– 1.67 (0.25 to 21.4) 1.67 (0.25 to 21.4)
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FIGURE 54 Rankogram for licensed interventions examined in acute treatment of VTE. CR, clinically relevant. (continued)
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FIGURE 54 Rankogram for licensed interventions examined in acute treatment of VTE. CR, clinically relevant.
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Chapter 9 Clinical results (4): secondary
prevention of venous thromboembolism
Included studies
Ten completed RCTs with 11 references,206,213–222 one ongoing trial223 and one trial224 reported in
insufficient detail to include in the quantitative synthesis met the eligibility criteria for the review
(see Figure 32). A summary of the characteristics of the 10 studies included in the analyses is presented in
Table 134. All were multicentre and many were conducted across countries in North and South America,
Europe, Asia, and Australia, New Zealand, South Africa, Russia and Israel. All were Phase III trials. A total
of 10,390 patients were included; the number of patients randomised ranged from 162 to 2866. Four
studies, with a randomised total of 7902 patients, examined a NOAC (against placebo in three studies and
against warfarin in one study). Four studies, with a randomised total of 1263 patients, examined warfarin
(against placebo in two studies and against no treatment in two studies). Two studies, with a randomised
total of 1225 patients, examined aspirin against placebo.
Eligibility criteria were similar across the studies, all patients having already been treated for first-ever
objectively confirmed symptomatic DVT and/or PE. The mean age of patients was similar across studies that
compared NOACs, ranging from 54.7 to 58 years. The mean age of patients across all the 10 included
studies206,213–222 ranged from 53 to 67.3 years. The percentage of male patients was similar across studies that
compared NOACs, ranging from 55.5% to 61%. The percentage of males across the 10 studies206,213–222
ranged from 52.8% to 63.9%. Mean BMI was reported in only three studies216,219,221 and ranged from 27.1
to 29.9 kg/m2 across study arms. Mean body weight ranged from 83.7 to 86.1 kg across study arms when
data were reported. The proportion of patients with comorbidities was not well reported. Three studies216,222
reported the proportion of patients who were diabetic, which ranged from 6.7% to 10.5%. Two studies221,222
reported proportions with hypertension and cancer, which ranged from 36.3% to 41.3% and from 1% to
4%, respectively. Half of the studies that reported each comorbidity examined a NOAC.
Two studies examined dabigatran 150 mg bd: against standard intensity warfarin (INR 2–3) in one study
and against placebo in the other. One study examined each of apixaban 2.5 mg and 5 mg bd, and
rivaroxaban 20 mg od, against placebo in both studies. Two studies examined aspirin 100 mg od against
placebo. Four studies examined warfarin: against placebo in two studies and against no treatment in
two studies. Three of these four studies examined standard intensity warfarin and one study examined low
intensity warfarin (INR 1.5–2). Mean TTR for standard intensity warfarin arms was reported in only
one study215 and was 83%.
The duration of treatment varied across studies, ranging from 6 to 36 months in the NOAC studies,
from 24 to 48 months in the aspirin studies and from 3 to 51.6 months in the warfarin studies. Efficacy
and safety outcomes reported across studies were similar irrespective of the intervention examined, and
were reported at the end of the treatment periods. All 10 studies206,213–222 reported data on symptomatic
VTE and major bleeding. Nine studies each reported data on symptomatic DVT, symptomatic PE and
all-cause mortality. Six studies reported data on CRB, and five studies reported data on MI. Only the four
NOACs studies were sponsored by a pharmaceutical company. Four other studies were conducted with
funding from more than one source: mainly medical research councils or institutes. In all sponsored
studies, the sponsors were responsible for study design and data collection, and in the majority of cases
data analysis (particularly the pharmaceutical company funded studies). Funding source was not declared
in two studies.
DOI: 10.3310/hta21090 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 9
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Sterne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
197
TA
B
LE
13
4
C
h
ar
ac
te
ri
st
ic
s
o
f
10
in
cl
u
d
ed
ra
n
d
o
m
is
ed
tr
ia
ls
in
se
co
n
d
ar
y
p
re
ve
n
ti
o
n
o
f
V
TE
St
u
d
y
(c
en
tr
e
ty
p
e)
[c
o
u
n
tr
ie
s]
Sp
o
n
so
r
(s
p
o
n
so
r’
s
ro
le
)
A
g
e
el
ig
ib
ili
ty
(m
ea
n
ag
e,
ye
ar
s)
[%
m
al
e]
C
lin
ic
al
co
n
d
it
io
n
N
o
.
ra
n
d
o
m
is
ed
In
te
rv
en
ti
o
n
s
co
m
p
ar
ed
Tr
ea
tm
en
t
d
u
ra
ti
o
n
(m
o
n
th
s)
O
u
tc
o
m
es
Ti
m
e
o
f
o
u
tc
o
m
e
as
se
ss
m
en
t
(m
o
n
th
s)
A
M
PL
IF
Y
-E
X
T2
21
(M
ul
tic
en
tr
e)
[N
or
th
an
d
So
ut
h
A
m
er
ic
a,
Eu
ro
pe
,
Ru
ss
ia
,
Is
ra
el
,
A
us
tr
al
ia
,
A
si
a
an
d
So
ut
h
A
fr
ic
a]
Pf
iz
er
an
d
Br
is
to
l-M
ye
rs
Sq
ui
bb (T
he
sp
on
so
rs
co
lle
ct
ed
an
d
m
ai
nt
ai
ne
d
th
e
da
ta
;
th
e
ac
ad
em
ic
au
th
or
s
ha
d
ac
ce
ss
to
th
e
da
ta
at
al
l
tim
es
,
th
ro
ug
h
th
e
sp
on
so
rs
)
≥
18
(5
6.
7)
[5
7.
4]
A
lre
ad
y
tr
ea
te
d
fo
r
a
fir
st
-e
ve
r
ob
je
ct
iv
el
y
co
nf
irm
ed
,s
ym
pt
om
at
ic
D
V
T
or
PE
(w
ith
or
w
ith
ou
t
D
V
T)
24
86
A
p
ix
ab
an
1.
2.
5
m
g
bd
2.
5
m
g
bd
3.
Pl
ac
eb
o
bd
12
Ef
fic
ac
y:
Sy
m
pt
om
at
ic
V
TE
,
sy
m
pt
om
at
ic
D
V
T,
sy
m
pt
om
at
ic
no
n-
fa
ta
l
PE
,
fa
ta
lP
E
Sa
fe
ty
:
M
aj
or
bl
ee
di
ng
,
C
RN
M
bl
ee
di
ng
,
co
m
po
si
te
C
RB
,
fa
ta
l
bl
ee
di
ng
,
M
I,
de
at
h
(c
ar
di
ov
as
cu
la
r)
,
de
at
h
(a
ll
ca
us
es
)
12
A
SP
IR
E2
20
(M
ul
tic
en
tr
e)
[A
rg
en
tin
a,
A
us
tr
al
ia
,
N
ew
Ze
al
an
d
an
d
A
si
a]
N
at
io
na
lH
ea
lth
an
d
M
ed
ic
al
Re
se
ar
ch
C
ou
nc
il
A
us
tr
al
ia
an
d
ot
he
rs
(n
ot
sp
ec
ifi
ed
)
(T
he
fu
nd
er
w
as
re
sp
on
si
bl
e
fo
r
th
e
co
lle
ct
io
n,
m
ai
nt
en
an
ce
,
in
te
gr
ity
,
an
d
co
nf
id
en
tia
lit
y
of
al
ld
at
a)
≥
18
(5
4.
5)
[5
4.
4]
A
lre
ad
y
tr
ea
te
d
fo
r
a
fir
st
-e
ve
r
un
pr
ov
ok
ed
ep
is
od
e
of
ob
je
ct
iv
el
y
di
ag
no
se
d
sy
m
pt
om
at
ic
D
V
T
or
an
ac
ut
e
PE
82
2
A
sp
ir
in
1.
10
0
m
g
od
2.
Pl
ac
eb
o
od
U
p
to
48
Ef
fic
ac
y:
Sy
m
pt
om
at
ic
V
TE
,
sy
m
pt
om
at
ic
D
V
T,
sy
m
pt
om
at
ic
di
st
al
D
V
T,
sy
m
pt
om
at
ic
pr
ox
im
al
D
V
T,
sy
m
pt
om
at
ic
PE
,
fa
ta
lP
E
Sa
fe
ty
:
A
ll
bl
ee
di
ng
,
m
aj
or
bl
ee
di
ng
,
C
RN
M
bl
ee
di
ng
,
co
m
po
si
te
C
RB
,
fa
ta
lb
le
ed
in
g,
M
I,
al
ls
tr
ok
e,
de
at
h
(c
ar
di
ov
as
cu
la
r)
,
de
at
h
(a
ll
ca
us
es
)
37
.2
(m
ed
ia
n)
EI
N
ST
EI
N
-
EX
TE
N
SI
O
N
20
6 ,
21
7 ,
21
8
(M
ul
tic
en
tr
e)
[N
or
th
an
d
So
ut
h
A
m
er
ic
a,
Eu
ro
pe
,
Is
ra
el
,
A
us
tr
al
ia
,
N
ew
Ze
al
an
d,
A
si
a
an
d
So
ut
h
A
fr
ic
a]
Ba
ye
r
H
ea
lth
ca
re
(T
he
da
ta
w
er
e
co
lle
ct
ed
an
d
m
ai
nt
ai
ne
d
by
th
e
sp
on
so
r)
≥
18
(5
8.
3)
[5
8]
A
lre
ad
y
tr
ea
te
d
fo
r
m
ix
ed
(f
irs
t
ev
er
an
d
≥
1
pr
ev
io
us
V
TE
)
co
nf
irm
ed
sy
m
pt
om
at
ic
PE
or
D
V
T
11
97
R
iv
ar
o
xa
b
an
1.
20
m
g
od
2.
Pl
ac
eb
o
od
6–
12
Ef
fic
ac
y:
Sy
m
pt
om
at
ic
V
TE
,
sy
m
pt
om
at
ic
D
V
T,
sy
m
pt
om
at
ic
no
n-
fa
ta
l
PE
,
fa
ta
lP
E
Sa
fe
ty
:
M
aj
or
bl
ee
di
ng
,
C
RN
M
bl
ee
di
ng
,
co
m
po
si
te
C
RB
,
fa
ta
l
bl
ee
di
ng
,
de
at
h
(a
ll
ca
us
es
)
6.
2
(m
ea
n)
CLINICAL RESULTS (4): SECONDARY PREVENTION OF VENOUS THROMBOEMBOLISM
NIHR Journals Library www.journalslibrary.nihr.ac.uk
198
St
u
d
y
(c
en
tr
e
ty
p
e)
[c
o
u
n
tr
ie
s]
Sp
o
n
so
r
(s
p
o
n
so
r’
s
ro
le
)
A
g
e
el
ig
ib
ili
ty
(m
ea
n
ag
e,
ye
ar
s)
[%
m
al
e]
C
lin
ic
al
co
n
d
it
io
n
N
o
.
ra
n
d
o
m
is
ed
In
te
rv
en
ti
o
n
s
co
m
p
ar
ed
Tr
ea
tm
en
t
d
u
ra
ti
o
n
(m
o
n
th
s)
O
u
tc
o
m
es
Ti
m
e
o
f
o
u
tc
o
m
e
as
se
ss
m
en
t
(m
o
n
th
s)
LA
FI
T2
13
(M
ul
tic
en
tr
e)
[C
an
ad
a
an
d
U
SA
]
Su
pp
or
te
d
by
a
gr
an
t
fr
om
D
uP
on
t
Ph
ar
m
a,
W
ilm
in
gt
on
,
D
E,
U
SA
,
an
d
by
th
e
M
ed
ic
al
Re
se
ar
ch
C
ou
nc
il
of
C
an
ad
a,
th
e
H
ea
rt
an
d
St
ro
ke
Fo
un
da
tio
n
of
C
an
ad
a
an
d
th
e
M
in
is
tr
y
of
H
ea
lth
of
O
nt
ar
io
(N
ot
de
cl
ar
ed
)
A
du
lts
(5
9)
[6
0]
A
lre
ad
y
tr
ea
te
d
fo
r
a
fir
st
-e
ve
r
ep
is
od
e
of
id
io
pa
th
ic
V
TE
16
2
W
ar
fa
ri
n
1.
IN
R
2–
3
(m
ea
n
TT
R:
64
%
)
2.
Pl
ac
eb
o
od
24
Ef
fic
ac
y:
Sy
m
pt
om
at
ic
V
TE
,
sy
m
pt
om
at
ic
D
V
T,
sy
m
pt
om
at
ic
no
n-
fa
ta
l
PE
,
fa
ta
lP
E
Sa
fe
ty
:
A
ll
bl
ee
di
ng
,
m
aj
or
bl
ee
di
ng
,
m
in
or
bl
ee
di
ng
,
de
at
h
(a
ll
ca
us
es
)
24
PR
EV
EN
T2
16
(M
ul
tic
en
tr
e)
[U
SA
]
N
at
io
na
lH
ea
rt
,
Lu
ng
,
an
d
Bl
oo
d
In
st
itu
te
,
U
SA
(N
ot
e:
St
ud
y
dr
ug
an
d
pl
ac
eb
o
w
er
e
su
pp
lie
d
w
ith
ou
t
fe
e
by
Br
is
to
l-M
ye
rs
Sq
ui
bb
)
(T
he
fu
nd
er
ap
po
in
te
d
an
in
de
pe
nd
en
t
da
ta
an
d
sa
fe
ty
m
on
ito
rin
g
co
m
m
itt
ee
th
at
m
on
ito
re
d
th
e
pr
im
ar
y
en
d
po
in
t
of
re
cu
rr
en
t
ve
no
us
th
ro
m
bo
em
bo
lis
m
)
≥
30
(m
ed
ia
n
53
)
[5
2.
8]
A
lre
ad
y
tr
ea
te
d
fo
r
id
io
pa
th
ic
V
TE
.
V
TE
ep
is
od
e
is
no
t
cl
ea
rly
re
po
rt
ed
bu
t
te
xt
s
su
gg
es
t
th
is
m
ay
be
a
fir
st
-e
ve
r
ev
en
t
50
8
W
ar
fa
ri
n
1.
IN
R
1.
5–
2
(m
ea
n
TT
R:
N
R)
2.
Pl
ac
eb
o
od
51
.6
(m
ea
n
25
.2
)
Ef
fic
ac
y:
Sy
m
pt
om
at
ic
V
TE
,
fa
ta
lP
E
Sa
fe
ty
:
M
aj
or
bl
ee
di
ng
,
m
in
or
bl
ee
di
ng
,
M
I,
de
at
h
(a
ll
ca
us
es
)
51
.6
(m
ea
n
25
.2
)
co
nt
in
ue
d
DOI: 10.3310/hta21090 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 9
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Sterne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
199
TA
B
LE
13
4
C
h
ar
ac
te
ri
st
ic
s
o
f
10
in
cl
u
d
ed
ra
n
d
o
m
is
ed
tr
ia
ls
in
se
co
n
d
ar
y
p
re
ve
n
ti
o
n
o
f
V
TE
(c
o
n
ti
n
u
ed
)
St
u
d
y
(c
en
tr
e
ty
p
e)
[c
o
u
n
tr
ie
s]
Sp
o
n
so
r
(s
p
o
n
so
r’
s
ro
le
)
A
g
e
el
ig
ib
ili
ty
(m
ea
n
ag
e,
ye
ar
s)
[%
m
al
e]
C
lin
ic
al
co
n
d
it
io
n
N
o
.
ra
n
d
o
m
is
ed
In
te
rv
en
ti
o
n
s
co
m
p
ar
ed
Tr
ea
tm
en
t
d
u
ra
ti
o
n
(m
o
n
th
s)
O
u
tc
o
m
es
Ti
m
e
o
f
o
u
tc
o
m
e
as
se
ss
m
en
t
(m
o
n
th
s)
R
E-
M
ED
Y
22
2
(M
ul
tic
en
tr
e)
[N
or
th
an
d
So
ut
h
A
m
er
ic
a,
Eu
ro
pe
,
Ru
ss
ia
,
Is
ra
el
,
A
us
tr
al
ia
,
N
ew
Ze
al
an
d,
A
si
a,
N
ew
Ze
al
an
d
an
d
So
ut
h
A
fr
ic
a]
Bo
eh
rin
ge
r
In
ge
lh
ei
m
(S
tu
dy
w
as
de
si
gn
ed
,
co
nd
uc
te
d,
an
d
da
ta
an
al
ys
ed
by
th
e
fu
nd
er
in
co
nj
un
ct
io
n
w
ith
th
e
st
ee
rin
g
co
m
m
itt
ee
)
≥
18
(5
4.
7)
[6
1]
A
lre
ad
y
tr
ea
te
d
fo
r
m
ix
ed
(f
irs
t-
ev
er
an
d
≥
1
pr
ev
io
us
)
ob
je
ct
iv
el
y
co
nf
irm
ed
,
sy
m
pt
om
at
ic
,
pr
ox
im
al
D
V
T
or
PE
28
66
D
ab
ig
at
ra
n
1.
15
0
m
g
bd
W
ar
fa
ri
n
2.
IN
R
2–
3
(m
ed
ia
n
TT
R:
65
.3
%
)
6–
36
Ef
fic
ac
y:
Sy
m
pt
om
at
ic
V
TE
,
sy
m
pt
om
at
ic
D
V
T,
sy
m
pt
om
at
ic
no
n-
fa
ta
l
PE Sa
fe
ty
:
A
ll
bl
ee
di
ng
,
m
aj
or
bl
ee
di
ng
,
co
m
po
si
te
C
RB
,
in
tr
ac
ra
ni
al
bl
ee
di
ng
,
M
I,
de
at
h
(a
ll
ca
us
es
)
36
R
E-
SO
N
A
TE
22
2
(M
ul
tic
en
tr
e)
[N
or
th
A
m
er
ic
a,
Eu
ro
pe
,
Ru
ss
ia
,
A
us
tr
al
ia
,
N
ew
Ze
al
an
d,
A
si
a
an
d
So
ut
h
A
fr
ic
a]
Bo
eh
rin
ge
r
In
ge
lh
ei
m
(S
tu
dy
w
as
de
si
gn
ed
,
co
nd
uc
te
d,
an
d
da
ta
an
al
ys
ed
by
th
e
fu
nd
er
in
co
nj
un
ct
io
n
w
ith
th
e
st
ee
rin
g
co
m
m
itt
ee
)
≥
18
(5
5.
8)
[5
5.
5]
A
lre
ad
y
tr
ea
te
d
fo
r
m
ix
ed
(f
irs
t-
ev
er
an
d
≥
1
pr
ev
io
us
)
ob
je
ct
iv
el
y
co
nf
irm
ed
,
sy
m
pt
om
at
ic
,
pr
ox
im
al
D
V
T
or
PE
.
A
sm
al
l
pr
op
or
tio
n
(<
1%
)
ha
d
≥
1
pr
ev
io
us
13
53
D
ab
ig
at
ra
n
1.
15
0
m
g
bd
2.
Pl
ac
eb
o
bd
6
Ef
fic
ac
y:
Sy
m
pt
om
at
ic
V
TE
,
sy
m
pt
om
at
ic
D
V
T,
sy
m
pt
om
at
ic
no
n-
fa
ta
l
PE Sa
fe
ty
:
A
ll
bl
ee
di
ng
,
m
aj
or
bl
ee
di
ng
,
C
RN
M
bl
ee
di
ng
,
co
m
po
si
te
C
RB
,
M
I
6
W
A
R
FA
SA
21
9
(M
ul
tic
en
tr
e)
[A
us
tr
ia
an
d
Ita
ly
]
U
ni
ve
rs
ity
of
Pe
ru
gi
a,
Ita
ly
,
an
d
ot
he
rs
(n
ot
sp
ec
ifi
ed
)
(D
at
a
w
er
e
co
lle
ct
ed
,
m
ai
nt
ai
ne
d,
an
d
an
al
ys
ed
by
th
e
C
lin
ic
al
Re
se
ar
ch
U
ni
t
of
th
e
U
ni
ve
rs
ity
of
Pe
ru
gi
a)
≥
18
(6
2)
[6
3.
9]
A
lre
ad
y
tr
ea
te
d
fo
r
a
fir
st
-e
ve
r,
ob
je
ct
iv
el
y
co
nf
irm
ed
,
sy
m
pt
om
at
ic
,
un
pr
ov
ok
ed
,
pr
ox
im
al
D
V
T,
PE
,
or
bo
th
40
3
A
sp
ir
in
1.
10
0
m
g
od
2.
Pl
ac
eb
o
od
24
Ef
fic
ac
y:
Sy
m
pt
om
at
ic
V
TE
,
sy
m
pt
om
at
ic
D
V
T,
sy
m
pt
om
at
ic
PE
,
fa
ta
l
PE
,
ar
te
ria
le
ve
nt
Sa
fe
ty
:
M
aj
or
bl
ee
di
ng
,
C
RN
M
bl
ee
di
ng
,
co
m
po
si
te
C
RB
,
de
at
h
(a
ll
ca
us
es
)
24
CLINICAL RESULTS (4): SECONDARY PREVENTION OF VENOUS THROMBOEMBOLISM
NIHR Journals Library www.journalslibrary.nihr.ac.uk
200
St
u
d
y
(c
en
tr
e
ty
p
e)
[c
o
u
n
tr
ie
s]
Sp
o
n
so
r
(s
p
o
n
so
r’
s
ro
le
)
A
g
e
el
ig
ib
ili
ty
(m
ea
n
ag
e,
ye
ar
s)
[%
m
al
e]
C
lin
ic
al
co
n
d
it
io
n
N
o
.
ra
n
d
o
m
is
ed
In
te
rv
en
ti
o
n
s
co
m
p
ar
ed
Tr
ea
tm
en
t
d
u
ra
ti
o
n
(m
o
n
th
s)
O
u
tc
o
m
es
Ti
m
e
o
f
o
u
tc
o
m
e
as
se
ss
m
en
t
(m
o
n
th
s)
W
O
D
IT
-D
V
T2
14
(M
ul
tic
en
tr
e)
[It
al
y]
N
ot
de
cl
ar
ed
15
–
85
(6
7.
3)
[5
7.
9]
A
lre
ad
y
tr
ea
te
d
fo
r
a
fir
st
-e
ve
r
ep
is
od
e
of
sy
m
pt
om
at
ic
ob
je
ct
iv
el
y
co
nf
irm
ed
id
io
pa
th
ic
pr
ox
im
al
D
V
T
26
7
W
ar
fa
ri
n
1.
IN
R
2–
3
(m
ea
n
TT
R:
81
%
)
2.
N
o
tr
ea
tm
en
t
9
Ef
fic
ac
y:
Sy
m
pt
om
at
ic
V
TE
,
sy
m
pt
om
at
ic
D
V
T,
sy
m
pt
om
at
ic
no
n-
fa
ta
l
PE
,
fa
ta
lP
E
Sa
fe
ty
:
M
aj
or
bl
ee
di
ng
,
fa
ta
lb
le
ed
in
g,
de
at
h
(c
ar
di
ov
as
cu
la
r)
,
de
at
h
(a
ll
ca
us
es
)
33
W
O
D
IT
-P
E2
15
(M
ul
tic
en
tr
e)
[It
al
y]
N
ot
de
cl
ar
ed
15
–
85
(6
2)
[5
9.
5]
A
lre
ad
y
tr
ea
te
d
fo
r
a
fir
st
-e
ve
r
ep
is
od
e
of
sy
m
pt
om
at
ic
,
ob
je
ct
iv
el
y
co
nf
irm
ed
PE
32
6
W
ar
fa
ri
n
1.
IN
R
2–
3
(m
ea
n
TT
R:
N
R)
2.
N
o
tr
ea
tm
en
t
3
Ef
fic
ac
y:
Sy
m
pt
om
at
ic
V
TE
,
sy
m
pt
om
at
ic
PE
,
sy
m
pt
om
at
ic
no
n-
fa
ta
l
PE
,
sy
m
pt
om
at
ic
D
V
T,
fa
ta
lP
E
Sa
fe
ty
:
A
ll
bl
ee
di
ng
,
m
aj
or
bl
ee
di
ng
,
fa
ta
l
bl
ee
di
ng
,
de
at
h
(c
ar
di
ov
as
cu
la
r)
,
de
at
h
(a
ll
ca
us
es
)
3
N
R,
no
t
re
po
rt
ed
.
DOI: 10.3310/hta21090 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 9
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Sterne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
201
Time in therapeutic range for warfarin interventions
Table 135 shows the comparator interventions, target INR and (where reported) mean TTR for the
five studies213–216,222 that included a warfarin intervention arm. Three (60%) of these studies213,214,222
reported mean TTR, which was 64% in LAFIT,213 65.3% in RE-MEDY222 and 81% in WODIT-DVT.214
Risk of bias in included studies
Table 136 shows detailed risk-of-bias assessments for each included study for each domain of the
Cochrane assessment tool. Generally, the studies were judged to be at low risk of bias for sequence
generation, blinding of outcome assessment and incomplete outcome data. However, one study did
not describe how the randomisation sequence was generated. Eight studies described how treatment
allocation was concealed: these studies were judged to be at low risk of bias for this domain. One study
provided insufficient information to enable a judgement on allocation concealment, and one study
provided no information on this domain: these studies were judged to be at unclear and high risk of bias,
respectively. Overall, the risk of bias due to selective reporting was judged to be low. Three studies were
open-label and so were judged to be at a high risk of bias for blinding of participants and personnel.
Results of clinical effectiveness and safety
This review included 10 trials comparing a total number of nine interventions (Table 137). The outcomes
reported in the 10 studies, along with the number of events per outcome, are displayed in Tables 138 and
139. We performed NMAs for seven outcomes: symptomatic DVT, symptomatic PE, symptomatic VTE, MI,
major bleeding, CRB and all-cause mortality.
Results are presented as follows for each of the six outcomes. First, we provide network plots to illustrate
the comparisons of interventions made in the different trials. Second, we illustrate the risk-of-bias
assessments that were specific to the outcome for each trial included in the network. Third, we present
results tables for each intervention compared with the reference treatment (placebo). Fourth, we present
for each NOAC intervention compared with aspirin and warfarin. Fifth, we present results tables for
pairwise comparisons among licensed doses of the NOACs. For all sets of results tables, posterior median
ORs and 95% credible intervals from Bayesian fixed-effects analyses are shown, although we refer to
the latter as CIs for convenience. In these tables, we present results separately for any available direct
evidence, for any indirect comparisons that can be made (excluding the direct evidence) and for the NMA
(which combines the direct and the indirect evidence). Comparisons from the NMA with a ratio between
TABLE 135 Mean TTR for warfarin in secondary prevention of VTE
Study Interventions that were compared with warfarin Warfarin INR Mean TTR (INR)
LAFIT213 Placebo od, warfarin 2–3 64%
PREVENT216 Placebo od 1.5–2 NR
RE-MEDY222 Dabigatran 150 mg bd 2–3 65.3% (median)
WODIT-DVT214 No treatment 2–3 81%
WODIT-PE215 No treatment 2–3 NR
NR, not reported.
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interval limits exceeding nine were considered ‘imprecisely estimated’ and are presented at the bottom
of each table (note that calculation of indirect evidence was not undertaken for imprecisely estimated
comparisons). A summary of results across outcomes is provided at the end, in the form of a ‘rankogram’,
which illustrates the probability that each treatment is best, second best, and so on, for each outcome.
Lastly, forest plots of all contributing data, with ORs calculated using standard frequentist methods, are
included in Appendix 5.
Symptomatic venous thromboembolism
All 10 studies206,213–222 reported on symptomatic VTE (578 events), leading to a network of all nine
interventions (Figure 55). The included studies were judged to be at mostly low risk of bias, with concerns
about only lack of blinding of participants and personnel in some studies (Table 140). There was evidence
that aspirin (100 mg od) decreased the risk of symptomatic VTE compared with placebo (Table 141). Both
warfarin (INR 1.5–2) and warfarin (INR 2–3) substantially reduced risk of symptomatic VTE compared with
placebo. All NOACs at the doses included in the network substantially reduced risk of symptomatic VTE
compared with placebo. Risk of symptomatic VTE was lower for all NOACs at doses included in the network
compared with aspirin (Table 142). However, there was no clear evidence that risk of symptomatic VTE
differed between these NOAC interventions and warfarin (INR 2–3), although most comparisons were
imprecisely estimated (Table 143). There was no clear evidence that risk of symptomatic VTE differed
between licensed doses of NOACs (Table 144), although all comparisons were imprecisely estimated.
We conducted a supplementary analysis using HRs for symptomatic recurrent VTE. The structure of the
network was exactly the same as that presented in Figure 55. Results, presented in Tables 145–148, were
similar to those based on ORs.
Symptomatic deep-vein thrombosis
Nine studies204,211–213,215–220 reported 342 symptomatic DVT events, leading to a network of eight
interventions (Figure 56). These studies were mostly judged to be at low risk of bias (Table 149), with some
concerns about lack of blinding of participants and personnel. There was no clear evidence that aspirin
(100 mg od) reduced risk of symptomatic DVT compared with placebo (Table 150). There was evidence
that warfarin (INR 2–3) and all NOACs at doses included in the network substantially reduced risk of
symptomatic DVT compared with placebo. These NOAC interventions substantially reduced risk of
symptomatic DVT compared with aspirin (Table 151). By contrast, there was no clear evidence that
risk of symptomatic DVT differed between these NOACs and warfarin (INR 2–3), although comparisons
were imprecisely estimated (Table 152). There was no clear evidence that risk of symptomatic DVT
differed between NOACs at licensed doses, although all comparisons were imprecisely estimated
(Table 153).
TABLE 137 List of distinct interventions examined by included randomised trials in secondary prevention of VTE
No. Intervention
1 Placebo
2 No treatment
3 Aspirin (100mg od)
4 Warfarin (INR 1.5–2)
5 Warfarin (INR 2–3)
6 Apixaban (2.5 mg bd)
7 Apixaban (5 mg bd)
8 Dabigatran (150 mg bd)
9 Rivaroxaban (20mg od)
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1. Placebo
2. No treatment
3. Aspirin (100 mg od)
4. Warfarin (INR 1.5–2)
5. Warfarin (INR 2–3)6. Apixaban (2.5 mg bd)
7. Apixaban (5 mg bd)
8. Dabigatran (150 mg bd)
9. Rivaroxaban (20 mg od)
FIGURE 55 Network plot for symptomatic VTE (secondary prevention of VTE).
TABLE 140 Included trials and risk-of-bias assessment for symptomatic VTE (secondary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
AMPLIFY-EXT221 1, 6, 7 + + ? + + +
ASPIRE220 1, 3 + + + + + +
EINSTEIN-EXTENSION206,217,218 1, 9 + + – + + +
LAFIT211 1, 5 + + + + + ?
PREVENT216 1, 4 + + + + + +
RE-MEDY222 5, 8 + + + + + +
RE-SONATE222 1, 8 + + ? + + +
WARFASA219 1, 3 + ? ? + + +
WODIT-DVT214 2, 5 ? – – + + ?
WODIT-PE215 2, 5 + + – + + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 141 Results for symptomatic VTE (secondary prevention of VTE): comparisons with placebo
Comparisons with placebo
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Aspirin (100 mg od) 0.68 (0.50 to 0.92) – 0.68 (0.50 to 0.92)
Warfarin (INR 1.5–2) 0.33 (0.17 to 0.63) – 0.33 (0.17 to 0.63)
Apixaban (2.5 mg bd) 0.17 (0.09 to 0.30) – 0.17 (0.09 to 0.30)
Apixaban (5 mg bd) 0.18 (0.09 to 0.31) – 0.18 (0.09 to 0.31)
Dabigatran (150mg bd) 0.07 (0.02 to 0.18) – 0.07 (0.02 to 0.18)
Rivaroxaban (20 mg od) 0.17 (0.07 to 0.35) 0.17 (0.07 to 0.35)
Imprecisely estimated comparisons
No treatment – 0.05 (0.01 to 0.17) 0.05 (0.01 to 0.17)
Warfarin (INR 2–3) 0.05 (0.01 to 0.14) – 0.05 (0.01 to 0.14)
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TABLE 142 Results for symptomatic VTE (secondary prevention of VTE): comparisons with aspirin
Comparisons with aspirin
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (2.5 mg bd) – 0.25 (0.13 to 0.48) 0.25 (0.13 to 0.48)
Apixaban (5 mg bd) – 0.26 (0.13 to 0.50) 0.26 (0.13 to 0.50)
Rivaroxaban (20 mg od) – 0.25 (0.10 to 0.55) 0.25 (0.10 to 0.55)
Imprecisely estimated comparisons
Dabigatran (150 mg bd) – 0.10 (0.03 to 0.28) 0.10 (0.03 to 0.28)
TABLE 143 Results for symptomatic VTE (secondary prevention of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin
(INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150 mg bd) 1.36 (0.67 to 2.80) – 1.36 (0.67 to 2.80)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) – 2.10 (0.42 to 14.0) 2.10 (0.42 to 14.0)
Apixaban (5 mg bd) – 2.96 (0.64 to 19.1) 2.96 (0.64 to 19.1)
Rivaroxaban (20 mg od) – 3.01 (0.55 to 20.4) 3.01 (0.55 to 20.4)
TABLE 144 Results for symptomatic VTE (secondary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 1.04 (0.48 to 2.22) – 1.04 (0.48 to 2.22)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) – 0.99 (0.36 to 2.6) 0.99 (0.36 to 2.6)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) – 0.96 (0.35 to 2.48) 0.96 (0.35 to 2.48)
Imprecisely estimated comparisons
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd) – 0.41 (0.11 to 1.29) 0.41 (0.11 to 1.29)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) – 0.40 (0.11 to 1.25) 0.40 (0.11 to 1.25)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) – 2.41 (0.67 to 9.93) 2.41 (0.67 to 9.93)
TABLE 145 Results for recurrent VTE (secondary prevention of VTE): comparisons with placebo
Comparisons with placebo HR (95% CI)
Aspirin (100mg od) 0.68 (0.51 to 0.90)
Warfarin (INR 1.5–2) 0.36 (0.19 to 0.68)
Warfarin (INR 2–3) 0.05 (0.02 to 0.16)
Apixaban (2.5 mg bd) 0.17 (0.10 to 0.31)
Apixaban (5 mg bd) 0.18 (0.10 to 0.32)
Dabigatran (150 mg bd) 0.08 (0.03 to 0.22)
Rivaroxaban (20 mg od) 0.18 (0.09 to 0.37)
Imprecisely estimated comparisons
No treatment 0.06 (0.02 to 0.23)
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TABLE 146 Results for recurrent VTE (secondary prevention of VTE): comparisons with aspirin
Comparisons with aspirin HR (95% CI)
Apixaban (2.5 mg bd) 0.25 (0.13 to 0.49)
Apixaban (5 mg bd) 0.26 (0.14 to 0.51)
Dabigatran (150mg bd) 0.11 (0.04 to 0.34)
Rivaroxaban (20 mg od) 0.27 (0.12 to 0.58)
TABLE 147 Results for recurrent VTE (secondary prevention of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3) HR (95% CI)
Dabigatran (150mg bd) 1.45 (0.80 to 2.60)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) 3.24 (0.92 to 11.4)
Apixaban (5 mg bd) 3.36 (0.95 to 11.7)
Rivaroxaban (20 mg od) 3.41 (0.88 to 12.6)
TABLE 148 Results for recurrent VTE (secondary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only HR (95% CI)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 0.57 (0.14 to 1.94)
Dabigatran (150mg bd) vs. apixaban (2.5 mg bd) 0.48 (0.01 to 6.79)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) 0.86 (0.02 to 13.0)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) 0.85 (0.02 to 13.4)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) 1.54 (0.04 to 25.7)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) 1.79 (0.03 to 121)
1. Placebo
2. No treatment
3. Aspirin (100 mg od)
5. Warfarin (INR 2–3)
6. Apixaban (2.5 mg bd)
7. Apixaban (5 mg bd)
8. Dabigatran (150 mg bd)
9. Rivaroxaban (20 mg od)
FIGURE 56 Network plot for symptomatic DVT (secondary prevention of VTE).
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TABLE 149 Included trials and risk-of-bias assessment for symptomatic DVT (secondary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
AMPLIFY-EXT221 1, 6, 7 + + ? + + +
ASPIRE220 1, 3 + + + + + +
EINSTEIN-EXTENSION206,217,218 1, 9 + + – + + +
LAFIT211 1, 5 + + + + + ?
RE-MEDY222 5, 8 + + + + + +
RE-SONATE222 1, 8 + + ? + + +
WARFASA219 1, 3 + ? ? + + +
WODIT-DVT214 2, 5 ? – – + + ?
WODIT-PE215 2, 5 + + – + + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 150 Results for symptomatic DVT (secondary prevention of VTE): comparisons with placebo
Comparisons with placebo
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Aspirin (100mg od) 0.74 (0.51 to 1.07) – 0.74 (0.51 to 1.07)
Apixaban (2.5 mg bd) 0.1 (0.04 to 0.22) – 0.1 (0.04 to 0.22)
Apixaban (5 mg bd) 0.14 (0.06 to 0.28) – 0.14 (0.06 to 0.28)
Rivaroxaban (20 mg od) 0.14 (0.05 to 0.34) – 0.14 (0.05 to 0.34)
Imprecisely estimated comparisons
No treatment – 0.05 (0.01 to 0.22) 0.05 (0.01 to 0.22)
Warfarin (INR 2–3) 0.05 (0.01 to 0.17) – 0.05 (0.01 to 0.17)
Dabigatran (150 mg bd) 0.07 (0.01 to 0.21) – 0.07 (0.01 to 0.21)
TABLE 151 Results for symptomatic DVT (secondary prevention of VTE): comparisons with aspirin
Comparisons with aspirin
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (2.5 mg bd) – 0.14 (0.05 to 0.32) 0.14 (0.05 to 0.32)
Apixaban (5 mg bd) – 0.19 (0.08 to 0.42) 0.19 (0.08 to 0.42)
Rivaroxaban (20 mg od) – 0.19 (0.06 to 0.51) 0.19 (0.06 to 0.51)
Imprecisely estimated comparisons
Dabigatran (150 mg bd) – 0.09 (0.02 to 0.30) 0.09 (0.02 to 0.30)
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Symptomatic pulmonary embolism
Three studies reported symptomatic PE events, and a further six studies reported symptomatic non-fatal
and fatal PE events, which were added together. The studies reported a total 173 symptomatic PE events,
leading to a network comparing eight interventions (Figure 57). The included studies were mostly judged
to be at low risk of bias (Table 154), with some concerns about lack of blinding of participants and
personnel. There was evidence that warfarin (INR 2–3), apixaban (5 mg bd), dabigatran (150 mg bd) and
rivaroxaban (20 mg od) substantially reduce the risk of symptomatic PE compared with placebo (Table 155).
TABLE 152 Results for symptomatic DVT (secondary prevention of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin
(INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) – 2.10 (0.42 to 14.0) 2.10 (0.42 to 14.0)
Apixaban (5 mg bd) – 2.96 (0.64 to 19.1) 2.96 (0.64 to 19.1)
Dabigatran (150mg bd) 1.36 (0.67 to 2.80) – 1.36 (0.67 to 2.80)
Rivaroxaban (20 mg od) – 3.01 (0.55 to 20.4) 3.01 (0.55 to 20.4)
TABLE 153 Results for symptomatic DVT (secondary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 1.40 (0.48 to 4.37) – 1.40 (0.48 to 4.37)
Dabigatran (150mg bd) vs. apixaban (2.5 mg bd) – 0.65 (0.10 to 3.04) 0.65 (0.10 to 3.04)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) – 1.44 (0.37 to 5.36) 1.44 (0.37 to 5.36)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) – 0.46 (0.07 to 1.98) 0.46 (0.07 to 1.98)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) – 1.02 (0.28 to 3.46) 1.02 (0.28 to 3.46)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) – 2.21 (0.43 to 14.2) 2.21 (0.43 to 14.2)
1. Placebo
2. No treatment
3. Aspirin (100 mg od)
4. Warfarin (INR 1.5–2)
5. Warfarin (INR 2–3)6. Apixaban (2.5 mg bd)
7. Apixaban (5 mg bd)
8. Dabigatran (150 mg bd)
9. Rivaroxaban (20 mg od)
FIGURE 57 Network plot for symptomatic PE (secondary prevention of VTE).
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There was evidence that dabigatran (150 mg bd) and rivaroxaban (20 mg od) reduce the risk of
symptomatic PE compared with aspirin (Table 156). There was evidence that risk of symptomatic PE was
higher for apixaban (2.5 mg bd) than warfarin (INR 2–3) (Table 157). There was weak evidence that risk
of symptomatic PE was lower for dabigatran (150 mg bd) and rivaroxaban (20 mg od) than apixaban
(2.5 mg bd) (Table 158).
TABLE 154 Included trials and risk-of-bias assessment for symptomatic PE (secondary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
AMPLIFY-EXT221 1, 6, 7 + + ? + + +
ASPIRE220 1, 3 + + + + + +
EINSTEIN-EXTENSION206,217,218 1, 9 + + – + + +
LAFIT211 1, 5 + + + + + ?
RE-MEDY222 5, 8 + + + + + +
RE-SONATE222 1, 8 + + ? + + +
WARFASA219 1, 3 + ? ? + + +
WODIT-DVT214 2, 5 ? – – + + ?
WODIT-PE215 2, 5 + + – + + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 155 Results for symptomatic PE (secondary prevention of VTE): comparisons with placebo
Comparisons with placebo
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Aspirin (100mg od) 0.63 (0.38 to 1.02) – 0.63 (0.38 to 1.02)
Imprecisely estimated comparisons
No treatment – 0.05 (0.01 to 0.32) 0.05 (0.01 to 0.32)
Warfarin (INR 2–3) 0.05 (0.01 to 0.24) – 0.05 (0.01 to 0.24)
Apixaban (2.5 mg bd) 0.51 (0.20 to 1.21) – 0.51 (0.20 to 1.21)
Apixaban (5 mg bd) 0.25 (0.07 to 0.71) – 0.25 (0.07 to 0.71)
Dabigatran (150 mg bd) 0.09 (0.01 to 0.35) – 0.09 (0.01 to 0.35)
Rivaroxaban (20 mg od) 0.12 (0.02 to 0.45) – 0.12 (0.02 to 0.45)
TABLE 156 Results for symptomatic PE (secondary prevention of VTE): comparisons with aspirin
Comparisons with aspirin
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (2.5 mg bd) – 0.81 (0.29 to 2.19) 0.81 (0.29 to 2.19)
Imprecisely estimated comparisons
Apixaban (5 mg bd) – 0.40 (0.10 to 1.28) 0.40 (0.10 to 1.28)
Dabigatran (150 mg bd) – 0.14 (0.02 to 0.61) 0.14 (0.02 to 0.61)
Rivaroxaban (20 mg od) – 0.19 (0.03 to 0.78) 0.19 (0.03 to 0.78)
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Myocardial infarction
Five studies214,218–220 reported 35 MI events, leading to a network of seven interventions (Figure 58).
These studies were judged to be at low risk of bias (Table 159). All comparisons were imprecisely
estimated (Tables 160–163).
Major bleeding
All 10 studies204,212–220 reported on major bleeding (87 events), leading to a network of nine interventions
(Figure 59). These studies204,212–220 were mostly judged to be at low risk of bias (Table 164), with some
concerns about lack of blinding of participants and personnel. There was evidence that risk of major bleeding
TABLE 157 Results for symptomatic PE (secondary prevention of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150mg bd) 1.76 (0.64 to 5.24) – 1.76 (0.64 to 5.24)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) – 10.1 (1.66 to 102) 10.1 (1.66 to 102)
Apixaban (5 mg bd) – 4.94 (0.66 to 53.6) 4.94 (0.66 to 53.6)
Rivaroxaban (20 mg od) – 2.29 (0.19 to 28.4) 2.29 (0.19 to 28.4)
TABLE 158 Results for symptomatic PE (secondary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 0.49 (0.13 to 1.62) – 0.49 (0.13 to 1.62)
Dabigatran (150mg bd) vs. apixaban (2.5 mg bd) – 0.18 (0.02 to 0.92) 0.18 (0.02 to 0.92)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) – 0.23 (0.03 to 1.18) 0.23 (0.03 to 1.18)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) – 0.36 (0.04 to 2.38) 0.36 (0.04 to 2.38)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) – 0.47 (0.05 to 3.04) 0.47 (0.05 to 3.04)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) – 1.31 (0.12 to 14.0) 1.31 (0.12 to 14.0)
1. Placebo
3. Aspirin (100 mg od)
4. Warfarin (INR 1.5–2)
5. Warfarin (INR 2–3)6. Apixaban (2.5 mg bd)
7. Apixaban (5 mg bd)
8. Dabigatran (150 mg bd)
FIGURE 58 Network plot for MI (secondary prevention of VTE).
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TABLE 159 Included trials and risk-of-bias assessment for MI (secondary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
AMPLIFY-EXT221 1, 6, 7 + + ? + + +
ASPIRE220 1, 3 + + + + + +
PREVENT216 1, 4 + + + + + +
RE-MEDY222 5, 8 + + + + + +
RE-SONATE222 1, 8 + + ? + + +
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 160 Results for MI (secondary prevention of VTE): comparisons with placebo
Comparisons with placebo
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Aspirin (100mg od) 0.29 (0.04 to 1.37) – 0.29 (0.04 to 1.37)
Warfarin (INR 1.5–2) 1.57 (0.24 to 14.0) – 1.57 (0.24 to 14.0)
Warfarin (INR 2–3) 0.06 (0 to 3.26) – 0.06 (0 to 3.26)
Apixaban (2.5 mg bd) 0.45 (0.06 to 2.51) – 0.45 (0.06 to 2.51)
Apixaban (5 mg bd) 0.74 (0.13 to 3.59) – 0.74 (0.13 to 3.59)
Dabigatran (150 mg bd) 0.90 (0.02 to 29.8) – 0.90 (0.02 to 29.8)
TABLE 161 Results for MI (secondary prevention of VTE): comparisons with aspirin
Comparisons with aspirin
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) – 1.57 (0.12 to 21.7) 1.57 (0.12 to 21.7)
Apixaban (5 mg bd) – 2.60 (0.26 to 33.1) 2.60 (0.26 to 33.1)
Dabigatran (150 mg bd) – 3.19 (0.05 to 174) 3.19 (0.05 to 174)
TABLE 162 Results for MI (secondary prevention of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) – 7.48 (0.08 to 1220) 7.48 (0.08 to 1220)
Apixaban (5 mg bd) – 12.6 (0.15 to 2000) 12.6 (0.15 to 2000)
Dabigatran (150 mg bd) 13.6 (2.26 to 409) – 13.6 (2.26 to 409)
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is higher for warfarin (INR 2–3) and rivaroxaban (20 mg od) than placebo, although these comparisons were
imprecisely estimated (Table 165). Comparisons of the risk of major bleeding for NOACs compared with
aspirin were imprecisely estimated (Table 166). There was evidence that risk of major bleeding is lower with
dabigatran (150mg bd), apixaban (2.5 mg bd) and apixaban (5mg bd) than warfarin (INR 2–3) (Table 167).
There was evidence that risk of major bleeding is higher with dabigatran (150 mg bd) and rivaroxaban
(20 mg od) than apixaban (2.5 mg bd and 5 mg bd) (Table 168).
TABLE 163 Results for MI (secondary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 1.65 (0.25 to 14.2) – 1.65 (0.25 to 14.2)
Dabigatran (150mg bd) vs. apixaban (2.5 mg bd) – 2.06 (0.03 to 117) 2.06 (0.03 to 117)
Dabigatran (150mg bd) vs. apixaban (5 mg bd) – 1.22 (0.02 to 57.5) 1.22 (0.02 to 57.5)
1. Placebo
2. No treatment
3. Aspirin (100 mg od)
4. Warfarin (INR 1.5–2)
5. Warfarin (INR 2–3)6. Apixaban (2.5 mg bd)
7. Apixaban (5 mg bd)
8. Dabigatran (150 mg bd)
9. Rivaroxaban (20 mg od)
FIGURE 59 Network plot for major bleeding (secondary prevention of VTE).
TABLE 164 Included trials and risk-of-bias assessment for major bleeding (secondary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
AMPLIFY-EXT221 1, 6, 7 + + ? + + +
ASPIRE220 1, 3 + + + + + +
EINSTEIN-EXTENSION206,217,218 1, 9 + + – + + +
LAFIT211 1, 5 + + + + + ?
PREVENT216 1, 4 + + + + + +
RE-MEDY222 5, 8 + + + + + +
RE-SONATE222 1, 8 + + ? + + +
WARFASA219 1, 3 + ? ? + + +
WODIT-DVT214 2, 5 ? – – + + ?
WODIT-PE215 2, 5 + + – + + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
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TABLE 165 Results for major bleeding (secondary prevention of VTE): comparisons with placebo
Comparisons with placebo
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Aspirin (100mg od) 1.3 (0.47 to 3.76) – 1.3 (0.47 to 3.76)
Imprecisely estimated comparisons
No treatment – 4.93 (0.36 to 142) 4.93 (0.36 to 142)
Warfarin (INR 1.5–2) 2.78 (0.55 to 22.2) – 2.78 (0.55 to 22.2)
Warfarin (INR 2–3) 12.0 (1.66 to 279) – 12.0 (1.66 to 279)
Apixaban (2.5 mg bd) 0.45 (0.06 to 2.57) – 0.45 (0.06 to 2.57)
Apixaban (5 mg bd) 0.19 (0.01 to 1.56) – 0.19 (0.01 to 1.56)
Dabigatran (150 mg bd) 6.11 (0.83 to 145) – 6.11 (0.83 to 145)
Rivaroxaban (20 mg od) 17.8 (1.25 to 8340) – 17.8 (1.25 to 8340)
TABLE 166 Results for major bleeding (secondary prevention of VTE): comparisons with aspirin
Comparisons with aspirin
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) – 0.34 (0.03 to 2.60) 0.34 (0.03 to 2.60)
Apixaban (5 mg bd) – 0.14 (0 to 1.54) 0.14 (0 to 1.54)
Dabigatran (150 mg bd) – 4.81 (0.50 to 126) 4.81 (0.50 to 126)
Rivaroxaban (20 mg od) – 13.9 (0.78 to 6690) 13.9 (0.78 to 6690)
TABLE 167 Results for major bleeding (secondary prevention of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150 mg bd) 0.51 (0.25 to 0.98) – 0.51 (0.25 to 0.98)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) – 0.03 (0 to 0.53) 0.03 (0 to 0.53)
Apixaban (5 mg bd) – 0.01 (0 to 0.29) 0.01 (0 to 0.29)
Rivaroxaban (20 mg od) – 1.52 (0.03 to 712) 1.52 (0.03 to 712)
TABLE 168 Results for major bleeding (secondary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 0.43 (0.01 to 5.42) – 0.43 (0.01 to 5.42)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd) – 14.7 (0.96 to 582) 14.7 (0.96 to 582)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) – 44.8 (1.60 to 24,100) 44.8 (1.60 to 24,100)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) – 37.1 (1.70 to 2980) 37.1 (1.70 to 2980)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) – 116 (2.87 to 92,100) 116 (2.87 to 92,100)
Rivaroxaban (20 mg od) vs. dabigatran (150mg bd) – 3.01 (0.05 to 1390) 3.01 (0.05 to 1390)
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Clinically relevant bleeding
Six studies204,215–220 reported 430 CRB events across trials, leading to a network of seven interventions
(Figure 60). These studies204,215–220 were mostly judged to be at low risk of bias (Table 169) with some
concerns about lack of blinding of participants and personnel. There was evidence that risk of CRB is
substantially higher with warfarin (INR 2–3), dabigatran (150 mg od) and rivaroxaban (20 mg od) than
placebo (Table 170) and that risk of CRB is higher with rivaroxaban (20 mg od) than aspirin (Table 171).
1. Placebo
3. Aspirin (100 mg od)
5. Warfarin (INR 2–3)
6. Apixaban (2.5 mg bd)
7. Apixaban (5 mg bd)
8. Dabigatran (150 mg bd)
9. Rivaroxaban (20 mg od)
FIGURE 60 Network plot for CRB (secondary prevention of VTE).
TABLE 169 Included trials and risk-of-bias assessment for CRB (secondary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
AMPLIFY-EXT221 1, 6, 7 + + ? + + +
ASPIRE220 1, 3 + + + + + +
EINSTEIN-EXTENSION206,217,218 1, 9 + + – + + +
RE-MEDY222 5, 8 + + + + + +
RE-SONATE222 1, 8 + + ? + + +
WARFASA219 1, 3 + ? ? + + +
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 170 Results for CRB (secondary prevention of VTE): comparisons with placebo
Comparisons with placebo
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Aspirin (100 mg od) 1.51 (0.72 to 3.27) – 1.51 (0.72 to 3.27)
Warfarin (INR 2–3) 5.85 (2.93 to 12.6) – 5.85 (2.93 to 12.6)
Apixaban (2.5 mg bd) 1.22 (0.69 to 2.19) – 1.22 (0.69 to 2.19)
Apixaban (5 mg bd) 1.66 (0.96 to 2.89) – 1.66 (0.96 to 2.89)
Dabigatran (150mg bd) 3.05 (1.62 to 6.25) – 3.05 (1.62 to 6.25)
Rivaroxaban (20 mg od) 5.56 (2.58 to 14.0) – 5.56 (2.58 to 14.0)
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There was evidence that risk of CRB is lower with apixaban (2.5 mg or 5 mg bd) and dabigatran
(150 mg bd) than warfarin (INR 2–3) (Table 172). All comparisons between NOACs at licensed doses
were imprecisely estimated, but there was evidence that risk of CRB is higher with dabigatran (150 mg bd)
and rivaroxaban (20 mg od) than apixaban (2.5 mg bd and 5 mg bd) (Table 173).
Bleeding (sensitivity analysis)
We conducted a supplementary analysis based on HRs for bleeding events reported in some studies.
We extracted HRs for CRB, or for major bleeding if that was the only information available. The structure
of this resulting network is presented in Figure 61. Results are similar to those for CRB (Tables 174–177).
TABLE 171 Results for CRB (secondary prevention of VTE): comparisons with aspirin
Comparisons with aspirin
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (2.5 mg bd) – 0.81 (0.31 to 2.08) 0.81 (0.31 to 2.08)
Apixaban (5 mg bd) – 1.10 (0.43 to 2.78) 1.10 (0.43 to 2.78)
Dabigatran (150 mg bd) – 2.03 (0.75 to 5.66) 2.03 (0.75 to 5.66)
Rivaroxaban (20 mg od) – 3.70 (1.25 to 12.0) 3.70 (1.25 to 12.0)
TABLE 172 Results for CRB (secondary prevention of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Apixaban (2.5 mg bd) – 0.21 (0.08 to 0.52) 0.21 (0.08 to 0.52)
Apixaban (5 mg bd) – 0.28 (0.11 to 0.69) 0.28 (0.11 to 0.69)
Dabigatran (150 mg bd) 0.52 (0.39 to 0.69) – 0.52 (0.39 to 0.69)
Rivaroxaban (20 mg od) – 0.95 (0.32 to 3.01) 0.95 (0.32 to 3.01)
TABLE 173 Results for CRB (secondary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 0.43 (0.01 to 5.42) – 0.43 (0.01 to 5.42)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd) – 14.7 (0.96 to 582) 14.7 (0.96 to 582)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) – 44.8 (1.60 to 24,100) 44.8 (1.60 to 24,100)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) – 37.1 (1.70 to 2980) 37.1 (1.70 to 2980)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) – 116 (2.87 to 92,100) 116 (2.87 to 92,100)
Rivaroxaban (20mg od) vs. dabigatran (150mg bd) – 3.01 (0.05 to 1390) 3.01 (0.05 to 1390)
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1. Placebo
3. Aspirin (100 mg od)
4. Warfarin (INR 1.5–2)
5. Warfarin (INR 2–3)
6. Apixaban (2.5 mg bd)
7. Apixaban (5 mg bd)
8. Dabigatran (150 mg bd)
9. Rivaroxaban (20 mg od)
FIGURE 61 Network plot for bleeding (secondary prevention of VTE).
TABLE 174 Results for bleeding (secondary prevention of VTE): comparisons with placebo
Comparisons with placebo
NMA
HR (95% CI)
Aspirin (100 mg od) 1.48 (0.70 to 3.09)
Warfarin (INR 2–3) 5.39 (2.64 to 10.8)
Apixaban (2.5 mg bd) 1.29 (0.72 to 2.33)
Apixaban (5 mg bd) 1.82 (1.05 to 3.17)
Dabigatran (150mg bd) 2.91 (1.51 to 5.54)
Rivaroxaban (20 mg od) 5.19 (2.28 to 11.6)
Imprecisely estimated comparisons
Warfarin (INR 1.5–2) 2.54 (0.48 to 13.1)
TABLE 175 Results for bleeding (secondary prevention of VTE): comparisons with aspirin
Comparisons with aspirin
NMA
HR (95% CI)
Apixaban (2.5 mg bd) 0.87 (0.34 to 2.25)
Apixaban (5 mg bd) 1.23 (0.48 to 3.14)
Dabigatran (150mg bd) 1.97 (0.73 to 5.25)
Rivaroxaban (20 mg od) 3.51 (1.17 to 10.5)
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All-cause mortality
Nine studies204,211–220 reported 158 all-cause mortality events, leading to a network of nine interventions
(Figure 62). These studies204,211–220 were mostly judged to be at low risk of bias (Table 178), with some
concerns about lack of blinding of participants and personnel. All comparisons of risk of all-cause mortality
with placebo, except that for aspirin (100 mg od), were imprecisely estimated (Table 179). However, there
was evidence that risk of all-cause mortality was lower for apixaban (5 mg bd) than placebo. Comparisons
of NOACs with aspirin were imprecisely estimated, although there was weak evidence that risk of all-cause
mortality is lower with apixaban (5 mg bd) than aspirin (Table 180). There was no evidence that risk of
all-cause mortality differed for NOACs compared with warfarin (INR 2–3), although all comparisons –
except that with dabigatran (150 mg bd) – were imprecisely estimated (Table 181). Comparisons of risk
of all-cause mortality between NOACs at licensed doses were imprecisely estimated (Table 182).
TABLE 176 Results for bleeding (secondary prevention of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin (INR 2–3)
NMA
HR (95% CI)
Apixaban (2.5 mg bd) 0.24 (0.09 to 0.61)
Apixaban (5 mg bd) 0.34 (0.14 to 0.84)
Dabigatran (150 mg bd) 0.54 (0.41 to 0.71)
Rivaroxaban (20 mg od) 0.96 (0.33 to 2.82)
TABLE 177 Results for bleeding (secondary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
NMA
HR (95% CI)
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) 1.65 (0.25 to 14.2)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd) 2.06 (0.03 to 117)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) 1.22 (0.02 to 57.5)
1. Placebo
2. No treatment
3. Aspirin (100 mg od)
4. Warfarin (INR 1.5–2)
5. Warfarin (INR 2–3)6.  Apixaban (2.5 mg bd)
7.  Apixaban (5 mg bd)
8. Dabigatran (150 mg bd)
9. Rivaroxaban (20 mg od)
FIGURE 62 Network plot for all-cause mortality (secondary prevention of VTE).
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TABLE 178 Included trials and risk-of-bias assessment for all-cause mortality (secondary prevention of VTE)
Study Interventions compared SG AC BPP BOA IOD SR
AMPLIFY-EXT221 1, 6, 7 + + ? + + +
ASPIRE220 1, 3 + + + + + +
EINSTEIN-EXTENSION206,217,218 1, 9 + + – + + +
LAFIT211 1, 5 + + + + + ?
PREVENT216 1, 4 + + + + + +
RE-MEDY222 5, 8 + + + + + +
WARFASA219 1, 3 + ? ? + + +
WODIT-DVT214 2, 5 ? – – + + ?
WODIT-PE215 2, 5 + + – + + ?
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; AC, allocation concealment; BOA, blinding of outcome
assessment; BPP, blinding of participants and personnel; IOD, incomplete outcome data; SG, sequence generation;
SR, selective reporting.
TABLE 179 Results for all-cause mortality (secondary prevention of VTE): comparisons with placebo
Comparisons with placebo
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Aspirin (100 mg od) 0.94 (0.52 to 1.73) – 0.94 (0.52 to 1.73)
Apixaban (2.5 mg bd) 0.48 (0.18 to 1.17) – 0.48 (0.18 to 1.17)
Imprecisely estimated comparisons
No treatment – 0.20 (0.01 to 2.03) 0.20 (0.01 to 2.03)
Warfarin (INR 1.5–2) 0.47 (0.12 to 1.54) – 0.47 (0.12 to 1.54)
Warfarin (INR 2–3) 0.28 (0.01 to 2.47) – 0.28 (0.01 to 2.47)
Apixaban (5 mg bd) 0.27 (0.07 to 0.78) – 0.27 (0.07 to 0.78)
Dabigatran (150mg bd) 0.25 (0.01 to 2.50) – 0.25 (0.01 to 2.50)
Rivaroxaban (20 mg od) 0.41 (0.01 to 5.21) – 0.41 (0.01 to 5.21)
TABLE 180 Results for all-cause mortality (secondary prevention of VTE): comparisons with aspirin
Comparisons with aspirin
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) – 0.50 (0.16 to 1.49) 0.50 (0.16 to 1.49)
Apixaban (5 mg bd) – 0.29 (0.07 to 0.98) 0.29 (0.07 to 0.98)
Dabigatran (150mg bd) – 0.26 (0.01 to 2.87) 0.26 (0.01 to 2.87)
Rivaroxaban (20 mg od) – 0.43 (0.01 to 5.90) 0.43 (0.01 to 5.90)
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Summary of results
Our analyses of a network of 10 RCTs found evidence that warfarin (INR 2–3), apixaban (2.5 mg bd),
apixaban (5 mg bd), dabigatran (150 mg bd) and rivaroxaban (20 mg od) reduce the risk of recurrent VTE,
symptomatic DVT and symptomatic PE compared with placebo. Some of these reductions were substantial.
We also found evidence that aspirin (100 mg od) and warfarin (INR 1.5–2) reduce the risk of recurrent VTE.
The risk of recurrent VTE and symptomatic DVT is generally lower for NOACs at doses included in the
network than for aspirin (100 mg od). However, there was little evidence that risks of recurrent VTE and
symptomatic DVT differ comparing NOACs with warfarin (INR 2–3) or that the risk of these outcomes
differs between licensed doses of NOACs. There was evidence that risk of symptomatic PE is higher with
apixaban (2.5 mg bd) than warfarin (INR 2–3), and lower with dabigatran (150 mg bd) and rivaroxaban
(20 mg od) than apixaban (2.5 mg bd).
By contrast, the risk of major bleeding and CRB is higher with warfarin (INR 2–3), dabigatran (150 mg od)
and rivaroxaban (20 mg od) than placebo. However, the risk of these outcomes is lower for dabigatran
(150 mg bd), apixaban (2.5 mg bd) and apixaban (5 mg bd) than warfarin (INR 2–3). There was evidence
that the risk of major bleeding and CRB is higher with dabigatran (150 mg bd) and rivaroxaban (20 mg od)
than apixaban (2.5 mg bd and 5 mg bd). However, results should be interpreted with caution because
many comparisons were imprecisely estimated: for this reason it was not possible to derive a rankogram
for this network.
For some outcomes there was evidence that patients who remained untreated had lower outcome risks
than those on active interventions. This counterintuitive finding is based on the from WODIT-DVT214
and WODIT-PE215 trials. With regard to model appraisal, we did not identify any instance of lack of
convergence among the Markov chains, poor model fit or inconsistency.
TABLE 181 Results for all-cause mortality (secondary prevention of VTE): comparisons with warfarin (INR 2–3)
Comparisons with warfarin
(INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Dabigatran (150 mg bd) 0.89 (0.45 to 1.73) – 0.89 (0.45 to 1.73)
Imprecisely estimated comparisons
Apixaban (2.5 mg bd) – 1.71 (0.15 to 60.6) 1.71 (0.15 to 60.6)
Apixaban (5 mg bd) – 0.97 (0.08 to 35.1) 0.97 (0.08 to 35.1)
Rivaroxaban (20 mg od) – 1.52 (0.03 to 98.3) 1.52 (0.03 to 98.3)
TABLE 182 Results for all-cause mortality (secondary prevention of VTE): NOACs (licensed doses only)
Licensed NOACs only
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Imprecisely estimated comparisons
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd) – 0.57 (0.14 to 1.94) 0.57 (0.14 to 1.94)
Dabigatran (150 mg bd) vs. apixaban (2.5 mg bd) – 0.51 (0.01 to 6.39) 0.51 (0.01 to 6.39)
Rivaroxaban (20 mg od) vs. apixaban (2.5 mg bd) – 0.85 (0.02 to 12.9) 0.85 (0.02 to 12.9)
Dabigatran (150 mg bd) vs. apixaban (5 mg bd) – 0.91 (0.02 to 13.0) 0.91 (0.02 to 13.0)
Rivaroxaban (20 mg od) vs. apixaban (5 mg bd) – 1.52 (0.04 to 26.3) 1.52 (0.04 to 26.3)
Rivaroxaban (20mg od) vs. dabigatran (150 mg bd) – 1.79 (0.03 to 121) 1.79 (0.03 to 121)
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Chapter 10 Clinical results (5): combined
safety analyses
In this chapter, we present network plots and pairwise comparisons from NMAs using the informationfrom all four reviews. These should not be regarded as main results, but as a set of supplementary
analyses in which we aimed to gain power by combining all databases in a single network for each of
the following outcomes: MI, major bleeding, CRB and all-cause mortality.
A number of decisions were made in order to define the list of relevant nodes (e.g. interventions). We
excluded the TOPIC-1,197 TOPIC-2197 and ARDEPARIN ARTHROPLASTY STUDY196 trials, as for the analyses
of primary prevention of VTE. We also excluded several individual interventions that were not considered
to provide relevant information and were not necessary to keep our networks connected. These were
warfarin arms with a subtherapeutic INR range, arms combined dabigatran and aspirin (considered only
in PETRO102), no treatment arms (only found in WODIT-DVT214 and WODIT-PE215 and compared with
warfarin), LMWH (nadroparin 3800 IU anti-Xa od, implemented only in PROTECHT170 and compared
with placebo), and warfarin with INR range 3–4 (considered only in AFASAK95 and compared with aspirin).
If the intervention had been implemented in a two-arm trial then the trial was excluded from these
analyses.
We also made several decisions in order to reduce the number of intervention arms compared.
The reference treatment in our networks was warfarin (INR 2–3), which may include other VKA
interventions, as was described for the analyses of AF. The antiplatelet interventions were defined as in
the AF review (e.g. < 150 mg od and ≥ 150 mg od). The standard dose of LMWH was as in the review
of primary prevention of VTE, and LMWH administered to non-surgical patients was combined with
post-op LMWH. We merged some NOAC intervention doses and labelled these according to total daily
dose. The edoxaban (60 mg) intervention included one arm from the review of acute VTE treatment in
which 17% of patients received 30 mg instead. The list of interventions included in the networks is
presented in Table 183.
Results are presented as follows for each outcome. First, we provide network plots. Second, we present results
tables for each intervention compared with the reference treatment [warfarin (INR range 2–3)]. These tables
show posterior median ORs and 95% credible intervals from Bayesian fixed-effects analyses are shown, but
we refer to the latter as CIs for convenience. We present results separately for any available direct evidence,
for any indirect comparisons that can be made and for the NMA (which combines the direct and the indirect
evidence). Comparisons from the NMA with a ratio between interval limits exceeding nine were considered to
be imprecisely estimated and are presented at the bottom of each table (back-calculation of indirect evidence
was not done for imprecisely estimated comparisons).
Myocardial infarction
A total of 34 trials reported on MI across the four reviews, leading to a network of 18 interventions
(Figure 63). The total number of events was 1489. Comparisons with the reference interventions
[warfarin (INR 2–3)], presented in Table 184, suggest that the risk of MI is higher with dabigatran
(220 mg daily), dabigatran (300–600 mg daily) and edoxaban (30–45 mg daily) than warfarin (INR 2–3).
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TABLE 183 List of distinct interventions examined in the
combined safety analyses
Warfarin INR 2–3
LMWH post-op Standard dose
LMWH pre-op Standard dose
LMWH Enoxaparin 20 mg bd
Antiplatelet < 150mg od
≥ 150mg od
Placebo
Apixaban 5mg
10mg
20mg
Betrixaban 30–60mg
80mg
Dabigatran 100–150mg
220mg
300–600mg
Edoxaban 5–15mg
30–45mg
60mg
90–120mg
Rivaroxaban 5mg
10mg
20–30mg
Warfarin (INR 2–3)
LMWH post op (standard dose)
LMWH pre op (standard dose)
Antiplatelet (< 150 mg od)
Antiplatelet (> 150 mg od)
Placebo
Apixaban (5 mg)
Apixaban (10 mg)
Apixaban (20 mg)
Betrixaban (30–60 mg)
Betrixaban (80 mg)
Dabigatran (220 mg)
Dabigatran (300–600 mg)
Edoxaban (30–45 mg)
Edoxaban (60 mg)
Edoxaban (90–120 mg)
Rivaroxaban (10 mg)
Rivaroxaban (20–30 mg)
FIGURE 63 Network plot for MI (combined analysis).
CLINICAL RESULTS (5): COMBINED SAFETY ANALYSES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
228
Major bleeding
A total of 71 trials reported on major bleeding across the four reviews, leading to a network of 23 interventions
(Figure 64). In total there were 5335 major bleeding events. The pairwise comparisons with warfarin, shown in
Table 185, suggest that the risk of major bleeding is similar for both pre-op and post-op LMWH than warfarin
(INR 2–3). However, there was notable inconsistency between the directly and indirectly estimated ORs.
There was evidence that risk of major bleeding is lower for NOAC interventions than warfarin (INR 2–3),
in agreement with the results from the AF review. This applies to the apixaban (10 mg daily), dabigatran
(100–150mg and 220mg daily) and edoxaban interventions. Risk of major bleeding appeared higher with
rivaroxaban (10 mg and 30–40mg daily) than warfarin (INR 2–3), a finding that might stem from the evidence
on primary prevention of VTE.
TABLE 184 Results for MI (combined analysis): comparisons with warfarin (INR 2–3)
Comparisons with warfarin
(INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
Antiplatelet (< 150mg) 1.01 (0.63 to 1.60) – 1.01 (0.63 to 1.60)
Antiplatelet (≥ 150mg) 1.36 (0.88 to 2.13) – 1.36 (0.88 to 2.13)
Placebo – 2.23 (0.79 to 6.72) 2.23 (0.79 to 6.72)
Apixaban (10 mg) 0.90 (0.69 to 1.18) – 0.90 (0.69 to 1.18)
Dabigatran (220 mg) 1.39 (1.03 to 1.89) – 1.39 (1.03 to 1.89)
Dabigatran (300–600mg) 1.44 (1.08 to 1.91) – 1.44 (1.08 to 1.91)
Edoxaban (30–45mg) 1.25 (1.00 to 1.56) – 1.25 (1.00 to 1.56)
Edoxaban (60 mg) 1.01 (0.81 to 1.26) – 1.01 (0.81 to 1.26)
Rivaroxaban (20–30mg) 0.84 (0.64 to 1.09) – 0.84 (0.64 to 1.09)
Imprecisely estimated comparisons
LMWH post-op (standard dose) – 2.17 (0.50 to 9.72) 2.17 (0.50 to 9.72)
LMWH pre-op (standard dose) – 0.82 (0.19 to 3.42) 0.82 (0.19 to 3.42)
Apixaban (5 mg) – 1.33 (0.40 to 4.46) 1.33 (0.40 to 4.46)
Apixaban (20 mg) – 0.46 (0.01 to 4.23) 0.46 (0.01 to 4.23)
Edoxaban (90–120mg) 0.19 (0 to 2.61) – 0.19 (0 to 2.61)
Rivaroxaban (10 mg) – 0.60 (0.13 to 2.80) 0.60 (0.13 to 2.80)
Warfarin (INR 2–3)
LMWH post op (standard dose)
LMWH pre op (standard dose)
LMWH (enoxaparin 20 mg bd)
Antiplatelet (< 150 mg od)
Antiplatelet (> 150 mg od)
Placebo
Apixaban (5 mg)
Apixaban (10 mg)
Apixaban (20 mg)
Betrixaban (30–60 mg)
Betrixaban (80 mg)Dabigatran (100–150 mg)
Dabigatran (220 mg)
Dabigatran (300–600 mg)
Edoxaban (5–15 mg)
Edoxaban (30–45 mg)
Edoxaban (60 mg)
Edoxaban (90–120 mg)
Rivaroxaban (5 mg)
Rivaroxaban (10 mg)
Rivaroxaban (20–30 mg)
Rivaroxaban (40–60 mg)
FIGURE 64 Network plot for major bleeding (combined analysis).
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Clinically relevant bleeding
A total of 51 trials reported on CRB, leading to a network of 22 interventions (Figure 65). These trials
reported a total of 14,324 CRB events. Comparisons with the reference intervention [warfarin (INR 2–3)],
presented in Table 186, suggest that risk of CRB was lower with LMWH than warfarin (INR 2–3). The risk
of CRB was also lower for antiplatelets and placebo than warfarin (INR 2–3), as found in the AF and VTE
secondary prevention reviews. Among the NOAC interventions, risk of CRB was lower with apixaban
(5 mg and 10 mg daily), betrixaban (30–60 mg daily), dabigatran, edoxaban (30–45 mg and 60 mg daily)
and rivaroxaban (5 mg and 10 mg daily) than warfarin (INR 2–3) but higher with edoxaban (90 mg daily).
These findings are generally in agreement with those from the AF and VTE treatment reviews.
All-cause mortality
In total 59 trials reported on all-cause mortality, leading to a network of 23 interventions (Figure 66).
The total number of deaths was 8508. Comparisons with the reference intervention [warfarin (INR 2–3)],
shown in Table 187, suggest that risk of all-cause mortality was higher with antiplatelet therapy
(≥ 150 mg daily) than warfarin (INR 2–3). Risk of all-cause mortality was generally lower among the
NOAC interventions [estimated ORs compared with warfarin (INR 2–3) were between 0.87 and 0.93].
TABLE 185 Results for major bleeding (combined analysis): comparisons with warfarin (INR 2–3)
Comparisons with warfarin
(INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
LMWH post-op (standard dose) 1.65 (1.11 to 2.44) 0.61 (0.41 to 0.89) 0.99 (0.75 to 1.29)
LMWH pre-op (standard dose) 2.14 (1.36 to 3.36) 0.62 (0.45 to 0.89) 0.99 (0.75 to 1.3)
LMWH (enoxaparin 40 mg) – 0.61 (0.21 to 1.84) 0.61 (0.21 to 1.84)
Antiplatelet (< 150mg) 1.01 (0.57 to 1.80) 0.62 (0.41 to 0.93) 0.73 (0.52 to 1.03)
Antiplatelet (≥ 150mg) 1.07 (0.82 to 1.41) – 1.07 (0.82 to 1.41)
Placebo 0.60 (0.36 to 0.99) – 0.60 (0.36 to 0.99)
Apixaban (5 mg) – 0.89 (0.60 to 1.31) 0.89 (0.60 to 1.31)
Apixaban (10 mg) 0.67 (0.59 to 0.77) – 0.67 (0.59 to 0.77)
Apixaban (20 mg) 1.77 (0.84 to 3.76) – 1.77 (0.84 to 3.76)
Dabigatran (100–150mg) – 0.62 (0.39 to 0.97) 0.62 (0.39 to 0.97)
Dabigatran (220mg) 0.82 (0.71 to 0.94) – 0.82 (0.71 to 0.94)
Dabigatran (300–600mg) 0.91 (0.80 to 1.04) – 0.91 (0.80 to 1.04)
Edoxaban (30–45mg) 0.47 (0.40 to 0.54) – 0.47 (0.40 to 0.54)
Edoxaban (60 mg) 0.80 (0.70 to 0.90) – 0.80 (0.70 to 0.90)
Edoxaban (90–120mg) 2.43 (0.97 to 5.76) – 2.43 (0.97 to 5.76)
Rivaroxaban (5 mg) – 0.65 (0.22 to 1.55) 0.65 (0.22 to 1.55)
Rivaroxaban (10 mg) – 1.71 (1.14 to 2.57) 1.71 (1.14 to 2.57)
Rivaroxaban (20–30mg) 1.01 (0.88 to 1.15) – 1.01 (0.88 to 1.15)
Rivaroxaban (40–60mg) 1.18 (0.45 to 3.12) 3.53 (2.00 to 6.22) 2.67 (1.63 to 4.36)
Imprecisely estimated comparisons
Betrixaban (30–60mg) – 0.09 (0 to 2.87) 0.09 (0 to 2.87)
Betrixaban (80 mg) – 0.10 (0 to 3.07) 0.10 (0 to 3.07)
Edoxaban (5–15mg) – 0.63 (0.10 to 2.64) 0.63 (0.10 to 2.64)
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Warfarin (INR 2–3)
LMWH post op (standard dose)
LMWH pre op (standard dose)
LMWH (enoxaparin 20 mg bd)
Antiplatelet (< 150 mg od)
Placebo
Apixaban (5 mg)
Apixaban (10 mg)
Apixaban (20 mg)
Betrixaban (30–60 mg)
Betrixaban (80 mg)
Dabigatran (100–150 mg)
Dabigatran (220 mg)
Dabigatran (300–600 mg)
Edoxaban (5–15 mg)
Edoxaban (30–45 mg)
Edoxaban (60 mg)
Edoxaban (90–120 mg)
Rivaroxaban (5 mg)
Rivaroxaban (10 mg)
Rivaroxaban (20–30 mg)
Rivaroxaban (40–60 mg)
FIGURE 65 Network plot for CRB (combined analysis).
TABLE 186 Results for CRB (combined analysis): comparisons with warfarin (INR 2–3)
Comparisons with warfarin
(INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
LMWH post-op (standard dose) – 0.39 (0.29 to 0.53) 0.39 (0.29 to 0.53)
LMWH pre-op (standard dose) – 0.48 (0.36 to 0.66) 0.48 (0.36 to 0.66)
LMWH (enoxaparin 40 mg) – 0.52 (0.31 to 0.86) 0.52 (0.31 to 0.86)
Antiplatelet (< 150mg) – 0.52 (0.40 to 0.67) 0.52 (0.40 to 0.67)
Placebo 0.28 (0.21 to 0.37) – 0.28 (0.21 to 0.37)
Apixaban (5 mg) 0.40 (0.30 to 0.54) – 0.40 (0.30 to 0.54)
Apixaban (10 mg) 0.61 (0.55 to 0.67) – 0.61 (0.55 to 0.67)
Apixaban (20 mg) 0.74 (0.40 to 1.38) – 0.74 (0.40 to 1.38)
Betrixaban (30–60mg) 0.24 (0.08 to 0.64) – 0.24 (0.08 to 0.64)
Betrixaban (80 mg) 0.45 (0.16 to 1.21) – 0.45 (0.16 to 1.21)
Dabigatran (100–150mg) 0.54 (0.37 to 0.78) – 0.54 (0.37 to 0.78)
Dabigatran (220 mg) – 0.57 (0.39 to 0.82) 0.57 (0.39 to 0.82)
Dabigatran (300–600mg) 0.62 (0.52 to 0.73) – 0.62 (0.52 to 0.73)
Edoxaban (5–15mg) – 0.53 (0.25 to 1.08) 0.53 (0.25 to 1.08)
Edoxaban (30–45mg) 0.59 (0.54 to 0.64) – 0.59 (0.54 to 0.64)
Edoxaban (60 mg) 0.83 (0.78 to 0.89) – 0.83 (0.78 to 0.89)
Edoxaban (90–120mg) 2.04 (1.15 to 3.62) 0.82 (0.27 to 2.52) 1.69 (1.00 to 2.80)
Rivaroxaban (5 mg) – 0.42 (0.21 to 0.80) 0.42 (0.21 to 0.80)
Rivaroxaban (10 mg) – 0.72 (0.53 to 0.98) 0.72 (0.53 to 0.98)
Rivaroxaban (20–30mg) 1.00 (0.93 to 1.07) – 1.00 (0.93 to 1.07)
Rivaroxaban (40–60mg) 0.23 (0.06 to 0.85) 1.46 (0.97 to 2.21) 1.24 (0.84 to 1.83)
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Warfarin (INR 2 – 3)
LMWH post op (standard dose)
LMWH pre op (standard dose)
LMWH (Enoxaparin 20 mg bd)
Antiplatelet (< 150 mg od)
Antiplatelet (> 150 mg od)
Placebo
Apixaban (5 mg)
Apixaban (10 mg)
Apixaban (20 mg)
Betrixaban (30–60 mg)
Betrixaban (80 mg)Dabigatran (100–150 mg)
Dabigatran (220 mg)
Dabigatran (300–600 mg)
Edoxaban (5–15 mg)
Edoxaban (30–45 mg)
Edoxaban (60 mg)
Edoxaban (90–120 mg)
Rivaroxaban (5 mg)
Rivaroxaban (10 mg)
Rivaroxaban (20–30 mg)
Rivaroxaban (40–60 mg)
FIGURE 66 Network plot for all-cause mortality (combined analysis).
TABLE 187 Results for all-cause mortality (combined analysis): comparisons with warfarin (INR 2–3)
Comparisons with warfarin
(INR 2–3)
Direct evidence,
OR (95% CI)
Indirect evidence,
OR (95% CI) NMA, OR (95% CI)
LMWH pre-op (standard dose) – 1.70 (0.84 to 3.50) 1.70 (0.84 to 3.50)
LMWH post-op (standard dose) 0.68 (0.32 to 1.47) 1.26 (0.80 to 1.98) 1.07 (0.72 to 1.6)
Antiplatelet (< 150mg) 1.02 (0.76 to 1.37) 1.13 (0.87 to 1.47) 1.08 (0.88 to 1.32)
Antiplatelet (≥ 150mg) 1.23 (1.02 to 1.48) – 1.23 (1.02 to 1.48)
Placebo 1.15 (0.77 to 1.71) – 1.15 (0.77 to 1.71)
Apixaban (5 mg) – 1.07 (0.54 to 2.08) 1.07 (0.54 to 2.08)
Apixaban (10 mg) 0.87 (0.78 to 0.97) – 0.87 (0.78 to 0.97)
Dabigatran (220mg) 0.92 (0.81 to 1.04) – 0.92 (0.81 to 1.04)
Dabigatran (300–600mg) 0.89 (0.79 to 1.01) – 0.89 (0.79 to 1.01)
Edoxaban (30–45mg) 0.88 (0.79 to 0.97) – 0.88 (0.79 to 0.97)
Edoxaban (60 mg) 0.93 (0.85 to 1.02) – 0.93 (0.85 to 1.02)
Rivaroxaban (10 mg) – 1.10 (0.70 to 1.72) 1.10 (0.70 to 1.72)
Rivaroxaban (20–30mg) 0.87 (0.75 to 1.02) – 0.87 (0.75 to 1.02)
Imprecisely estimated comparisons
Apixaban (20 mg) 0.67 (0.17 to 2.34) – 0.67 (0.17 to 2.34)
Betrixaban (30–60mg) 0.71 (0.07 to 10.2) – 0.71 (0.07 to 10.2)
Betrixaban (80 mg) 0.19 (0 to 5.78) – 0.19 (0 to 5.78)
Dabigatran (100–150mg) – 1.36 (0.32 to 5.00) 1.36 (0.32 to 5.00)
Edoxaban (5–15mg) – 0.76 (0.06 to 4.54) 0.76 (0.06 to 4.54)
Edoxaban (90–120mg) – 0.16 (0 to 2.30) 0.16 (0 to 2.30)
Rivaroxaban (40–60mg) 0.27 (0.04 to 1.03) – 0.27 (0.04 to 1.03)
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Chapter 11 Cost-effectiveness results (2):
venous thromboembolism
Introduction
In this chapter we present the results of the CEA for first-line secondary prevention, acute treatment and
primary prevention of venous thromboembolic disease. The decision questions, populations, interventions,
outcomes, model structures, cost and utility inputs have been previously described in Chapter 4. In this
chapter we begin by describing clinical effectiveness inputs to the models, including relative treatment effects
based on the evidence identified in the systematic reviews (see Chapters 7–9), transition probabilities on the
reference treatment on which relative effects are applied, other state-transition probabilities based on
evidence from longitudinal studies, and mortality. We then present the results from our cost-effectiveness
model, together with sensitivity analyses to key assumptions made. Results are presented from Bayesian
analyses with 95% credible intervals, although we refer to these as confidence intervals for convenience.
Model inputs: venous thromboembolism secondary prevention
Overview
The state-transition parameters that inform the secondary prevention model have two components.
The relative effects of the different treatments come from the NMAs of the studies that were identified
in the systematic review (see Chapter 9). The transition parameters under standard care (i.e. no
pharmacological treatment) are taken from longitudinal studies that provide information on the natural
history of VTE.
Relative treatment efficacy
Hazard ratios for the relative treatment effects of aspirin, warfarin and three NOACs (apixaban, dabigatran
and rivaroxaban) compared with placebo are derived from the NMA (see Table 145). These HRs were
applied to the risk of symptomatic VTE on the reference treatment (no pharmacotherapy) to estimate the
efficacy of each intervention. The NMA revealed inconsistent results between the WODIT trials,212,213 which
used a no-treatment control arm and other trials that used a placebo control arm. The estimated hazard
for no treatment lacked face validity, as it was much lower than placebo and aspirin, and was similar to
the NOACs. Therefore, we decided that aspirin, warfarin and NOAC efficacy relative to placebo was the
more reliable estimate for the cost-effectiveness model.
Given a recurrent VTE event, we estimated the probability that it is a DVT, which can be subtracted from
1 to give the probability that it is a PE. If the recurrent VTE is a PE, we estimated the probability that is
a non-fatal PE. Owing to very small numbers of events in the secondary prevention RCTs, we are unable to
estimate relative treatment effects for these conditional probabilities and assumed that they are treatment
independent. We therefore treat each arm of each trial as an independent source of information on
the probability of (1) a DVT only, given a recurrent VTE event, and (2) a non-fatal PE, given a PE event.
Eight out of the 10 studies in the systematic review were included in this analysis; two studies did not
record counts of DVT, non-fatal PE and fatal PE. The counts of VTE, DVT, non-fatal PE and fatal PE are in
Table 138. Both fixed- and random-effects single-arm meta-analyses were explored (including study arms
with zero events). The random-effects models did not show evidence of a better fit than the fixed-effects
models. We therefore used the results from the fixed-effects meta-analysis to estimate conditional
probabilities and uncertainty using beta distributions (Table 188).
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Relative treatment safety
The criteria for and classification of bleeding events is not uniform across RCTs and is the subject of
wider debate.225 Our model distinguishes between fatal bleeds, non-fatal ICH and other clinically relevant
bleeds (those which require an intervention or hospital admission). Minor bleeds, identified through close
monitoring in RCTs, which do not require intervention, are not considered clinically relevant and have
not been included in the model because of the minimal impact on quality of life and costs.
The incidence of ICH was not commonly reported in the secondary prevention VTE RCTs. Therefore, the
relative treatment effects of the NOACs compared with warfarin for ICH were derived from RCTs conducted
in the AF population (see Table 59). These trials included all NOAC and dose combinations compared in the
secondary prevention of VTE. We assumed that the relative treatment effects of no pharmacotherapy and
aspirin compared with warfarin for ICH are similar to those estimated for CRB (see Table 174).
The VTE secondary prevention RCTs did not provide sufficient information to determine what proportion
of ICHs are fatal. Therefore, the proportion of non-fatal ICHs was estimated from a study226 that
investigated ICHs in patients with AF using data from the RE-LY104 trial. In total there were 56 fatal and
98 non-fatal ICHs. The relative treatment effects for other CRB, compared with the reference group
(no pharmacotherapy), for the interventions, were estimated in a NMA (see Table 174).
Transition probabilities with usual care (no pharmacotherapy)
A rapid literature review was conducted to identify long-term follow-up studies in a patient population
with VTE to inform the natural history of VTE with usual care (no pharmacotherapy). The initial search
identified 3915 abstracts. After abstract selection and full-paper review of the most relevant subset of
papers, the following three studies,227–229 based in the same region of Italy, were selected as most relevant
to parameterise the secondary prevention model.
Prandoni et al.227 recruited 528 patients with a first episode of venography proven DVT in a prospective
cohort study conducted in a single centre in Italy. Patients were treated initially with unfractioned heparin
or LMWH and then warfarin (INR target 2–3) for at least 3 months. Patients were advised to wear
compression stockings for at least 2 years and followed up every 6 months for up to 8 years. The aim of
the study was to assess VTE recurrence, PTS incidence and mortality. The results of this study were used to
parameterise the rate of mild/moderate and severe PTS.
Prandoni et al.228 broadened their previous work and reported on a prospective cohort of 1626 patients,
recruited in three centres in Italy. Patients with a previous, imaging confirmed, symptomatic proximal DVT
or a PE after discontinuation of anticoagulation (warfarin for, on average, 3 months) treatment were
eligible. Patients were followed up in clinic or by telephone at least once every 6 months for a maximum of
10 years (median 50 months). The study228 estimated the cumulative incidence of symptomatic recurrent
VTE, confirmed by imaging, and we used these results to estimate the risk of recurrent VTE with no
anticoagulation in our model.
Pengo et al.229 estimated the incidence of CTPH in a prospective cohort of 223 patients with a first episode
of acute PE in one Italian centre. Patients initially received heparin and then oral anticoagulation for at least
6 months (target INR 2–3). Follow-up was performed at least every 6 months during the first 2 years and
then annually for up to 10 years; mean follow-up was 94.3 months. CTPH was diagnosed in patients with
TABLE 188 Estimated risk for DVT given VTE recurrence and non-fatal PE given PE
Event Proportion Alpha Beta Distribution
DVT given recurrent VTE 0.626 268 160 Beta
Non-fatal PE, given PE 0.919 147 13 Beta
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unexplained persistent dyspnoea, with supportive evidence on pulmonary angiography and mean
pulmonary artery pressures. We used these findings to estimate transition from ‘post PE’ and ‘post PE DVT’
to CTPH in our model.
Parameters informing the risk of recurrent VTE in the usual care group (no long-term pharmacotherapy) were
derived from Prandoni et al.228 Individual patient data were reconstructed from the cumulative risk plot, and
exponential and Weibull parametric distributions were fitted to these data. The Akaike information criterion
(AIC)230 was used to determine the best-fitting curve for the within-study period (preferring models with
lower AIC) and a visual examination determined the validity of the extrapolation. The best-fitting curve for
the within-study period was the Weibull distribution (Figure 67 and Table 189).
The risk of a clinically relevant bleed in the reference group was estimated based on PREVENT.216 The
PREVENT trial216 had a follow-up of up to 4.3 years, with a mean of 2.1 years. The observed rate of major
bleeding – requiring hospitalisation or transfusion – in the placebo arm was 4 per 1000 person-years.
Patients not receiving pharmacotherapy are assumed to be at equal risk of bleeds as placebo.
Future venous thromboembolism-related events
A proportion of patients develop PTS after a DVT. The incidence of PTS, stratified by mild/moderate or
severe, was derived from Prandoni et al.,227 which provides a plot of the cumulative incidence of all PTS and
severe PTS. Data from this plot were extracted using WebPlotDigitizer (http://arohatgi.info/WebPlotDigitizer/)
to estimate the yearly incidence of severe PTS and mild/moderate PTS (Table 190). The cumulative incidence
of PTS levels off 2 years after the index VTE event, and we assume that patients have no additional risk of
PTS after that time. The rate of CTPH given a PE was taken from Pengo et al.229 In total, 7 of 223 patients
developed symptoms of CTPH, and all seven events occurred in the initial 2 years (Table 191).
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FIGURE 67 Parametric distributions for recurrent VTE baseline risk fitted to results reported in Prandoni et al.228
TABLE 189 Parameters and AIC for recurrent VTE baseline risk based on Prandoni et al.228
Distribution Scale Shape AIC
Exponential 0.005487 – 2758.604
Weibull 0.016565 0.721213 2702.246
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Mortality
In the model, patients can die from a fatal PE, an ICH or other, all-cause, mortality. The rates of recurrent
VTE and ICH including fatal PE and ICH events are described previously. We assumed that ICH was the
cause of all of the fatal bleeding events. Seven trials213–216,218,220,222 reported on fatal bleeds; all had low
counts and four had zero events. We assumed that sudden fatal PEs do not accrue a cost and non-sudden
fatal PEs accrue the full cost of treating a PE. This proportion of sudden fatal PEs was assumed to be
74.4% as recorded in Prandoni et al.228
All-cause mortality rates are applied to every health state in the model to incorporate other causes of
death. These were obtained from the ONS,10 stratified by gender and age to match our population
(see Appendix 10).
Model inputs: venous thromboembolism acute treatment
Overview
Relative treatment effects for the probabilities in the first-line acute treatment decision tree model
have been derived from three NMAs and a pairwise meta-analysis (described below) for the following
four events: (1) recurrent VTE; 2) non-fatal ICH (pairwise meta-analysis); (3) other CRB; and
(4) non-VTE-related mortality.
Relative treatment efficacy
The ORs of four NOACs (apixaban, dabigatran, edoxaban, rivaroxaban) compared with warfarin were derived
from the NMA (Table 192, and see Table 114). The probabilities of DVT given recurrent VTE and non-fatal
PE given PE were, as with secondary prevention, assumed to be treatment independent and derived from
single arms from all nine studies in the acute treatment review using a fixed-effects meta-analysis (Table 193
and see Table 111).
TABLE 190 Cumulative PTS rates, given DVT
Year
Cumulative incidence
SourcePTS (95% CI) Severe PTS (95% CI)
1 0.172 (0.135 to 0.215) 0.029 (0.009 to 0.044) Prandoni227
2 0.231 (0.180 to 0.277) 0.062 (0.032 to 0.090)
TABLE 191 Incidence of CTPH, given PE
Month Cumulative incidence of CTPH 95% CI Source
12 0.031 0.007 to 0.055 Pengo229
24 0.038 0.011 to 0.065
TABLE 192 Odds ratios of VTE recurrence on acute treatment: all ORs are compared with warfarin
Intervention OR 95% CI Distribution
Dabigatran 1.09 0.75 to 1.59 MCMC posterior simulations
Rivaroxaban 0.90 0.67 to 1.21
Apixaban 0.83 0.58 to 1.18
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Relative treatment safety
Four out of the nine studies identified in the literature review reported non-fatal ICH. The incidence was
low: 38 patients out of 21,916 experienced an event, and there were not enough data to perform a NMA.
Instead, we assumed that all NOACs have a similar risk, and performed a pairwise meta-analysis for all
NOACs combined compared with warfarin. Fixed- and random-effects pairwise meta-analyses were
explored resulting in DIC23 values of 40.31 and 39.54, respectively. We preferred models with lower DIC,
for which differences of at least ‘3’ are considered to be meaningful. On this basis, the fixed-effects model
was used to estimate the OR and uncertainty (Table 194). This assumption was explored in a sensitivity
analysis, for which we assumed that the risk of non-fatal ICH for NOACs is the same as the risk for
warfarin. The relative treatment effects for individual NOACs compared with warfarin for other clinically
relevant bleeds were estimated in Table 129 and are provided below (Table 195).
Mortality
To derive the mortality in the 6 months of acute treatment a NMA was performed. The counts are the
reported all-cause mortality with VTE-related mortality deducted. Eight out of the nine studies identified
in the literature review reported all-cause mortality and VTE-related mortality separately (see Table 111).
The data used in the NMA are provided in Appendix 9. The results relative to warfarin are in Table 196.
Transition probabilities with usual care (warfarin)
The risks of experiencing recurrent VTE, non-fatal ICH, clinically relevant bleed and non-VTE-related
mortality on usual care (warfarin) have been estimated from a single-arm, fixed-effects meta-analysis
model for each outcome using all of the warfarin arms that were identified in the systematic review
(including study arms with zero counts). The fixed-effects model was chosen over the random-effects
model on the basis of lower DIC. Each of the outcomes is considered to be independent and so each is
modelled separately to estimate parameters and beta distributions representing uncertainty (Table 197).
TABLE 193 Estimated risk of DVT given VTE recurrence and non-fatal PE given PE
Event Proportion Alpha Beta Distribution
DVT given recurrent VTE 0.47 341 387 Beta
Non-fatal PE given a PE event 0.73 283 104
TABLE 194 Odds ratios of non-fatal ICH in the acute treatment: NOACs combined, compared with warfarin
Intervention OR 95% CI Distribution
NOACs 0.395 0.189 to 0.790 MCMC posterior simulations
TABLE 195 Odds ratios of clinically relevant bleeds in acute treatment: all ORs are compared with warfarin
Intervention OR 95% CI Distribution
Dabigatran 0.61 0.49 to 0.76 MCMC posterior simulations
Rivaroxaban 0.93 0.81 to 1.08
Edoxaban 0.81 0.70 to 0.94
Apixaban 0.44 0.35 to 0.55
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Model inputs: venous thromboembolism primary prevention
Overview
Absolute probabilities of VTE, clinically relevant bleeds and mortality on reference treatment (LMWH) are
estimated from the LMWH arms of the primary prevention trials identified in our systematic review, and
these probabilities differ between THR and TKR populations (due to different length of time on treatment).
All of the relative effects of NOACs have been derived from NMAs, and the MCMC simulations are used
directly as inputs to our probabilistic model, retaining all correlations between parameter estimates.
We stratified relative effects of NOACs compared with LMWH by THR and TKR populations. However,
as a result of sparse data for AEs, and for consistency with the clinical effectiveness results, we assumed
that relative effects are common across THR and TKR populations for clinically relevant bleeds and
all-cause mortality.
Relative treatment efficacy
The proportion of patients who experience a symptomatic VTE event was derived from NMAs stratified
by post THR and TKR, reported in Tables 75 and Table 77, respectively. The reference comparator for
these two populations is post-op LMWH. We pooled relative treatment effects over the THR and TKR
populations in a sensitivity analysis.
Relative treatment safety
Intracranial haemorrhage was reported in only 12 primary prevention studies. Within these studies, the
total count of ICH is 6 out of 32,879 patients (it may also be the case that studies that did not report
ICH did not observe any events, which would mean that the risk is even lower). Patients who are receiving
primary prevention (for up to 35 days) are at much lower risk of ICH than patients who are receiving
acute treatment (up to 6 months) or long-term secondary prevention. Owing to extremely low incidence,
this outcome has not been incorporated into the primary prevention model. The relative treatment effects
for CRB compared with post-op LMWH are reported in Table 102.
Mortality
Relative treatment effects for all-cause mortality have been derived from the NMA. This includes fatal VTE
events, so to avoid double counting VTE-related mortality, only the rates from all-cause mortality informed
TABLE 196 Odds ratios of non-VTE/ICH-related mortality in acute treatment: all ORs are compared with warfarin
Intervention OR 95% CI Distribution
Dabigatran 0.98 0.64 to 4.84 MCMC posterior simulations
Rivaroxaban 0.96 0.71 to 1.30
Edoxaban 1.06 0.81 to 1.39
Apixaban 0.87 0.54 to 1.39
TABLE 197 Estimated risk on warfarin for recurrent VTE, non-fatal ICH, CRB and non-VTE-related mortality
Event Proportion Alpha Beta Distribution
Recurrent VTE 0.027 378 13,474 Beta
Non-fatal ICH 0.002 27 10,930
Clinically relevant bleed 0.097 1319 12,288
Non-VTE-related mortality 0.018 244 13,496
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the transition to death in the model. The results relative to post-op LMWH are given in Table 105. The
mortality rates for patients who do not experience a symptomatic VTE and enter the two-stage Markov
model were taken from the ONS all-cause mortality (see Appendix 10).
Transition probabilities with usual care (low-molecular-weight heparin)
Usual care in the primary prevention model is post-op LMWH.8 The risk of experiencing each event
(VTE, clinically relevant bleed and mortality) on the reference treatment was estimated from single-arm,
fixed-effects meta-analyses for each outcome and population (THR or TKR), using reference treatment
arms that were identified in the systematic review (including studies with zero events). The outcomes are
considered to be independent and so are modelled separately. The absolute risk of recurrent VTE and
all-cause mortality on LMWH was estimated separately for the THR and TKR populations, as THR patients
remain on treatment for longer. There was not enough information on other CRB in the THR population to
estimate an absolute risk; we therefore pooled over TKR and THR populations. We fitted a random-effects
model over the pooled TKR and THR population for clinically relevant bleeds as a result of the substantial
heterogeneity, with the random-effects model giving a DIC of 22.7 compared with 43.0 for a fixed-effects
model. The resulting parameter estimates and beta distributions that represent the uncertainty in these
estimates are given in Table 198.
Sensitivity analyses
We tested the robustness of the models’ results to some of the model parameters in one-way sensitivity
analyses, listed below.
Proportion of venous thromboembolism events that are fatal and non-fatal
pulmonary embolism (secondary prevention)
We varied the proportion of DVT, non-fatal PE and fatal PE when a patient experienced a recurrent VTE
event in the secondary prevention model. Having a large proportion of non-fatal recurrent VTE events has
a small effect on quality of life compared with having a large proportion of fatal events. We used a beta
distribution with proportions estimated in Prandoni et al.:227 101 recurrent events consisting of 80 DVTs,
10 non-fatal PEs and 11 fatal PEs.
Risk of clinically relevant bleed on warfarin (secondary prevention)
The rate used in the base case was the observed rate for major bleeds in a secondary prevention RCT
(PREVENT216). This could be an underestimate as a result of including only major and not clinically relevant
minor bleeds. In sensitivity analysis we use, instead, the odds of experience of a CRB taken from the AF
population [see Chapter 6, Transition probabilities with usual care (warfarin)].
TABLE 198 Estimated risk on LMWH for VTE, CRB and mortality minus VTE-related mortality
Event Proportion Alpha Beta Distribution
Recurrent VTE THR 0.035 65 1,787 Beta
Recurrent VTE TKR 0.023 36 1,527
Mortality THR 0.019 53 2,619
Mortality TKR 0.004 16 4,342
Event Proportion LB UB Distribution
Clinically relevant bleed 0.029 0.005 0.121 MCMC simulations
LB, lower bound; UP, upper bound.
Beta distributions, Beta (alpha,beta), representing uncertainty in the estimates are given.
DOI: 10.3310/hta21090 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 9
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Sterne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
239
Rate of non-fatal intracranial haemorrhage (acute treatment)
We did not have enough data to perform a NMA on this outcome. In the base case we assumed that all
NOACs have the same relative treatment effect compared with warfarin. We tested this assumption
by instead assuming that the rate of non-fatal ICH is equal among NOACs and warfarin in this
sensitivity analysis.
Cost of edoxaban (acute treatment)
Edoxaban does not currently have a list price in the UK. For the base case we assume a cost similar to the
list price of other NOACs, and test this assumption in a sensitivity analysis. We do this through a threshold
analyses to see what the cost of edoxaban would have to be for it to be considered cost-effective at a
willingness-to-pay threshold of £20,000 per QALY. We begin by assuming a zero drug cost for edoxaban,
noting that if it is not found to be cost-effective at a zero cost then increasing the cost will not change
our results.
Changing the time on treatment (acute treatment)
In the majority of trials in our review, patients receive acute treatment for 6 months; however, NICE
guidance recommends 3 months in acute treatment, with an additional 3 months treatment if necessary.
We assume 6 months’ treatment in our base case, and reduce this to 3 months in a sensitivity analysis.
Note that due to a lack of evidence, we assume that relative treatment efficacy is unchanged if given for
3 months rather than 6 months; however; absolute event rates for AEs decrease with time on treatment,
and treatment costs are reduced.
Pooling post total hip replacement and post total knee replacement
populations for relative treatment effect of venous thromboembolism
(primary prevention)
We pooled THR and TKR populations to estimate relative treatment effects of VTE in primary prevention in
this sensitivity analysis. The relative treatment effects are provide in Appendix 11.
Dabigatran dose for elderly patients (primary prevention)
In this sensitivity analysis we costed dabigatran at a lower dose in the primary prevention models to match
the dose recommended in the BNF for elderly patients: 150 mg od.
Cost of treatment-related adverse events (all models)
We varied the cost of treatment-related AEs by ± 50%. These included clinically relevant bleeds,
ICH and post ICH.
Cost of venous thromboembolism events (all models)
We varied the cost of VTE events by ± 50%. These included DVT, PE, mild moderate PTS, severe PTS
and CTPH.
Utility decrements of treatment-related adverse events (all models)
We varied the utility decrement of treatment-related AEs by ± 50%. These included clinically relevant
bleeds, ICH and post ICH.
Utility decrements of venous thromboembolism events (all models)
We varied the utility decrement of VTE events by ± 50%. These included DVT, PE, mild moderate PTS,
severe PTS and CTPH.
Cost of warfarin (all models)
We assessed sensitivity of our results to administration and monitoring cost of warfarin through a threshold
analysis to see what the cost of warfarin would have to be for it to be considered cost-effective at a
willingness-to-pay threshold of £20,000 per QALY. We begin by assuming a zero cost for warfarin,
noting that if it is not found to be cost-effective at a zero cost then increasing the cost will not change
our results.
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Results of the cost-effectiveness model: venous
thromboembolism secondary prevention
We estimated expected costs, QALYs, incremental costs, incremental QALYs and incremental NMB at
willingness to pay of £20,000 and £30,000 for first-line prevention therapy (Table 199). The cheapest
comparator is aspirin (total expected cost £20,671). No pharmacotherapy is the next cheapest treatment,
with benefits similar to aspirin. Warfarin and the NOACs all have substantially higher costs than aspirin and
no pharmacotherapy, and the NOACs are more expensive than warfarin. Dabigatran and apixaban (5 mg)
have marginally higher expected QALYs than no pharmacotherapy. Apixaban (2.5 mg) has the lowest
expected QALYs, followed by warfarin. Apixaban (2.5 mg) has the highest HR for the risk of ICH,
albeit estimated imprecisely. Although the NOACs and warfarin prevent more recurrent VTEs than no
pharmacotherapy or aspirin, the rate of recurrent VTE is low and the rate of AEs (ICH and clinically relevant
bleeds), which can have a long-term impact on quality of life, are generally higher for the NOACs than
aspirin or no pharmacotherapy.
Aspirin has the highest expected net benefit at willingness-to-pay thresholds of £20,000 and £30,000
per QALY (see Table 199). However, the CI for the INB of aspirin includes zero, indicating uncertainty
about whether or not it is more cost-effective than no pharmacotherapy. All NOACs have negative
expected INBs at the £20,000 and £30,000 thresholds, and all CIs are negative at the £20,000
threshold, indicating that they are not cost-effective compared with no pharmacotherapy. Dabigatran,
which had the lowest estimated HR for recurrent VTE and ICH of all the NOACs, also has the
highest expected net benefit of any NOAC. However, dabigatran is not cost-effective relative to no
pharmacotherapy, even at the £30,000 threshold, as the incremental NMB is negative (–£3402; 95% CI
–£12,338 to £5424). Figure 68 shows that although there is uncertainty in the estimated costs and
QALYs, it is clear that aspirin has lower costs and similar benefits in the majority of the samples.
Over a wide range of willingness-to-pay-per-QALY thresholds, aspirin has the highest expected net
benefit (Figure 69), and also the highest probability of being the most cost-effective (Figure 70),
although there is a non-negligible probability that no pharmacotherapy is the most cost-effective
intervention for secondary prevention of VTE at a threshold of £20,000–30,000. These results
suggest that it is not cost-effective to prescribe NOACs or warfarin for secondary prevention
of VTE over the range of willingness-to-pay thresholds that we explored (up to £40,000 per QALY).
The estimated per-person EVPI was £757 at a willingness to pay of £20,000, and £1291 at £30,000.
Assuming a VTE incidence of 183 per 100,000 in a European population,7 and a population of
65- to 70-year-olds in England and Wales of approximately 3 million (2011 Census), gives an estimated
VTE incidence rate per year of 5490. Population EVPI over a 10-year time horizon, discounting
at 3.5%, is approximately £36M and £61M at willingness-to-pay thresholds of £20,000 and £30,000,
respectively.
Figure 71 shows the proportion of the EVPI that is attributable to different groups of parameters.
The optimal decision is most sensitive to the relative treatment effects, suggesting that there may
be value in running a large trial comparing a NOAC with aspirin and no pharmacotherapy.
Note, however, that, as a result of low event rates, a study that is powered to capture VTE events may
be prohibitive.
Results of the cost-effectiveness model: low-molecular-weight
heparin acute treatment
We estimated expected costs, QALYs, incremental costs, incremental QALYs and incremental NMB at
a willingness to pay of £20,000 and £30,000 for first-line therapy (Table 200). Expected costs and benefits
are similar across all treatments because of the short (6-month) treatment duration and the small,
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FIGURE 68 Incremental cost-effectiveness plane for secondary prevention (no pharmacotherapy: reference).
See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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FIGURE 69 Cost-effectiveness acceptability frontier for secondary prevention. See Chapter 4 (Outcomes of atrial
fibrillation and venous thromboembolism models) for further details.
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and imprecisely estimated, effects of NOACs on VTE recurrence and AEs compared with warfarin. Warfarin
has the lowest expected cost (£19,651), followed by dabigatran, edoxaban and apixaban, and rivaroxaban
is the most expensive (£19,753). Apixaban had the highest expected QALYs (12.02) but this is only
0.04 QALYs greater than the interventions with the lowest expected QALYs (edoxaban, warfarin
and dabigatran).
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FIGURE 70 Cost-effectiveness acceptability curve for secondary prevention. See Chapter 4 (Outcomes of atrial
fibrillation and venous thromboembolism models) for further details.
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FIGURE 71 Expected value of partial perfect information for subsets of model input parameters in the VTE
secondary prevention model, presented as a proportion of the total EVPI. SAVI-estimated EVPPI scaled by EVPPI of
all parameters as estimated by SAVI. 95% intervals are ± 1.96 × standard error and are truncated above at 1 and
below at 0.
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The expected net benefit is highest for apixaban at willingness-to-pay thresholds of £20,000 and £30,000
per QALY. This is due to the marginally lower risk of recurrent VTE, CRB and non-VTE-related mortality
with apixaban relative to other NOACs. However, there is substantial uncertainty around this estimate.
Rivaroxaban also has a positive INB compared with warfarin. CIs for INB are wide for all treatments,
reflecting substantial uncertainty that is also seen in the incremental cost-effectiveness plane (Figure 72).
The CEACs (Figure 73) show that for very low willingness to pay per QALY, warfarin is the most cost-effective
treatment (because it has lowest expected costs). For willingness-to-pay thresholds of > £1000, apixaban
(5 mg) has the highest expected net benefit (Figure 74), with a probability of being most cost-effective at
£20,000–30,000 per QALY thresholds of approximately 0.54. However, it is possible that rivaroxaban or
dabigatran are the most cost-effective interventions, even at high willingness-to-pay thresholds.
The per-person EVPI was £365 at willingness-to-pay thresholds of £20,000 and £579 at £30,000.
Assuming a VTE incidence rate per year of 5490 (as for secondary prevention). Population EVPI over a
10-year time horizon, discounting at 3.5%, is approximately £17M and £27M at willingness-to-pay
thresholds of £20,000 and £30,000, respectively.
Figure 75 shows the proportion of the EVPI that is attributable to different groups of parameters.
The optimal decision is most sensitive to uncertainty in the cost and utility model inputs. This suggests
there may be value in conducting a study to estimate the utilities associated with VTE events and
treatment-related events. As such a study is likely to be relatively inexpensive to conduct (compared with
a RCT), and given the magnitude of likely benefits, this should be considered a research priority.
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FIGURE 72 Incremental cost-effectiveness plane for acute treatment (warfarin: reference). See Chapter 4
(Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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The optimal decision is not very sensitive to event rates on the reference comparator (baseline risk),
relative treatment effects for all comparators, relative treatment effects of apixaban compared with warfarin
(the two comparators with the highest probability of being cost-effective at a willingness to pay of £20,000
per QALY) and treatment-independent transition parameters.
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FIGURE 74 Cost-effectiveness acceptability frontier for acute treatment. See Chapter 4 (Outcomes of atrial
fibrillation and venous thromboembolism models) for further details.
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FIGURE 73 Cost-effectiveness acceptability curve for acute treatment. See Chapter 4 (Outcomes of atrial fibrillation
and venous thromboembolism models) for further details.
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Results of the cost-effectiveness model: low-molecular-weight
heparin primary prevention
Total hip replacement
The expected total costs, QALYs, incremental costs, incremental QALYs and incremental NMB at
willingness-to-pay thresholds of £20,000 and £30,000 per QALY for first-line prevention therapy are
reported in Table 201 and illustrated in Figure 76). The lowest expected total costs are for apixaban (£702)
followed by rivaroxaban (£718) and then dabigatran (£893). LMWH has the highest expected cost (£1062).
Expected benefits are highest for rivaroxaban and LMWH (9.10 QALYs), followed by dabigatran (9.04
QALYs) then apixaban (8.96 QALYs). At both willingness-to-pay thresholds of £20,000 and £30,000 per
QALY, rivaroxaban has the highest expected INB, although CIs around net benefit are wide (particularly for
dabigatran) and also skewed (apixaban).
All utilities
Baseline log-hazard/odds
Relative treatment effects
Treatment independent transition parameters
Baseline and relative treatment effects
Apixaban vs. warfarin relative treatment effects
Relative treatment and VTE split
Relative treatment, VTE split and baseline risk
All costs
0.0 0.2 0.4 0.6 0.8 1.0
Proportion total EVPI
FIGURE 75 Expected value of partial perfect information subsets of parameters in the VTE acute treatment model,
as a proportion of the total EVPI. SAVI-estimated EVPPI scaled by EVPPI of all parameters as estimated by SAVI.
95% intervals are ± 1.96 × standard error and are truncated above at 1 and below at 0.
TABLE 201 Results of the THR primary prevention CEA: costs, QALYs, incremental costs, incremental QALYs and
incremental NMB
Estimated costs
and outcomes LMWH Dabigatran Rivaroxaban Apixaban
Costs £1062 (£888 to £1311) £893 (£635 to £1495) £718 (£571 to £1045) £702 (£573 to £953)
QALYs 9.1 (8.85 to 9.35) 9.04 (8.44 to 9.40) 9.10 (8.84 to 9.36) 8.96 (8.47 to 9.31)
Incremental costs –£169 (–£430 to £345) –£344 (–£558 to –£99) –£360 (–£559 to –£156)
Incremental QALYs –0.06 (–0.61 to 0.15) 0.01 (–0.04 to 0.04) –0.13 (–0.57 to 0.09)
Incremental NMB
(at £20,000)
–£1066 (–£12,127 to
£3191)
£453 (–£485 to £1312) –£2284 (–£11,017 to
£2085)
Incremental NMB
(at £30,000)
–£1684 (–£18,241 to
£4649)
£507 (–£883 to £1739) –£3606 (–£16,704 to
£2917)
Incremental results are relative to LMWH.
Figures are presented as mean (CI).
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Rivaroxaban has the highest expected net benefit over the range of willingness-to-pay thresholds that
we explored (Figure 77) but with substantial uncertainty: its probability of being the most cost-effective
was 0.35 for willingness-to-pay threshold of £30,000 per QALY (Figure 78). Because of the very wide
confidence limits for dabigatran, there is an apparently contradictory finding that it has the highest
probability of being the most cost-effective NOAC (see Figure 77) for thresholds of > £14,000 but does
not have the highest expected net benefit (see Figure 78 and Table 201). This phenomenon is documented
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FIGURE 77 Cost-effectiveness acceptability curve for THR primary prevention. See Chapter 4 (Outcomes of atrial
fibrillation and venous thromboembolism models) for further details.
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FIGURE 76 Incremental cost-effectiveness plane for THR primary prevention (LMWH reference). See Chapter 4
(Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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in the literature, and in these circumstances the CEAF (see Figure 78) is a better summary than the CEAC
(see Figure 77).231 Note the general high degree of uncertainty as to which treatment is the most
cost-effective.
The per-person EVPI estimated was £730 at a willingness-to-pay threshold of £20,000, and £1138 at
£30,000. Assuming an annual incidence of primary THR operations per year69 of 76,000, population EVPI
over a 10-year time horizon, discounting at 3.5%, is approximately £475M and £741M at willingness-to-pay
thresholds of £20,000 and £30,000, respectively. These very high figures reflect the high per-person EVPI
(driven by the uncertainty in the available evidence) and also the large volume of primary THR operations
that are conducted.
Figure 79 shows the proportion of the EVPI that is attributable to different groups of parameters.
The optimal decision is most sensitive to uncertainty in the treatment-independent transition parameters,
and also sensitive to uncertainty in the cost parameters. The decision is not very sensitive to uncertainty in
utility values, event rates on the reference comparator (baseline risk), relative treatment effects for all
comparators, relative treatment effects of rivaroxaban compared with LMWH (the two comparators with
the highest probability of being cost-effective at a willingness-to-pay threshold of £20,000 per QALY),
and the proportion of VTE events. This suggests that there may be value in running a longitudinal study
examining the treatment-independent transition parameters: rates of mild/moderate PTS, severe PTS,
CTPH and the proportion split of VTE events.
Total knee replacement
The expected total costs, QALYs, incremental costs, incremental QALYs and incremental NMB at a
willingness to pay of £20,000 and £30,000 for first-line prevention therapy are reported in Table 202.
Both benefits and uncertainty in the benefits are similar across interventions. Rivaroxaban has the lowest
expected total costs (£834), followed by post-op LMWH (£855) and dabigatran (£871), whereas apixaban
has the highest expected total costs of £932. Rivaroxaban and LMH had similar INB at willingness-to-pay
thresholds of £20,000 and £30,000 per QALY. Dabigatran and apixaban have negative INB compared with
post-op LMWH.
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FIGURE 78 Cost-effectiveness acceptability frontier for THR primary prevention. See Chapter 4 (Outcomes of atrial
fibrillation and venous thromboembolism models) for further details.
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The cost-effectiveness plane (Figure 80) and the CEACs (Figure 81) show substantial uncertainty around the
relative costs and benefits of these interventions. Rivaroxaban has the highest expected net benefit over
the range of willingness-to-pay thresholds that we explored (Figure 82), and the highest probability of being
the most cost-effective treatment for willingness-to-pay thresholds of up to approximately £20,000 per QALY
(see Figure 81). Beyond that, dabigatran has the highest probability of being the most cost-effective but
not the highest expected net benefit because of the high level of uncertainty around the cost-effectiveness
of dabigatran (as seen also in the THR population). As previously noted we prefer the CEAF summary
(see Figure 82) in this situation. Note that there is a non-negligible chance that each of the treatments
may be the most cost-effective, and this decision uncertainty increases as we increase our willingness to
pay per QALY.
The per-person EVPI was £171 at a willingness-to-pay threshold of £20,000, and £249 at £30,000, which
is lower than that seen in other populations, reflecting the larger number of studies on this population.
TABLE 202 Results of the TKR primary prevention CEA: costs, QALYs, incremental costs, incremental QALYs and
incremental NMB at willingness-to-pay thresholds of £20,000 and £30,000
Estimated costs and
outcomes LMWH Dabigatran Rivaroxaban Apixaban
Costs £855 (£706 to £1078) £871 (£646 to £1252) £834 (£632 to £1183) £932 (£688 to £1388)
QALYs 9.25 (9.00 to 9.49) 9.24 (8.96 to 9.48) 9.25 (9.00 to 9.49) 9.22 (8.96 to 9.46)
Incremental costs £16 (–£149 to £284) –£20 (–£187 to £223) £77 (–£113 to £417)
Incremental QALYs –0.02 (–0.14 to 0.03) 0.00 (–0.01 to 0.01) –0.03 (–0.12 to 0.01)
Incremental NMB
(at £20,000)
–£320 (–£2844 to £638) £16 (–£406 to £329) –£686 (–£2458 to £266)
Incremental NMB
(at £30,000)
–£472 (–£4214 to £919) £13 (–£509 to £414) –£991 (–£3658 to £375)
Incremental results are relative to LMWH.
Figures are presented as mean (CI).
All utilities
Baseline log-hazard/odds
Relative treatment effects
Treatment independent transition parameters
Baseline and relative treatment effects
Rivaroxaban vs. LMWH relative treatment effects
Relative treatment and VTE split
Relative treatment, VTE split, baseline risk, short-term costs and utilities
Relative treatment, VTE split and baseline risk
All costs
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Proportion total EVPI
FIGURE 79 Expected value of partial perfect information for subsets of model input parameters in the VTE
primary prevention THR model, presented as a proportion of the total EVPI. SAVI-estimated EVPPI scaled by
EVPPI of all parameters as estimated by SAVI. 95% intervals are ± 1.96 × standard error and are truncated above
at 1 and below at 0.
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Assuming an annual incidence of primary TKR operations per year69 of 76,000, population EVPI over
a 10-year time horizon, discounting at 3.5%, is approximately £111M and £161M at willingness-to-pay
thresholds of £20,000 and £30,000, respectively. These high figures reflect the large volume of primary
TKR operations that are conducted.
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FIGURE 80 Incremental cost-effectiveness plane for TKR primary prevention (LMWH: reference). See Chapter 4
(Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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FIGURE 81 Cost-effectiveness acceptability curve for TKR primary prevention. See Chapter 4 (Outcomes of atrial
fibrillation and venous thromboembolism models) for further details.
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Figure 83 shows the proportion of the EVPI that is attributable to different groups of parameters. The optimal
decision is most sensitive to uncertainty in the utilities, relative treatment effects and treatment-independent
transition parameters, and also sensitive to uncertainty in the cost parameters, but not to uncertainty in the
risk on the reference comparator. This suggests that there may be value in running a large trial comparing
NOACs and warfarin to reduce the uncertainty in the relative treatment effects. There may also be value in
conducting a study to estimate the utility values associated with VTE events and treatment-related events,
and a longitudinal study examining the treatment-independent transition parameters: rates of mild/moderate
PTS, severe PTS, CTPH and the proportion split of VTE events.
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FIGURE 82 Cost-effectiveness acceptability frontier for TKR primary prevention. See Chapter 4 (Outcomes of atrial
fibrillation and venous thromboembolism models) for further details.
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FIGURE 83 Expected value of partial perfect information for subsets of parameters in the VTE primary prevention
TKR model, as a proportion of the total EVPI. SAVI-estimated EVPPI scaled by EVPPI of all parameters as estimated
by SAVI. 95% intervals are ± 1.96 × standard error and are truncated above at 1 and below at 0.
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Results of sensitivity analyses for secondary prevention model
We varied the proportion of recurrent VTEs that are DVT, non-fatal PE and fatal PE using the proportions
estimated in the study by Prandoni et al.227 (79% DVT, 10% non-fatal PE and 11% fatal PE) rather than
the proportions estimated from the RCTs included in the systematic review. At a willingness-to-pay
threshold of > £25,000 per QALY dabigatran becomes the most cost-effective treatment (Figure 84). This
indicates that NOACs are more likely to be cost-effective in secondary prevention if the risk of fatal VTE is
higher than we assumed in our base-case analysis.
We varied the clinically relevant bleed rate to match that assumed in the AF model. The results were
robust to this assumption, with aspirin having the highest expected net benefit over all willingness-to-pay
thresholds that we explored. We explored sensitivity of results to a policy of switching patients to warfarin
after a second VTE event, and the sensitivity to the cost of warfarin by reducing the cost to £0 in one-way
sensitivity analyses. The results were robust to these assumptions (see Appendix 12).
The results were robust to the seven sensitivity analyses for which we varied the utilities of VTE and AEs
by ± 50%, the AE costs by ± 50% and the VTE costs by +50% (see Appendix 12). When we reduced
the cost of VTE events by 50%, no pharmacotherapy has the highest expected net benefit over the
willingness-to-pay thresholds that we explored (Figure 85).
When the rate of ICH for no pharmacotherapy was assumed to be zero, no pharmacotherapy then had
the highest probability of being cost-effective and the highest net benefit over a willingness-to-pay range
of £0–40,000 (Figure 86). In this analysis the risk of having an ICH while on aspirin and NOACs
outweighed the benefit gained from reduced recurrent VTE.
Results of sensitivity analyses for acute treatment model
Changing the time on treatment from 6 months to 3 months and varying the cost and utilities by ± 50%
over VTE events and AEs did not alter the conclusion that apixaban was most likely to be cost-effective
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FIGURE 84 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: vary proportion
of DVT, non-fatal PE and fatal PE of recurrent VTE. See Chapter 4 (Outcomes of atrial fibrillation and venous
thromboembolism models) for further details.
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over a threshold of £1000 (see Appendix 12). The assumption that NOACs have the same non-fatal ICH
rate as warfarin had little effect on the conclusion that apixaban has the highest expected net benefit at
a willingness-to-pay thresholds of £20,000 and £30,000 per QALY (see Appendix 12).
Assuming a zero cost for edoxaban, we find that edoxaban has the highest expected net benefit and
highest probability of being cost-effective at a willingness-to-pay threshold of < £10,000 per QALY.
However, as willingness to pay per QALY increases to > £10,000, apixaban is the most cost-effective
treatment because of the higher benefits (Figure 87, and see Table 200).
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FIGURE 85 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analyses: reduction in VTE
costs by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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FIGURE 86 Cost-effectiveness acceptability frontier secondary prevention: risk of ICH for no pharmacotherapy is set
to zero. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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Results of sensitivity analyses for primary prevention model
Total knee replacement
When we increased the AEs utilities by 50%, LMWH became the most cost-effective treatment at a
willingness-to-pay threshold of > £27,000 per QALY (Figure 88). Increasing the AE costs by 50% changed
the comparators with the highest average net benefit from rivaroxaban to LMWH over willingness-to-pay
thresholds that we explored (Figure 89).
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FIGURE 87 Cost-effectiveness acceptability frontier acute treatment model: assuming a zero cost for edoxaban.
See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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FIGURE 88 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: increasing AE costs
by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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Decreasing the VTE event costs by 50% changed the comparators with the highest average net benefit
from rivaroxaban to LMWH over willingness-to-pay thresholds that we explored (Figure 90). When we
decreased the VTE utilities by 50%, LMWH became the most cost-effective comparator above a
willingness-to-pay threshold of £20,000 (Figure 91).
Our results were robust to all other sensitivity analyses that were conducted on the primary prevention
populations: pooling post-THR and post-TKR populations for relative treatment effect of VTE; costing
dabigatran at a lower dose to match the licensed dose for an elderly population; decreasing the costs and
utilities for AEs; and increasing the costs and utilities for VTE events by 50% (see Appendix 12).
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FIGURE 89 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: increasing AE utilities
by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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FIGURE 90 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: decreasing VTE costs
by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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Total hip replacement
Our results were robust to all of the sensitivity analyses conducted on the primary prevention populations:
pooling post-THR and post-TKR populations for relative treatment effect of VTE, costing dabigatran at a
lower dose to match the licensed dose for an elderly population; and varying the costs and utilities for VTE
and AEs by ± 50% (see Appendix 12).
Summary of cost-effectiveness findings
The economic analyses of the use of NOACs in the prevention and treatment of VTE attempt to balance
the costs of pharmacotherapy against the benefits of reducing VTE-related events and the risks of
anti-coagulant-related AEs. To a large extent the findings of the economic analyses reflect the evidence
and uncertainty identified by the NMAs in previous chapters.
In secondary prevention, we found no strong evidence that NOACs (apixaban, dabigatran and rivaroxaban)
were more cost-effective than no pharmacotherapy or aspirin. The RCT evidence that NOACs reduce the
risk of VTE was counterbalanced by the relatively low underlying risk of VTE, the low proportion of fatal
VTE events and the potentially elevated risk of AEs as a result of bleeding. Our base-case analysis indicated
that the relatively small benefits of NOACs compared with no pharmacotherapy or aspirin did not justify
the high costs of long-term NOAC treatment. This finding was sensitive to assumptions about the
incidence of fatal PE. We found that aspirin was most likely to be cost-effective for secondary prevention,
although there was uncertainty whether or not no pharmacotherapy was more cost-effective, and choice
between aspirin and no pharmacotherapy was particularly sensitive to assumptions around AEs (ICH) under
no pharmacotherapy, and costs associated with VTEs. Further research on the relative cost-effectiveness
of aspirin and no pharmacotherapy would be of value.
In acute treatment, we found that NOACs, particularly apixaban, are likely to be cost-effective compared
with warfarin at conventional NICE willingness-to-pay thresholds of £20,000–30,000 per QALY. Although
there was little evidence that NOACs substantially reduced the risk of VTE compared with warfarin, the
reduced risk of ICH and CRB contributed to our finding that there was a relatively high probability (> 0.5)
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FIGURE 91 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: decreasing VTE
utilities by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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that apixaban is the most cost-effective intervention in this setting. This finding was robust to sensitivity
analyses on the model assumptions, although further research on the relative efficacy and safety of
apixaban compared with other NOACs would be valuable to increase the strength of evidence.
For primary prevention of VTE following hip surgery, expected clinical benefits were similar for rivaroxaban
and LMWH, whereas the lower costs of intervention with rivaroxaban meant that it was the most
cost-effective intervention at the usual NICE thresholds. For primary prevention of VTE following knee
surgery there was little difference in clinical benefit between the interventions, with rivaroxaban and
LMWH being similarly cost-effective. There is a substantial potential value of further research in both THR
and TKR populations, partly due to the large volume of these operations, meaning that a large population
of patients may be given these treatments, but also because of the high levels of uncertainty in the relative
treatment effects. This arises partly because of the fact that events are rare, and so very large studies are
required to provide sufficient power to detect treatment differences when they exist, especially for AEs,
which can have long-term consequences.
Our models make several assumptions (summarised in Box 1). In order to make the models tractable for
each decision problem, we assumed that the most cost-effective comparator in secondary prevention
would be used after acute treatment and that the most cost-effective comparator in acute treatment
would be used after the failure of primary prevention. This assumes independence between treatments
(i.e. the efficacy of secondary prevention does not depend on the therapy used for acute treatment).
It also assumes that evidence from the wider acute/secondary prevention population (e.g. including
medical patients) provides valid evidence for those primary prevention (i.e. surgical) patients who require
acute treatment and secondary prevention.
In our base-case secondary prevention model, we assumed that patients would stop treatment only after
ICH. In reality, patients may discontinue or switch treatment for various reasons. A proportion of patients
will not comply with treatment because of side-effects or difficulty achieving a stable INR (on warfarin).
Patients may also switch treatment after a recurrent symptomatic VTE event, which may be interpreted as
‘treatment failure’. The secondary prevention RCTs, which have relatively short follow periods, provide very
BOX 1 Main assumptions of the VTE models
Transition probabilities/model structure
Patients with asymptomatic VTE have no greater risk of symptomatic recurrent VTE than patients with no VTE event.
VTE and bleeding events are independent.
Patients cannot move out of the ‘PTS’ or ‘CTPH’ states, with the exception to the death state.
All anticoagulation will be stopped for patients who have an ICH.
Proportion of VTE that is DVT vs. non-fatal PE vs. fatal PE is treatment independent.
ICH relative safety from AF population.
Quality of life and costs
Minor bleeds do not impact on quality of life and costs.
Clinically relevant bleeds, DVT and non-fatal PE do not have a long-term impact on quality of life.
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little evidence on long-term treatment compliance. Our finding that NOACs were not more cost-effective
than aspirin or ‘no pharmacotherapy’ was robust to a sensitivity analysis showing that patients switched to
warfarin after a recurrent VTE, but may be sensitive to other treatment switching and non-compliance.
There is evidence that dabigatran is associated with MI in the AF population. The VTE RCTs typically did
not report MI as an outcome, and we did not include it in the VTE models. It is likely to be most influential
in the secondary prevention of VTE, when patients may be on therapy for prolonged periods. However,
including the risk of MI in the secondary prevention model would not change our conclusion that none of
the NOACs (including dabigatran) was cost-effective.
Edoxaban for the acute treatment of VTE is under review by NICE, but has not yet been approved
and does not have BNF list cost in the UK. We assumed that the cost would be similar to other NOACs,
and we performed a threshold analysis on cost to see how price influenced cost-effectiveness in acute
treatment. Because edoxaban had very similar efficacy to warfarin, with lower benefits to apixaban,
we found that it was not cost-effective at willingness-to-pay-threshold values of £20,000 or £30,000 per
QALY, even at zero cost. When willingness to pay per QALY was low then it became cost-effective as the
price decreased below that of warfarin, but such low threshold values are not used in practice.
Our systematic literature review identified evidence to inform model parameters for two primary prevention
models (post THR and post TKR). We did not identify enough data to parameterise a model to estimate the
cost-effectiveness of NOACs for patients who were hospitalised for medical treatment. These findings may
not generalise to these patients and other patient groups.
Comparisons with the literature
There have been relatively few previous CEAs of NOACs for the prevention or treatment of VTE in the
peer-reviewed literature. Most of the published studies focus on primary prevention after surgery and few
compare more than one NOAC to LMWH.59–61,232 The published comparisons of rivaroxaban, dabigatran
and LMWH are based on direct trial evidence and conclude that, although rivaroxaban, in particular,
may be cost-effective, there is great uncertainty about which strategy is the most cost-effective.60,61,232 One
industry-sponsored cost-effectiveness model comparing rivaroxaban to LMWH and a VKA, based on the
EINSTEIN trial,204,215,216 concluded that there was a high probability that rivaroxaban was cost-effective.233
We also found that rivaroxaban was likely to be cost-effective for primary prevention after TKR and THR.
However, despite including a larger number of trials in a NMA than previous cost-effectiveness models,
our interpretation is tentative because of imprecise estimates about effect and safety.
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Chapter 12 Discussion and conclusions
Main findings
In the following sections, we summarise the main findings for each therapeutic area, first summarising
efficacy and safety comparisons of NOACs with established treatments and then comparing individual
NOACs with one another. We also summarise the results of the CEAs.
Atrial fibrillation: results of clinical effectiveness analyses
There was evidence that apixaban (5 mg bd), dabigatran (150 mg bd), edoxaban (60 mg od) and
rivaroxaban (20 mg od) all reduce the risk of stroke or SE compared with warfarin (INR 2–3). Among the
NOACs, there was evidence of a higher risk of stroke or SE with edoxaban (60 mg od) and rivaroxaban
(20 mg od) than dabigatran (150 mg bd).
There was evidence that dabigatran (150 mg bd) reduces the risk of ischaemic stroke compared with
warfarin, whereas edoxaban (30 mg od) increases that risk. There was little evidence that the risk of
ischaemic stroke differed between licensed doses of NOACs.
There was weak evidence that the risk of MI is higher with dabigatran (110 mg bd), dabigatran (150 mg bd)
and edoxaban (30 mg od) than warfarin (INR 2–3), and weak evidence that the risk of MI is lower with
rivaroxaban (20 mg od) than warfarin (INR 2–3). Among the NOACs, there was weak evidence that MI risk
is higher with dabigatran (150 mg bd) than apixaban (5 mg bd), and lower with rivaroxaban (20 mg od)
than dabigatran (150 mg bd).
There was evidence that apixaban (5 mg bd), dabigatran (110 mg bd), edoxaban (30 mg od) and edoxaban
(60 mg od) all reduced risk of major bleeding compared with warfarin (INR 2–3). Among the NOACs,
there was evidence that risk of major bleeding is higher with dabigatran (150 mg bd) than apixaban
(5 mg bd), and with rivaroxaban (20 mg od) than apixaban (5 mg bd) and edoxaban (60 mg od).
There was evidence that the risk of CRB during antiplatelet therapy (aspirin < 150 mg od) is lower than with
warfarin (INR 2–3). There was evidence that the risk of CRB with apixaban (5 mg bd), edoxaban (30 mg od)
and edoxaban (60 mg od) is also lower than with warfarin (INR 2–3). However, edoxaban (30 mg bd) and
edoxaban (60 mg bd) increased CRB compared with warfarin (INR 2–3). In comparisons among NOACs,
there was evidence that CRB with edoxaban (60 mg od) and rivaroxaban (20 mg od) is higher than with
apixaban (5 mg bd), and that rivaroxaban (20 mg od) increases CRB compared with edoxaban (60 mg od).
There was strong evidence that risk of intracranial bleeding was lower with apixaban (5 mg bd), dabigatran
(110 mg bd), dabigatran (150 mg bd), edoxaban (30 mg od), edoxaban (60 mg od) and rivaroxaban
(20 mg od) than warfarin (INR 2–3). For each of these NOACs and doses, except for rivaroxaban (20 mg od),
the estimated relative risk reduction for intracranial bleeding was > 50%. There was weak evidence that
risk of intracranial bleeding is higher with rivaroxaban (20 mg od) than apixaban (5 mg bd), dabigatran
(150 mg bd) and edoxaban (60 mg od).
Risk of all-cause mortality was lower with apixaban (5 mg bd), dabigatran (110 mg bd), dabigatran
(150 mg bd), edoxaban (30 mg od), edoxaban (60 mg od) and rivaroxaban (20 mg od) than warfarin
(INR 2–3), but there was little evidence of a difference between the licensed doses of NOACs for
this outcome.
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Apixaban (5 mg bd) was ranked as being among the best interventions for a wide range of the outcomes
that were evaluated, including stroke or SE, MI, major bleeding and all-cause mortality. Edoxaban
(60 mg od) was ranked second for major bleeding and all-cause mortality. Except for all-cause mortality,
outcomes for rivaroxaban (20 mg od) were ranked less highly than several other NOACs. The non-NOAC
interventions [warfarin (INR 2–3) and antiplatelet therapy (aspirin/clopidogrel ≥ 150 mg od)] were ranked
worst for stroke or SE and were not among the best three interventions for any of the outcomes. We did
not include apixaban (2.5 mg bd) or betrixaban (40 mg od) because comparisons involving these
interventions were imprecisely estimated.
In our sensitivity analyses, results were similar when using HRs instead of ORs. Moreover, we found
no evidence of effect modification according to mean TTR for patients on warfarin. However, our
meta-regression models assumed a common interaction effect across treatments: that assumption could
not be empirically tested because of a lack of replication for most comparisons. An important limitation is
that primary studies did not report the mean time above or below therapeutic range for warfarin arms.
Therefore, we were unable to address some clinically relevant questions regarding the impact of treatment
settings for warfarin on stroke prevention, as well as on bleeding and other AEs.
Atrial fibrillation: results of cost-effectiveness analyses
Dabigatran (150 mg bd) has the lowest expected total cost (£23,064), followed by apixaban (5 mg bd),
edoxaban (60 mg od), warfarin (INR 2–3) and rivaroxaban (20 mg od), which had the highest expected
total cost (£24,841). Expected costs are similar across all treatments, and there is a high degree of
uncertainty around the costs for all treatments.
Apixaban (5 mg bd) has the highest expected QALYs (5.49), followed by rivaroxaban (20 mg od) (5.45),
dabigatran (150 mg bd) (5.42), edoxaban (60 mg od) (5.41) and warfarin (INR 2–3) (5.17). The NOACs
have similar expected QALYs, all of which are higher than for warfarin (INR 2–3). There is a high degree of
uncertainty around the QALY estimates.
At a willingness-to-pay threshold of £20,000 per QALY, all NOACs have positive expected INB compared
with warfarin (INR 2–3), suggesting that they may be a cost-effective use of NHS resources. Apixaban
(5 mg bd) has the highest expected INB (£7533), followed by dabigatran (150 mg bd) (£6365), rivaroxaban
(20 mg od) (£5279) and edoxaban (60 mg od) (£5212). Apixaban (5 mg bd) is the only NOAC for which
the 95% CI around INB is positive, suggesting that apixaban is cost-effective compared with warfarin.
These conclusions also hold at the higher threshold of £30,000. The key drivers of these results are the
lower rates of MI, ICH and other CRB for apixaban (5 mg bd).
The CEAC indicates that apixaban (5 mg bd) has the highest probability of being the most cost-effective
first-line therapy for AF, close to 60% in the £20,000–30,000 range of willingness-to-pay thresholds
generally considered by NICE. Dabigatran (150 mg bd) has the highest probability of being cost-effective
if the willingness-to-pay threshold is very low as a result of having the lowest expected total costs.
Warfarin (INR 2–3) and edoxaban (60 mg od) are unlikely to be cost-effective. These results are further
highlighted by the CEAF. Apixaban (5 mg bd) has the highest expected net benefit at a wide range of
willingness-to-pay thresholds. Apixaban (5 mg bd) is likely to be the most cost-effective first-line therapy
for AF, under the assumptions of our model.
Primary prevention of venous thromboembolism: results of clinical
effectiveness analyses
In hip surgery patients most treatment comparisons were imprecisely estimated, but there was evidence
that risk of symptomatic VTE is lower with rivaroxaban (10 mg od) than LMWH (pre-op, standard dose)
but higher with LMWH (post-op, standard dose) and warfarin (INR 2–3) than LMWH (pre-op, standard
dose). Comparisons between the licensed doses of NOACs were imprecisely estimated. For knee surgery
patients, there was little evidence that risk of symptomatic VTE differed between apixaban (2.5 mg bd),
dabigatran (220 mg od) or rivaroxaban (10 mg od) compared with LMWH (post-op, standard dose).
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Comparisons between licensed doses of NOACs were also imprecisely estimated. For medical patients
there was weak evidence that the risk of symptomatic VTE is lower with apixaban (2.5 mg bd) than LMWH
(standard dose), and also compared with rivaroxaban (10 mg od), although these comparisons were
imprecisely estimated.
For symptomatic DVT, all comparisons for hip surgery patients were imprecisely estimated, but there was
evidence that risk of symptomatic DVT is higher for LMWH (post-op, standard dose) and warfarin (INR 2–3)
than LMWH (pre-op, standard dose). All comparisons for knee surgery patients were imprecisely estimated
but there was evidence that risk of symptomatic DVT was higher for LMWH pre-op (standard dose) than
LMWH (post-op, standard dose). For medical patients, all comparisons were imprecisely estimated, but
there was evidence that risk of symptomatic DVT is lower for apixaban (2.5 mg bd) than LMWH
(standard dose).
For symptomatic PE, all comparisons for trials in hip surgery, knee surgery and medical patients were
imprecisely estimated. For knee surgery patients, there was some evidence that the risk of symptomatic
PE is lower with dabigatran (150 mg od) and higher with apixaban (2.5 mg bd) than LMWH (post-op,
standard dose). Among licensed doses of NOACs the risk of symptomatic PE may be lower for rivaroxaban
(10 mg od) than apixaban (2.5 mg bd).
For MI, all comparisons were imprecisely estimated, although there was some evidence that risk of MI is
lower for rivaroxaban (10 mg od) than LMWH (post-op, standard dose).
There was little evidence that risk of major bleeding differs between pre-op and post-op LMWH
(standard dose). There was evidence that risk of major bleeding is lower with warfarin (INR 2–3) and
higher with rivaroxaban (10 mg od) than LMWH (post-op, standard dose). There was evidence that risk of
major bleeding is higher with rivaroxaban (10 mg od) than apixaban (2.5 mg bd) and dabigatran
(220 mg od).
There was evidence that risk of CRB is higher for pre-op LMWH (standard dose) than post-op LMWH
(standard dose), and higher for dabigatran (150 mg or 220 mg od) and rivaroxaban (10 mg od) than
LMWH (post-op, standard dose). There was evidence that risk of CRB is higher for dabigatran (220 mg od)
and rivaroxaban (10 mg od) than apixaban (2.5 mg bd).
There was little evidence that risk of all-cause mortality differed for any intervention compared with LMWH
(post-op, standard dose). Comparisons between licensed doses of NOACs were imprecisely estimated.
Warfarin was ranked with high probability as the best intervention for major bleeding events, and LMWH
(post-op, standard dose) was ranked with high probability as best or second-best intervention for CRB.
Rivaroxaban (10 mg od) was ranked among the worst interventions for bleeding outcomes.
Primary prevention of venous thromboembolism following hip and knee
surgery: results of cost-effectiveness analyses
Total hip replacement
The lowest expected total costs are for apixaban (£702), followed by rivaroxaban (£718) then dabigatran
(£893). LMWH has the highest expected cost (£1062). Expected benefits are highest for rivaroxaban and
LMWH (9.10 QALYs), followed by dabigatran (9.04 QALYs) then apixaban (8.96 QALYs). At both £20,000
and £30,000 willingness-to-pay QALY thresholds per QALY, rivaroxaban has the highest expected INB,
although CIs around net benefit are wide (particularly for dabigatran) and also skewed (apixaban).
Rivaroxaban has the highest expected net benefit over the range of willingness-to-pay thresholds we
explored, but with substantial uncertainty: its probability of being the most cost-effective was 0.35 for
willingness-to-pay threshold of £30,000 per QALY.
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Total knee replacement
Rivaroxaban has the lowest expected total costs (£834), followed by post-op LMWH (£855) and dabigatran
(£871), whereas apixaban has the highest expected total costs of £932. Rivaroxaban and LMWH had
similar INB at willingness-to-pay thresholds of £20,000 and £30,000 per QALY. Dabigatran and apixaban
have negative INB compared with post-op LMWH. The cost-effectiveness plane and the CEACs show
substantial uncertainty around the relative costs and benefits of these interventions. Rivaroxaban has the
highest expected net benefit over the range of willingness-to-pay thresholds that we explored, and the
highest probability of being the most cost-effective treatment for willingness-to-pay thresholds of up to
approximately £20,000 per QALY.
Acute treatment of venous thromboembolic disease: results of clinical
effectiveness analyses
The planned edoxaban dose in the HOKUSAI-VTE study206,207 was 60 mg od but 17.6% of the patients in
that intervention arm received a lower dose of 30 mg od. This intervention is denoted ‘Edoxaban [60 or 30
(17.6%) mg od]’.
Compared with warfarin (INR 2–3), none of the NOACs reduced the risk of symptomatic VTE, symptomatic
DVT or symptomatic PE on follow-up, nor did the risk of any of these outcomes differ between licensed
doses of NOACs.
For risk of MI, all comparisons were imprecisely estimated.
There was strong evidence that apixaban (5 mg bd) and rivaroxaban (15 mg bd then 20 mg od) reduce
risk of major bleeding compared with warfarin (INR 2–3). There was evidence that risk of major bleeding
was higher for edoxaban [60 or 30 (17.6%) mg od] and dabigatran (150 mg bd) compared with apixaban
(5 mg bd).
There was evidence that apixaban (5mg bd), dabigatran (150 mg bd) and edoxaban [60 or 30 (17.6%) mg od]
reduce risk of CRB compared with warfarin (INR 2–3). There was some evidence that rivaroxaban (15 mg bd
then 20mg od) reduces risk of CRB compared with warfarin (INR 2–3). There was evidence that risk of CRB is
higher with dabigatran (150 mg bd), edoxaban [60 or 30 (17.6%) mg od] and rivaroxaban (15 mg bd then
20 mg od) than apixaban (5 mg bd). There was evidence that risk of CRB is higher with edoxaban [60 or 30
(17.6%) mg od] and rivaroxaban (15 mg bd then 20mg od) than dabigatran (150 mg bd).
There was little evidence that risk of all-cause mortality differed for any of the NOAC interventions
compared with warfarin (INR 2–3). Neither was there evidence that risk of all-cause mortality differed
between licensed doses of NOACs.
There was a high probability that warfarin (INR 2–3) is ranked worst for major bleeding and CRB.
There was a high probability that apixaban (5 mg bd) is ranked best for major bleeding and CRB, and this
intervention also had a high probability of being ranked best or second best for symptomatic DVT,
symptomatic VTE and all-cause mortality.
Acute treatment of venous thromboembolic disease: results of
cost-effectiveness analyses
We estimated expected costs, QALYs, incremental costs, incremental QALYs and incremental NMB at
willingness-to-pay thresholds of £20,000 and £30,000. Expected costs and benefits are similar across all
treatments because of the short (6-month) treatment duration, and the small and imprecisely estimated
effects of NOACs on VTE recurrence and AEs compared with warfarin. Warfarin has the lowest expected
cost (£19,651), followed by dabigatran, edoxaban and apixaban, with rivaroxaban the most expensive
(£19,753). Apixaban had the highest expected QALYs (12.02) but this is only 0.04 QALYs greater than the
interventions with the lowest expected QALYs (edoxaban, warfarin and dabigatran).
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The expected net benefit is highest for apixaban at willingness-to-pay thresholds of £20,000 and £30,000
per QALY. This is due to the marginally lower risk of recurrent VTE, CRB and non-VTE-related mortality
with apixaban relative to other NOACs. However, there is substantial uncertainty around this estimate.
Rivaroxaban also has a positive INB compared with warfarin. CIs for INB are wide for all treatments,
reflecting substantial uncertainty that is also seen in the incremental cost-effectiveness plane.
The CEACs show that for very low willingness to pay per QALY, warfarin is the most cost-effective
treatment (because it has lowest expected costs). For willingness-to-pay thresholds of > £1000,
apixaban (5 mg) has the highest expected net benefit, with a probability of being most cost-effective at
£20,000–30,000 per QALY thresholds of approximately 0.54. However, it is possible that rivaroxaban or
dabigatran are the most cost-effective interventions, even at high willingness-to-pay thresholds.
Secondary prevention of venous thromboembolism: results of clinical
effectiveness analyses
There was evidence that aspirin (100 mg od), warfarin (INR 1.5–2) and warfarin (INR 2–3) substantially
reduced risk of symptomatic VTE compared with placebo. All NOACS at the doses included in the network
also substantially reduced risk of symptomatic VTE compared with placebo. Risk of symptomatic VTE was
lower for all NOACs at doses included in the network than aspirin. However, there was no clear evidence
that risk of symptomatic VTE differed between these NOAC interventions and warfarin, although most
comparisons were imprecisely estimated. There was no clear evidence that risk of symptomatic VTE
differed between licensed doses of NOACs, although these comparisons were imprecisely estimated.
There was no clear evidence that aspirin (100 mg od) reduced risk of symptomatic DVT considered as an
individual end point compared with placebo. There was evidence that warfarin (INR 2–3) and all NOACs
at doses included in the network substantially reduced risk of symptomatic DVT compared with placebo.
These NOAC interventions substantially reduced risk of symptomatic DVT compared with aspirin.
By contrast, there was no clear evidence that risk of symptomatic DVT differed between these NOACs
and warfarin (INR 2–3), although comparisons were imprecisely estimated. There was no clear evidence
that risk of symptomatic DVT differed between NOACs at licensed doses, although all comparisons were
imprecisely estimated.
There was evidence that warfarin (INR 2–3), apixaban (5 mg bd), dabigatran (150 mg bd) and rivaroxaban
(20 mg od) substantially reduce risk of symptomatic PE compared with placebo. There was evidence that
dabigatran (150 mg bd) and rivaroxaban (20 mg od) reduce risk of symptomatic PE compared with aspirin.
There was evidence that risk of symptomatic PE was higher for apixaban (2.5 mg bd) than warfarin
(INR 2–3). There was weak evidence that risk of symptomatic PE was lower for dabigatran (150 mg bd)
and rivaroxaban (20 mg od) than apixaban (2.5 mg bd).
All comparisons of risk of MI were imprecisely estimated.
There was evidence that risk of major bleeding is higher for warfarin (INR 2–3) and rivaroxaban (20 mg od)
than placebo, although these comparisons were imprecisely estimated. Comparisons of the risk of major
bleeding for NOACs compared with aspirin were imprecisely estimated. There was evidence that risk of
major bleeding is lower for dabigatran (150 mg bd), apixaban (2.5 mg bd) and apixaban (5 mg bd) than
warfarin (INR 2–3). There was evidence that risk of major bleeding is higher with dabigatran (150 mg bd)
and rivaroxaban (20 mg od) than apixaban (2.5 mg bd and 5 mg bd).
There was evidence that risk of CRB is substantially higher with warfarin (INR 2–3), dabigatran (150 mg od)
and rivaroxaban (20 mg od) than placebo, and that risk of CRB is higher with rivaroxaban (20 mg od)
than aspirin. There was evidence that risk of CRB is lower with apixaban (2.5 mg or 5 mg bd) and
dabigatran (150 mg bd) than warfarin (INR 2–3). All comparisons between NOACs at licensed doses
were imprecisely estimated, but there was evidence that risk of CRB is higher with dabigatran (150 mg bd)
and rivaroxaban (20 mg od) than apixaban (2.5 mg bd and 5 mg bd).
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All comparisons of risk of all-cause mortality with placebo, except that for aspirin (100 mg od), were
imprecisely estimated. However, there was evidence that risk of all-cause mortality was lower for apixaban
(5 mg bd) than placebo. Comparisons of NOACs with aspirin were imprecisely estimated, although there
was weak evidence that risk of all-cause mortality is lower with apixaban (5 mg bd) than aspirin. There was
no evidence that risk of all-cause mortality differed for NOACs than warfarin (INR 2–3), although all
comparisons except that with dabigatran (150 mg bd) were imprecisely estimated. Comparisons of risk of
all-cause mortality between NOACs at licensed doses were imprecisely estimated.
Secondary prevention of venous thromboembolism: results of
cost-effectiveness analyses
We estimated expected costs, QALYs, incremental costs, incremental QALYs and incremental NMB
at willingness-to-pay thresholds of £20,000 and £30,000. The cheapest comparator is aspirin (total
expected cost £20,671). No pharmacotherapy is the next cheapest treatment with benefits similar to
aspirin. Warfarin and the NOACs all have substantially higher costs than aspirin and no pharmacotherapy,
and the NOACs are more expensive than warfarin. Dabigatran and apixaban (5 mg) have marginally
higher expected QALYs than no pharmacotherapy. Apixaban (2.5 mg) has the lowest expected QALYs,
followed by warfarin. Apixaban (2.5 mg) has the highest HR for the risk of ICH, albeit estimated
imprecisely. Although the NOACs and warfarin prevent more recurrent VTEs than no pharmacotherapy or
aspirin, the rate of recurrent VTE is low, and the rate of AEs (ICH and clinically relevant bleeds), which
can have a long-term impact on quality of life, are generally higher for the NOACs than aspirin or
no pharmacotherapy.
Aspirin has the highest expected net benefit at willingness-to-pay thresholds of £20,000 and £30,000 per
QALY. However, the CI for the INB of aspirin includes zero, indicating uncertainty about whether or not it
is more cost-effective than no pharmacotherapy. All NOACs have negative expected INBs at the £20,000
and £30,000 thresholds, and all CIs are negative at the £20,000 threshold, indicating that they are not
cost-effective compared with no pharmacotherapy. Dabigatran, which had the lowest estimated HR for
recurrent VTE and ICH of all the NOACs, also has the highest expected net benefit of any NOAC.
However, dabigatran is not cost-effective relative to no pharmacotherapy, even at the £30,000 threshold,
as the incremental NMB is negative (–£3402; 95% CI –£12,388 to £5424). Although there is uncertainty
in the estimated costs and QALYs, it is clear that aspirin has lower costs and similar benefits in the majority
of the samples. Over a wide range of willingness-to-pay-per-QALY thresholds, aspirin has the highest
expected net benefit, and also the highest probability of being the most cost-effective, although there is
a non-negligible probability that no pharmacotherapy is the most cost-effective intervention for secondary
prevention of VTE at a threshold of £20,000–30,000. These results suggest that it is not cost-effective to
prescribe NOACs or warfarin for secondary prevention of VTE over the range of willingness-to-pay
thresholds that we explored (up to £40,000 per QALY).
Analyses of the value of information from future research
Value of information analyses exploit the cost-effectiveness models to quantify and summarise the value
(in cost terms) of evidence that could potentially be generated from future research studies.
For AF, the optimal decision regarding the most cost-effective NOAC is most sensitive to the HRs comparing
the NOACs, suggesting that a head-to-head trial comparing NOACs may be of value. The decision is
also sensitive to costs, the effect of past events on future HRs, and probabilities of treatment switching.
A head-to-head trial could also provide information about baseline event rates, costs and switching
probabilities. However, a study powered to measure all of these outcomes with sufficient precision would
require a very large sample size, which may be prohibitively expensive.
For VTE primary prevention in the THR population, the optimal decision is most sensitive to uncertainty in
the treatment-independent transition parameters, and also the cost parameters. This suggests that there
may be value in running a longitudinal study examining the treatment-independent transition parameters:
rates of mild/moderate PTS, severe PTS, CTPH and the proportion split of VTE events.
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For VTE primary prevention in the TKR population, the optimal decision is most sensitive to uncertainty
in the utilities, relative treatment effects and treatment-independent transition parameters, and is also
sensitive to the cost parameters. This suggests that there may be value in running a large trial comparing
NOACs and warfarin, which would reduce the uncertainty in the relative treatment effects. There
may also be value in conducting a study to estimate the utility values associated with VTE events and
treatment-related events, and a longitudinal study examining the treatment-independent transition
parameters: rates of mild/moderate PTS, severe PTS, CTPH and the proportion split of VTE events.
For VTE acute treatment, the optimal decision is most sensitive to uncertainty in the cost and utility model
inputs. This suggests there may be value in conducting a study to estimate the utilities and costs associated
with VTE events and treatment-related events. As such, a study is likely to be relatively inexpensive to
conduct (compared with a RCT), and given the magnitude of likely benefits, this should be considered a
research priority.
For VTE secondary prevention, the optimal decision is most sensitive to the relative treatment effects,
suggesting that there may be value in running a large trial comparing one or more NOACs with aspirin
and no pharmacotherapy. However, a study powered to capture VTE events may be prohibitively
expensive, because event rates are low.
Strengths and limitations
Strengths
The strengths of this technology appraisal include its comprehensive coverage of all the therapeutic areas
in which NOACS have been evaluated to date, using the same methodology. Previous analyses of
comparative effectiveness have focused on individual therapeutic areas, making it more difficult to judge
if one of the four licensed NOACs might emerge as a frontrunner in more than one therapeutic area.
Additional strengths include careful appraisal of study quality; focus on clinically relevant end points;
an evaluation of safety that considers evidence spanning all therapeutic areas together, to maximise
power; the development of a possible treatment hierarchy for the different anticoagulant indications,
where the data allowed it; and a CEA that is relevant to the NHS.
Limitations
The limitations of this technology appraisal relate mainly to shortfalls in the primary data, on which the
overview is based. In particular:
l There were no direct head-to-head comparisons between different NOAC drugs – all such comparisons
were therefore based on indirect evidence derived from the networks.
l Economic analyses for conditions such as AF and VTE necessarily make long-term projections on the
basis of short-term trial evidence, observational data and clinically informed assumptions about plausible
treatment pathways and health-state transitions. These assumptions and evidence limitations are
discussed in previous sections [see Chapter 6 (Summary of cost-effectiveness findings) and Chapter 11
(Summary of cost-effectiveness findings)].
l The profile of patients entering trials may not be the same as those treated in practice, who may be
older and have more comorbidities. Treatment benefits in such patients may be smaller, and rates of
harm higher, than estimated by trials.
l As for all new drugs, adverse effects that remained undetected during development may come to light
with high-volume use post licensing.
l It is possible that patients treated with warfarin in practice are at higher risk of bleeding complications
than those in trials because of a greater number of comorbidities and less stringent control of
anticoagulation. However, concerns have also been raised previously that the time spent in the
therapeutic range was suboptimal among patients in clinical trials who were assigned to warfarin.
Thus, clinical trials could have underestimated both the benefits and the risks of warfarin treatment.
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For these reasons, guideline developers, prescribers and patients may wish to exercise caution when
considering the prescription of new therapies over older, more established ones.
Several factors led to imprecision in the estimation of certain treatment effects. These included low rates
of occurrence of certain end points, particularly in trials evaluating the safety and efficacy of NOACs in
the primary and secondary prevention of VTE; widespread use of composite end points, with low rates
of occurrence of certain (more clinically relevant) components of the composite; as well as substantial
inconsistency in the reporting of end points in different trials in the same therapeutic area, leading to a
substantial number of missing end point data (see Tables 22, 23, 72, 73, 111, 112, 138 and 139). Owing
to the low event rates and lack of substantial replication of specific comparisons across studies, we used
fixed-effects models for the NMA. This does not account for heterogeneity in treatment effects. Under
fixed-effects models, our Bayesian analyses with vague priors will produce results very similar to
frequentist analyses.
The evidence base for established antiplatelet and anticoagulant treatments in primary prevention of VTE
among hospitalised patients extends to groups of patients beyond those who were evaluated in this
report, for which comparisons were focused on patients undergoing hip and knee surgery. No trials of
NOACS were identified among patients who were undergoing neurosurgery, gastroenterological surgery
or gynaecological surgery. For this reason, conclusions about the comparative effectiveness of NOACs
compared with established antiplatelet and anticoagulant medications for primary prevention of VTE
should be limited to hip and knee surgery patients.
The apparent efficacy of NOACs when compared with warfarin could be inflated if control of the INR
was suboptimal among patients who were randomised to warfarin. For this reason, many of the studies
reported time spent in the therapeutic range (TTR), as an index of anticoagulant control. This is a
potentially important issue for the studies of stroke prevention in AF, for which 16 (73%) of the 22 studies
that included a warfarin intervention arm reported mean TTR. There was substantial variation in TTR
(from 45.1% to 83%) between these studies. For acute treatment of VTE, eight (89%) of the nine studies
that included a warfarin intervention arm reported mean TTR, but variation between them was less
marked than for the AF studies (from 56.9% to 63.5%). For secondary prevention of VTE, mean TTR was
reported in three (60%) of the five studies that included a warfarin intervention arm. The prespecified
protocol for this health technology appraisal specified TTR as a potential modifier of NOAC treatment
effect in trials in which warfarin was the comparator. We plan future analyses that address this issue.
The clinical effectiveness analyses reported are based on relative rather than absolute risk differences.
However, event rates for different safety and efficacy end points were estimated within and contributed to
the CEAs.
Factors beyond those considered in this technology appraisal could influence the choice of the optimal
anticoagulant in each of the therapeutic areas evaluated.
In some situations, the need for anticoagulation monitoring with warfarin treatment may be viewed as a
useful means to confirm adherence to anticoagulant therapy rather than as an inconvenience.
Recent studies have suggested that the efficacy and safety of dabigatran could be improved by monitoring
of achieved drug levels, because these exhibit wide inter-individual variation. This may reduce the
convenience of this NOAC and increase its cost compared with warfarin or other NOACs but we did not
model this in the current report. Only one of the studies included in our reviews considered whether or
not monitoring improves the efficacy and safety of NOACs: in a subsample of 9183 patients in the RE-LY
trial,13 ischaemic stroke and major bleeding both correlated with dabigatran plasma concentrations.
Specific tests to measure the anticoagulation effects of NOACs are being developed but are not yet
widely available234 and routine coagulation tests such as prothrombin time and activated partial
thromboplastin time are of limited use.235,236 It is therefore currently unclear whether or not the efficacy
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and safety profiles of NOACs can be improved by monitoring and dose adjustment. Monitoring may be
particularly helpful in certain clinical situations (e.g. emergency surgery or patients presenting with
bleeding236) and patient groups (advanced age, renal impairment).
Finally, therapeutic decision making may be influenced by recognition that effective treatments for reversal
of anticoagulation with NOACs are still in the developmental phase. For example:
l Aripazine (PER-977; PER 977; ciraparantag) is a synthetic cationic molecule that binds unfractionated
and LMWH, the factor Xa inhibitors edoxaban, rivaroxaban and apixaban, and the factor II inhibitor
dabigatran, but not to warfarin.237 In a Phase I trial involving 80 healthy volunteers, intravenous PER977
reversed the prolongation of whole blood clotting time induced by a single oral dose of edoxaban
60 mg in a dose-dependent fashion, within 10–30 minutes of administration.238 Phase II clinical studies
of this agent are in progress.
l Andexanet alpha (PRT4445; PRT064445) is a recombinant modified factor Xa molecule that acts as an
antidote to factor Xa inhibitors through a decoy mechanism. A number of Phase III studies of this agent
are under way.239,240
l Idarucizumab (BI 655075) is a humanised monoclonal antibody fragment that binds dabigatran to
reverse its anticoagulant activity.241,242 Phase I/II studies of this agent have been completed. A Phase III
study investigating reversal of anticoagulation in patients receiving dabigatran who have uncontrolled
bleeding or who require emergency surgery or invasive procedures is under way.
Research needs
Evidence on the comparative efficacy of NOACs in this review has come exclusively from indirect
comparisons, because of the lack of head-to-head trials. Among patients with AF, a long-term condition,
the trials have also been of relatively short duration. A different manufacturer has developed each of the
agents evaluated in this review and it is therefore unlikely that any head-to-head trials will be initiated
by industry.
Reliable estimation of the cost-effectiveness of NOACs in different clinical scenarios requires high-quality
data on absolute event rates for the various efficacy and safety outcomes. NHS health record data could
provide a rich source for information, but so far health record data have been insufficiently utilised for
this purpose.
Although NOACs were developed in part to supersede warfarin by obviating the need for therapeutic
monitoring of anticoagulation, to improve convenience, recent studies13 have suggested that monitoring of
drug levels may improve safety and efficacy of dabigatran treatment. Whether or not this is also the case
for other NOACs is not known.
The requirement for therapeutic drug monitoring with warfarin also serves as a means to assess
adherence. Thus far, long-term adherence rates for NOACs (e.g. among patients with AF who may require
anticoagulation for many years have not been evaluated).
For secondary prevention of VTE, use of NOACs in high-risk patients is a potential area for further study.
Further research is needed to clarify whether aspirin or no treatment should be the standard of care in
this setting.
The research needs identified by this review are therefore as follows:
l To complete calculations of the expected value of sample information, in order to clarify whether it is
justifiable to conduct one or more trials making direct comparisons between the most promising
NOACs and NOAC doses, in situations typical of NHS clinical practice.
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l To consider the merits of conducting cohort studies that reduce uncertainties in costs, utilities and
transition probabilities in order to improve estimates of relative cost-effectiveness, in particular in the
context of primary prevention of VTE in THR and TKR, and acute treatment of VTE.
l Information on long-term rates of the main efficacy and safety outcomes among patients receiving
anticoagulants for AF (e.g. from registries or health record data).
l Information on the role (if any) of therapeutic monitoring to enhance the safety and efficacy of NOACs.
l Information on long-term adherence rates in patients receiving NOACs for AF.
l Development of tools to stratify risk of recurrent VTE.
l Further research is also needed to establish whether the secondary prevention of VTE with aspirin or
other agents is cost-effective, with an adequate safety margin, in patients identified as being at
particularly high risk of recurrence by validated risk stratification tools.
Implications for practice
This health technology appraisal was conducted to help guideline developers, doctors and patients
decide when a NOAC might be preferred to an established anticoagulant and, when a NOAC is preferred
to warfarin, if there is sufficient evidence to support the use of one particular NOAC over another.
The evidence provided by this health technology appraisal indicates:
l NOACs have advantages over warfarin in patients with AF and, of the available NOACs, apixaban
5 mg bd offers the best balance between efficacy and safety, and has the highest probability of being
most cost-effective.
l NOACs offer no efficacy advantage over warfarin in the acute treatment of VTE, but have a lower rate
of bleeding complications albeit at a higher cost. For a willingness-to-pay threshold of > £5000,
apixaban 5 mg bd emerges as the most cost-effective alternative to warfarin.
l Neither the clinical nor CEA provided strong evidence that NOACs replace post-op LMWH in primary
prevention of VTE in patients who are undergoing hip or knee surgery.
l If secondary prevention after 3–6 months of anticoagulation for a first episode of VTE is to be
considered (this is not currently established practice), NOACs provide no advantage over aspirin
100 mg od.
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Chapter 13 Patient perspective
Anticoagulation Europe is a charity that provides education, information and support to patientsrequiring anticoagulation therapy in the UK.
Patients requiring anticoagulants for the treatment and prevention of VTE are given VKAs warfarin,
heparin and LMWH. These treatments are effective and are now joined by newer technologies that work
differently to warfarin.
The NOACs have become available to be used in the prevention of stroke in non-valvular AF and the
treatment and secondary prevention of DVT and PE, complementing existing treatments.
In the UK, NICE and the Scottish Medicines Consortium (SMC) have produced guidelines that recommend
the new agents. The benefits to patients and clinicians are that there is now a broader range of treatment
options available to treat and prevent blood clots.
AntiCoagulation Europe has welcomed the opportunity to participate in this project, and has contributed
the patient perspective of current anticoagulation practice, as captured by the experiences and feedback
derived from their patient databases.
In our role as a dedicated anticoagulation charity, we have highlighted the need for equality of access
to all of the anticoagulation therapies as recommended by NICE and the SMC. We advocate that patients
should be adequately informed of the benefits and risks of all anticoagulation treatments in order
that they can make an informed choice around their therapy options with the appropriate health-care
professionals.
AntiCoagulation Europe anticipates that this comprehensive study will provide a helpful and informative
reference resource for clinicians when considering and presenting the most effective and safe
anticoagulation treatment options to patients for their condition.
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Appendix 1 MEDLINE search strategy
Venous thromboembolism
Database: MEDLINE 1950 to present (search date: 20 March 2014).
Search strategy
1. exp Venous Thrombosis/ (43,921)
2. exp Pulmonary Embolism/ (30,904)
3. thromboembolism/ or venous thromboembolism/ (24,405)
4. ((venous or vein$) adj3 (thrombus$ or thrombo$)).ti,ab. (45,827)
5. (DVT or VTE).ti,ab. (9537)
6. (thrombophlebitis or thromboprophylaxis or thrombo-prophylaxis or thrombophlebitides).ti,ab. (7132)
7. ((pulmonary or lung or lungs) adj3 embol$).ti,ab. (27,169)
8. ((leg or legs) adj3 (embol$ or thrombo$ or thrombus$)).ti,ab. (1141)
9. or/1-8 (111,695)
10. exp *Anticoagulants/ (94,334)
11. exp *Coumarins/ (24,282)
12. Warfarin/ (14,323)
13. exp Vitamin K/ai [Antagonists & Inhibitors] (1537)
14. Thrombin/ai [Antagonists & Inhibitors] (3372)
15. Factor Xa/ai [Antagonists & Inhibitors] (2203)
16. Aspirin/ (37,741)
17. (anticoagula$ or anti-coagula$).ti. (20,512)
18. (oral anticoagula$ or oral anti-coagula$).ti,ab. (7048)
19. (coumarin$ or coumadin$ or warfarin or marevan or dicoumarol or dicoumarin or dicumarin or
dicumarol or acenocoumarol or phenindione or aldocumar).ti,ab. (24,194)
20. (factor Xa adj2 (antagonist$ or inhibitor$)).ti,ab. (1356)
21. (factor 10a adj2 (antagonist$ or inhibitor$)).ti,ab. (2)
22. (factor IIa adj2 (antagonist$ or inhibitor$)).ti,ab. (25)
23. ((vitamin K or vitamin-k) adj2 (antagonist$ or inhibitor$)).ti,ab. (1830)
24. (dabigatram or pradaxa or BIBR1048 or Apixaban or Eliquis or BMS-562247-01 or Edoxaban or Lixiana
or savaysa or DU-176b or betrixaban or PRT-054021 or PRT0504021 or rivaroxaban or xarelto or
BAY-59739 or Erixaban or D0913).ti,ab. (1015)
25. (NOAC or NOACS).ti,ab. (86)
26. (aspirin or acetyl-salicylic acid or acetylsalicylic acid).ti,ab. (40,463)
27. or/10-26 (170,042)
28. *heparin/ or exp heparin, low-molecular-weight/ or heparinoids/ (33,841)
29. (Dalteparin or fragmin$ or enoxaparin or clexane or lovenox or tinzaparin or innohep or bemiparin or
badyket or hepadren or hibor or ivor or ivorat or zibor or certoparin or mono-embolex or sandoparin$
or nadroparin$ or fraxiparin$ or parnaparin or fluxum or reviparin or clivarine or lowmorin).ti,ab. (4597)
30. (LMWH$ or heparinoid$ or danaparoid or orgaran).ti,ab. (4469)
31. (low$ molecular adj2 heparin$).ti,ab. (9114)
32. or/28-31 (37,314)
33. 27 or 32 (173,069)
34. 9 and 33 (22,835)
35. letter/ (803,375)
36. editorial/ (333,336)
37. news/ (151,695)
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38. exp historical article/ (318,208)
39. Anecdotes as topic/ (4506)
40. comment/ (528,857)
41. case report/ (1,665,228)
42. (letter or comment$).ti. (84,259)
43. or/35-42 (3,214,189)
44. randomized controlled trial/ or Randomized Controlled Trials as Topic/ or random$.ti,ab. (774,175)
45. 43 not 44 (3,185,399)
46. animals/ not humans/ (3,810,079)
47. exp Animals, Laboratory/ (714,848)
48. exp Animal Experimentation/ (6196)
49. exp Models, Animal/ (407,481)
50. exp rodentia/ (2,630,754)
51. (rat or rats or mouse or mice).ti. (1,065,119)
52. or/45-51 (7,547,456)
53. 34 not 52 (16,525)
54. meta-analysis/ (45,670)
55. meta-analysis as topic/ (13,522)
56. (meta analy$ or metaanaly$ or metanaly$ or meta regression).ti,ab. (54,350)
57. ((systematic$ or evidence$) adj2 (review$ or overview$)).ti,ab. (61,810)
58. (reference list$ or bibliograph$ or hand search$ or manual search$ or relevant journals).ab. (22,477)
59. (search strategy or search criteria or systematic search or study selection or data extraction).ab. (24,122)
60. (search$ adj4 literature).ab. (23,275)
61. (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or cinahl or science
citation index or bids or cancerlit).ab. (71,805)
62. cochrane.jw. (9850)
63. ((multiple treatment$ or indirect or mixed) adj2 comparison).ti,ab. (813)
64. or/54-63 (169,922)
65. randomized controlled trial.pt. or randomized controlled trial/ or Randomized Controlled Trials as
Topic/ (452,316)
66. controlled clinical trial.pt. (87,802)
67. randomi#ed.ab. (318,385)
68. placebo.ab. (143,748)
69. drug therapy.fs. (1,675,613)
70. randomly.ab. (189,528)
71. trial.ab. (275,251)
72. groups.ab. (1,220,973)
73. or/65-72 (3,169,503)
74. clinical trials as topic.sh. (168,638)
75. trial.ti. (114,737)
76. or/65-68,70,74-75 (899,851)
77. 64 or 76 (1,015,181)
78. 53 and 77 (4596)
79. limit 78 to yr=“2008-Current” (1408)
80. atrial fibrillation.ti. (19,641)
81. *atrial fibrillation/ (25,973)
82. 80 or 81 (26,290)
83. 79 not 82 (1281)
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
294
Atrial fibrillation
Database: MEDLINE In-Process & Other Non-Indexed Citations – Current week, MEDLINE 1950 to present.
Search date: 20 March 2014.
Search strategy
1. tachycardia, supraventricular/ or tachycardia, ectopic atrial/ (5440)
2. atrial fibrillation/ (33,510)
3. ((atrial or atrium or auricular) adj3 fibrillat$).ti,ab. (38,980)
4. heart fibrillat$.ti,ab. (42)
5. (supraventricul$ adj3 (arrhythmi$ or tachycardia$)).ti,ab. (7547)
6. ((atrial or atrium) adj3 (tachycardia$ or arrhythmi$)).ti,ab. (6888)
7. (atrial adj3 tachyarrhythmi$).ti,ab. (1210)
8. Atrial Flutter/ (4944)
9. ((atrial or auricular) adj3 flutter$).ti,ab. (5382)
10. or/1-9 (59,756)
11. exp *Anticoagulants/ (94,278)
12. exp *Coumarins/ (24,265)
13. Warfarin/ (14,307)
14. exp Vitamin K/ai [Antagonists & Inhibitors] (1534)
15. Thrombin/ai [Antagonists & Inhibitors] (3370)
16. Factor Xa/ai [Antagonists & Inhibitors] (2197)
17. Aspirin/ (37,712)
18. (anticoagula$ or anti-coagula$).ti. (21,584)
19. (oral anticoagula$ or oral anti-coagula$).ti,ab. (7768)
20. (coumarin$ or coumadin$ or warfarin or marevan or dicoumarol or dicoumarin or dicumarin or
dicumarol or enocoumarol or phenindione or aldocumar).ti,ab. (26,479)
21. (factor Xa adj2 (antagonist$ or inhibitor$)).ti,ab. (1502)
22. (factor 10a adj2 (antagonist$ or inhibitor$)).ti,ab. (2)
23. (factor IIa adj2 (antagonist$ or inhibitor$)).ti,ab. (29)
24. ((vitamin K or vitamin-k) adj2 (antagonist$ or inhibitor$)).ti,ab. (2080)
25. (dabigatram or pradaxa or BIBR1048 or Apixaban or Eliquis or BMS-562247-01 or Edoxaban or Lixiana
or savaysa or DU-176b or betrixaban or PRT-054021 or PRT0504021 or rivaroxaban or xarelto or
BAY-59739 or Erixaban or D0913).ti,ab. (1330)
26. (NOAC or NOACS).ti,ab. (152)
27. (aspirin or acetyl-salicylic acid or acetylsalicylic acid).ti,ab. (42,763)
28. or/11-27 (175,520)
29. 10 and 28 (6721)
30. letter/ (829,317)
31. editorial/ (348,841)
32. news/ (159,814)
33. exp historical article/ (318,220)
34. Anecdotes as topic/ (4506)
35. comment/ (572,414)
36. case report/ (1,665,104)
37. (letter or comment$).ti. (94,907)
38. or/30-37 (3,300,100)
39. randomized controlled trial/ or Randomized Controlled Trials as Topic/ or random$.ti,ab. (835,720)
40. 38 not 39 (3,270,043)
41. animals/ not humans/ (3,807,926)
42. exp Animals, Laboratory/ (714,413)
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43. exp Animal Experimentation/ (6188)
44. exp Models, Animal/ (407,073)
45. exp rodentia/ (2,629,200)
46. (rat or rats or mouse or mice).ti. (1,097,935)
47. or/40-46 (7,662,407)
48. 29 not 47 (5201)
49. systematic review/ (0)
50. meta analysis/ (45,623)
51. (meta analy$ or metaanaly$ or metanaly$ or meta regression).ti,ab. (61,909)
52. ((systematic$ or evidence$) adj2 (review$ or overview$)).ti,ab. (71,965)
53. (reference list$ or bibliograph$ or hand search$ or manual search$ or relevant journals).ab. (24,936)
54. (search strategy or search criteria or systematic search or study selection or data extraction).ab. (26,492)
55. (search$ adj4 literature).ab. (26,789)
56. (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or cinahl or science
citation dex or bids or cancerlit).ab. (82,698)
57. cochrane.jw. (10,337)
58. ((multiple treatment$ or indirect or mixed) adj2 comparison).ti,ab. (901)
59. or/49-58 (186,127)
60. randomized controlled trial.pt. or randomized controlled trial/ or Randomized Controlled Trials as
Topic/ (452,445)
61. controlled clinical trial.pt. (87,837)
62. randomi#ed.ab. (343,274)
63. placebo.ab. (151,447)
64. drug therapy.fs. (1,674,296)
65. randomly.ab. (208,182)
66. trial.ab. (297,177)
67. groups.ab. (1,328,911)
68. or/60-67 (3,312,451)
69. clinical trials as topic.sh. (168,554)
70. trial.ti. (123,158)
71. or/60-63,65,69-70 (946,554)
72. 59 or 71 (1,075,719)
73. 48 and 72 (1764)
74. 74 limit 73 to yr=“2010-Current” (728)
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Appendix 2 Forest plots: stroke prevention in
atrial fibrillation
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51/2808, 113/2791
0/71, 0/72
212/9120, 265/9081
0/71, 3/75
0/127, 0/127
1/127, 0/127
1/127, 0/127
1/127, 0/127
1/127, 1/127
1/127, 0/127
0/46, 1/62
183/6015, 202/6022
0/33, 0/36
0/33, 0/27
0/33, 1/21
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 92 Stroke or SE [1/4] (stroke prevention in AF).
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Dabigatran (150 mg bd) + aspirin (325 mg bd) vs. warfarin (INR 2 – 3)
PETRO102
Dabigatran (150 mg bd) + aspirin (81 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) + aspirin (81 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
Dabigatran (150 mg bd) + aspirin (81 mg bd) vs. warfarin (INR 2 – 3)
PETRO102
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (110 mg bd)
RE-LY104,109
AF-DABIG-VKA-JAPAN110
Dabigatran (150 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (300 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (300 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (50 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. warfarin (INR 1.6 – 3)
AF-DABIG-VKA-JAPAN110
Dabigatran (150 mg bd) vs. warfarin (INR 2 – 3)
RE-LY104,109
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (300 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. warfarin (INR 2 – 3)
PETRO102
Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
(Excluded)
(Excluded)
0/33, 0/70
0/36, 0/27
0.19 (0.01 to 4.81)
(Excluded)
0.72 (0.57 to 0.90)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
0.19 (0.01 to 4.84)
(Excluded)
0.07 (0.00 to 1.73)
0.35 (0.01 to 8.78)
0.65 (0.52 to 0.81)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
0.22 (0.01 to 5.77)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
0.20 (0.01 to 5.09)
OR (95% CI)
0/36, 1/21
0/36, 0/70
134/6076, 183/6015
0/58, 0/46
0/100, 0/33
0/100, 0/36
0/100, 0/30
0/100, 0/34
0/100, 1/59
0/100, 0/27
0/100, 1/21
0/58, 1/62
134/6076, 202/6022
0/100, 0/70
0/30, 0/33
0/30, 0/36
0/30, 0/34
0/30, 0/27
0/30, 1/21
0/30, 0/70
0/34, 0/33
0/34, 0/36
0/34, 0/27
0/34, 1/21
Events / total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 93 Stroke or SE [2/4] (stroke prevention in AF).
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Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (150 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (300 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (300 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (50 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (50 mg bd) + aspirin (325 mg bd) vs. dabigatran (50 mg bd) + aspirin (81mg bd)
PETRO102
Dabigatran (50 mg bd) + aspirin (325 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (50 mg bd) + aspirin (81 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (300 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (300 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. warfarin (INR 2–3)
PETRO102
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
0.18 (0.01 to 4.61)
(Excluded)
0.06 (0.00 to 1.65)
(Excluded)
0.25 (0.01 to 6.42)
(Excluded)
10.32 (0.40 to 262.95)
1.72 (0.07 to 43.37)
1.87 (0.07 to 47.19)
1.56 (0.06 to 39.56)
1.77 (0.07 to 44.64)
1.41 (0.06 to 35.74)
0.34 (0.02 to 5.77)
3.62 (0.14 to 90.43)
OR (95% CI)
0/34, 0/70
0/105, 0/100
0/105, 0/33
0/105, 0/36
0/105, 0/30
0/105, 0/34
0/105, 1/59
0/105, 0/27
0/105, 1/21
0/105, 0/70
0/27, 1/21
0/27, 0/70
1/21, 0/70
1/59, 0/33
1/59, 0/36
1/59, 0/30
1/59, 0/34
1/59, 0/27
1/59, 1/21
1/59, 0/70
Events / total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 94 Stroke or SE [3/4] (stroke prevention in AF).
DOI: 10.3310/hta21090 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 9
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Sterne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
299
Edoxaban (30 mg bd) vs. edoxaban (30 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (30 mg bd) vs. edoxaban (60 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (30 mg bd) vs. warfarin (INR 2–3)
AF-EDOX-VKA-MULTI108
Edoxaban (30 mg od) vs. warfarin (INR 1.6–3)
AF-EDOX-VKA-JAPAN118
Edoxaban (30 mg od) vs. warfarin (INR 2–3)
AF-EDOX-VKA-MULTI108
ENGAGE AF-TIMI 48111,131
AF-EDOX-VKA-ASIA115
Edoxaban (45 mg od) vs. edoxaban (30 mg od)
AF-EDOX-VKA-JAPAN118
Edoxaban (45 mg od) vs. warfarin (INR 1.6–3)
AF-EDOX-VKA-JAPAN118
Edoxaban (60 mg bd) vs. edoxaban (30 mg bd)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg bd) vs. edoxaban (30 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg bd) vs. edoxaban (60 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg bd) vs. warfarin (INR 2–3)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg od) vs. edoxaban (30 mg od)
AF-EDOX-VKA-MULTI108
ENGAGE AF-TIMI 48111,131
AF-EDOX-VKA-ASIA115
AF-EDOX-VKA-JAPAN118
Edoxaban (60 mg od) vs. edoxaban (45mg od)
AF-EDOX-VKA-JAPAN118
Edoxaban (60 mg od) vs. warfarin (INR 1.6–3)
AF-EDOX-VKA-JAPAN118
Edoxaban (60 mg od) vs. warfarin (INR 2–3)
AF-EDOX-VKA-MULTI108
ENGAGE AF-TIMI 48111,131
AF-EDOX-VKA-ASIA115
Rivaroxaban (15 mg od) vs. warfarin (INR 1.6–3)
J-ROCKET AF120
Rivaroxaban (20 mg od) vs. warfarin (INR 2–3)
ROCKET AF106,112,123,129
2.91 (0.30 to 28.20)
2.90 (0.30 to 28.08)
0.77 (0.17 to 3.46)
(Excluded)
0.26 (0.03 to 2.37)
1.14 (0.98 to 1.33)
(Excluded)
2.96 (0.12 to 73.20)
2.91 (0.12 to 72.09)
0.90 (0.15 to 5.46)
2.63 (0.24 to 29.23)
2.62 (0.24 to 29.10)
0.69 (0.13 to 3.81)
1.00 (0.06 to 16.15)
0.76 (0.65 to 0.89)
(Excluded)
(Excluded)
0.34 (0.01 to 8.38)
(Excluded)
0.26 (0.03 to 2.38)
0.87 (0.74 to 1.02)
(Excluded)
0.49 (0.24 to 1.02)
0.88 (0.74 to 1.04)
OR (95% CI)
3/244, 1/235
3/244, 1/234
3/244, 4/250
0/131, 0/129
1/235, 4/250
383/7034, 337/7036
0/79, 0/75
1/134, 0/131
1/134, 0/129
2/180, 3/244
2/180, 1/235
2/180, 1/234
2/180, 4/250
1/234, 1/235
296/7035, 383/7034
0/80, 0/79
0/131, 0/131
0/131, 1/134
0/131, 0/129
1/234, 4/250
296/7035, 337/7036
0/80, 0/75
11/637, 22/637
269/7061, 306/7082
Events / total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 95 Stroke or SE [4/4] (stroke prevention in AF).
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Antiplatelet (< 150 mg od) vs. warfarin (INR 1.6–3)
AF-ASA-VKA-CHINA135
Antiplatelet (> 150 mg od) vs. warfarin (INR 2–3)
ACTIVE-W100
AFASAK II97
AF-VKA-ASA-CHINA122
PATAF98
SPAF II96
Apixaban (2.5 mg bd) vs. warfarin (INR 2–3)
ARISTOTLE-J113
Antiplatelet (< 150 mg od) vs. apixaban (5 mg bd)
AVERROES105,116,117,121
Apixaban (2.5 mg bd) vs. apixaban (5 mg bd)
ARISTOTLE-J113
Apixaban (5 mg bd) vs. warfarin (INR 2–3)
ARISTOTLE107,114,119,124–127,130,132–134
ARISTOTLE-J113
Betrixaban (40 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Betrixaban (40 mg od) vs. betrixaban (60 mg od)
EXPLORE-Xa128
Betrixaban (60 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Betrixaban (40 mg od) vs. betrixaban (80 mg od)
EXPLORE-Xa128
Betrixaban (60 mg od) vs. betrixaban (80 mg od)
EXPLORE-Xa128
Betrixaban (80 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Dabigatran (110 mg bd) vs. warfarin (INR 2–3)
RE-LY104,109
Dabigatran (110 mg bd) vs. dabigatran (150 mg bd)
RE-LY104,109
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
RE-LY104,109
Edoxaban (30 mg od) vs. warfarin (INR 2–3)
ENGAGE AF-TIMI 48111,131
Edoxaban (30 mg od) vs. edoxaban (60 mg od)
ENGAGE AF-TIMI 48111,131
Edoxaban (60 mg od) vs. warfarin (INR 2–3)
ENGAGE AF-TIMI 48111,131
Rivaroxaban (15 mg od) vs. warfarin (INR 1.6–3)
J-ROCKET AF120
Rivaroxaban (20 mg od) vs. warfarin (INR 2–3)
ROCKET AF106,112,123,129
2.94 (0.86 to 10.09)
2.20 (1.52 to 3.18)
1.70 (0.40 to 7.22)
9.87 (1.22 to 79.56)
1.25 (0.27 to 5.67)
1.48 (0.88 to 2.48)
0.34 (0.01 to 8.55)
0.37 (0.25 to 0.54)
(Excluded)
0.92 (0.74 to 1.14)
0.35 (0.01 to 8.67)
(Excluded)
3.02 (0.12 to 74.93)
3.02 (0.12 to 74.93)
3.02 (0.12 to 74.93)
1.00 (0.06 to 16.16)
3.02 (0.12 to 74.93)
1.14 (0.90 to 1.44)
0.67 (0.52 to 0.86)
0.76 (0.58 to 0.98)
1.44 (1.21 to 1.71)
0.70 (0.59 to 0.83)
1.00 (0.84 to 1.21)
0.41 (0.17 to 0.98)
0.93 (0.74 to 1.16)
OR (95% CI)
10/50, 4/51
90/3335, 42/3371
5/169, 3/170
8/201, 1/239
4/141, 3/131
37/545, 26/555
0/72, 1/75
35/2808, 93/2791
0/71, 0/72
162/9120, 175/9081
0/71, 1/75
0/127, 0/127
1/127, 0/127
1/127, 0/127
1/127, 0/127
1/127, 1/127
1/127, 0/127
152/6015, 134/6022
103/6076, 152/6015
103/6076, 134/6022
333/7034, 235/7036
236/7035, 333/7034
236/7035, 235/7036
7/637, 17/637
149/7061, 161/7082
Events / total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 96 Ischaemic stroke (stroke prevention in AF).
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Antiplatelet (< 150 mg od) vs. warfarin (INR 1.6–3)
AF-ASA-VKA-CHINA135
Antiplatelet (< 150 mg od) vs. warfarin (INR 2–3)
BAFTA103
Antiplatelet (> 150 mg od) vs. warfarin (INR 2–3)
ACTIVE-W100
AFASAK II97
PATAF98
SPAF II96
Apixaban (2.5 mg bd) vs. warfarin (INR 2–3)
ARISTOTLE-J113
Apixaban (5 mg bd) vs. antiplatelet (< 150 mg od)
AVERROES105,116,117,121
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
ARISTOTLE-J113
Apixaban (5 mg bd) vs. warfarin (INR 2–3)
ARISTOTLE107,114,119,124–127,130,132–134
ARISTOTLE-J113
Betrixaban (40 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Betrixaban (60 mg od) vs. betrixaban (40 mg od)
EXPLORE-Xa128
Betrixaban (60 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Betrixaban (80 mg od) vs. betrixaban (40 mg od)
EXPLORE-Xa128
Betrixaban (80 mg od) vs. betrixaban (60 mg od)
EXPLORE-Xa128
Betrixaban (80 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Dabigatran (110 mg bd) vs. warfarin (INR 2–3)
RE-LY104,109
Dabigatran (150 mg bd) vs. dabigatran (110 mg bd)
RE-LY104,109
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
RE-LY104,109
Edoxaban (30 mg bd) vs. edoxaban (30 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (30 mg bd) vs. edoxaban (60 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (30 mg bd) vs. warfarin (INR 2–3)
AF-EDOX-VKA-MULTI108
Edoxaban (30 mg od) vs. warfarin (INR 2–3)
AF-EDOX-VKA-MULTI108
ENGAGE AF-TIMI 48111,131
Edoxaban (60 mg bd) vs. edoxaban (30 mg bd)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg bd) vs. edoxaban (30 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg bd) vs. edoxaban (60 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg bd) vs. warfarin (INR 2–3)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg od) vs. edoxaban (30 mg od)
AF-EDOX-VKA-MULTI108
ENGAGE AF-TIMI 48111,131
Edoxaban (60 mg od) vs. warfarin (INR 2–3)
AF-EDOX-VKA-MULTI108
ENGAGE AF-TIMI 48111,131
Rivaroxaban (15 mg od) vs. warfarin (INR 1.6–3)
J-ROCKET AF120
Rivaroxaban (20 mg od) vs. warfarin (INR 2–3)
ROCKET AF106,112,123,129
1.56 (0.25 to 9.78)
1.01 (0.49 to 2.08)
1.59 (0.94 to 2.69)
1.01 (0.25 to 4.09)
0.61 (0.10 to 3.73)
1.30 (0.65 to 2.59)
(Excluded)
0.85 (0.49 to 1.47)
(Excluded)
0.88 (0.66 to 1.17)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
1.31 (0.97 to 1.78)
0.98 (0.74 to 1.30)
1.29 (0.95 to 1.74)
0.48 (0.04 to 5.32)
0.48 (0.04 to 5.30)
3.09 (0.13 to 76.13)
5.36 (0.26 to 112.32)
1.20 (0.96 to 1.51)
0.45 (0.02 to 11.10)
0.26 (0.01 to 5.42)
0.26 (0.01 to 5.40)
(Excluded)
1.00 (0.14 to 7.19)
0.78 (0.62 to 0.98)
5.39 (0.26 to 112.80)
0.94 (0.74 to 1.20)
3.01 (0.31 to 29.01)
0.80 (0.62 to 1.04)
OR (95% CI)
3/50, 2/51
15/485, 15/488
36/3335, 23/3371
4/169, 4/170
2/141, 3/131
19/545, 15/555
0/72, 0/75
24/2808, 28/2791
0/71, 0/72
90/9120, 102/9081
0/71, 0/75
0/127, 0/127
0/127, 0/127
0/127, 0/127
0/127, 0/127
0/127, 0/127
0/127, 0/127
98/6015, 75/6022
97/6076, 98/6015
97/6076, 75/6022
1/244, 2/235
1/244, 2/234
1/244, 0/250
2/235, 0/250
169/7034, 141/7036
0/180, 1/244
0/180, 2/235
0/180, 2/234
0/180, 0/250
2/234, 2/235
133/7035, 169/7034
2/234, 0/250
133/7035, 141/7036
3/637, 1/637
101/7061, 126/7082
Events / total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 97 Myocardial infarction (stroke prevention in AF).
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Antiplatelet (< 150 mg od) vs. warfarin (INR 1.6–3)
AF-ASA-VKA-CHINA135
Antiplatelet (< 150 mg od) vs. warfarin (INR 2–3)
BAFTA103
Antiplatelet (> 150 mg od) vs. warfarin (INR 2–3)
ACTIVE-W100
AFASAK II97
AF-VKA-ASA-CHINA122
WASPO101
Apixaban (2.5 mg bd) vs. warfarin (INR 2–3)
ARISTOTLE-J113
Apixaban (5 mg bd) vs. antiplatelet (< 150 mg od)
AVERROES105,116,117,121
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
ARISTOTLE-J113
Apixaban (5 mg bd) vs. warfarin (INR 2–3)
ARISTOTLE107,114,119,124–127,130,132–134
ARISTOTLE-J113
Betrixaban (40 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Betrixaban (60 mg od) vs. betrixaban (40 mg od)
EXPLORE-Xa128
Betrixaban (60 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Betrixaban (80 mg od) vs. betrixaban (40 mg od)
EXPLORE-Xa128
Betrixaban (80 mg od) vs. betrixaban (60 mg od)
EXPLORE-Xa128
Betrixaban (80 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Dabigatran (110 mg bd) vs. warfarin (INR 1.6–3)
AF-DABIG-VKA-JAPAN110
Dabigatran (110 mg bd) vs. warfarin (INR 2–3)
RE-LY104,109
0.50 (0.04 to 5.70)
1.01 (0.57 to 1.78)
1.10 (0.83 to 1.47)
1.27 (0.33 to 4.80)
0.17 (0.02 to 1.36)
7.00 (0.35 to 140.39)
0.34 (0.01 to 8.55)
1.12 (0.73 to 1.73)
(Excluded)
0.69 (0.60 to 0.80)
0.35 (0.01 to 8.67)
0.09 (0.00 to 1.60)
(Excluded)
0.09 (0.00 to 1.60)
7.17 (0.37 to 140.22)
7.17 (0.37 to 140.22)
0.59 (0.14 to 2.52)
0.26 (0.01 to 5.55)
0.80 (0.69 to 0.93)
OR (95% CI)
1/50, 2/51
25/485, 25/488
101/3335, 93/3371
5/169, 4/170
1/201, 7/239
3/39, 0/36
0/72, 1/75
44/2808, 39/2791
0/71, 0/72
327/9088, 462/9052
0/71, 1/75
0/127, 5/127
0/127, 0/127
0/127, 5/127
3/127, 0/127
3/127, 0/127
3/127, 5/127
0/46, 2/62
342/6015, 421/6022
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 98 Major bleeding [1/4] (stroke prevention in AF).
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Dabigatran (150 mg bd) + aspirin (325 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) + aspirin (325 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) + aspirin (325 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) + aspirin (325 mg bd) vs. warfarin (INR 2-3)
PETRO102
Dabigatran (150 mg bd) + aspirin (81 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) + aspirin (81 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) + aspirin (81 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (110 mg bd)
AF-DABIG-VKA-JAPAN110
RE-LY104,109
Dabigatran (150 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (300 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (300 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (50 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. warfarin (INR 1.6–3)
AF-DABIG-VKA-JAPAN110
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
RE-LY104,109
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (300 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (50 mg bd)  + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. warfarin (INR 2–3)
PETRO102
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
2.43 (0.10 to 60.96)
1.17 (1.00 to 1.35)
(Excluded)
(Excluded)
0.04 (0.00 to 0.78)
0.11 (0.00 to 2.79)
(Excluded)
(Excluded)
(Excluded)
0.53 (0.05 to 5.96)
0.94 (0.81 to 1.08)
(Excluded)
8.53 (0.42 to 172.27)
9.29 (0.46 to 187.40)
3.67 (0.36 to 37.30)
7.00 (0.35 to 142.01)
5.47 (0.27 to 111.74)
17.95 (0.90 to 358.92)
OR (95% CI)
0/33, 0/36
0/33, 0/27
0/33, 0/21
0/33, 0/70
0/36, 0/27
0/36, 0/21
0/36, 0/70
1/58, 0/46
399/6076, 342/6015
0/100, 0/33
0/100, 0/36
0/100, 3/30
0/100, 1/34
0/100, 0/59
0/100, 0/27
0/100, 0/21
1/58, 2/62
399/6076, 421/6022
0/100, 0/70
3/30, 0/33
3/30, 0/36
3/30, 1/34
3/30, 0/27
3/30, 0/21
3/30, 0/70
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 99 Major bleeding [2/4] (stroke prevention in AF).
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Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (150 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (300 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (300 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (50 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (50 mg bd) + aspirin (325 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (50 mg bd) + aspirin (325 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (50 mg bd) + aspirin (81 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (300 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (300 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
3.00 (0.12 to 76.31)
3.27 (0.13 to 83.03)
2.46 (0.10 to 62.89)
1.93 (0.07 to 49.46)
6.31 (0.25 to 159.11)
(Excluded)
(Excluded)
(Excluded)
0.04 (0.00 to 0.74)
0.11 (0.00 to 2.66)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
0.07 (0.00 to 1.32)
0.19 (0.01 to 4.74)
(Excluded)
(Excluded)
OR (95% CI)
1/34, 0/33
1/34, 0/36
1/34, 0/27
1/34, 0/21
1/34, 0/70
0/105, 0/100
0/105, 0/33
0/105, 0/36
0/105, 3/30
0/105, 1/34
0/105, 0/59
0/105, 0/27
0/105, 0/21
0/105, 0/70
0/27, 0/21
0/27, 0/70
0/21, 0/70
0/59, 0/33
0/59, 0/36
0/59, 3/30
0/59, 1/34
0/59, 0/27
0/59, 0/21
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 100 Major bleeding [3/4] (stroke prevention in AF).
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Dabigatran (50 mg bd) vs. warfarin (INR 2–3)
PETRO102
Edoxaban (30 mg bd) vs. edoxaban (30 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (30 mg bd) vs. edoxaban (60 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (30 mg bd) vs. warfarin (INR 2–3)
AF-EDOX-VKA-MULTI108
Edoxaban (30 mg od) vs. warfarin (INR 1.6–3)
AF-EDOX-VKA-JAPAN118
Edoxaban (30 mg od) vs. warfarin (INR 2–3)
AF-EDOX-VKA-ASIA115
AF-EDOX-VKA-MULTI108
ENGAGE AF-TIMI 48111,131
Edoxaban (45 mg od) vs. edoxaban (30 mg od)
AF-EDOX-VKA-JAPAN118
Edoxaban (45 mg od) vs. warfarin (INR 1.6–3)
AF-EDOX-VKA-JAPAN118
Edoxaban (60 mg bd) vs. edoxaban (30 mg bd)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg bd) vs. edoxaban (30 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg bd) vs. edoxaban (60 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg bd) vs. warfarin (INR 2–3)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg od) vs. edoxaban (30 mg od)
AF-EDOX-VKA-JAPAN118
AF-EDOX-VKA-MULTI108
ENGAGE AF-TIMI 48111,131
AF-EDOX-VKA-ASIA115
Edoxaban (60 mg od) vs. edoxaban (45 mg od)
AF-EDOX-VKA-JAPAN118
Edoxaban (60 mg od) vs. warfarin (INR 1.6–3)
AF-EDOX-VKA-JAPAN118
Edoxaban (60 mg od) vs. warfarin (INR 2–3)
AF-EDOX-VKA-ASIA115
AF-EDOX-VKA-MULTI108
ENGAGE AF-TIMI 48111,131
Rivaroxaban (20 mg od) vs. warfarin (INR 2–3)
ROCKET AF106,112,123,129
(Excluded)
10.82 (0.59 to 196.70)
4.87 (0.57 to 42.04)
5.21 (0.60 to 44.92)
(Excluded)
0.18 (0.01 to 3.92)
0.35 (0.01 to 8.71)
0.47 (0.40 to 0.54)
6.95 (0.36 to 135.82)
6.68 (0.34 to 130.64)
1.65 (0.50 to 5.49)
17.54 (0.98 to 313.51)
8.03 (0.96 to 67.35)
8.59 (1.02 to 71.95)
5.08 (0.24 to 106.80)
3.03 (0.12 to 74.65)
1.68 (1.44 to 1.98)
(Excluded)
0.68 (0.11 to 4.15)
4.88 (0.23 to 102.73)
0.18 (0.01 to 3.87)
1.07 (0.07 to 17.18)
0.78 (0.69 to 0.90)
1.03 (0.89 to 1.19)
OR (95% CI)
0/59, 0/70
5/244, 0/235
5/244, 1/234
5/244, 1/250
0/130, 0/125
0/79, 2/75
0/235, 1/250
254/7002, 524/7012
3/134, 0/130
3/134, 0/125
6/180, 5/244
6/180, 0/235
6/180, 1/234
6/180, 1/250
2/130, 0/130
1/234, 0/235
418/7012, 254/7002
0/80, 0/79
2/130, 3/134
2/130, 0/125
0/80, 2/75
1/234, 1/250
418/7012, 524/7012
395/7111, 386/7125
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 101 Major bleeding [4/4] (stroke prevention in AF).
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Apixaban (2.5 mg bd) vs. warfarin (INR 2–3)
ARISTOTLE-J113
Apixaban (5 mg bd) vs. antiplatelet (< 150 mg od)
AVERROES105,116,117,121
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
ARISTOTLE-J113
Apixaban (5 mg bd) vs. warfarin (INR 2–3)
ARISTOTLE107,114,119,124–127,130,132–134
ARISTOTLE-J113
Betrixaban (40 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Betrixaban (60 mg od) vs. betrixaban (40 mg od)
EXPLORE-Xa128
Betrixaban (60 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Betrixaban (80 mg od) vs. betrixaban (40 mg od)
EXPLORE-Xa128
Betrixaban (80 mg od) vs. betrixaban (60 mg od)
EXPLORE-Xa128
Betrixaban (80 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Dabigatran (110 mg bd) vs. warfarin (INR 1.6–3)
AF-DABIG-VKA-JAPAN110
Dabigatran (150 mg bd) + aspirin (325 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) + aspirin (325 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) + aspirin (325 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) + aspirin (325 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (150 mg bd) + aspirin (81 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) + aspirin (81 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) + aspirin (81 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (110 mg bd)
AF-DABIG-VKA-JAPAN110
Dabigatran (150 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (300 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (300 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (50 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (150 mg bd) vs. warfarin (INR 1.6–3)
AF-DABIG-VKA-JAPAN110
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
PETRO102
0.25 (0.03 to 2.29)
1.14 (0.89 to 1.46)
1.01 (0.06 to 16.54)
0.67 (0.61 to 0.75)
0.25 (0.03 to 2.33)
0.14 (0.02 to 1.12)
5.16 (0.59 to 44.84)
0.70 (0.22 to 2.27)
5.16 (0.59 to 44.84)
1.00 (0.28 to 3.54)
0.70 (0.22 to 2.27)
0.36 (0.07 to 1.81)
1.10 (0.15 to 8.26)
1.68 (0.14 to 19.56)
1.29 (0.11 to 15.18)
1.06 (0.18 to 6.13)
1.53 (0.13 to 17.80)
1.18 (0.10 to 13.81)
0.97 (0.17 to 5.57)
2.08 (0.38 to 11.22)
1.53 (0.31 to 7.48)
1.68 (0.35 to 8.18)
0.40 (0.13 to 1.22)
0.57 (0.18 to 1.85)
12.36 (0.71 to 216.28)
2.57 (0.31 to 21.24)
1.98 (0.24 to 16.51)
0.74 (0.22 to 2.48)
1.63 (0.48 to 5.53)
OR (95% CI)
1/72, 4/75
140/2808, 123/2791
1/71, 1/72
613/9088, 877/9052
1/71, 4/75
1/127, 7/127
5/127, 1/127
5/127, 7/127
5/127, 1/127
5/127, 5/127
5/127, 7/127
2/46, 7/62
2/33, 2/36
2/33, 1/27
2/33, 1/21
2/33, 4/70
2/36, 1/27
2/36, 1/21
2/36, 4/70
5/58, 2/46
9/100, 2/33
9/100, 2/36
9/100, 6/30
9/100, 5/34
9/100, 0/59
9/100, 1/27
9/100, 1/21
5/58, 7/62
9/100, 4/70
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 102 Clinically relevant bleeding [1/3] (stroke prevention in AF).
DOI: 10.3310/hta21090 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 9
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Sterne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
307
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (300 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (325 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) + aspirin (81 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (150 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (300 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (300 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (50 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (300 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (50 mg bd) + aspirin (325 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (50 mg bd) + aspirin (325 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (50 mg bd) + aspirin (81 mg bd) vs. warfarin (INR 2–3)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (150 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (150 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (300 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (300 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (50 mg bd) + aspirin (325 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. dabigatran (50 mg bd) + aspirin (81 mg bd)
PETRO102
Dabigatran (50 mg bd) vs. warfarin (INR 2–3)
PETRO102
3.88 (0.72 to 20.93)
4.25 (0.79 to 22.88)
1.45 (0.39 to 5.34)
6.50 (0.73 to 57.99)
5.00 (0.55 to 45.06)
4.13 (1.07 to 15.89)
2.67 (0.48 to 14.87)
2.93 (0.53 to 16.25)
4.48 (0.49 to 40.92)
3.45 (0.37 to 31.79)
2.84 (0.71 to 11.37)
0.61 (0.21 to 1.79)
0.94 (0.18 to 4.89)
1.03 (0.20 to 5.35)
0.24 (0.07 to 0.82)
0.35 (0.10 to 1.24)
7.77 (0.43 to 140.48)
1.58 (0.18 to 13.67)
1.21 (0.14 to 10.63)
1.00 (0.27 to 3.68)
0.77 (0.05 to 13.07)
0.63 (0.07 to 5.95)
0.82 (0.09 to 7.81)
0.11 (0.00 to 2.27)
0.12 (0.01 to 2.49)
0.03 (0.00 to 0.58)
0.05 (0.00 to 0.84)
0.15 (0.01 to 3.76)
0.11 (0.00 to 2.93)
0.12 (0.01 to 2.36)
6/30, 2/33
6/30, 2/36
6/30, 5/34
6/30, 1/27
6/30, 1/21
6/30, 4/70
5/34, 2/33
5/34, 2/36
5/34, 1/27
5/34, 1/21
5/34, 4/70
6/105, 9/100
6/105, 2/33
6/105, 2/36
6/105, 6/30
6/105, 5/34
6/105, 0/59
6/105, 1/27
6/105, 1/21
6/105, 4/70
1/27, 1/21
1/27, 4/70
1/21, 4/70
0/59, 2/33
0/59, 2/36
0/59, 6/30
0/59, 5/34
0/59, 1/27
0/59, 1/21
0/59, 4/70
OR (95% CI) Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 103 Clinically relevant bleeding [2/3] (stroke prevention in AF).
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Edoxaban (30 mg bd) vs. edoxaban (30 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (30 mg bd) vs. edoxaban (60 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (30 mg bd) vs. warfarin (INR 2–3)
AF-EDOX-VKA-MULTI108
Edoxaban (30 mg od) vs. warfarin (INR 1.6–3)
AF-EDOX-VKA-MULTI108
Edoxaban (30 mg od) vs. warfarin (INR 2–3)
AAF-EDOX-VKA-ASIA115
AF-EDOX-VKA-MULTI108
ENGAGE AF-TIMI 48111,131
Edoxaban (45 mg od) vs. edoxaban (30 mg od)
AF-EDOX-VKA-JAPAN118
Edoxaban (45 mg od) vs. warfarin (INR 1.6–3)
AF-EDOX-VKA-JAPAN118
Edoxaban (60 mg bd) vs. edoxaban (30 mg bd)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg bd) vs. edoxaban (30 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg bd) vs. edoxaban (60 mg od)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg bd) vs. warfarin (INR 2–3)
AF-EDOX-VKA-MULTI108
Edoxaban (60 mg od) vs. edoxaban (30 mg od)
AF-EDOX-VKA-ASIA115
AF-EDOX-VKA-JAPAN118
AF-EDOX-VKA-MULTI108
ENGAGE AF-TIMI 48111,131
Edoxaban (60 mg od) vs. edoxaban (45 mg od)
AF-EDOX-VKA-JAPAN118
Edoxaban (60 mg od) vs. warfarin (INR 1.6–3)
AF-EDOX-VKA-JAPAN118
Edoxaban (60 mg od) vs. warfarin (INR 2–3)
AF-EDOX-VKA-ASIA115
AF-EDOX-VKA-MULTI108
ENGAGE AF-TIMI 48111,131
Rivaroxaban (15 mg od) vs. warfarin (INR 1.6–3)
J-ROCKET AF120
Rivaroxaban (20 mg od) vs. warfarin (INR 2–3)
ROCKET AF106,112,123,129
2.75 (1.13 to 6.67)
2.11 (0.94 to 4.77)
2.55 (1.10 to 5.95)
0.47 (0.09 to 2.63)
0.08 (0.00 to 1.48)
0.93 (0.33 to 2.60)
0.59 (0.55 to 0.64)
3.53 (0.72 to 17.31)
1.67 (0.48 to 5.84)
1.40 (0.72 to 2.72)
3.84 (1.58 to 9.36)
2.95 (1.30 to 6.69)
3.57 (1.53 to 8.35)
13.87 (0.77 to 250.55)
3.64 (0.74 to 17.88)
1.30 (0.48 to 3.56)
1.40 (1.29 to 1.53)
1.03 (0.35 to 3.03)
1.72 (0.49 to 6.03)
1.14 (0.33 to 3.89)
1.21 (0.46 to 3.19)
0.83 (0.77 to 0.90)
1.14 (0.87 to 1.50)
1.03 (0.95 to 1.11)
OR (95% CI)
19/244, 7/235
19/244, 9/234
19/244, 8/250
2/130, 4/125
0/79, 5/75
7/235, 8/250
1161/7002, 1761/7012
7/134, 2/130
7/134, 4/125
19/180, 19/244
19/180, 7/235
19/180, 9/234
19/180, 8/250
6/80, 0/79
7/130, 2/130
9/234, 7/235
1528/7012, 1161/7002
7/130, 7/134
7/130, 4/125
6/80, 5/75
9/234, 8/250
1528/7012, 1761/7012
138/639, 124/639
1475/7111, 1449/7125
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 104 Clinically relevant bleeding [3/3] (stroke prevention in AF).
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Antiplatelet (> 150 mg od) vs. warfarin (INR 2–3)
AFASAK II97
SPAF II96
Apixaban (5 mg bd) vs. antiplatelet (< 150 mg od)
AVERROES105,116,117,121
Apixaban (5 mg bd) vs. warfarin (INR 2–3)
ARISTOTLE107,114,119,124–127,130,132–134
Dabigatran (110 mg bd) vs. warfarin (INR 2–3)
RE-LY104,109
Dabigatran (150 mg bd) vs. dabigatran (110 mg bd)
RE-LY104,109
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
RE-LY104,109
Edoxaban (30 mg od) vs. warfarin (INR 2–3)
ENGAGE AF-TIMI 48111,131
Edoxaban (60 mg od) vs. edoxaban (30 mg od)
ENGAGE AF-TIMI 48111,131
Edoxaban (60 mg od) vs. warfarin (INR 2–3)
ENGAGE AF-TIMI 48111,131
Rivaroxaban (15 mg od) vs. warfarin (INR 1.6–3)
J-ROCKET AF120
Rivaroxaban (20 mg od) vs. warfarin (INR 2–3)
ROCKET AF106,112,123,129
0.84 (0.38 to 1.88)
0.42 (0.30 to 0.58)
0.31 (0.20 to 0.47)
0.50 (0.17 to 1.46)
0.65 (0.46 to 0.92)
11/2808, 13/2791
52/9088, 122/9052
27/6015, 87/6022
5/639, 10/639
55/7111, 84/7125
0.50 (0.04 to 5.57)
0.39 (0.14 to 1.09)
1.32 (0.80 to 2.18)
0.41 (0.28 to 0.60)
0.31 (0.22 to 0.44)
1.49 (1.00 to 2.22)
0.46 (0.34 to 0.62)
OR (95% CI)
1/169, 2/170
5/545, 13/555
36/6076, 27/6015
36/6076, 87/6022
41/7002, 132/7012
61/7012, 41/7002
61/7012, 132/7012
Events/total
0.0625 0.125 0.25 0.5 2 4 8 161
OR
FIGURE 105 Intracranial bleeding (stroke prevention in AF).
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Antiplatelet (< 150 mg od) vs. warfarin (INR 1.6–3)
AF-ASA-VKA-CHINA135
Antiplatelet (< 150 mg od) vs. warfarin (INR 2–3)
BAFTA103
Antiplatelet (< 150 mg od) vs. warfarin (INR 3–4)
AFASAK95
Antiplatelet (> 150 mg od) vs. warfarin (INR 1.6–3)
Chinese ATAFS99
Antiplatelet (> 150 mg od) vs. warfarin (INR 2–3)
ACTIVE-W100
AFASAK II97
AF-VKA-ASA-CHINA122
PATAF98
SPAF II96
WASPO101
Apixaban (2.5 mg bd) vs. warfarin (INR 2–3)
ARISTOTLE-J113
Apixaban (5 mg bd) vs. antiplatelet (< 150 mg od)
AVERROES105,116,117,121
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
ARISTOTLE-J113
Apixaban (5 mg bd) vs. warfarin (INR 2–3)
ARISTOTLE107,114,119,124–127,130,132–134
ARISTOTLE-J113
Betrixaban (40 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Betrixaban (60 mg od) vs. betrixaban (40 mg od)
EXPLORE-Xa128
Betrixaban (60 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Betrixaban (80 mg od) vs. betrixaban (40 mg od)
EXPLORE-Xa128
Betrixaban (80 mg od) vs. betrixaban (60 mg od)
EXPLORE-Xa128
Betrixaban (80 mg od) vs. warfarin (INR 2–3)
EXPLORE-Xa128
Dabigatran (110 mg bd) vs. warfarin (INR 2–3)
RE-LY104,109
Dabigatran (150 mg bd) vs. dabigatran (110 mg bd)
RE-LY104,109
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
RE-LY104,109
Edoxaban (30 mg od) vs. warfarin (INR 2–3)
ENGAGE AF-TIMI 48111,131
Edoxaban (60 mg od) vs. edoxaban (30 mg od)
ENGAGE AF-TIMI 48111,131
Edoxaban (60 mg od) vs. warfarin (INR 2–3)
ENGAGE AF-TIMI 48111,131
Rivaroxaban (15 mg od) vs. warfarin (INR 1.6–3)
J-ROCKET AF120
Rivaroxaban (20 mg od) vs. warfarin (INR 2–3)
ROCKET AF106,112,123,129
1.02 (0.14 to 7.54)
1.02 (0.75 to 1.38)
4.10 (1.15 to 14.66)
1.83 (0.55 to 6.15)
1.02 (0.81 to 1.28)
0.81 (0.39 to 1.71)
1.44 (0.43 to 4.79)
1.36 (0.62 to 2.97)
1.08 (0.74 to 1.56)
1.89 (0.16 to 21.80)
(Excluded)
0.78 (0.60 to 1.01)
(Excluded)
0.89 (0.79 to 1.00)
(Excluded)
1.00 (0.06 to 16.16)
0.33 (0.01 to 8.20)
0.33 (0.01 to 8.20)
0.33 (0.01 to 8.20)
(Excluded)
0.33 (0.01 to 8.20)
0.91 (0.80 to 1.04)
0.97 (0.85 to 1.11)
0.88 (0.77 to 1.01)
0.86 (0.78 to 0.96)
1.05 (0.95 to 1.17)
0.91 (0.82 to 1.01)
1.40 (0.44 to 4.45)
0.83 (0.69 to 1.00)
OR (95% CI)
2/50, 2/51
108/485, 107/488
12/336, 3/335
8/369, 4/335
159/3335, 158/3371
14/169, 17/170
6/201, 5/239
17/141, 12/131
65/545, 62/555
2/39, 1/36
0/72, 0/75
111/2808, 140/2791
0/71, 0/72
603/9120, 669/9081
0/71, 0/75
1/127, 1/127
0/127, 1/127
0/127, 1/127
0/127, 1/127
0/127, 0/127
0/127, 1/127
446/6015, 487/6022
438/6076, 446/6015
438/6076, 487/6022
737/7034, 839/7036
773/7035, 737/7034
773/7035, 839/7036
7/637, 5/637
208/7061, 250/7082
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 106 All-cause mortality (stroke prevention in AF).
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Appendix 3 Forest plots: primary prevention of
venous thromboembolism
Apixaban (10 mg bd) vs. apixaban (10 mg od)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg bd) vs. warfarin variable
APROPOS162
Apixaban (10 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg od) vs. warfarin variable
APROPOS162
Apixaban (2.5 mg bd) vs. LMWH (standard dose)
ADOPT188
Apixaban (2.5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
ADVANCE-1175
Apixaban (2.5 mg bd) vs. LMWH pre-op (standard dose)
ADVANCE-3176
Apixaban (2.5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg od)
APROPOS162
Apixaban (20 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (20 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (20 mg od) vs. warfarin variable
APROPOS162
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (5 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg od) vs. warfarin variable
APROPOS162
0.19 (0.01 to 3.95)
0.33 (0.01 to 8.27)
(Excluded)
(Excluded)
0.33 (0.01 to 8.12)
0.33 (0.01 to 8.12)
2.14 (0.19 to 23.91)
5.10 (0.24 to 107.45)
4.71 (0.22 to 99.35)
2.10 (0.19 to 23.48)
2.10 (0.19 to 23.48)
0.31 (0.11 to 0.86)
0.98 (0.06 to 15.90)
0.43 (0.11 to 1.65)
0.20 (0.02 to 1.70)
0.98 (0.06 to 15.90)
(Excluded)
0.19 (0.01 to 3.95)
0.33 (0.01 to 8.27)
(Excluded)
(Excluded)
0.33 (0.01 to 8.12)
0.33 (0.01 to 8.12)
0.35 (0.01 to 8.67)
(Excluded)
0.34 (0.01 to 8.51)
0.34 (0.01 to 8.51)
0.38 (0.02 to 9.38)
0.37 (0.01 to 9.21)
0.37 (0.01 to 9.21)
OR (95% CI)
0/110, 2/105
0/110, 1/111
0/110, 0/105
0/110, 0/97
0/110, 1/109
0/110, 1/109
2/105, 1/111
2/105, 0/105
2/105, 0/97
2/105, 1/109
2/105, 1/109
5/3255, 16/3273
1/111, 1/109
3/1599, 7/1596
1/2708, 5/2699
1/111, 1/109
0/110, 0/110
0/110, 2/105
0/110, 1/111
0/110, 0/105
0/110, 0/97
0/110, 1/109
0/110, 1/109
0/105, 1/111
0/105, 0/97
0/105, 1/109
0/105, 1/109
0/97, 1/111
0/97, 1/109
0/97, 1/109
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 107 Symptomatic DVT [1/3] (primary prevention of VTE).
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Betrixaban (15 mg bd) vs. LMWH post-op (standard dose)
EXPERT168
Betrixaban (40 mg bd) vs. betrixaban (15 mg bd)
EXPERT168
Betrixaban (40 mg bd) vs. LMWH post-op (standard dose)
EXPERT168
Dabigatran (110 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Dabigatran (150 mg od) vs. dabigatran (110 mg od)
VTE-DABIG-PLAC-JAPAN175
Dabigatran (150 mg od) vs. LMWH post-op (standard dose)
RE-MOBILISE167
Dabigatran (150 mg od) vs. LMWH pre-op (standard dose)
RE-MODEL161
RE-NOVATE160
Dabigatran (150 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. dabigatran (110 mg od)
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. dabigatran (150 mg od)
RE-MOBILISE167
RE-MODEL161
RE-NOVATE160
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. LMWH post-op (standard dose)
RE-MOBILISE167
Dabigatran (220 mg od) vs. LMWH pre-op (standard dose)
RE-MODEL161
RE-NOVATE160
RE-NOVATE II183,189
Dabigatran (220 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Edoxaban (15 mg od) vs. edoxaban (5 mg od)
STARS J-1172,180
Edoxaban (15 mg od) vs. placebo
STARS J-1172,180
Edoxaban (30 mg od) vs. edoxaban (15 mg od)
STARS J-1172,180
Edoxaban (30 mg od) vs. edoxaban (5 mg od)
STARS J-1172,180
Edoxaban (30 mg od) vs. LMWH (enoxaparin 20 mg bd)
STARS J-4181,193
STARS J-V179
Edoxaban (30 mg od) vs. placebo
STARS J-1172,180
Edoxaban (5 mg od) vs. placebo
STARS J-1172,180
Edoxaban (60 mg od) vs. edoxaban (15 mg od)
STARS J-1172,180
Edoxaban (60 mg od) vs. edoxaban (30 mg od)
STARS J-1172,180
Edoxaban (60 mg od) vs. edoxaban (5 mg od)
STARS J-1172,180
Edoxaban (60 mg od) vs. placebo
STARS J-1172,180
0.57 (0.03 to 9.29)
0.35 (0.01 to 8.84)
0.20 (0.01 to 5.06)
0.46 (0.04 to 5.16)
2.13 (0.19 to 23.77)
1.42 (0.54 to 3.76)
0.37 (0.10 to 1.39)
8.95 (1.13 to 70.78)
0.98 (0.14 to 7.10)
1.03 (0.06 to 16.66)
0.97 (0.39 to 2.40)
0.34 (0.04 to 3.30)
0.68 (0.24 to 1.91)
0.48 (0.04 to 5.41)
1.37 (0.51 to 3.71)
0.13 (0.02 to 1.01)
6.05 (0.73 to 50.36)
0.11 (0.01 to 2.04)
0.48 (0.04 to 5.32)
0.32 (0.01 to 7.84)
(Excluded)
(Excluded)
0.33 (0.01 to 8.20)
(Excluded)
(Excluded)
(Excluded)
3.07 (0.12 to 76.35)
(Excluded)
(Excluded)
0.33 (0.01 to 8.20)
(Excluded)
OR (95% CI)
1/70, 1/40
0/65, 1/70
0/65, 1/40
1/133, 2/124
2/126, 1/133
10/649, 7/643
3/696, 8/685
9/1156, 1/1142
2/126, 2/124
1/129, 1/133
9/604, 10/649
1/675, 3/696
6/1137, 9/1156
1/129, 2/126
9/604, 7/643
1/675, 8/685
6/1137, 1/1142
0/1001, 4/992
1/129, 2/124
0/92, 1/88
0/92, 0/89
0/88, 0/92
0/88, 1/88
0/46, 0/27
0/255, 0/248
0/88, 0/89
1/88, 0/89
0/88, 0/92
0/88, 0/88
0/88, 1/88
0/88, 0/89
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 108 Symptomatic DVT [2/3] (primary prevention of VTE).
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LMWH pre-op (standard dose) vs. LMWH post-op (standard dose)
VTE-VKA-LMWH-US-3153
Placebo vs. LMWH (Enoxaparin 20 mg bd)
VTE-LMWH-PLAC-JAPAN186
Placebo vs. LMWH (Nadroparin 3800 IU anti-Xa od)
PROTECHT170
Rivaroxaban (10 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (10 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Rivaroxaban (10 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
Rivaroxaban (10 mg od) vs. LMWH (standard dose)
MAGELLAN184,191
Rivaroxaban (10 mg od) vs. LMWH post-op (standard dose)
RECORD 4173
Rivaroxaban (2.5 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. rivaroxaban (10 mg bd)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. rivaroxaban (10 mg bd)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. rivaroxaban (20 mg bd)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
Rivaroxaban (5 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (5 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Warfarin (INR 2 – 3) vs. LMWH post-op (standard dose)
VTE-VKA-LMWH-US-3153
VTE-VKA-LMWH-US-2154
Warfarin (INR 2 – 3) vs. LMWH pre-op (standard dose)
VTE-VKA-LMWH-US-3153
Warfarin variable vs. LMWH post-op (standard dose)
APROPOS162
0.49 (0.17 to 1.45)
(Excluded)
2.04 (0.76 to 5.48)
0.23 (0.01 to 4.81)
0.34 (0.01 to 8.62)
(Excluded)
0.89 (0.42 to 1.88)
0.59 (0.21 to 1.64)
0.55 (0.05 to 6.20)
0.61 (0.05 to 6.87)
3.21 (0.13 to 80.49)
1.11 (0.07 to 18.12)
3.05 (0.12 to 76.54)
0.23 (0.01 to 4.89)
(Excluded)
0.35 (0.01 to 8.77)
0.32 (0.01 to 7.93)
(Excluded)
0.24 (0.01 to 5.06)
0.36 (0.01 to 9.07)
1.51 (0.67 to 3.42)
0.97 (0.65 to 1.46)
3.08 (1.11 to 8.58)
1.00 (0.06 to 16.19)
OR (95% CI)
5/337, 10/336
0/83, 0/83
8/381, 8/769
0/60, 2/70
0/60, 1/63
0/60, 0/57
13/2967, 15/3057
6/965, 10/959
1/63, 2/70
1/57, 2/70
1/57, 0/60
1/57, 1/63
1/57, 0/57
0/59, 2/70
0/59, 0/60
0/59, 1/63
0/59, 1/57
0/59, 0/57
0/57, 2/70
0/57, 1/63
15/338, 10/336
47/1495, 49/1516
15/338, 5/337
1/109, 1/109
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 109 Symptomatic DVT [3/3] (primary prevention of VTE).
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Apixaban (10 mg bd) vs. apixaban (10 mg od)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg bd) vs. warfarin variable
APROPOS162
Apixaban (10 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg od) vs. warfarin variable
APROPOS162
Apixaban (2.5 mg bd) vs. LMWH (standard dose)
ADOPT188
Apixaban (2.5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
ADVANCE-1171
Apixaban (2.5 mg bd) vs. LMWH pre-op (standard dose)
ADVANCE-3176
ADVANCE-2178
Apixaban (2.5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg od)
APROPOS162
Apixaban (20 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (20 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (20 mg od) vs. warfarin variable
APROPOS162
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (5 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg od) vs. warfarin variable
APROPOS162
2.89 (0.12 to 71.75)
3.05 (0.12 to 75.81)
3.00 (0.12 to 74.45)
(Excluded)
(Excluded)
(Excluded)
0.20 (0.01 to 4.30)
(Excluded)
0.88 (0.32 to 2.43)
0.19 (0.01 to 4.06)
0.99 (0.14 to 7.07)
0.60 (0.14 to 2.50)
9.03 (0.49 to 167.86)
(Excluded)
1.00 (0.06 to 16.19)
2.89 (0.12 to 71.75)
3.05 (0.12 to 75.81)
2.89 (0.12 to 71.75)
2.67 (0.11 to 66.34)
0.49 (0.04 to 5.49)
3.00 (0.12 to 74.45)
(Excluded)
(Excluded)
0.20 (0.01 to 4.30)
(Excluded)
(Excluded)
0.22 (0.01 to 4.65)
(Excluded)
OR (95% CI)
1/110, 0/105
1/110, 0/111
2.89 (0.12 to 71.75)
2.67 (0.11 to 66.34)
0.49 (0.04 to 5.49)
1/110, 0/105
1/110, 0/97
1/110, 2/109
1/110, 0/109
0/105, 0/111
0/105, 0/105
0/105, 0/97
0/105, 2/109
0/105, 0/109
7/3251, 8/3266
0/111, 2/109
2/1596, 2/1588
3/2708, 5/2699
4/1528, 0/1529
0/111, 0/109
1/110, 1/110
1/110, 0/105
1/110, 0/111
1/110, 0/105
1/110, 0/97
1/110, 2/109
1/110, 0/109
0/105, 0/111
0/105, 0/97
0/105, 2/109
0/105, 0/109
0/97, 0/111
0/97, 2/109
0/97, 0/109
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 110 Symptomatic PE [1/4] (primary prevention of VTE).
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Apixaban (10 mg bd) vs. apixaban (10 mg od)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg bd) vs. warfarin variable
APROPOS162
Apixaban (10 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg od) vs. warfarin variable
APROPOS162
Apixaban (2.5 mg bd) vs. LMWH (standard dose)
ADOPT188
Apixaban (2.5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
ADVANCE-1171
Apixaban (2.5 mg bd) vs. LMWH pre-op (standard dose)
ADVANCE-3176
ADVANCE-2178
Apixaban (2.5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg od)
APROPOS162
Apixaban (20 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (20 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (20 mg od) vs. warfarin variable
APROPOS162
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (5 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg od) vs. warfarin variable
APROPOS162
2.89 (0.12 to 71.75)
3.05 (0.12 to 75.81)
2.89 (0.12 to 71.75)
2.67 (0.11 to 66.34)
0.49 (0.04 to 5.49)
3.00 (0.12 to 74.45)
(Excluded)
(Excluded)
(Excluded)
0.20 (0.01 to 4.30)
(Excluded)
0.88 (0.32 to 2.43)
0.19 (0.01 to 4.06)
0.99 (0.14 to 7.07)
0.60 (0.14 to 2.50)
9.03 (0.49 to 167.86)
(Excluded)
1.00 (0.06 to 16.19)
2.89 (0.12 to 71.75)
3.05 (0.12 to 75.81)
2.89 (0.12 to 71.75)
2.67 (0.11 to 66.34)
0.49 (0.04 to 5.49)
3.00 (0.12 to 74.45)
(Excluded)
(Excluded)
0.20 (0.01 to 4.30)
(Excluded)
(Excluded)
0.22 (0.01 to 4.65)
(Excluded)
OR (95% CI)
1/110, 0/105
1/110, 0/111
1/110, 0/105
1/110, 0/97
1/110, 2/109
1/110, 0/109
0/105, 0/111
0/105, 0/105
0/105, 0/97
0/105, 2/109
0/105, 0/109
7/3251, 8/3266
0/111, 2/109
2/1596, 2/1588
3/2708, 5/2699
4/1528, 0/1529
0/111, 0/109
1/110, 1/110
1/110, 0/105
1/110, 0/111
1/110, 0/105
1/110, 0/97
1/110, 2/109
1/110, 0/109
0/105, 0/111
0/105, 0/97
0/105, 2/109
0/105, 0/109
0/97, 0/111
0/97, 2/109
0/97, 0/109
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 111 Symptomatic PE [2/4] (primary prevention of VTE). (continued )
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Betrixaban (15 mg bd) vs. LMWH post-op (standard dose)
EXPERT168
Betrixaban (40 mg bd) vs. betrixaban (15 mg bd)
EXPERT168
Betrixaban (40 mg bd) vs. LMWH post-op (standard dose)
EXPERT168
Dabigatran (110 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Dabigatran (150 mg od) vs. dabigatran (110 mg od)
VTE-DABIG-PLAC-JAPAN175
Dabigatran (150 mg od) vs. LMWH post-op (standard dose)
RE-MOBILISE167
Dabigatran (150 mg od) vs. LMWH pre-op (standard dose)
RE-MODEL161
RE-NOVATE160
Dabigatran (150 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. dabigatran (110 mg od)
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. dabigatran (150 mg od)
RE-MOBILISE167
RE-MODEL161
RE-NOVATE160
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. LMWH post-op (standard dose)
RE-MOBILISE167
Dabigatran (220 mg od) vs. LMWH pre-op (standard dose)
RE-MODEL161
RE-NOVATE160
RE-NOVATE II183,189
Dabigatran (220 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Edoxaban (15 mg od) vs. edoxaban (5 mg od)
STARS J-1172,180
Edoxaban (15 mg od) vs. placebo
STARS J-1172,180
Edoxaban (30 mg od) vs. edoxaban (15 mg od)
STARS J-1172,180
Edoxaban (30 mg od) vs. edoxaban (5 mg od)
STARS J-1172,180
Edoxaban (30 mg od) vs. LMWH (enoxaparin 20 mg bd)
STARS E-3182
STARS J-4181,193
STARS J-V179
Edoxaban (30 mg od) vs. placebo
STARS J-1172,180
Edoxaban (5 mg od) vs. placebo
STARS J-1172,180
Edoxaban (60 mg od) vs. edoxaban (15 mg od)
STARS J-1172,180
Edoxaban (60 mg od) vs. edoxaban (30 mg od)
STARS J-1172,180
Edoxaban (60 mg od) vs. edoxaban (5 mg od)
STARS J-1172,180
Edoxaban (60 mg od) vs. placebo
STARS J-1172,180
1.75 (0.07 to 43.93)
1.08 (0.07 to 17.60)
1.88 (0.07 to 47.37)
(Excluded)
(Excluded)
0.07 (0.00 to 1.15)
0.98 (0.06 to 15.77)
0.33 (0.03 to 3.16)
(Excluded)
(Excluded)
18.51 (1.07 to 321.39)
0.34 (0.01 to 8.44)
5.10 (0.60 to 43.74)
(Excluded)
1.22 (0.44 to 3.38)
0.34 (0.01 to 8.31)
1.68 (0.40 to 7.03)
0.50 (0.04 to 5.47)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
OR (95% CI)
1/70, 0/40
1/65, 1/70
1/65, 0/40
0/133, 0/124
0/126, 0/133
0/649, 7/643
1/696, 1/685
1/1156, 3/1142
0/126, 0/124
0/129, 0/133
8/604, 0/649
0/675, 1/696
5/1137, 1/1156
0/129, 0/126
8/604, 7/643
0/675, 1/685
5/1137, 3/1142
1/1001, 2/992
0/129, 0/124
0/92, 0/88
0/92, 0/89
0/88, 0/92
0/88, 0/88
0/299, 0/295
0/46, 0/27
0/255, 0/248
0/88, 0/89
0/88, 0/89
0/88, 0/92
0/88, 0/88
0/88, 0/88
0/88, 0/89
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 111 Symptomatic PE [2/4] (primary prevention of VTE).
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Apixaban (10 mg bd) vs. apixaban (10 mg od)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg bd) vs. warfarin variable
APROPOS162
Apixaban (10 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg od) vs. warfarin variable
APROPOS162
Apixaban (2.5 mg bd) vs. LMWH (standard dose)
ADOPT188
Apixaban (2.5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
ADVANCE-1171
Apixaban (2.5 mg bd) vs. LMWH pre-op (standard dose)
ADVANCE-3176
ADVANCE-2178
Apixaban (2.5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg od)
APROPOS162
Apixaban (20 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (20 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (20 mg od) vs. warfarin variable
APROPOS162
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (5 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg od) vs. warfarin variable
APROPOS162
2.89 (0.12 to 71.75)
3.05 (0.12 to 75.81)
2.89 (0.12 to 71.75)
2.67 (0.11 to 66.34)
0.49 (0.04 to 5.49)
3.00 (0.12 to 74.45)
(Excluded)
(Excluded)
(Excluded)
0.20 (0.01 to 4.30)
(Excluded)
0.88 (0.32 to 2.43)
0.19 (0.01 to 4.06)
0.99 (0.14 to 7.07)
0.60 (0.14 to 2.50)
9.03 (0.49 to 167.86)
(Excluded)
1.00 (0.06 to 16.19)
2.89 (0.12 to 71.75)
3.05 (0.12 to 75.81)
2.89 (0.12 to 71.75)
2.67 (0.11 to 66.34)
0.49 (0.04 to 5.49)
3.00 (0.12 to 74.45)
(Excluded)
(Excluded)
0.20 (0.01 to 4.30)
(Excluded)
(Excluded)
0.22 (0.01 to 4.65)
(Excluded)
OR (95% CI)
1/110, 0/105
1/110, 0/111
1/110, 0/105
1/110, 0/97
1/110, 2/109
1/110, 0/109
0/105, 0/111
0/105, 0/105
0/105, 0/97
0/105, 2/109
0/105, 0/109
7/3251, 8/3266
0/111, 2/109
2/1596, 2/1588
3/2708, 5/2699
4/1528, 0/1529
0/111, 0/109
1/110, 1/110
1/110, 0/105
1/110, 0/111
1/110, 0/105
1/110, 0/97
1/110, 2/109
1/110, 0/109
0/105, 0/111
0/105, 0/97
0/105, 2/109
0/105, 0/109
0/97, 0/111
0/97, 2/109
0/97, 0/109
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 112 Symptomatic PE [3/4] (primary prevention of VTE). (continued )
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Placebo vs. LMWH (enoxaparin 20 mg bd)
VTE-DABIG-PLAC-JAPAN175
Placebovs. LMWH (nadroparin 3800 IU anti-Xa od)
PROTECHT170
Rivaroxaban (10 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (10 mg bd) vs. LMWH pre-op (standard dose)
ODiXa-HIP194
Rivaroxaban (10 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (10 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (10 mg od) vs. LMWH (standard dose)
MAGELLAN184,191
Rivaroxaban (10 mg od) vs. LMWH post-op (standard dose)
RECORD 4173
Rivaroxaban (10 mg od) vs. LMWH pre-op (standard dose)
RECORD 2166
RECORD 3163
ODiXa-OD.HIP158
VTE-RIVAROX-LMWH-BRAZIL164
Rivaroxaban (10 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (2.5 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (2.5 mg bd) vs. LMWH pre-op (standard dose)
ODiXa-HIP2159
Rivaroxaban (20 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. LMWH pre-op (standard dose)
ODiXa-HIP2159
Rivaroxaban (20 mg bd) vs. rivaroxaban (10 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (20 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (20 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (20 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Rivaroxaban (20 mg od) vs. rivaroxaban (10 mg od)
ODiXa-OD.HIP158
Rivaroxaban (20 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
(Excluded)
2.03 (0.41 to 10.09)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
0.18 (0.01 to 3.91)
(Excluded)
0.74 (0.33 to 1.66)
2.97 (0.12 to 72.88)
0.20 (0.02 to 1.72)
0.12 (0.01 to 2.19)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
0.19 (0.01 to 4.11)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
OR (95% CI)
0/83, 0/83
3/381, 3/769
0/60, 0/70
0/101, 0/106
0/60, 0/63
0/101, 0/104
0/60, 2/57
0/101, 0/109
10/2967, 14/3057
1/1526, 0/1508
1/864, 5/869
0/824, 4/878
0/113, 0/107
0/33, 0/32
0/113, 0/94
0/63, 0/70
0/104, 0/106
0/57, 0/70
0/99, 0/106
0/57, 0/60
0/99, 0/101
0/57, 0/63
0/99, 0/104
0/57, 2/57
0/99, 0/109
0/106, 0/107
0/106, 0/113
0/106, 0/94
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 112 Symptomatic PE [3/4] (primary prevention of VTE).
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Apixaban (10 mg bd) vs. apixaban (10 mg od)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg bd) vs. warfarin variable
APROPOS162
Apixaban (10 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg od) vs. warfarin variable
APROPOS162
Apixaban (2.5mg bd) vs. LMWH (standard dose)
ADOPT188
Apixaban (2.5  mg bd) vs. LMWH post-op (standard dose)
APROPOS162
ADVANCE-1171
Apixaban (2.5 mg bd) vs. LMWH pre-op (standard dose)
ADVANCE-3176
ADVANCE-2178
Apixaban (2.5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg od)
APROPOS162
Apixaban (20 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (20 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (20 mg od) vs. warfarin variable
APROPOS162
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (5 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg od) vs. warfarin variable
APROPOS162
2.89 (0.12 to 71.75)
3.05 (0.12 to 75.81)
2.89 (0.12 to 71.75)
2.67 (0.11 to 66.34)
0.49 (0.04 to 5.49)
3.00 (0.12 to 74.45)
(Excluded)
(Excluded)
(Excluded)
0.20 (0.01 to 4.30)
(Excluded)
0.88 (0.32 to 2.43)
0.19 (0.01 to 4.06)
0.99 (0.14 to 7.07)
0.60 (0.14 to 2.50)
9.03 (0.49 to 167.86)
(Excluded)
1.00 (0.06 to 16.19)
2.89 (0.12 to 71.75)
3.05 (0.12 to 75.81)
2.89 (0.12 to 71.75)
2.67 (0.11 to 66.34)
0.49 (0.04 to 5.49)
3.00 (0.12 to 74.45)
(Excluded)
(Excluded)
0.20 (0.01 to 4.30)
(Excluded)
(Excluded)
0.22 (0.01 to 4.65)
(Excluded)
OR (95% CI)
1/110, 0/105
1/110, 0/111
1/110, 0/105
1/110, 0/97
1/110, 2/109
1/110, 0/109
0/105, 0/111
0/105, 0/105
0/105, 0/97
0/105, 2/109
0/105, 0/109
7/3251, 8/3266
0/111, 2/109
2/1596, 2/1588
3/2708, 5/2699
4/1528, 0/1529
0/111, 0/109
1/110, 1/110
1/110, 0/105
1/110, 0/111
1/110, 0/105
1/110, 0/97
1/110, 2/109
1/110, 0/109
0/105, 0/111
0/105, 0/97
0/105, 2/109
0/105, 0/109
0/97, 0/111
0/97, 2/109
0/97, 0/109
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 113 Symptomatic PE [4/4] (primary prevention of VTE). (continued )
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Rivaroxaban (30 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. LMWH pre-op (standard dose)
ODiXa-HIP194
Rivaroxaban (30 mg bd) vs. rivaroxaban (10 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (30 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (30 mg bd) vs. rivaroxaban (20 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (30 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (30 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Rivaroxaban (30 mg od) vs. rivaroxaban (10 mg od)
ODiXa-OD.HIP158
Rivaroxaban (30 mg od) vs. rivaroxaban (20 mg od)
ODiXa-OD.HIP158
Rivaroxaban (30 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (10 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (20 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (30 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (5 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (5 mg bd) vs. LMWH pre-op (standard dose)
ODiXa-HIP194
Rivaroxaban (5 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (5 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Warfarin (INR 2–3) vs. LMWH post-op (standard dose)
VTE-VKA-LMWH-US-4156
VTE-VKA-LMWH-US-2154
VTE-VKA-LMWH-US-3153
VTE-VKA-LMWH-US-3153
Warfarin variable vs. LMWH post-op (standard dose)
APROPOS162
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
0.19 (0.01 to 3.97)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
6.35 (0.30 to 135.01)
(Excluded)
5.72 (0.27 to 121.72)
(Excluded)
(Excluded)
2.97 (0.12 to 73.31)
0.81 (0.38 to 1.74)
(Excluded)
(Excluded)
0.20 (0.01 to 4.14)
OR (95% CI)
0/59, 0/70
0/29, 0/106
0/59, 0/60
0/29, 0/101
0/59, 0/63
0/29, 0/104
0/59, 0/57
0/29, 0/99
0/59, 2/57
0/29, 0/109
0/104, 0/107
0/104, 0/113
0/104, 0/106
0/104, 0/94
0/94, 0/107
0/94, 0/113
0/94, 0/106
0/94, 0/104
0/94, 0/94
2/57, 0/70
0/109, 0/106
2/57, 0/63
0/109, 0/104
0/94, 0/107
1/176, 0/173
12/1495, 15/1516
0/489, 0/496
0/489, 0/487
0/109, 2/109
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 113 Symptomatic PE [4/4] (primary prevention of VTE).
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Apixaban (10 mg bd) vs. apixaban (10 mg od)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg bd) vs. warfarin variable
APROPOS162
Apixaban (10 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg od)
APROPOS162
VTE-APIX-PLACEBO-USACAN190
Apixaban (10 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg od) vs. placebo
VTE-APIX-PLACEBO-USACAN190
Apixaban (10 mg od) vs. warfarin variable
APROPOS162
Apixaban (2.5 mg bd) vs. LMWH (standard dose)
ADOPT188
Apixaban (2.5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
ADVANCE-1171
Apixaban (2.5 mg bd) vs. LMWH pre-op (standard dose)
ADVANCE-3176
Apixaban (2.5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg od)
APROPOS162
VTE-APIX-PLACEBO-USACAN190
Apixaban (20 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg od)
APROPOS162
VTE-APIX-PLACEBO-USACAN190
Apixaban (20 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (20 mg od) vs. placebo
VTE-APIX-PLACEBO-USACAN190
Apixaban (20 mg od) vs. warfarin variable
APROPOS162
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (5 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg od) vs. placebo
VTE-APIX-PLACEBO-USACAN190
Apixaban (5 mg od) vs. warfarin variable
APROPOS162
0.47 (0.04 to 5.29)
1.01 (0.06 to 16.34)
2.89 (0.12 to 71.75)
2.67 (0.11 to 66.34)
0.32 (0.03 to 3.17)
0.99 (0.06 to 16.04)
2.14 (0.19 to 23.91)
5.10 (0.24 to 107.45)
4.71 (0.22 to 99.35)
(Excluded)
0.69 (0.11 to 4.19)
0.13 (0.01 to 2.60)
2.10 (0.19 to 23.48)
0.50 (0.25 to 1.00)
0.32 (0.03 to 3.14)
1.46 (0.72 to 2.97)
0.40 (0.12 to 1.27)
0.98 (0.06 to 15.90)
1.00 (0.06 to 16.19)
0.47 (0.04 to 5.29)
(Excluded)
1.01 (0.06 to 16.34)
2.89 (0.12 to 71.75)
2.67 (0.11 to 66.34)
(Excluded)
0.32 (0.03 to 3.17)
0.12 (0.01 to 2.36)
0.99 (0.06 to 16.04)
0.35 (0.01 to 8.67)
(Excluded)
0.14 (0.01 to 2.83)
0.34 (0.01 to 8.51)
0.38 (0.02 to 9.38)
0.16 (0.01 to 3.06)
0.12 (0.01 to 2.36)
0.37 (0.01 to 9.21)
OR (95% CI)
1/110, 2/105
1/110, 1/111
1/110, 0/105
1/110, 0/97
1/110, 3/109
1/110, 1/109
2/105, 1/111
2/105, 0/105
2/105, 0/97
0/29, 0/32
2/105, 3/109
0/29, 3/29
2/105, 1/109
12/3255, 24/3273
1/111, 3/109
19/1596, 13/1588
4/2708, 10/2699
1/111, 1/109
1/110, 1/110
1/110, 2/105
0/32, 0/29
1/110, 1/111
1/110, 0/105
1/110, 0/97
0/32, 0/32
1/110, 3/109
0/32, 3/29
1/110, 1/109
0/105, 1/111
0/105, 0/97
0/105, 3/109
0/105, 1/109
0/97, 1/111
0/97, 3/109
0/32, 3/29
0/97, 1/109
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 114 Symptomatic VTE [1/3] (primary prevention of VTE).
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Rivaroxaban (10 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (10 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Rivaroxaban (10 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
Rivaroxaban (10 mg od) vs. LMWH (standard dose)
MAGELLAN184,191
Rivaroxaban (10 mg od) vs. LMWH post-op (standard dose)
RECORD 4173
Rivaroxaban (10 mg od) vs. LMWH pre-op (standard dose)
RECORD 2166
ODiXa-OD.HIP158
RECORD 1165
RECORD 3163
Rivaroxaban (10 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (2.5 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. rivaroxaban (10 mg bd)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
Rivaroxaban (20 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Rivaroxaban (20 mg od) vs. rivaroxaban (10 mg od)
ODiXa-OD.HIP158
Rivaroxaban (20 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (30 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Rivaroxaban (30 mg od) vs. rivaroxaban (10 mg od)
ODiXa-OD.HIP158
Rivaroxaban (30 mg od) vs. rivaroxaban (20 mg od)
ODiXa-OD.HIP158
Rivaroxaban (30 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (10 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (20 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (30 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (5 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (5 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Rivaroxaban (5 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
0.23 (0.01 to 4.81)
0.34 (0.01 to 8.62)
0.18 (0.01 to 3.91)
1.50 (0.72 to 3.13)
0.66 (0.33 to 1.30)
0.23 (0.08 to 0.70)
0.31 (0.01 to 7.76)
0.45 (0.18 to 1.12)
0.51 (0.26 to 0.99)
(Excluded)
0.55 (0.05 to 6.20)
0.61 (0.05 to 6.87)
3.21 (0.13 to 80.49)
1.11 (0.07 to 18.12)
0.49 (0.04 to 5.57)
0.33 (0.01 to 8.28)
(Excluded)
(Excluded)
0.34 (0.01 to 8.43)
(Excluded)
(Excluded)
(Excluded)
0.38 (0.02 to 9.33)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
1.24 (0.17 to 9.06)
2.25 (0.20 to 25.55)
0.38 (0.02 to 9.33)
OR (95% CI)
0/60, 2/70
0/60, 1/63
0/60, 2/57
18/3997, 12/4001
14/965, 21/959
4/864, 17/869
0/113, 1/107
7/1595, 15/1558
13/824, 27/878
0/113, 0/94
1/63, 2/70
1/57, 2/70
1/57, 0/60
1/57, 1/63
1/57, 2/57
0/106, 1/107
0/106, 0/113
0/106, 0/94
0/104, 1/107
0/104, 0/113
0/104, 0/106
0/104, 0/94
0/94, 1/107
0/94, 0/113
0/94, 0/106
0/94, 0/104
0/94, 0/94
2/57, 2/70
2/57, 1/63
0/94, 1/107
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 115 Symptomatic VTE [2/3] (primary prevention of VTE).
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Betrixaban (15 mg bd) vs. LMWH post-op (standard dose)
EXPERT168
Betrixaban (40 mg bd) vs. betrixaban (15 mg bd)
EXPERT168
Betrixaban (40 mg bd) vs. LMWH post-op (standard dose)
EXPERT168
Dabigatran (110 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Dabigatran (150 mg od) vs. dabigatran (110 mg od)
VTE-DABIG-PLAC-JAPAN175
Dabigatran (150 mg od) vs. LMWH post-op (standard dose)
RE-MOBILISE167
Dabigatran (150 mg od) vs. LMWH pre-op (standard dose)
RE-MODEL161
RE-NOVATE160
Dabigatran (150 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. dabigatran (110 mg od)
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. dabigatran (150 mg od)
RE-MOBILISE167
RE-MODEL161
RE-NOVATE160
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. LMWH post-op (standard dose)
RE-MOBILISE167
Dabigatran (220 mg od) vs. LMWH pre-op (standard dose)
RE-MODEL161
RE-NOVATE160
RE-NOVATE II183,189
Dabigatran (220 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
LMWH pre-op (standard dose) vs. LMWH post-op (standard dose)
VTE-VKA-LMWH-US-3153
Placebo vs. LMWH (enoxaparin 20 mg bd)
VTE-DABIG-PLAC-JAPAN175
Placebo vs. LMWH (nadroparin 3800 IU anti-Xa od)
PROTECHT170
Warfarin (INR 2–3) vs. LMWH post-op (standard dose)
VTE-VKA-LMWH-CANADA152
VTE-VKA-LMWH-US-3153
VTE-VKA-LMWH-US-2154
Warfarin (INR 2–3) vs. LMWH pre-op (standard dose)
VTE-VKA-LMWH-US-3153
Warfarin variable vs. LMWH post-op (standard dose)
APROPOS162
1.15 (0.10 to 13.06)
0.53 (0.05 to 6.00)
0.61 (0.04 to 10.02)
0.46 (0.04 to 5.16)
2.13 (0.19 to 23.77)
0.82 (0.35 to 1.92)
0.43 (0.13 to 1.42)
2.48 (0.78 to 7.94)
0.98 (0.14 to 7.10)
1.03 (0.06 to 16.66)
1.63 (0.73 to 3.65)
0.26 (0.03 to 2.30)
1.12 (0.47 to 2.65)
0.48 (0.04 to 5.41)
1.34 (0.62 to 2.88)
0.11 (0.01 to 0.88)
2.78 (0.88 to 8.75)
0.16 (0.02 to 1.37)
0.48 (0.04 to 5.32)
0.49 (0.17 to 1.45)
(Excluded)
2.05 (0.88 to 4.77)
0.32 (0.03 to 3.12)
1.51 (0.67 to 3.42)
1.03 (0.71 to 1.51)
3.08 (1.11 to 8.58)
0.33 (0.03 to 3.20)
OR (95% CI)
2/70, 1/40
1/65, 2/70
1/65, 1/40
1/133, 2/124
2/126, 1/133
10/649, 12/643
4/696, 9/685
10/1156, 4/1142
2/126, 2/124
1/129, 1/133
15/604, 10/649
1/675, 4/696
11/1137, 10/1156
1/129, 2/126
15/604, 12/643
1/675, 9/685
11/1137, 4/1142
1/1001, 6/992
1/129, 2/124
5/337, 10/336
0/83, 0/83
11/381, 11/769
1/211, 3/206
15/338, 10/336
56/1495, 55/1516
15/338, 5/337
1/109, 3/109
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 116 Symptomatic VTE [3/3] (primary prevention of VTE).
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Apixaban (10 mg bd) vs. apixaban (10 mg od)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg bd) vs. warfarin variable
APROPOS162
Apixaban (10 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg od) vs. warfarin variable
APROPOS162
Apixaban (2.5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
ADVANCE-1171
Apixaban (2.5 mg bd) vs. LMWH pre-op (standard dose)
ADVANCE-3176
ADVANCE-2178
Apixaban (2.5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg od)
APROPOS162
Apixaban (20 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (20 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (20 mg od) vs. warfarin variable
APROPOS162
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (5 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg od) vs. warfarin variable
APROPOS162
Dabigatran (220 mg od) vs. LMWH pre-op (standard dose)
RE-NOVATE II183,189
Rivaroxaban (10 mg od) vs. LMWH post-op (standard dose)
RECORD 4173
RECORD 4173
RECORD 4173
RECORD 4173
Rivaroxaban (10 mg od) vs. LMWH pre-op (standard dose)
RECORD 1165
RECORD 1165
RECORD 1165
RECORD 1165
RECORD 3163
Warfarin variable vs. LMWH post-op (standard dose)
APROPOS162
(Excluded)
0.20 (0.01 to 4.17)
(Excluded)
0.33 (0.01 to 8.09)
(Excluded)
0.33 (0.01 to 8.09)
0.20 (0.01 to 4.12)
(Excluded)
0.32 (0.01 to 7.98)
(Excluded)
0.32 (0.01 to 7.98)
4.90 (0.23 to 102.96)
0.25 (0.03 to 2.22)
1.66 (0.40 to 6.95)
1.00 (0.06 to 16.08)
1.97 (0.18 to 22.00)
(Excluded)
(Excluded)
0.20 (0.01 to 4.23)
(Excluded)
0.33 (0.01 to 8.19)
(Excluded)
0.33 (0.01 to 8.19)
0.20 (0.01 to 4.17)
0.33 (0.01 to 8.09)
(Excluded)
0.33 (0.01 to 8.09)
0.51 (0.05 to 5.65)
2.98 (0.12 to 73.74)
1.00 (0.06 to 16.14)
0.99 (0.06 to 15.90)
0.33 (0.03 to 3.17)
0.33 (0.03 to 3.17)
0.20 (0.02 to 1.69)
0.20 (0.02 to 1.69)
0.50 (0.13 to 2.01)
1.18 (0.39 to 3.50)
0.50 (0.13 to 2.01)
1.18 (0.39 to 3.50)
0.51 (0.05 to 5.60)
2.98 (0.12 to 73.74)
OR (95% CI)
0/153, 0/155
0/153, 2/154
0/153, 0/153
0/153, 1/151
0/153, 0/149
0/153, 1/151
0/155, 2/154
0/155, 0/153
0/155, 1/151
0/155, 0/149
0/155, 1/151
2/154, 0/149
1/1596, 4/1588
5/2673, 3/2659
1/1501, 1/1508
2/154, 1/151
0/151, 0/153
0/151, 0/155
0/151, 2/154
0/151, 0/153
0/151, 1/151
0/151, 0/149
0/151, 1/151
0/153, 2/154
0/153, 1/151
0/153, 0/149
0/153, 1/151
1/151, 2/154
1/151, 0/149
1/151, 1/151
1/1010, 1/1003
1/1526, 3/1508
1/1526, 3/1508
1/1526, 5/1508
1/1526, 5/1508
3/2209, 6/2224
7/2209, 6/2224
3/2209, 6/2224
7/2209, 6/2224
1/1220, 2/1239
1/151, 0/149
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 117 Myocardial infarction (primary prevention of VTE).
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Apixaban (10 mg bd) vs. apixaban (10 mg od)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg bd) vs. warfarin variable
APROPOS162
Apixaban (10 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg od)
APROPOS162
VTE-APIX-PLACEBO-USACAN190
Apixaban (10 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg od) vs. placebo
VTE-APIX-PLACEBO-USACAN190
Apixaban (10 mg od) vs. warfarin variable
APROPOS162
Apixaban (2.5 mg bd) vs. LMWH (standard dose)
ADOPT188
Apixaban (2.5 mg bd) vs. LMWH post-op (standard dose)
ADVANCE-1171
APROPOS162
Apixaban (2.5 mg bd) vs. LMWH pre-op (standard dose)
ADVANCE-3176
ADVANCE-2178
Apixaban (2.5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg od)
APROPOS162
VTE-APIX-PLACEBO-USACAN190
Apixaban (20 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg od)
APROPOS162
VTE-APIX-PLACEBO-USACAN190
Apixaban (20 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (20 mg od) vs. placebo
VTE-APIX-PLACEBO-USACAN190
Apixaban (20 mg od) vs. warfarin variable
APROPOS162
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (5 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg od) vs. placebo
VTE-APIX-PLACEBO-USACAN190
Apixaban (5 mg od) vs. warfarin variable
APROPOS162
4.13 (0.46 to 37.42)
9.30 (0.50 to 174.25)
1.00 (0.25 to 4.07)
0.99 (0.24 to 4.02)
9.00 (0.48 to 168.64)
9.12 (0.49 to 170.88)
3.00 (0.12 to 74.22)
0.24 (0.03 to 2.19)
0.24 (0.03 to 2.16)
(Excluded)
2.90 (0.12 to 71.82)
0.32 (0.01 to 8.24)
2.94 (0.12 to 72.78)
2.53 (0.98 to 6.54)
0.49 (0.24 to 1.02)
(Excluded)
1.22 (0.65 to 2.28)
0.64 (0.28 to 1.49)
(Excluded)
1.28 (0.34 to 4.84)
5.27 (0.61 to 45.68)
4.84 (0.22 to 105.04)
11.60 (0.64 to 211.65)
1.28 (0.34 to 4.84)
1.26 (0.33 to 4.78)
5.33 (0.25 to 115.50)
11.23 (0.62 to 204.83)
1.87 (0.16 to 21.74)
11.38 (0.62 to 207.56)
9.30 (0.50 to 174.25)
0.99 (0.24 to 4.02)
9.00 (0.48 to 168.64)
9.12 (0.49 to 170.88)
9.43 (0.50 to 176.63)
9.12 (0.49 to 170.93)
0.29 (0.01 to 7.46)
9.24 (0.49 to 173.21)
OR (95% CI)
4/153, 1/155
4/153, 0/154
4/153, 4/153
4/153, 4/151
4/153, 0/149
4/153, 0/151
1/155, 0/154
1/155, 4/153
1/155, 4/151
0/29, 0/32
1/155, 0/149
0/29, 1/29
1/155, 0/151
15/3184, 6/3217
11/1596, 22/1588
0/154, 0/149
22/2673, 18/2659
9/1501, 14/1508
0/154, 0/151
5/151, 4/153
5/151, 1/155
2/32, 0/29
5/151, 0/154
5/151, 4/153
5/151, 4/151
2/32, 0/32
5/151, 0/149
2/32, 1/29
5/151, 0/151
4/153, 0/154
4/153, 4/151
4/153, 0/149
4/153, 0/151
4/151, 0/154
4/151, 0/149
0/32, 1/29
4/151, 0/151
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 118 Major bleeding [1/4] (primary prevention of VTE).
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Betrixaban (15 mg bd) vs. LMWH post-op (standard dose)
EXPERT168
Betrixaban (40 mg bd) vs. betrixaban (15 mg bd)
EXPERT168
Betrixaban (40 mg bd) vs. LMWH post-op (standard dose)
EXPERT168
Dabigatran (110 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Dabigatran (150 mg od) vs. dabigatran (110 mg od)
VTE-DABIG-PLAC-JAPAN175
Dabigatran (150 mg od) vs. LMWH post-op (standard dose)
RE-MOBILISE167
Dabigatran (150 mg od) vs. LMWH pre-op (standard dose)
RE-MODEL161
RE-NOVATE160
Dabigatran (150 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. dabigatran (110 mg od)
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. dabigatran (150 mg od)
RE-MOBILISE167
RE-MODEL161
RE-NOVATE160
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. LMWH post-op (standard dose)
RE-MOBILISE167
Dabigatran (220 mg od) vs. LMWH pre-op (standard dose)
RE-MODEL161
RE-NOVATE160
RE-NOVATE II183,189
Dabigatran (220 mg od) vs. placebo
VTE-LMWH-PLAC-JAPAN186
Edoxaban (15 mg od) vs. edoxaban (5 mg od)
STARS J-1172,180
Edoxaban (15 mg od) vs. LMWH post-op (standard dose)
VTE-EDOX-LMWH-MULTI177
Edoxaban (15mg od) vs. placebo
STARS J-1172,180
Edoxaban (30 mg od) vs. edoxaban (15 mg od)
VTE-EDOX-LMWH-MULTI177
STARS J-1172,180
Edoxaban (30 mg od) vs. edoxaban (5 mg od)
STARS J-1172,180
Edoxaban (30 mg od) vs. LMWH (enoxaparin 20 mg bd)
STARS E-3182
STARS J-4181,193
STARS J-V179
Edoxaban (30 mg od) vs. LMWH post-op (standard dose)
VTE-EDOX-LMWH-MULTI177
Edoxaban (30 mg od) vs. placebo
STARS J-1172,180
Edoxaban (5 mg od) vs. placebo
STARS J-1172,180
Edoxaban (60 mg od) vs. edoxaban (15 mg od)
STARS J-1172,180
VTE-EDOX-LMWH-MULTI177
Edoxaban (60 mg od) vs. edoxaban (30 mg od)
STARS J-1172,180
VTE-EDOX-LMWH-MULTI177
Edoxaban (60 mg od) vs. edoxaban (5 mg od)
STARS J-1172,180
Edoxaban (60 mg od) vs. LMWH post-op (standard dose)
VTE-EDOX-LMWH-MULTI177
Edoxaban (60 mg od) vs. placebo
STARS J-1172,180
0.16 (0.01 to 4.01)
(Excluded)
0.17 (0.01 to 4.20)
0.93 (0.06 to 15.06)
0.35 (0.01 to 8.65)
0.41 (0.14 to 1.17)
0.99 (0.39 to 2.50)
0.82 (0.41 to 1.64)
0.33 (0.01 to 8.07)
3.14 (0.32 to 30.61)
1.02 (0.29 to 3.52)
1.15 (0.47 to 2.85)
1.57 (0.81 to 3.02)
7.00 (0.36 to 136.91)
0.42 (0.15 to 1.19)
1.14 (0.46 to 2.82)
1.29 (0.69 to 2.41)
1.55 (0.67 to 3.60)
2.93 (0.30 to 28.54)
(Excluded)
2.70 (0.11 to 66.78)
(Excluded)
1.13 (0.07 to 18.21)
(Excluded)
(Excluded)
3.69 (0.41 to 33.17)
0.48 (0.03 to 8.00)
0.33 (0.07 to 1.63)
3.05 (0.12 to 75.47)
(Excluded)
(Excluded)
3.03 (0.12 to 75.19)
1.04 (0.06 to 16.72)
2.94 (0.12 to 73.08)
0.92 (0.06 to 14.80)
2.94 (0.12 to 73.08)
2.80 (0.11 to 69.32)
2.91 (0.12 to 72.38)
OR (95% CI)
0/88, 1/43
0/84, 0/88
0/84, 1/43
1/133, 1/124
0/126, 1/133
5/871, 12/868
9/703, 9/694
15/1163, 18/1154
0/126, 1/124
3/129, 1/133
5/857, 5/871
10/679, 9/703
23/1146, 15/1163
3/129, 0/126
5/857, 12/868
10/679, 9/694
23/1146, 18/1154
14/1010, 9/1003
3/129, 1/124
0/106, 0/103
1/192, 0/172
0/106, 0/102
1/170, 1/192
0/103, 0/106
0/103, 0/103
4/364, 1/333
1/59, 1/29
2/303, 6/301
1/170, 0/172
0/103, 0/102
0/103, 0/102
1/106, 0/106
1/185, 1/192
1/106, 0/103
1/185, 1/170
1/106, 0/103
1/185, 0/172
1/106, 0/102
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 119 Major bleeding [2/4] (primary prevention of VTE).
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Edoxaban (90mg od) vs. Edoxaban (15 mg od)
VTE-EDOX-LMWH-MULTI177
Edoxaban (90mg od) vs. Edoxaban (30 mg od)
VTE-EDOX-LMWH-MULTI177
Edoxaban (90mg od) vs. Edoxaban (60 mg od)
VTE-EDOX-LMWH-MULTI177
Edoxaban (90mg od) vs. LMWH post-op (standard dose)
VTE-EDOX-LMWH-MULTI177
Placebo vs. LMWH (Enoxaparin 20 mg bd)
VTE-LMWH-PLAC-JAPAN186
Placebo vs. LMWH (Nadroparin 3800 IU anti-Xa od)
PROTECHT170
Placebo vs. LMWH (standard dose)
LIFENOX185
Placebo vs. LMWH post-op (standard dose)
VTE-LMWH-PLAC-CAN169
Rivaroxaban (10mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (10mg bd) vs. LMWH pre-op (standard dose)
ODiXa-HIP194
Rivaroxaban (10mg bd) vs. Rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (10mg bd) vs. Rivaroxaban (5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (10mg od) vs. LMWH (standard dose)
MAGELLAN184,191
Rivaroxaban (10mg od) vs. LMWH post-op (standard dose)
RECORD 4173
Rivaroxaban (10mg od) vs. LMWH pre-op (standard dose)
RECORD 1165
RECORD 3163
ODiXa-OD.HIP158
Rivaroxaban (10mg od) vs. Rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (2.5mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (2.5mg bd) vs. LMWH pre-op (standard dose)
ODiXa-HIP194
Rivaroxaban (20mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (20mg bd) vs. LMWH pre-op (standard dose)
ODiXa-HIP194
Rivaroxaban (20mg bd) vs. Rivaroxaban (10 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (20mg bd) vs. Rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (20mg bd) vs. Rivaroxaban (5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
2.18 (0.20 to 24.28)
1.93 (0.17 to 21.50)
2.10 (0.19 to 23.40)
4.91 (0.23 to 103.11)
(Excluded)
0.18 (0.01 to 3.30)
0.69 (0.32 to 1.49)
(Excluded)
1.01 (0.14 to 7.31)
1.50 (0.25 to 9.13)
1.96 (0.17 to 21.97)
3.02 (0.31 to 29.44)
5.05 (0.24 to 106.48)
1.02 (0.20 to 5.16)
2.89 (1.60 to 5.21)
2.48 (0.78 to 7.93)
3.03 (0.61 to 15.01)
1.19 (0.40 to 3.54)
0.36 (0.04 to 3.54)
0.30 (0.03 to 2.88)
0.52 (0.05 to 5.77)
0.50 (0.04 to 5.54)
1.61 (0.26 to 9.85)
3.05 (0.60 to 15.38)
1.59 (0.26 to 9.75)
2.03 (0.50 to 8.30)
3.13 (0.32 to 30.58)
6.14 (0.73 to 51.72)
7.51 (0.38 to 147.37)
2.08 (0.51 to 8.49)
OR (95% CI)
2/177, 1/192
2/177, 1/170
2/177, 1/185
2/177, 0/172
0/85, 0/85
0/381, 5/769
11/4136, 16/4171
0/111, 0/126
2/103, 2/104
3/133, 2/132
2/103, 1/100
3/133, 1/132
2/103, 0/102
3/133, 3/136
43/3997, 15/4001
10/1526, 4/1508
6/2209, 2/2224
7/1220, 6/1239
1/142, 3/157
1/142, 3/128
1/100, 2/104
1/132, 2/132
3/98, 2/104
6/134, 2/132
3/98, 2/103
6/134, 3/133
3/98, 1/100
6/134, 1/132
3/98, 0/102
6/134, 3/136
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 120 Major bleeding [3/4] (primary prevention of VTE).
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Rivaroxaban (20 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-HIP194
Rivaroxaban (20 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Rivaroxaban (20 mg od) vs. rivaroxaban (10 mg od)
ODiXa-OD.HIP158
Rivaroxaban (20 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (30 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. LMWH pre-op (standard dose)
ODiXa-HIP194
Rivaroxaban (30 mg bd) vs. rivaroxaban (10 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (30 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (30 mg bd) vs. rivaroxaban (20 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (30 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (30 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Rivaroxaban (30 mg od) vs. rivaroxaban (10 mg od)
ODiXa-OD.HIP158
Rivaroxaban (30 mg od) vs. rivaroxaban (20 mg od)
ODiXa-OD.HIP158
Rivaroxaban (30 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (10 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (20 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (30 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (5 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (5 mg bd) vs. LMWH pre-op (standard dose)
ODiXa-HIP194
Rivaroxaban (5 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
ODiXa-HIP194
Rivaroxaban (5 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Warfarin (INR 2–3) vs. LMWH post-op (standard dose)
VTE-VKA-LMWH-US-4156
VTE-VKA-LMWH-CANADA152
VTE-VKA-LMWH-US-3153
VTE-VKA-LMWH-US-2154
Warfarin (INR 2–3) vs. LMWH pre-op (standard dose)
VTE-VKA-LMWH-US-3153
VTE-VKA-LMWH-US153
Warfarin variable vs. LMWH post-op (standard dose)
APROPOS162
LMWH pre-op (standard dose) vs. LMWH post-op (standard dose)
VTE-VKA-LMWH-US-3153
2.08 (0.51 to 8.49)
2.32 (0.57 to 9.44)
6.36 (0.76 to 53.54)
1.88 (0.46 to 7.68)
4.16 (0.86 to 20.09)
3.71 (0.51 to 27.31)
4.12 (0.85 to 19.90)
2.48 (0.40 to 15.40)
8.08 (0.99 to 65.83)
7.49 (0.66 to 84.97)
2.59 (0.67 to 10.04)
1.22 (0.24 to 6.31)
17.69 (1.01 to 310.62)
2.53 (0.41 to 15.75)
2.66 (0.67 to 10.50)
7.31 (0.89 to 60.22)
1.15 (0.38 to 3.51)
2.16 (0.55 to 8.54)
2.76 (0.70 to 10.90)
7.59 (0.92 to 62.55)
1.19 (0.39 to 3.65)
1.04 (0.35 to 3.04)
2.24 (0.57 to 8.87)
0.20 (0.01 to 4.22)
1.47 (0.24 to 8.92)
0.32 (0.01 to 8.04)
2.95 (0.30 to 28.77)
1.23 (0.24 to 6.21)
0.42 (0.13 to 1.40)
0.86 (0.29 to 2.59)
0.67 (0.38 to 1.17)
0.45 (0.19 to 1.03)
0.48 (0.29 to 0.82)
0.64 (0.18 to 2.30)
(Excluded)
1.38 (0.86 to 2.22)
OR (95% CI)
6/134, 3/136
6/139, 3/157
6/139, 1/142
6/139, 3/128
8/106, 2/104
2/37, 2/132
8/106, 2/103
2/37, 3/133
8/106, 1/100
2/37, 1/132
8/106, 3/98
2/37, 6/134
8/106, 0/102
2/37, 3/136
7/142, 3/157
7/142, 1/142
7/142, 6/139
7/142, 3/128
7/137, 3/157
7/137, 1/142
7/137, 6/139
7/137, 7/142
7/137, 3/128
0/102, 2/104
3/136, 2/132
0/102, 1/100
3/136, 1/132
3/128, 3/157
4/176, 9/173
6/334, 7/336
22/489, 32/487
8/1495, 18/1516
22/489, 44/496
4/279, 6/271
0/151, 0/149
44/496, 32/487
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 121 Major bleeding [4/4] (primary prevention of VTE).
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Apixaban (10 mg od) vs. apixaban (5 mg od)
VTE-APIX-PLACEBO-USACAN190
Apixaban (10 mg od) vs. placebo
VTE-APIX-PLACEBO-USACAN190
Apixaban (2.5 mg bd) vs. LMWH (standard dose)
ADOPT188
Apixaban (2.5 mg bd) vs. LMWH post-op (standard dose)
ADVANCE-1171
Apixaban (2.5 mg bd) vs. LMWH pre-op (standard dose)
ADVANCE-2178
Apixaban (20 mg od) vs. apixaban (10 mg od)
VTE-APIX-PLACEBO-USACAN190
Apixaban (20 mg od) vs. apixaban (5 mg od)
VTE-APIX-PLACEBO-USACAN190
Apixaban (20 mg od) vs. placebo
VTE-APIX-PLACEBO-USACAN190
Apixaban (5 mg od) vs. placebo
VTE-APIX-PLACEBO-USACAN190
Edoxaban (15 mg od) vs. edoxaban (5 mg od)
STARS J-1172,180
Edoxaban (15 mg od) vs. LMWH (enoxaparin 20 mg bd)
STARS J-2174
Edoxaban (15 mg od) vs. LMWH post-op (standard dose)
VTE-EDOX-LMWH-MULTI177
Edoxaban (15 mg od) vs. placebo
STARS J-1172,180
Edoxaban (30 mg od) vs. edoxaban (15 mg od)
STARS J-1172,180
VTE-EDOX-LMWH-MULTI177
STARS J-2174
Edoxaban (30 mg od) vs. edoxaban (5 mg od)
STARS J-1172,180
Edoxaban (30 mg od) vs. LMWH (enoxaparin 20 mg bd)
STARS E-3182
STARS J-4181,183
STARS J-V179
STARS J-2174
Edoxaban (30 mg od) vs. LMWH post-op (standard dose)
VTE-EDOX-LMWH-MULTI177
Edoxaban (30 mg od) vs. placebo
STARS J-1172,180
Edoxaban (5 mg od) vs. placebo
STARS J-1172,180
Edoxaban (60 mg od) vs. edoxaban (15 mg od)
STARS J-1172,180
VTE-EDOX-LMWH-MULTI177
Edoxaban (60 mg od) vs. edoxaban (30 mg od)
STARS J-1172,180
VTE-EDOX-LMWH-MULTI177
Edoxaban (60 mg od) vs. edoxaban (5 mg od)
STARS J-1172,180
Edoxaban (60 mg od) vs. LMWH post-op (standard dose)
VTE-EDOX-LMWH-MULTI177
Edoxaban (60 mg od) vs. placebo
STARS J-1172,180
Edoxaban (90 mg od) vs. edoxaban (15 mg od)
VTE-EDOX-LMWH-MULTI177
Edoxaban (90 mg od) vs. edoxaban (30 mg od)
VTE-EDOX-LMWH-MULTI177
Edoxaban (90 mg od) vs. edoxaban (60 mg od)
VTE-EDOX-LMWH-MULTI177
Edoxaban (90 mg od) vs. LMWH post-op (standard dose)
VTE-EDOX-LMWH-MULTI177
1.11 (0.07 to 18.55)
1.00 (0.06 to 16.79)
1.29 (0.93 to 1.78)
0.65 (0.45 to 0.96)
0.73 (0.51 to 1.05)
4.00 (0.42 to 38.07)
4.43 (0.47 to 42.02)
4.00 (0.42 to 38.07)
0.90 (0.05 to 15.13)
1.98 (0.35 to 11.05)
0.98 (0.13 to 7.09)
6.37 (0.33 to 124.25)
0.96 (0.23 to 3.95)
1.03 (0.25 to 4.23)
1.13 (0.23 to 5.68)
0.52 (0.05 to 5.82)
2.04 (0.37 to 11.39)
1.72 (0.85 to 3.47)
0.47 (0.06 to 3.54)
0.71 (0.28 to 1.80)
0.51 (0.05 to 5.69)
7.21 (0.37 to 140.63)
0.99 (0.24 to 4.07)
0.49 (0.09 to 2.71)
1.26 (0.33 to 4.84)
1.39 (0.31 to 6.31)
1.23 (0.32 to 4.70)
1.23 (0.27 to 5.58)
2.50 (0.47 to 13.19)
8.55 (0.46 to 160.06)
1.21 (0.32 to 4.65)
1.46 (0.32 to 6.60)
1.29 (0.28 to 5.84)
1.05 (0.26 to 4.25)
8.95 (0.48 to 167.47)
OR (95% CI)
1/29, 1/32
1/29, 1/29
85/3184, 67/3217
46/1596, 69/1588
53/1501, 72/1508
4/32, 1/29
4/32, 1/32
4/32, 1/29
1/32, 1/29
4/106, 2/103
2/89, 2/87
3/192, 0/172
4/106, 4/102
4/103, 4/106
3/170, 3/192
1/85, 2/89
4/103, 2/103
22/355, 13/351
2/59, 2/29
8/303, 11/301
1/85, 2/87
3/170, 0/172
4/103, 4/102
2/103, 4/102
5/106, 4/106
4/185, 3/192
5/106, 4/103
4/185, 3/170
5/106, 2/103
4/185, 0/172
5/106, 4/102
4/177, 3/192
4/177, 3/170
4/177, 4/185
4/177, 0/172
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 122 Clinically relevant bleeding [1/2] (primary prevention of VTE).
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Betrixaban (15 mg bd) vs. LMWH post-op (standard dose)
EXPERT168
Betrixaban (40 mg bd) vs. betrixaban (15 mg bd)
EXPERT168
Betrixaban (40 mg bd) vs. LMWH post-op (standard dose)
EXPERT168
Dabigatran (110 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Dabigatran (150 mg od) vs. dabigatran (110 mg od)
VTE-DABIG-PLAC-JAPAN175
Dabigatran (150 mg od) vs. LMWH pre-op (standard dose)
RE-MODEL161
RE-NOVATE160
Dabigatran (150 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. dabigatran (110 mg od)
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. dabigatran (150 mg od)
RE-MODEL161
RE-NOVATE160
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. LMWH pre-op (standard dose)
RE-MODEL161
RE-NOVATE160
RE-NOVATE II183,189
Dabigatran (220 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Rivaroxaban (10 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (10 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Rivaroxaban (10 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
Rivaroxaban (10 mg od) vs. LMWH (standard dose)
MAGELLAN184,191
Rivaroxaban (10 mg od) vs. LMWH post-op (standard dose)
RECORD 4173
Rivaroxaban (10 mg od) vs. LMWH pre-op (standard dose)
RECORD 2166
Rivaroxaban (2.5 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. rivaroxaban (10 mg bd)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. rivaroxaban (10 mg bd)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. rivaroxaban (20 mg bd)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
Rivaroxaban (5 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (5 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
0.07 (0.00 to 1.30)
5.36 (0.25 to 113.38)
0.33 (0.05 to 2.02)
0.23 (0.03 to 2.06)
1.06 (0.07 to 17.07)
1.24 (0.83 to 1.86)
1.21 (0.85 to 1.73)
0.24 (0.03 to 2.18)
5.32 (0.61 to 46.20)
0.90 (0.61 to 1.34)
1.03 (0.73 to 1.45)
5.04 (0.58 to 43.76)
1.12 (0.74 to 1.70)
1.25 (0.87 to 1.78)
1.28 (0.78 to 2.09)
1.21 (0.32 to 4.61)
0.59 (0.14 to 2.55)
0.97 (0.19 to 4.92)
0.99 (0.20 to 5.02)
2.51 (1.88 to 3.35)
1.44 (0.92 to 2.24)
1.33 (0.83 to 2.14)
0.61 (0.14 to 2.63)
1.76 (0.56 to 5.58)
2.96 (0.76 to 11.51)
2.87 (0.74 to 11.17)
2.93 (0.75 to 11.40)
3.26 (1.14 to 9.34)
5.49 (1.54 to 19.60)
5.33 (1.49 to 19.02)
1.85 (0.75 to 4.59)
5.44 (1.52 to 19.41)
0.60 (0.14 to 2.58)
0.98 (0.19 to 4.97)
OR (95% CI)
0/88, 3/43
2/84, 0/88
2/84, 3/43
1/133, 4/124
1/126, 1/133
57/703, 46/694
70/1163, 58/1154
1/126, 4/124
5/129, 1/133
50/679, 57/703
71/1146, 70/1163
5/129, 1/126
50/679, 46/694
71/1146, 58/1154
37/1010, 29/1003
5/129, 4/124
3/103, 5/104
3/103, 3/100
3/103, 3/102
164/3997, 67/4001
49/1526, 34/1508
41/1228, 31/1229
3/100, 5/104
8/98, 5/104
8/98, 3/103
8/98, 3/100
8/98, 3/102
15/106, 5/104
15/106, 3/103
15/106, 3/100
15/106, 8/98
15/106, 3/102
3/102, 5/104
3/102, 3/100
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 123 Clinically relevant bleeding [2/2] (primary prevention of VTE).
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Apixaban (10 mg bd) vs. apixaban (10 mg od)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg bd) vs. warfarin variable
APROPOS162
Apixaban (10 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (10 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (10 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (10 mg od) vs. warfarin variable
APROPOS162
Apixaban (2.5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
ADVANCE-1171
Apixaban (2.5 mg bd) vs. LMWH pre-op (standard dose)
ADVANCE-3176
ADVANCE-2178
Apixaban (2.5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (10 mg od)
APROPOS162
Apixaban (20 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg bd)
APROPOS162
Apixaban (20 mg od) vs. apixaban (5 mg od)
APROPOS162
Apixaban (20 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (20 mg od) vs. warfarin variable
APROPOS162
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg bd) vs. apixaban (5 mg od)
APROPOS162
Apixaban (5 mg bd) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg bd) vs. warfarin variable
APROPOS162
Apixaban (5 mg od) vs. apixaban (2.5 mg bd)
APROPOS162
Apixaban (5 mg od) vs. LMWH post-op (standard dose)
APROPOS162
Apixaban (5 mg od) vs. warfarin variable
APROPOS162
(Excluded)
0.33 (0.01 to 8.27)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
0.35 (0.01 to 8.67)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
2.97 (0.12 to 73.78)
0.50 (0.12 to 1.99)
2.99 (0.31 to 28.78)
5.01 (0.24 to 104.44)
0.33 (0.01 to 8.27)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
0.35 (0.01 to 8.67)
(Excluded)
(Excluded)
(Excluded)
0.38 (0.02 to 9.38)
(Excluded)
(Excluded)
OR (95% CI)
0/110, 0/105
0/110, 1/111
0/110, 0/105
0/110, 0/97
0/110, 0/109
0/110, 0/109
0/105, 1/111
0/105, 0/105
0/105, 0/97
0/105, 0/109
0/105, 0/109
1/111, 0/109
3/1596, 6/1588
3/2708, 1/2699
2/1528, 0/1529
2.97 (0.12 to 73.78)
(Excluded)
(Excluded)
1/111, 0/109
0/110, 0/110
0/110, 0/105
0/110, 1/111
0/110, 0/105
0/110, 0/97
0/110, 0/109
0/110, 0/109
0/105, 1/111
0/105, 0/97
0/105, 0/109
0/105, 0/109
0/97, 1/111
0/97, 0/109
0/97, 0/109
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 124 All-cause mortality [1/3] (primary prevention of VTE).
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Rivaroxaban (10 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (10 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Rivaroxaban (10 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
Rivaroxaban (10 mg od) vs. LMWH (standard dose)
MAGELLAN184,191
Rivaroxaban (10 mg od) vs. LMWH post-op (standard dose)
RECORD 4173
Rivaroxaban (10 mg od) vs. LMWH pre-op (standard dose)
RECORD 1165
RECORD 2166
RECORD 3163
ODiXa-OD.HIP158
Rivaroxaban (10 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (2.5 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. rivaroxaban (10 mg bd)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Rivaroxaban (20 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
Rivaroxaban (20 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Rivaroxaban (20 mg od) vs. rivaroxaban (10 mg od)
ODiXa-OD.HIP158
Rivaroxaban (20 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (30 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. rivaroxaban (10 mg bd)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. rivaroxaban (20 mg bd)
ODiXa-KNEE157
Rivaroxaban (30 mg bd) vs. rivaroxaban (5 mg bd)
ODiXa-KNEE157
Rivaroxaban (30 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Rivaroxaban (30 mg od) vs. rivaroxaban (10 mg od)
ODiXa-OD.HIP158
Rivaroxaban (30 mg od) vs. rivaroxaban (20 mg od)
ODiXa-OD.HIP158
Rivaroxaban (30 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (10 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (20 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (30 mg od)
ODiXa-OD.HIP158
Rivaroxaban (40 mg od) vs. rivaroxaban (5 mg od)
ODiXa-OD.HIP158
Rivaroxaban (5 mg bd) vs. LMWH post-op (standard dose)
ODiXa-KNEE157
Rivaroxaban (5 mg bd) vs. rivaroxaban (2.5 mg bd)
ODiXa-KNEE157
Rivaroxaban (5 mg od) vs. LMWH pre-op (standard dose)
ODiXa-OD.HIP158
(Excluded)
(Excluded)
(Excluded)
1.07 (0.85 to 1.34)
0.99 (0.32 to 3.07)
1.22 (0.33 to 4.56)
0.25 (0.05 to 1.17)
0.08 (0.00 to 1.38)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
OR (95% CI)
0/60, 0/70
0/60, 0/63
0/60, 0/57
159/3096, 153/3169
6/1526, 6/1508
5/1595, 4/1558
2/1228, 8/1229
0/1201, 6/1217
0/113, 0/107
0/113, 0/94
0/63, 0/70
0/57, 0/70
0/57, 0/60
0/57, 0/63
0/57, 0/57
0/106, 0/107
0/106, 0/113
0/106, 0/94
0/59, 0/70
0/59, 0/60
0/59, 0/63
0/59, 0/57
0/59, 0/57
0/104, 0/107
0/104, 0/113
0/104, 0/106
0/104, 0/94
0/94, 0/107
0/94, 0/113
0/94, 0/106
0/94, 0/104
0/94, 0/94
0/57, 0/70
0/57, 0/63
0/94, 0/107
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 125 All-cause mortality [2/3] (primary prevention of VTE).
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Dabigatran (110 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Dabigatran (150 mg od) vs. dabigatran (110 mg od)
VTE-DABIG-PLAC-JAPAN175
Dabigatran (150 mg od) vs. LMWH post-op (standard dose)
RE-MOBILISE167
Dabigatran (150 mg od) vs. LMWH pre-op (standard dose)
RE-MODEL161
Dabigatran (150 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. dabigatran (110 mg od)
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. dabigatran (150 mg od)
RE-MOBILISE167
RE-MODEL161
VTE-DABIG-PLAC-JAPAN175
Dabigatran (220 mg od) vs. LMWH post-op (standard dose)
RE-MOBILISE167
Dabigatran (220 mg od) vs. LMWH pre-op (standard dose)
RE-MODEL161
RE-NOVATE II183,189
Dabigatran (220 mg od) vs. placebo
VTE-DABIG-PLAC-JAPAN175
Edoxaban (15 mg od) vs. LMWH post-op (standard dose)
VTE-EDOX-LMWH-MULTI177
Edoxaban (30 mg od) vs. edoxaban (15 mg od)
VTE-EDOX-LMWH-MULTI177
Edoxaban (30 mg od) vs. LMWH (enoxaparin 20 mg bd)
STARS J-4181,193
Edoxaban (30 mg od) vs. LMWH post-op (standard dose)
VTE-EDOX-LMWH-MULTI177
Edoxaban (60 mg od) vs. edoxaban (15 mg od)
VTE-EDOX-LMWH-MULTI177
Edoxaban (60 mg od) vs. edoxaban (30 mg od)
VTE-EDOX-LMWH-MULTI177
Edoxaban (60 mg od) vs. LMWH post-op (standard dose)
VTE-EDOX-LMWH-MULTI177
Edoxaban (90 mg od) vs. edoxaban (15 mg od)
VTE-EDOX-LMWH-MULTI177
Edoxaban (90 mg od) vs. edoxaban (30 mg od)
VTE-EDOX-LMWH-MULTI177
Edoxaban (90 mg od) vs. edoxaban (60 mg od)
VTE-EDOX-LMWH-MULTI177
Edoxaban (90 mg od) vs. LMWH post-op (standard dose)
VTE-EDOX-LMWH-MULTI177
LMWH pre-op (standard dose) vs. LMWH post-op (standard dose)
VTE-VKA-LMWH-US-3153
Placebo vs. LMWH (nadroparin 3800 IU anti-Xa od)
PROTECHT170
Placebo vs. LMWH (standard dose)
LIFENOX185
Placebo vs. LMWH pre-op (standard dose)
VTE-LMWH-PLAC-CAN169
Warfarin (INR 2–3) vs. LMWH post-op (standard dose)
VTE-VKA-LMWH-US-4156
VTE-VKA-LMWH-CANADA152
VTE-VKA-LMWH-CANADA152
VTE-VKA-LMWH-CANADA152
VTE-VKA-LMWH-US-3153
VTE-VKA-LMWH-US-2154
VTE-VKA-LMWH-CANADA152
Warfarin (INR 2–3) vs. LMWH pre-op (standard dose)
VTE-VKA-LMWH-US-3153
Warfarin variable vs. LMWH post-op (standard dose)
APROPOS162
(Excluded)
(Excluded)
1.49 (0.25 to 8.94)
0.98 (0.06 to 15.77)
(Excluded)
(Excluded)
0.72 (0.12 to 4.30)
1.03 (0.06 to 16.52)
(Excluded)
1.06 (0.15 to 7.58)
1.01 (0.06 to 16.26)
0.33 (0.01 to 8.11)
(Excluded)
2.70 (0.11 to 66.78)
3.43 (0.35 to 33.30)
(Excluded)
7.21 (0.37 to 140.63)
0.34 (0.01 to 8.50)
0.13 (0.01 to 2.52)
(Excluded)
0.36 (0.01 to 8.89)
0.13 (0.01 to 2.63)
(Excluded)
(Excluded)
4.93 (0.24 to 102.94)
0.98 (0.53 to 1.80)
1.03 (0.88 to 1.20)
(Excluded)
2.98 (0.31 to 28.96)
1.86 (0.08 to 45.81)
0.53 (0.02 to 13.04)
1.01 (0.06 to 16.15)
5.00 (0.24 to 104.42)
1.13 (0.46 to 2.78)
(Excluded)
1.01 (0.14 to 7.23)
(Excluded)
OR (95% CI)
0/133, 0/124
0/126, 0/133
3/649, 2/643
1/696, 1/685
0/126, 0/124
0/129, 0/133
2/604, 3/649
1/675, 1/696
0/129, 0/126
2/604, 2/643
1/675, 1/685
0/1001, 1/992
0/129, 0/124
1/192, 0/172
3/170, 1/192
0/46, 0/27
3/170, 0/172
0/185, 1/192
0/185, 3/170
0/185, 0/172
0/177, 1/192
0/177, 3/170
0/177, 0/185
0/177, 0/172
2/496, 0/487
16/381, 33/769
355/4136, 348/4171
0/111, 0/126
3/176, 1/173
1/334, 0/206
0/211, 1/336
1/334, 1/336
2/489, 0/487
10/1495, 9/1516
0/211, 0/206
2/489, 2/496
0/109, 0/109
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 126 All-cause mortality [3/3] (primary prevention of VTE).
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Appendix 4 Forest plots: acute treatment of
venous thromboembolism
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FIGURE 127 Symptomatic DVT (acute treatment of VTE).
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FIGURE 128 Symptomatic PE (acute treatment of VTE).
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OR
FIGURE 129 Symptomatic VTE (acute treatment of VTE).
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FIGURE 130 Myocardial infarction (acute treatment of VTE).
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OR
FIGURE 131 Major bleeding (acute treatment of VTE).
DOI: 10.3310/hta21090 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 9
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Sterne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
341
Apixaban (10 mg bd) vs. apixaban (5 mg bd)
BOTTICELLI DVT204
Apixaban (10 mg bd) vs. warfarin (INR 2–3)
BOTTICELLI DVT204
Apixaban (20 mg od) vs. apixaban (10 mg bd)
BOTTICELLI DVT204
Apixaban (20 mg od) vs. apixaban (5 mg bd)
BOTTICELLI DVT204
Apixaban (20 mg od) vs. warfarin (INR 2–3)
BOTTICELLI DVT204
Apixaban (5 mg bd) vs. warfarin (INR 2–3)
BOTTICELLI DVT204
AMPLIFY210
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
RE-COVER205
RE-COVER II211
Edoxaban [60 or 30 (17.6%) mg od] vs. warfarin (INR 2–3)
HOKUSAI-VTE208,209
Rivaroxaban (15 mg bd then 20 mg od) vs. warfarin (INR 2–3)
EINSTEIN PE207
EINSTEIN DVT206
Rivaroxaban (20 mg od) vs. warfarin (INR 2–3)
EINSTEIN DVT dose-ranging study203
Rivaroxaban (30 mg od) vs. rivaroxaban (20 mg od)
EINSTEIN DVT dose-ranging study203
Rivaroxaban (30 mg od) vs. warfarin (INR 2–3)
EINSTEIN DVT dose-ranging study203
Rivaroxaban (40 mg od) vs. rivaroxaban (20 mg od)
EINSTEIN DVT dose-ranging study203
Rivaroxaban (40 mg od) vs. rivaroxaban (30 mg od)
EINSTEIN DVT dose-ranging study203
Rivaroxaban (40 mg od) vs. warfarin (INR 2–3)
EINSTEIN DVT dose-ranging study203
0.50 (0.18 to 1.40)
0.55 (0.19 to 1.56)
2.06 (0.74 to 5.75)
1.04 (0.43 to 2.48)
1.13 (0.46 to 2.76)
1.09 (0.45 to 2.67)
0.42 (0.33 to 0.52)
0.61 (0.45 to 0.84)
0.61 (0.44 to 0.85)
0.81 (0.70 to 0.94)
0.90 (0.75 to 1.07)
1.00 (0.78 to 1.28)
0.55 (0.22 to 1.42)
1.03 (0.37 to 2.84)
0.57 (0.22 to 1.46)
0.34 (0.09 to 1.31)
0.33 (0.09 to 1.28)
0.19 (0.05 to 0.69)
OR (95% CI)
6/133, 11/128
6/133, 10/126
11/124, 6/133
11/124, 11/128
11/124, 10/126
11/128, 10/126
115/2676, 261/2689
71/1274, 111/1265
64/1279, 102/1289
349/4118, 423/4122
249/2412, 274/2405
139/1718, 138/1711
8/115, 12/101
8/112, 8/115
8/112, 12/101
3/121, 8/115
3/121, 8/112
3/121, 12/101
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 132 Clinically relevant bleeding (acute treatment of VTE).
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Apixaban (10 mg bd) vs. apixaban (5 mg bd)
BOTTICELLI DVT204
Apixaban (10 mg bd) vs. warfarin (INR 2–3)
BOTTICELLI DVT204
Apixaban (20 mg od) vs. apixaban (10 mg bd)
BOTTICELLI DVT204
Apixaban (20 mg od) vs. apixaban (5 mg bd)
BOTTICELLI DVT204
Apixaban (20 mg od) vs. warfarin (INR 2–3)
BOTTICELLI DVT204
Apixaban (5 mg bd) vs. warfarin (INR 2–3)
BOTTICELLI DVT204
AMPLIFY210
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
RE-COVER205
RE-COVER II211
Edoxaban [60 or 30 (17.6%) mg od] vs. warfarin (INR 2–3)
HOKUSAI-VTE208,209
Rivaroxaban (15 mg bd then 20 mg od) vs. warfarin (INR 2–3)
EINSTEIN PE207
EINSTEIN DVT206
Rivaroxaban (20 mg od) vs. warfarin (INR 2–3)
EINSTEIN DVT dose-ranging study203
Rivaroxaban (30 mg od) vs. rivaroxaban (20 mg od)
EINSTEIN DVT dose-ranging study203
Rivaroxaban (30 mg od) vs. warfarin (INR 2–3)
EINSTEIN DVT dose-ranging study203
Rivaroxaban (40 mg od) vs. rivaroxaban (20mg od)
EINSTEIN DVT dose-ranging study203
Rivaroxaban (40 mg od) vs. rivaroxaban (30 mg od)
EINSTEIN DVT dose-ranging study203
Rivaroxaban (40 mg od) vs. warfarin (INR 2–3)
EINSTEIN DVT dose-ranging study203
0.32 (0.03 to 3.10)
2.89 (0.12 to 71.54)
1.05 (0.06 to 16.92)
0.33 (0.03 to 3.25)
3.02 (0.12 to 74.92)
7.05 (0.36 to 137.97)
0.79 (0.52 to 1.19)
0.99 (0.54 to 1.83)
1.01 (0.58 to 1.76)
1.05 (0.82 to 1.35)
1.16 (0.79 to 1.70)
0.77 (0.50 to 1.18)
0.81 (0.21 to 3.07)
2.08 (0.61 to 7.08)
1.68 (0.53 to 5.26)
0.49 (0.09 to 2.71)
0.24 (0.05 to 1.13)
0.39 (0.08 to 2.07)
OR (95% CI)
1/134, 3/130
1/134, 0/128
1/128, 1/134
1/128, 3/130
1/128, 0/128
3/130, 0/128
41/2676, 52/2689
21/1274, 21/1265
25/1279, 25/1289
132/4118, 126/4122
58/2412, 50/2405
38/1718, 49/1711
4/135, 5/137
8/134, 4/135
8/134, 5/137
2/136, 4/135
2/136, 8/134
2/136, 5/137
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 133 All-cause mortality (acute treatment of VTE).
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Appendix 5 Forest plots: secondary prevention of
venous thromboembolism
Apixaban (2.5mg bd) vs. placebo
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. placebo
AMPLIFY-EXT221
Aspirin (100 mg od) vs. placebo
ASPIRE220
WARFASA219
Dabigatran (150 mg bd) vs. placebo
RE-SONATE222
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
RE-MEDY222
Rivaroxaban (20 mg od) vs. placebo
EINSTEIN-EXTENSION206,217,218
Warfarin (INR 2–3) vs. no treatment
WODIT-DVT214
WODIT-PE215
Warfarin (INR 2–3) vs. placebo
LAFIT213
0.11 (0.05 to 0.25)
1.38 (0.48 to 4.00)
0.15 (0.07 to 0.31)
0.90 (0.57 to 1.42)
0.51 (0.27 to 0.98)
0.09 (0.02 to 0.37)
1.31 (0.63 to 2.70)
0.15 (0.06 to 0.39)
0.87 (0.42 to 1.78)
0.97 (0.33 to 2.84)
0.04 (0.00 to 0.68)
OR (95% CI)
6/840, 53/829
8/813, 6/840
8/813, 53/829
39/411, 43/411
16/205, 28/197
2/681, 22/662
17/1430, 13/1426
5/602, 31/594
16/134, 18/133
7/165, 7/161
0/79, 11/83
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 134 Symptomatic DVT (secondary prevention of VTE).
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Apixaban (2.5 mg bd) vs. placebo
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. placebo
AMPLIFY-EXT221
Aspirin (100 mg od) vs. placebo
ASPIRE220
WARFASA219
Dabigatran (150 mg bd) vs. placebo
RE-SONATE222
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
RE-MEDY222
Rivaroxaban (20 mg od) vs. placebo
EINSTEIN-EXTENSION206,217,218
Warfarin (INR 2–3) vs. no treatment
WODIT-DVT214
WODIT-PE215
Warfarin (INR 2–3) vs. placebo
LAFIT213
0.11 (0.05 to 0.25)
1.38 (0.48 to 4.00)
0.15 (0.07 to 0.31)
0.90 (0.57 to 1.42)
0.51 (0.27 to 0.98)
0.09 (0.02 to 0.37)
1.31 (0.63 to 2.70)
0.15 (0.06 to 0.39)
0.87 (0.42 to 1.78)
0.97 (0.33 to 2.84)
0.04 (0.00 to 0.68)
OR (95% CI)
6/840, 53/829
8/813, 6/840
8/813, 53/829
39/411, 43/411
16/205, 28/197
2/681, 22/662
17/1430, 13/1426
5/602, 31/594
16/134, 18/133
7/165, 7/161
0/79, 11/83
Events/total
0.0625 0.125 0.25 0.5 1 2 4 8 16
OR
FIGURE 135 Symptomatic PE (secondary prevention of VTE).
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Apixaban (2.5 mg bd) vs. placebo
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. placebo
AMPLIFY-EXT221
Aspirin (100 mg od) vs. placebo
ASPIRE220
WARFASA219
Dabigatran (150 mg bd) vs. placebo
RE-SONATE222
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
RE-MEDY222
Rivaroxaban (20 mg od) vs. placebo
EINSTEIN-EXTENSION206,217,218
Warfarin (INR 1.5–2) vs. placebo
PREVENT216
Warfarin (INR 2–3) vs. no treatment
WODIT-DVT214
WODIT-PE215
Warfarin (INR 2–3) vs. placebo
LAFIT213
0.18 (0.10 to 0.31)
1.03 (0.49 to 2.18)
0.18 (0.10 to 0.32)
0.75 (0.51 to 1.09)
0.57 (0.34 to 0.96)
0.08 (0.02 to 0.26)
1.45 (0.79 to 2.65)
0.18 (0.08 to 0.38)
0.34 (0.18 to 0.64)
0.99 (0.51 to 1.92)
0.79 (0.39 to 1.64)
0.05 (0.01 to 0.38)
OR (95% CI)
14/840, 73/829
14/813, 14/840
14/813, 73/829
57/411, 73/411
28/205, 43/197
3/681, 35/660
26/1430, 18/1426
8/602, 42/594
14/255, 37/253
21/134, 21/133
15/165, 18/161
1/79, 17/83
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 136 Symptomatic VTE (secondary prevention of VTE).
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Apixaban (2.5 mg bd) vs. placebo
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. placebo
AMPLIFY-EXT221
Aspirin (100 mg od) vs. placebo
ASPIRE220
Dabigatran (150 mg bd) vs. placebo
RE-SONATE222
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
RE-MEDY222
Warfarin (INR 1.5–2) vs. placebo
PREVENT216
0.49 (0.09 to 2.69)
1.55 (0.26 to 9.31)
0.76 (0.17 to 3.42)
0.33 (0.07 to 1.65)
0.97 (0.06 to 15.57)
10.04 (1.28 to 78.50)
1.49 (0.25 to 9.02)
OR (95% CI)
2/840, 4/829
3/813, 2/840
3/813, 4/829
2/411, 6/411
1/681, 1/662
10/1430, 1/1426
3/255, 2/253
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 137 Myocardial infarction (secondary prevention of VTE).
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Apixaban (2.5 mg bd) vs. placebo
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. placebo
AMPLIFY-EXT221
Aspirin (100 mg od) vs. placebo
ASPIRE220
WARFASA219
Dabigatran (150 mg bd) vs. placebo
RE-SONATE222
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
RE-MEDY222
Rivaroxaban (20 mg od) vs. placebo
EINSTEIN-EXTENSION206,217,218
Warfarin (INR 1.5–2) vs. placebo
PREVENT216
Warfarin (INR 2–3) vs. no treatment
WODIT-DVT214
WODIT-PE215
Warfarin (INR 2–3) vs. placebo
LAFIT213
0.49 (0.09 to 2.69)
0.52 (0.05 to 5.70)
0.25 (0.03 to 2.28)
1.34 (0.46 to 3.90)
0.96 (0.06 to 15.47)
4.87 (0.23 to 101.73)
0.51 (0.26 to 1.01)
9.25 (0.50 to 172.27)
2.51 (0.48 to 13.06)
2.02 (0.36 to 11.19)
2.96 (0.30 to 28.79)
7.64 (0.39 to 150.33)
OR (95% CI)
2/840, 4/829
1/813, 2/840
1/813, 4/829
8/411, 6/411
1/205, 1/197
2/681, 0/662
13/1430, 25/1426
4/571, 0/583
5/255, 2/253
4/134, 2/133
3/165, 1/161
3/79, 0/83
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 138 Major bleeding (secondary prevention of VTE).
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Apixaban (2.5 mg bd) vs. placebo
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. placebo
AMPLIFY-EXT221
Aspirin (100 mg od) vs. placebo
ASPIRE220
WARFASA219
Dabigatran (150 mg bd) vs. placebo
RE-SONATE222
Dabigatran (150 mg bd) vs. warfarin (INR 2–3)
RE-MEDY222
Rivaroxaban (20 mg od) vs. placebo
EINSTEIN-EXTENSION206,217,218
1.22 (0.69 to 2.16)
1.35 (0.81 to 2.26)
1.65 (0.96 to 2.84)
1.78 (0.74 to 4.28)
0.96 (0.24 to 3.89)
3.02 (1.56 to 5.86)
0.52 (0.39 to 0.70)
5.34 (2.35 to 12.09)
OR (95% CI)
27/840, 22/829
35/813, 27/840
35/813, 22/829
14/411, 8/411
4/205, 4/197
36/681, 12/662
80/1430, 145/1426
36/598, 7/590
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 139 Clinically relevant bleeding (secondary prevention of VTE).
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Apixaban (2.5 mg bd) vs. placebo
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. apixaban (2.5 mg bd)
AMPLIFY-EXT221
Apixaban (5 mg bd) vs. placebo
AMPLIFY-EXT221
Aspirin (100 mg od) vs. placebo
ASPIRE220
WARFASA219
Dabigatran (150 mg bd) vs. warfarin (INR 2 – 3)
RE-MEDY222
Rivaroxaban (20 mg od) vs. placebo
EINSTEIN-EXTENSION206,217,218
Warfarin (INR 1.5 – 2) vs. placebo
PREVENT216
Warfarin (INR 2 – 3) vs. no treatment
WODIT-DVT214
WODIT-PE215
Warfarin (INR 2 – 3) vs. placebo
LAFIT213
0.49 (0.20 to 1.22)
0.59 (0.17 to 2.02)
0.29 (0.09 to 0.88)
0.88 (0.44 to 1.76)
1.16 (0.35 to 3.86)
0.89 (0.46 to 1.72)
0.49 (0.04 to 5.45)
0.49 (0.15 to 1.64)
0.99 (0.34 to 2.91)
1.73 (0.66 to 4.50)
0.34 (0.03 to 3.36)
OR (95% CI)
7/840, 14/829
4/813, 7/840
4/813, 14/829
16/411, 18/411
6/205, 5/197
17/1430, 19/1426
1/598, 2/590
4/255, 8/253
7/134, 7/133
12/165, 7/161
1/79, 3/83
Events/total
10.0625 0.125 0.25 0.5 2 4 8 16
OR
FIGURE 140 For all-cause mortality (secondary prevention of VTE).
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Appendix 6 Discussion of previous economic
models
The earliest model we identified was developed by Gage et al.31 in 1995. This used a Markov modelcomparing warfarin, aspirin and no therapy. States, such as ‘second stroke’, were used to record the
event history of patients, and this history had an effect on risks of future events, costs and utilities. Strokes,
ICH and TIA were included, whereas MI and extracranial bleeds were not. The time horizon was 10 years
and the cycle length was 1 month. The RIND state [reversible ischaemic neurological deficit (RIND)] was
used to represent recovery from a temporary stroke or TIA. Patients were assumed to switch treatments
from warfarin to aspirin if they experienced a bleed, and from aspirin to warfarin if they experienced a
stroke. In common with this model, we will adopt a Markov modelling framework with states that record
event histories to account for their effect on risks, costs and utilities. In our model, we include all of the
events in this model, although we rename haemorrhage as a bleed and model it in more detail,
categorised by severity. We also account for the possibility of treatment switching. We also model the
general RIND state in more detail, recording specific event histories, such as history of both MI and stroke.
One of the first published models in the UK setting was that by Lightowlers and McGuire32 in 1998. They
used a very simple decision tree, with a 10-year time horizon, to assess the cost-effectiveness of different
monitoring strategies for warfarin, compared with each other and ‘no treatment’ for over 75-year-olds.
They included bleeding as an AE but made the simplifying assumption that it was roughly twice as likely in
the warfarin group as in the no-treatment group. Our model will be more sophisticated than this decision
tree approach. Our Markov model structure will allow us to evaluate lifetime cost-effectiveness as we can
account for recurring events and long-term treatment effects, costs and utilities.
Recently, some more complicated model structures have been explored. The Bayer submission to NICE
on rivaroxaban in 2011 used a 22-state Markov model to compare treatments for non-valvular AF in the
73-year-old population in the UK,33 similar to our target population. The cycle length for the Markov
model was 3 months and, as in our model, they used a life-time time horizon. The model accounted for
treatment switching and for discontinuation of treatment, both of which be accounted for in our model.
In a similar fashion to our model and that of Gage et al. 199531 patient history was accounted for by
memory states, such as the ‘post minor stroke’ states. Unlike in Gage et al. 199531 ICH and minor/major
bleed were distinguished and, under clinical advisement, this is a distinction we will also make. The model
also separated SE and stroke, a distinction that we will adopt. The evidence used to inform the model was
a mixture of trial data (ROCKET AF106,112,123,129) and the results of a Bayesian NMA comparing rivaroxaban
20 mg od, dabigatran 110 mg, dabigatran 150 mg, warfarin, aspirin and placebo. We do not have access
to individual patient trial data but will use a Bayesian NMA of aggregate data from RCTs to inform a
majority of our model’s transition probabilities.
Several recent publications have been largely based on the template set down by Gage et al.31 The
models by Shah and Gage in 2011,34 Freeman et al. 2011,35 two by Lee et al. 201236,37 separately looking
at rivaroxaban and apixaban, and by Harrington et al. 201338 all used a similar structure to Gage et al.31
but with updated input evidence, extra states and different treatments. As in our model, these models
used longer time horizons (up to 35 years). Owing to the availability of superior data, some of these
models used shorter cycle lengths (2 weeks). They additionally used TIA itself rather than RIND to represent
a non-disabling minor stroke, a choice that we will adopt in accordance with clinician advice, and some of
the models included a MI event, using evidence of adverse treatment effect on MI rate of dabigatran
110 mg and 150 mg compared with warfarin from the RE-LY trial104,109 and the Framingham study.243
As in the study by Gage et al.,31 memory states were used to record event histories but these models
also included a history of both stroke and ICH, a choice we will extend by including states with a history
of up to four events (stroke, bleed, ICH and MI). Kamel et al.39 used a similar structure to the Lee et al.
models,36,37 with evidence from the ARISTOTLE trial,107,114,119,124–127,130,132–134 but investigated apixaban and
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warfarin for the prevention of only secondary stroke. Our model will be interested in primary, secondary,
and any subsequent stroke, so this is not a model of particular interest. The Harrington et al. study,38
in the USA setting, is the latest of this series of models, and its parameters are based on the results of
the ARISTOTLE,107,114,119,124–127,130,132–134 RE-LY104,109 and ROCKET AF106,112,123,129 studies of the NOACs.
A highly complex model was published by the Canadian Agency for Drugs and Technologies in Health
(CADTH) comparing rivaroxaban, dabigatran and apixaban with each other and with warfarin in the
Canadian setting. As in our model and previous AF models, this was a Markov model.40 The model used a
cycle length of 3 months and base-case time horizon of 40 years. CADTH analysed populations that were
stratified by risk of stroke, assessed by CHADS2 and by age (< 75 and ≥ 75 years), and allowed event rates
to vary with the age of the cohort: an important feature that we will adopt for our model. A difference
from our model is that CADTH included fatal and non-fatal PE, an event that we will not include as clinical
advice was that PE was not an AF treatment. The CADTH model was informed by a broad evidence base,
combining results from RE-LY,104,109 ARISTOTLE107,114,119,124–127,130,132–134 and ROCKET AF106,112,123,129 via a NMA
conducted in both the Bayesian and frequentist setting.
Wisloff et al.41 used a decision tree followed by an eight-state Markov model to compare dabigatran,
apixaban and rivaroxaban with warfarin for populations with a range of ages in the Norwegian setting.
The model used eight health states, notably including gastrointestinal bleeding as the only possible bleed
type. We grouped all CRB events as clinical advice was that they would have similar sequelae and effects
on risks of future bleeds and other events. The cycle length of the Wisloff model41 was 12 months, as
shorter cycle lengths of only 1 month led to spurious results, most likely due to limited data, although
the model was based on the results of ROCKET AF, RE-LY and ARISOTLE. A lifetime time horizon was used
but a cut-off at 105 years was imposed. Our model will adopt a similar cut-off at 100 years. The Wisloff
study41 is significant, as it was one of the few to conduct a VOI analysis.
Discrete event simulation was used by Pink et al.46 in 2011 as an alternative to Markov modelling. This
modelled similar events to our model, including stroke, MI, ICH, TIA and major bleeding, and simulated
50,000 individuals over a lifetime time horizon in the UK to compare dabigatran and warfarin. The model
primarily used the RE-LY trial104,109 to inform its parameters. Although discrete event simulation has the
advantage over Markov models of modelling events in continuous time and modelling individual patients,
we decided that this extra level of detail was unnecessary and that the available data were, in any
case, insufficient.
A recent model of dabigatran for stroke prevention in AF in the UK setting was published by Kansal et al.42
in 2012. This was a Markov model, which built on a previous model by Sorensen et al.244 This model used
a 3-month cycle length and lifetime time horizon, with a cut-off at 100 years, as in our model. The model
used a NMA of Roskell et al.245 to inform its clinical parameters. Although we will use a separate NMA
and other long-term sources for clinical parameters, the costs and utilities in our model will largely follow
those used in this Kansal et al. model,42 although we will update or inflate to today’s prices where
possible. Kansal et al.42 found that dabigatran was both more effective and less costly than warfarin for
the prevention of stroke in AF, although they assumed that dabigatran did not require monitoring and the
results may be very sensitivity to this assumption.
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Appendix 7 Competing risks network
meta-analysis for hazard ratios of events
A ll event types reported in the systematic literature review must be included to account for correlationand competing risks, giving a total of 17 types of events, although all trials report only a subset of
these events:
1. ischaemic stroke
2. bleeding
3. minor bleeding
4. fatal bleeding
5. MI
6. death (all causes)
7. TIA
8. fatal stroke
9. composite CRB
10. hospital admission
11. death (cardiovascular)
12. arterial event
13. PE
14. extracranial minor bleeding
15. SE (obtained by subtracting ‘All stroke’ from ‘Stroke or SE’ in trials that report both)
16. intracranial bleeding (ICH) (to which we added haemorrhagic stroke, under clinical advice)
17. CRB (a combination of major bleeding and CRNM bleeding).
Events of interest to our model are death (‘All causes’), MI, TIA, CRB, ischaemic stroke, SE and ICH.
In all of the following models, λi is the rate of events of type i, which is modelled on the log-scale.
The data are reported in three different ways, which we describe, in turn, below. The interpretation of the
λi’s is the same across different data types and can be estimated in a shared parameter model.
For each study j, arm k, and outcome i, the log of the hazard λjki is related to the study-specific
baseline hazard µji and log-HR of the treatment in arm k (tjk) relative to the treatment in arm 1 (tj1):
log(λ jki) = µji + dt jki − dt j1 i.
The baseline hazards µji are treated as nuisance parameters and vague priors are placed on them:
µjiN(0,0.0001).
Vague priors are also placed on the log-HRs for all outcomes i and treatments t: dti ∼ N(0,0.0001)
Number of first events
Here, only the first event is recorded for each individual, and they are assumed censored at the point at
which the first event occurs. The outcomes are therefore competing risks, and need to be modelled jointly.
Let r1, r2, . . ., rm be the number of individuals with first event being of type i, for i = 1, . . ., m, and R =∑
m
i¼1
ri.
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Let E be the observed person-years at risk. Then the likelihood is:
R∼ Po E∑
m
i=1
λi
 
,
and conditional on R:
ðr1, r2,…, rm)∼Multinomial
λ1
∑
m
i=1
λ1
,…,
λm
∑
m
i=1
λ1
0
@
1
A; R
0
@
1
A.
There are five studies97,98,100,103,105,116,117,121 that report in this format, of which four report the mean
follow-up time. The observed person-years at risk can be obtained from the mean follow-up time by
multiplying by the number of individuals randomised. In one study,100 median follow-up and also study
duration are reported, but not mean follow-up. Median follow-up is just over half that of study duration,
owing to censoring. If we assume that mean follow-up is approximately equal to median follow-up then
we can obtain the person-years at risk as if mean follow-up were reported.
Number of individuals experiencing at least one event of a
given type
Here, the number of individuals experiencing at least one event of a given type are recorded. Each
individual may count towards more than one event type, but only once for each event type. We need to
consider mortality slightly differently from other event types because this event can happen only once.
Now let ri be the number of individuals with at least one event of type i and rm the number of mortalities.
The likelihood for the number of mortalities is: rm ∼ Po(Eλm).
The likelihood for other events is approximately (assuming an average follow-up time, ri ∼ Bin(pi, n), for
each individual, and number randomised n): ri ∼ Bin(pi,n), where pi is the probability that an individual
has one or more event of type i over the follow-up period t, giving cloglog(pi) = log(t) + log (λi), where
cloglog(pi) = log(–log(1 – pi)).
There are 14 studies12,95,99,101,102,106,108,110–113,115,120,122,123,128,129,131 reporting outcomes in this format. Of these,
only three studies111,122,128,131 report mean follow-up time, t, which can be used in the likelihood as
described above. Two studies96,106,112,123,129 report median follow-up time, which we can use if we assume
that the mean follow-up time is approximately equal to the median follow-up. One study120 does not
report any information on follow-up, and so has to be excluded from the analysis.
The remaining eight studies12,95,101,102,108,110,113,115 report only the study duration, which, we know from
those studies reporting both study duration and mean or median follow-up, greatly overestimates mean
follow-up time. In studies that report both, the mean follow-up time, as a proportion of the study
duration, ranges from 36% to 69%. We used a prior for this proportion, π, then set t = π t (where
t = study duration). This allowed us to include these studies but reflected our uncertainty in the mean
follow-up time.
Total number of events
Here we have total number of events of type i for given person-years at risk E.
Now let ri be the number events of type i, including repeat events within individuals.
The likelihood is ri ∼ Po(Eλi).
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There are three studies96,104,107,109,114,119,124–127,130,132–134 reporting results in this format. Of these, one study96
reports mean follow-up time, from which we can derive E. The other two studies104,107,109,114,119,124–127,130,132–134
report median follow-up time, which we can use if we assume mean follow-up time is approximately equal
to median follow-up time.
Estimating mean follow-up time from median follow-up time
If censoring follows an exponential distribution then mean =median/log(2) giving mean >median.
However, in the only study11 that reports both, they are very similar. This is probably because of the various
different censoring mechanisms (mortality, lost to follow-up). We will therefore make the assumption that
our analyses can use the median follow-up when the mean follow-up is not available.
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Appendix 8 Competing risks model for hazard in
warfarin arms of trials
The natural history model on standard care (warfarin, INR 2–3) requires estimates of the baselinelog-hazard, rather than HRs, of events of interest. As in the treatment effects NMA, there are three
types of outcomes data to be incorporated into the model. The main difference is that a common, random
effect, baseline log-hazard for the warfarin arm (labelled 1) is assumed across studies with mi and
precision ωi.
For each study j with a warfarin arm and outcome i, the log of the hazard λji is log(λji) = µji.
The trial-specific baseline hazards are related to the across trial baseline hazard: µji ∼ N(mi,ωi).
A vague prior is placed on the mean of baseline hazard: mi ∼ N(0,0.0001).
A vague prior is placed on the precision of the baseline hazard, on the SD scale: 1
√ωi
∼ Uniform(0, 5).
The rest of the model is identical to that presented in Appendix 7.
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Appendix 9 All-cause mortality minus venous
thromboembolism-related mortality data
(acute treatment of venous thromboembolism)
TABLE 203 All-cause mortality minus VTE-related mortality data (acute treatment of VTE)
Study Comparator n
All-cause mortality minus
VTE-related mortality
AMPLIFY210 Apixaban 2 × 5mg 2691 0
Warfarin 2704 37
BOTTICELLI DVT204 Apixaban 2 × 5mg 130 3
Apixaban 2 × 10mg 134 1
Apixaban 1 × 20mg 128 1
Warfarin 128 0
EINSTEIN DVT206 Rivaroxaban 2×15mg
(first 21 days), then 1 × 20mg
1731 36
Warfarin 1718 43
EINSTEIN DVT dose-ranging study203 Rivaroxaban 1 × 20 mg 115 4
Rivaroxaban 1 × 30 mg 112 6
Rivaroxaban 1 × 40 mg 121 1
Warfarin 101 0
EINSTEIN PE207 Rivaroxaban 2 × 15mg
(first 21 days) then 1 × 20mg
2419 48
Warfarin 2413 44
HOKUSAI-VTE208,209 Edoxaban 60 or 30 (17.6%) mg 4118 108
Warfarin 4122 102
RE-COVER205 Dabigatran 2 × 150 mg 1274 20
Warfarin 1265 18
RE-COVER II211 Dabigatran 2 × 50 mg 1279 22
Warfarin 1289 25
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Appendix 10 Office for National Statistics life
tables stratified by age and gender
TABLE 204 Office for National Statistics life tables stratified by age and gender
Age (years) Males Females
55 0.0052 0.0034
56 0.0059 0.0038
57 0.0062 0.0042
58 0.0069 0.0045
59 0.0074 0.0050
60 0.0082 0.0054
61 0.0090 0.0059
62 0.0098 0.0064
63 0.0105 0.0068
64 0.0115 0.0075
65 0.0124 0.0081
66 0.0142 0.0092
67 0.0155 0.0101
68 0.0167 0.0109
69 0.0190 0.0123
70 0.0213 0.0139
71 0.0235 0.0150
72 0.0257 0.0169
73 0.0279 0.0183
74 0.0311 0.0206
75 0.0340 0.0228
76 0.0380 0.0257
77 0.0420 0.0290
78 0.0470 0.0327
79 0.0516 0.0368
80 0.0581 0.0416
81 0.0657 0.0471
82 0.0735 0.0531
83 0.0817 0.0608
84 0.0915 0.0685
85 0.1019 0.0766
86 0.1130 0.0866
continued
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TABLE 204 Office for National Statistics life tables stratified by age and gender (continued )
Age (years) Males Females
87 0.1263 0.0959
88 0.1386 0.1082
89 0.1570 0.1217
90 0.1694 0.1392
91 0.1840 0.1507
92 0.1974 0.1672
93 0.2147 0.1792
94 0.2382 0.2028
95 0.2594 0.2240
96 0.2830 0.2455
97 0.3041 0.2631
98 0.3240 0.2828
99 0.3424 0.3056
100 0.3654 0.3252
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Appendix 11 Log-odds ratios relative to
low-molecular-weight heparin
TABLE 205 Estimated (posterior mean) log-ORs relative to LMWH post-op (standard dose): pooled surgical
primary population
Treatment Log-OR 95% CI Distribution
Apixaban (2.5 mg bd) –0.05 –0.63 to 0.52 MCMC posterior simulations
Dabigatran (220 mg od) –0.02 –0.60 to 0.56
Rivaroxaban (10 mg od) –0.67 –1.18 to –0.18
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Appendix 12 Venous thromboembolism
sensitivity analyses
Primary prevention of venous thromboembolism: total
knee replacement
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FIGURE 141 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: pooling post
THR and post TKR populations for relative treatment effect of VTE. See Chapter 4 (Outcomes of atrial fibrillation
and venous thromboembolism models) for further details.
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FIGURE 142 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: setting the cost
of dabigatran to 150mg od. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)
for further details.
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FIGURE 143 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: pooling over
surgical population for VTE relative treatment effects. See Chapter 4 (Outcomes of atrial fibrillation and venous
thromboembolism models) for further details.
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FIGURE 144 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: decreasing
AE costs by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 145 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: decreasing AE
utilities by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 146 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: increasing VTE
costs by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 147 Cost-effectiveness acceptability frontier for TKR primary prevention sensitivity analysis: increasing
VTE utilities by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
Primary prevention of venous thromboembolism: post hip
replacement surgery
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FIGURE 148 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: pooling post
THR and post TKR populations for relative treatment effect of VTE. See Chapter 4 (Outcomes of atrial fibrillation
and venous thromboembolism models) for further details.
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FIGURE 149 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: setting the cost
of dabigatran to 150mg od. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)
for further details.
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FIGURE 150 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: decreasing AE
costs by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 151 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: increasing AE
costs by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 152 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: decreasing AE
utilities by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 153 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: increasing AE
utilities by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 154 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: decreasing VTE
costs by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 155 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: increasing VTE
costs by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 156 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: decreasing VTE
utilities by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 157 Cost-effectiveness acceptability frontier for THR primary prevention sensitivity analysis: increasing VTE
utilities by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
Acute treatment of venous thromboembolism
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FIGURE 158 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: decreasing AE cost by
50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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FIGURE 159 Cost-effectiveness acceptability frontier acute treatment model: increasing AE costs by 50%.
See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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FIGURE 160 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: decreasing AE utility
by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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FIGURE 161 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: increasing AE utility by
50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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FIGURE 162 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: decreasing VTE cost
by 50%.
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FIGURE 163 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: increasing VTE cost by
50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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FIGURE 164 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: decreasing VTE utility
by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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FIGURE 165 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: increasing VTE utility
by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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FIGURE 166 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: NOACs rate of
non-fatal ICH rate equal to warfarin. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism
models) for further details.
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FIGURE 167 Cost-effectiveness acceptability frontier for acute treatment sensitivity analysis: changing time on
treatment from 6 months to 3 months. See Chapter 4 (Outcomes of atrial fibrillation and venous
thromboembolism models) for further details.
Secondary prevention of venous thromboembolism
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FIGURE 168 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: patients on no
pharmacotherapy and aspirin receive warfarin after a second VTE event. See Chapter 4 (Outcomes of atrial
fibrillation and venous thromboembolism models) for further details.
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FIGURE 169 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: change bleed
base rate. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for further details.
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FIGURE 170 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: setting the cost
of warfarin to £0. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 171 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: decreasing the
AE cost by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 172 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: increasing the AE
cost by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 173 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: decreasing the
AE utility by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 174 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: increasing the AE
utility by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 175 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: increasing the
cost of VTE events by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models)
for further details.
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FIGURE 176 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: decreasing VTE
utility by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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FIGURE 177 Cost-effectiveness acceptability frontier for secondary prevention sensitivity analysis: increasing VTE
utility by 50%. See Chapter 4 (Outcomes of atrial fibrillation and venous thromboembolism models) for
further details.
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